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Thesis Abstract 
 
The reduction of bacteria on the skin results in prophylactic and therapeutic 
benefits by reducing the occurrence of skin infections. Currently, chlorhexidine 
digluconate, a conventional topical antiseptic, permeates the skin poorly leaving 
viable opportunistic pathogens below the superficial layers of the stratum 
corneum. The aim of this study was to use polyamidoamine (PAMAM) dendrimers 
to enhance the topical delivery of chlorhexidine digluconate to improve its 
antimicrobial efficacy.  
This study has characterised the antimicrobial inhibition and mechanism of 
action of PAMAM dendrimers against clinically relevant skin pathogens. This 
thesis has showed that the PAMAM dendrimers antimicrobial effect is 
concentration and generation dependent (i.e. increasing number of surface 
groups) and that the mechanism of inhibition is through severe outer and inner 
bacterial membrane permeabilisation and disruption. A topical skin pre-treatment 
of various antimicrobial concentrations of PAMAM dendrimer followed by a clinical 
dose of chlorhexidine digluconate (2% w/v aq soln.) resulted in a significant 
increase in permeation of chlorhexidine digluconate in vitro using a Franz diffusion 
cell model. This study also reports possible mechanisms of penetration 
enhancement exerted by the PAMAM dendrimer and shows evidence that their 
effect upon the skin is multifactorial. A novel time-of-flight secondary ion mass 
spectrometry method was developed and employed that chemically mapped the 
distribution of chlorhexidine digluconate within skin tissue after topical application. 
The chemical distribution images showed an enhanced deposition of chlorhexidine 
digluconate within the upper skin strata after topical application of PAMAM 
dendrimer, supporting the Franz diffusion cell findings.  
Further, this study investigated the co-application of PAMAM dendrimer-
chlorhexidine digluconate to the skin and found that a one-step application 
significantly increased the deposition of chlorhexidine digluconate within the upper 
skin strata. PAMAM dendrimers have the capacity to be versatile topically-applied 
polyvalent biocides/drug delivery platforms that have many biomedical 
applications. 
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1.0 General introduction 
1.1 The barrier to topical drug delivery of antimicrobial compounds. 
 
Human skin is the largest organ of the body and plays a vital role as the 
interface between the internal and external environments (Figure 1.1). The skin 
protects the human body from the invasion of harmful exogenous chemicals, 
microorganisms and even radiation. It has a multitude of functions including 
thermoregulation and is an important sensory organ that can detect pressure, heat 
and pain.  It provides around 10 % of the body mass of an individual and covers 
an area of approximately 1.7 m2 in adults, thus making it an accessible and large 
surface area for the delivery of therapeutics (Williams, 2003). For efficacious 
topical and transdermal drug delivery systems, a drug must permeate the Stratum 
corneum (SC).  
 
The SC, the outer layer of the skin, is only 15-20 µm thick, yet provides the 
main barrier against the ingress of permeants (Hadgraft, 2001). It is sometimes 
described as a ‘brick wall’ with anucleate keratinized corneocytes as the “bricks” 
and the densely packed intercellular lipids making up the ‘mortar’ (Elias, 1983). 
The corneocytes are elongated and flattened cells that are approximately 
0.2-1.5 µm thick and have a diameter of 34-46 µm. It is the corneoctyes that 
account for most of the weight of the SC as they are filled with keratin (Alibardi et 
al. 2004). The corneocytes act as spacers and consist of a layer of lipids 
covalently bound to the cell envelope that act as a scaffold for the extracellular 
lipid matrix (Prausnitz and Langer, 2008). This acts as a template for the 
organisation of the non-polar intercellular lipids. The intercellular lipids are 
organised around the dense envelope of keratinized corneocytes. This tortuous 
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pathway around the corneocytes along the intercellular lipid lamellae is a 
significant route for many permeating substances (Bouwstra and Ponec, 2006). 
The intercellular lipids act as an organised and rigid domain that prevent the loss 
of moisture from the skin and prevents the ingress of xenobiotic permeants such 
as actives found in antiseptic products. The lipids of the SC are made up of a 
complex mixture of ceramides, cholesterol and free fatty acids. The latter, some 
argue, demonstrate antimicrobial effects and contribute to the prevention of the 
colonisation of pathogens (Bergsson et al. 2002).  
 
Ceramides account for 50 % of the lipid content of the SC and play an 
important role in the structure of the intercellular lipids (Schurer and Elias, 1991). 
There are at least six different ceramides with differing head groups and lengths of 
fatty acid chains that contribute to the barrier nature of the intercellular lipids 
(Bouwstra et al. 1998). It is ceramide 1 that contains linoleic acid linked to a fatty 
acid chain of 30 to 34 carbon atoms that is assumed to have the most important 
role in barrier function (Bouwstra et al. 1995). Secondly, the intercellular lipids 
consist of cholesterol sulphate at around 1-7 % depending on the skin site (Lampe 
et al. 1983). 
 
Cholesterol within the SC is very important as it regulates the proteases in 
the desquamation process of the SC. In patients that have recessive x-linked 
ichthyosis an increase of cholesterol sulphate accumulates within the SC that 
leads to thickening of the SC and hyperkeratosis (Sato et al. 1998). Cholesterol 
allows for the solubilisation of free fatty acids and regulates the phase behaviour of 
the SC lipids (Norlén et al. 1999). Therefore, the amount of cholesterol within the 
SC is important for maintaining the barrier homeostasis of the skin.  
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Free fatty acids are products from the hydrolysis of phospholipids by 
phospholipase and they consist of long chain (>18 carbon atoms) saturated 
species (Fluhr et al. 2001). To investigate the importance of free fatty acids to the 
skin barrier the production of free fatty acids was inhibited using 5-(tetradecyloxy)-
2-furancarboxylic acid to inhibit acetyl CoA carboxylase. The authors found that 
the skin barrier was impaired by up to 50 % and recovery of the SC was 
significantly delayed after disruption of the free fatty acids within the SC (Mao-
Qiang et al. 1993).  
 
It has also been shown that the ratio of free fatty acids to cholesterol and to 
ceramides is also of importance for the maintenance of the SC barrier function and 
alteration of the ratio of free fatty acids found within the SC can increase the trans-
epidermal water loss (TEWL), an indicator of barrier impairment (Lavrijsen et al. 
1995). The free fatty acids are also important in the maintenance of an ‘acid 
mantle’ whereby the external SC has an acidic pH of 4 to 6 (Ohman and Vahlquist, 
1994). Alterations to the pH of the SC results in a decrease in its barrier integrity 
and cohesion. It was reported that if neutralisation of the SC occurs for only 3 h, 
the skin barrier is impaired (Fluhr et al. 2001).  
 
As well as the composition and molar ratios of the SC lipids, the phase 
behaviour and therefore structural organisation is also important for the 
maintenance of SC barrier integrity. Using small angle X-ray diffraction (SAXD) it 
was found that in healthy human skin, SC lipids are structured in two lamellar 
phases found in two periodicities of 6 nm, short periodicity phase and 13 nm, long 
periodicity phase (Bouwstra et al., 1991).  The characteristic 13 nm long periodicity 
phase has been identified in many species’ lipid lamellar thus it is assumed that 
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this phase is of great importance to the barrier function of the SC and therefore the 
permeation of substances across the tortuous path (Bouwstra et al. 1998). 
 
The SC previously described as a ‘brick wall’ is the rate limiting barrier and 
quite a predicament for researchers within topical and transdermal drug delivery. It 
is not just composition and structure that contributes to the skin barrier 
homeostasis. The terminal differentiation process involves the proliferation of 
keratinocytes from the basal layer moving upwards to become anucelate 
corneocytes at the SC surface (Egelrud, 2000). This upward movement process 
terminates in desquamation i.e. sloughing of the outer SC layers. The SC turnover 
is around 14 days (Marks, 2004).  
 
The continuous upward movement of the corneocytes that are then 
sloughed from the body prevents the ingress of microorganisms and can help to 
eliminate cancerous cells and particulate debris from the skin (Prow et al. 2011). 
Using a mathematical model of SC turnover and drug absorption it was shown that 
the continuous turnover and thus sloughing of skin cells does significantly impede 
the absorption of highly lipophilic or high molecular weight drugs (Reddy et al. 
2000). This is due to highly lipophilic drugs forming a reservoir within the 
intercellular lipid matrix of the SC. High molecular weight drugs with slow diffusivity 
through the SC are not absorbed within the 14 day SC turn over.  
The SC is a challenging barrier to topical drug delivery therefore 
enhancement strategies to overcome the skin’s barrier function are required. 
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Figure 1.1 Schematic of a skin section. 
 
When considering the skin as a permeable drug delivery site, it should be 
noted that there are many biomolecules within the skin that could potentially affect 
the therapeutic drug or the excipients. These could include; free fatty acids, 
waxes, glycerides, phospholipids, hydrocarbons (e.g. squalene) and also sterols. 
Further, it is likely that Ca, Na, K, Cl, NH3, phosphate, thiocyanates, urea, uric acid, 
creatine, amino acids, lactic acid, glucose and vitamins (Wheatley, 1963) and 
(Rothman, 1954) will be encountered within the superficial layers of the SC by the 
active drug and excipients in the formulation. Molecules naturally found on the skin 
surface have the potential to interact with the formulation affecting its 
bioavailability by forming insoluble complexes.   
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1.2 Topical and transdermal drug delivery. 
 
Drugs can permeate through three possible routes across the SC for 
dermal absorption. The three routes are intercellular, intracellular and 
transappendageal as illustrated in Figure 1.2 (Williams, 2003). It is the tortuous 
intercellular channels of extruded lipid lamellae that are said to be the primary 
route for the dermal delivery of lipophilic drugs (Stoughton, 1989). It is the only 
continuous phase across the skin, though the long tortuous path length and dense 
packing of ~10 lipid bilayers compacted between each corneocyte cell still 
provides a significant permeability barrier (Karande et al., 2006). The stacking of 
the corneocytes is also important as they dictate the tortuous path taken by the 
drug (Christophers et al. 1974). The intercellular lipid channels are reported to be 
between 0.4 – 40 nm in width and this characteristic prevents the ingress of high 
molecular weight drugs and nanoparticles (Cevc and Vierl, 2010 and Van der 
Merwe et al. 2006).  
 
The transcellular pathway affords a polar route through the intact SC. For a 
drug to penetrate the SC using the transcellular route it would be required to 
diffuse across the hydrophilic, keratin filled environment of the corneocytes. The 
corneocytes are surrounded by the extruded lipid lamellae therefore any 
hydrophilic drug diffusing through the intracellular route would not only have to 
traverse the aqueous environments of the corneocytes but also partition into the 
lipid rich extracellular matrix (Williams, 2003). Though this would be the shortest 
path length for a drug to traverse the SC, a limiting factor is that a drug would have 
to partition into the corneocyte, diffuse across the corneocyte and then partition 
back into the lipid bilayer before diffusing across the bilayer and partition back into 
 
7 
 
a corneocyte and so forth (Figure 1.2). The rate-limiting barrier for a hydrophilic 
drug traversing the intracellular route is the lipid bilayer and would require a drug 
to have an optimal hydrophilic, lipophilic balance (Heisig et al. 1996). It is for this 
reason that hydrophilic drugs generally exhibit poor permeability across the SC 
(Prausnitz et al. 2004).  
 
The transappendageal route can include pilosebaceous units and apocrine/ 
eccrine sweat glands that emerge from the dermis that can be used by drugs to 
avoid traversing the SC for drug absorption. Eccrine sweat glands are distributed 
across the skin surface however their openings are very small and sensible sweat 
is continuously being excreted from the gland. This would reduce the likelihood of 
a drug to penetrate the skin using this path (Meiden et al. 2005). The 
pilosebaceous units or the follicular route provide a pathway for the drug or vesicle 
without the requirement to traverse the SC. The drug can permeate down the 
follicle to the dermis where there is a concentration gradient due to a copious 
blood supply allowing ‘sink’ conditions (Lauer et al. 1995).  
 
Siddiqui et al. (1989) demonstrated that the transappendageal routes are 
only minor contributors (5-10 %) in the steady state flux of steroids through 
excised human skin implying that the follicular pathway for topical and transdermal 
drug delivery systems is not significant. Recently Knorr et al. (2009), argued that 
the calculation claiming that the follicular penetration route accounts for only 0.1 % 
of the skin surface area and did not take into consideration that hair follicles 
represent invaginations offering a significant increase in skin surface area for 
permeants. The transappendageal or ‘shunt’ route is important for liposomes and 
other vesicles that are too large to penetrate the SC (Lieb et al. 1992). 
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Fluorescently labelled polystyrene nanoparticles of various diameters were shown 
to preferentially accumulate within the follicular openings of the skin (Alvarez-
Roman et al. 2004a and Alvarez-Roman et al. 2004b). Nanoparticles with a 
320 nm diameter were shown to deliver a fluorescent dye more effectively than the 
free solution if the skin was massaged after application (Lademann et al. 2007). 
The authors suggested that the physical motion of the hairs pumped the 
nanoparticles deeper within the follicle resulting in an enhanced delivery. 
 
 It is likely that the penetration pathways for topical and transdermal drug 
delivery are not mutually exclusive but that a number contribute to the ingress of 
the topically applied drugs and that it is dependent on the physiochemical 
properties of a drug.  
Figure 1.2. A schematic of the permeation routes through the skin.  
1.3 Physicochemical influences on the topical delivery of drugs within and 
across the skin. 
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The physicochemical properties that can affect the permeation of drugs 
within the skin are molecular mass, ionisation at physiological pH, the partition 
coefficient and the solubility/melting point (Beetge et al. 2000). It is the partitioning 
coefficient (log P) that determines how well a drug will partition into the SC and is 
the governing factor in determining which pathway the drug will take through the 
skin (Barry, 1987). Those with a high partition coefficient, i.e. hydrophobic drugs, 
are likely to take the intercellular pathway where as those with a low partition 
coefficient, hydrophilic drugs, will take the intracellular pathway. For a drug to be a 
likely candidate for transdermal or topical delivery it would ideally have a balanced 
hydrophilic/lipophilic character with a log P value of 2 or at the very least between 
1 - 3 (Guy and Hadgraft, 1989 and Finnin and Morgan, 1999).  
 
Beetge and co-workers (2000) demonstrated with a range of non-steroidal 
anti-inflammatory drugs (NSAIDs) that with increasing log P values the blood-
plasma concentration values decreased, with a minor discrepancy between 
indomethacin and ibuprofen that both have very similar log P values. The biocide 
used in this project, chlorhexidine (CHX) has an octanol/water partition coefficient 
of 0.754 (free base) and CHX digluconate (CHG) has a log P value of 0.037 
(Farkas et al. 2007) therefore the free base and its salt do not possess an optimal 
partition coefficient for topical drug delivery. 
 
The molecular mass of a drug is also a major factor in its success as a 
transdermally delivered drug. It is thought that one reason there are so few 
transdermal drug delivery systems on the market is because there are so few ideal 
therapeutic candidates <400 Daltons (Potts and Guy, 1992). There is said to be a 
500 Dalton cut off for drugs to be able to be absorbed after topical application (Bos 
 
10 
 
and Meinardi, 2000). Once below this cut-off point, NSAIDs with a molecular 
weight from 206.30 Da up to 357.80 Da resulted in no significant variation of drug 
flux due to the molecular mass (Beetge et al. 2000). Drugs possessing ideal 
characteristics for topical or transdermal drug delivery typically possess low 
melting points < 200 ºC (Finnin and Morgan, 1999). Unionised forms of a drug 
should be able to permeate the skin more effectively than ionized forms according 
to the pH-partition hypothesis, principally via the intercellular route (Smith and 
Irwin, 2000). It is possible for drugs that are ionised at physiological pH to 
permeate the skin as it has been reported that ionised drugs can permeate the 
skin via the intercellular lipid route due to ion pairing (Hadgraft and Valenta, 2000). 
Other reasons relating to the measured drug dose achieved in plasma after 
transdermal drug delivery include individual differences in permeability that are 
intrinsic, or in the case of skin disease.   
 
1.3 Micro-flora of the skin. 
 
Human skin is the host to a large and diverse population of 
microorganisms. It provides conditions for growth such as an uneven skin surface 
with sporadic openings of many pores and ducts. It is also irrigated with various 
fluids such as eccrine sweat, sebum and apocrine sweat which provide a film of 
nutrition across the surface of the skin. Nutrition is available for microbes in the 
form of dead squamous cells from the SC which can support a vast microbial flora 
(Gibbs and Stuttard, 1967).  
 
The three major determinants of cutaneous habitats for bacteria have been 
identified as: ability to maintain a reduced environment; availability of moisture; 
and the presence of sebaceous lipids (Leydon et al. 1983). One study by Gao and 
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co-workers (2007) identified 182 species of microorganisms found on the skin 
belonging to 8 different phyla. Of the 1,221 clones analysed, 54 % of them 
belonged to the genera of Propionibacteria, Corynebacteria, Staphylococcus and 
Streptococcus. The various layers of the skin host a diverse flora of commensual 
and pathogenic bacteria, not just the superficial layers of the SC (Grice et al. 
2008). The inaccessible proportion of bacteria (Figure 1.3) inhabiting the furrows 
and appendages of the skin was termed “hidden” flora by Reybrouck (1986) and 
this hidden flora remains undetected to conventional skin sampling such as 
swabbing. The depth of hair bulbs and apocrine sweat glands that are thought to 
be bacteria reservoirs are situated 400-700 µm (Figure 1.3) within the dermis 
(Touitou, et al. 1998). A topically-applied antimicrobial compound must reach this 
depth within the skin to reduce the resident microbial flora. Deep and efficient 
antisepsis is required to prevent the repopulation of the skin surface. For bacteria 
such as coagulase negative staphylococci (i.e. Methicillin-resistant 
Staphylococcus aureus) this re-population would occur within hours after the skin 
surface disinfection (Brown et al. 1989).  
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Figure 1.3. Large hair follicle showing Gram stained bacilli and cocci deep 
within the follicle taken from an abdomen skin biopsy. Top – magnification 
x116; bottom x336. Image taken from Selwyn and Ellis (1972). 
 
1.4 Skin and soft tissue infections- invasion of pathogenic bacteria. 
 
Though the skin is an effective barrier against the ingress of microorganisms, 
occasionally it can succumb to infection through a reduction of integrity to the skin 
barrier. Skin and soft tissue infections can range from non-complex cellulitis 
through to deep-seated subcutaneous tissue infections (Stulberg et al. 2002). 
Microorganisms that can cause infections of the skin include –  
 Viruses- Can cause childhood illnesses such as measles and chickenpox, 
or are known to cause non-cancerous tumours such as warts. 
 Bacterial infections- Often it is the Staphylococcal species that is the 
source of skin infections such as Staphylococcus aureus, or the 
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streptococcus species such as Streptococcus pyogenes. An example of a 
skin infection caused by both of the aforementioned organisms is impetigo. 
 Fungal infections- Are very common. An example being ring worm that is 
an infection of the keratin layer caused by Fungi imperfecti. 
(Fitzpatrick et al. 2005) 
 
Bacteria that have colonised the skin rarely cause infection if the individual is 
not immuno-compromised (Hoffman, 2001). Dermatological infections have 
multifactorial causes but generally older patients, very young patients or the 
immuno-compromised are those at the greatest risk of developing an infection 
(Pratt et al. 2005). Skin and soft tissue infections (SSTI’s)  can arise from a 
number of sources including animal or human bites, animal contact, infections due 
to an immuno-compromised patient, or surgical site incision infections (Stevens et 
al. 2005).  With regards to the latter two sources, it is typically the patient’s own 
resident microbial flora that invades and infects the epidermis (Dryden, 2009). 
SSTI’s exist as a significant problem to inpatients as well as outpatients and are 
increasingly acquired within the community (Rajan, 2012). 
 
S. aureus is the most common pathogen identified as causing SSTI’s and is 
the result of colonisation due to a breach of the skin barrier, i.e. surgical site 
incision or trauma. If a patient is colonised by S. aureus they are at a higher risk of 
obtaining a surgical site infection than those who are not, particularly when the 
colonization density is greater than 1x106 colony-forming units per anatomical site 
(Paulson, 2002). A Study of dissemination of S. aureus after inoculation of the skin 
in a mouse model by Hahn et al. (2009) showed that within six hours the pathogen 
had invaded the tape-stripped epidermis and had disseminated rapidly to the 
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spleen and kidneys before severe cutaneous damage and complete necrosis of 
the dermis 48 hours after inoculation. In humans from colonisation and thus 
infection, typically of the subcutaneous plane, there is a three day incubation 
period until the patient develops symptoms (Stone et al. 2000).  
 
S. aureus is responsible for a range of minor non-complex infections such as 
impetigo, folliculitis, subcutaneous abscesses and furnacles that would not require 
systemic antibiotic therapy but a topical localised treatment. An example of a 
severe infection as a result of S. aureus would be staphylococcal scalded skin 
syndrome triggered by the microorganism’s associated exfoliative toxins. The 
syndrome is characterised by the splitting of the epidermis just above the granular 
layer resulting in excessive desquamation (Patel and Finlay, 2003). S. aureus α-
toxin enhances transient membrane permeability to large molecules and causes 
vacuole formation and defects in mitochondrial enzymes resulting in a severe drop 
of Adenosine-5'-triphosphate (ATP) within viable keratinocytes (Suriyaphol et al. 
2009). Such SSTI’s could then develop into serious systemic infections such as 
septicaemia, meningitis and osteomyelitis which could potentially lead to death as 
a result of staphylococcal toxic shock syndrome (Iwatsuki et al. 2006). Increasing 
antibiotic resistance, particularly with regards to S. aureus and Streptococcus 
pyogenes to methicillin and erythromycin respectively, is of great concern as the 
opportunistic pathogens are frequently responsible for complex STTI’s (Stevens et 
al. 2005). Further, methicillin resistant Staphylococcus aureus (MRSA) is also now 
the predominant cause of community-acquired SSTI’s (Eady and Cove, 2003 and 
King et al. 2006). A bacterial skin infection can have serious consequences on a 
patient’s health and can place additional stress and anxiety on the family. MRSA 
bacteraemia cases with skin infection identified as the source, increased from 
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25 % to 32 % from October to December 2011 (Health Protection Agency, 2011). 
On average, a single infection acquired in hospital costs between £4000 and 
£10,000 and just 40 MRSA bacteraemia cases would incur an additional cost 
between £160,000- £400,000 for that Trust (Department of Health, 2006).  
With antibiotic resistance increasing amongst skin pathogens it is of paramount 
importance to prevent SSTI’s through effective skin antisepsis. Also of great 
importance is to develop novel strategies for the treatment of antibiotic resistant 
strains of bacteria through mechanisms that are low risk for microbial acquisition of 
resistance. 
 
1.5 Chlorhexidine. 
 
Chlorhexidine (CHX) is a cationic bisbiguanide that demonstrates a broad 
spectrum of antimicrobial activity but exhibits low level toxicity to mammalian cells 
(Figure 1.4). It has been used throughout the global healthcare sector since it was 
first synthesised in 1954 by Rose and Swain (Davies et al. 1954). It also has a 
strong affinity for the skin, thus it has been used extensively in topical antimicrobial 
formulations (Denton, 1991). It is typically used as the digluconate, acetate or 
hydrochloride salt form due to solubility issues with the free base. It is active 
against an extensive range of microorganisms such as vegetative gram positive 
and gram negative bacteria, fungi such as yeast, dermatophytes and some 
lipophilic viruses (Ranganathan, 1996). CHX has a cationic charge at physiological 
pH thus it has the ability to bind to negative surfaces such as the cell wall of 
bacteria (Jones, 2007). For example the cell wall of S. aureus contains teichoic 
acids that are highly anionic conferring a net negative charge over the cell 
membrane (Gross et al. 2001). It is this strong affinity that allows CHX to retain low 
 
16 
 
toxicity towards mammalian cells whilst remaining biocidal against a broad range 
of microorganisms.  
 
The mechanism of action of CHX is bacterial cell membrane disruption. In 
bacteriostatic concentrations, the binding of the biguanide groups of the drug to 
the membrane phospholipids of the bacteria induces structural modifications that 
allow the leakage of low molecular weight intracellular contents such as potassium 
ions (Carlotti and Maffart, 1996). If the concentration of CHX is high, i.e. 
bactericidal concentrations, it will cause a high degree of structural damage to the 
cell membrane leading to cytoplasmic leakage and precipitation (Kuyyakamond 
and Quesnel, 1992).  
 
 
 
 
 
 
 
 
Figure 1.4. Chemical structure of CHX free base and its commonly used salt 
CHG. (a) Structure of CHX free base and (b) structure of CHG. 
 
The physicochemical characteristics of CHX impart poor percutaneous 
absorption characteristics within the skin. CHG is water-soluble and is typically 
used in topical preparations. The physicochemical characteristics of CHG are not 
ideal for percutaneous permeation as it is in the ionized form when topically 
applied under physiological skin conditions (Smith and Irwin, 2000). CHG has a 
molecular weight of 897.8 g/mol which exceeds the optimal molecular weight for 
effective skin permeation that is described as a maximum of 500 g/mol (Bos and 
(a) (b) 
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Meinardi, 2000). Furthermore, a log P (octanol/water) of 0.0133 is also less than 
optimal for percutaneous absorption (Farkas et al. 2007) as outlined in Section 
1.2. Typically when drugs are ionised at skin pH, counter ions are utilised to 
neutralise the drug for enhanced deposition within the skin (Valenta et al. 2000). 
This is not a viable option for CHX as many counter anions form insoluble salts 
and neutralise CHX diminishing its antimicrobial properties (Denton, 1991). 
Further, CHX and its salts have been shown to aggregate at concentrations above 
> 40 mM therefore self-aggregation may contribute to the low skin penetration 
observed for CHG (Zeng et al. 2009, Heard and Ashworth, 1968, and Perrin and 
Witzke, 1971).  
 
CHX is known for its poor permeability into human skin as demonstrated by 
Karpanen et al. (2008). Using ex vivo human skin in a diffusion cell the authors 
found that CHG only permeated to a high enough concentration to kill 
microorganisms in the top 100 µm of the skin and below 300 µm the concentration 
of CHG was less than 0.002 µg/mg tissue as detected by high performance liquid 
chromatography (HPLC) (Karpanen et al. 2008). Lafforgue et al. (1997) used an 
ex vivo rat skin model to demonstrate low permeation of CHG across and within 
the rat skin. After a 48 h contact time, a concentration of 26 .63 ± 13.17 µg/cm2 of 
CHG was detected within the whole rat skin and a concentration of 4.03 ± 
0.6 µg/cm2 of CHG was detected within the receptor fluid. Wang et al. 1990 
investigated the permeation of CHX phosphanilate (CHP), a new salt of CHX, 
using ex vivo human skin in a static diffusion cell. After 48 h there was almost no 
CHP that had permeated the intact SC, however in damaged skin with the SC 
enzymatically removed CHP was detected throughout the skin strata and typically 
remained within the dermis (Wang et al. 1990).  
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Percutaneous absorption of CHG in vivo was shown to be negligible after 
researchers bathed neonatal rhesus monkeys in an 8 % CHG skin cleanser every 
day for 90 days (twice the concentration used typically) (Gongwer et al. 1980). A 
low concentration of CHG was detected within the skin 0.118 ± 0.051 µg/mg of 
tissue (n=5) after 90 days. The absorption of CHG across new-born infants’ skin 
was also investigated by venepuncture to obtain a blood sample after bathing the 
babies with a CHG containing wash, hibiscrub® (4 % CHG). Low concentrations of 
CHG almost at the limits of detection were detected within the blood serum 
samples for 5 out of 24 babies tested. No toxicity was observed as a result 
(Cowen et al. 1979). Further, in 1978 Chow et al. studied the distribution of CHX 
radio-labelled with C-14 after topical application in an in vivo rat model. It was 
found that over a 5 day period less than 5 % had been absorbed and the 
radiolabelled CHX was excreted within the faeces (Chow et al. 1978). More 
recently, Lee et al. (2011) studied the blood concentrations of CHX after 
hospitalised children underwent daily CHX bathing. Though low levels of CHX 
were detected in 15 % of the blood samples, there was no evidence that CHX 
accumulates within the bloodstream of children as young as three months 
following percutaneous absorption. This study was conducted on children with 
intact skin. There are very few studies within the literature investigating the 
percutaneous absorption of CHX despite the antimicrobial compound being widely 
used within the healthcare sector across the globe. The studies carried out within 
the literature show that CHX penetration within intact skin is minimal.   
 
If topical antimicrobial compounds do not permeate the upper strata of the 
skin in high enough concentrations, the bacteria in reservoirs found deep within 
the dermal structures are potentially left viable. Viable opportunistic pathogens are 
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then free to directly infect the impaired epidermis. The reasons for the lack of skin 
permeation for CHG are due to sub-optimal physiochemical characteristics for 
topical drug delivery that includes; high molecular weight, polycationic charge and 
a low log P. This is discussed in detail in the introduction to Chapter 3.0. Despite 
poor skin permeation there are many products on the market in which CHX is the 
active antimicrobial. Table 1.1 lists topical antiseptic preparations available on the 
UK market as listed within Martindale: Drug reference (Sweetman, 2011). Though 
none of the listed products contain a penetration enhancer per se, excipients such 
as surfactants, glycerol, propanol and lipophilic perfumes (e.g. essential oils) found 
within the formulations are known to act as penetration enhancers (Williams and 
Barry, 2012). CHX has many applications including hand washing, pre-operative 
skin preparation, vaginal antisepsis, gingivitis treatment and body washes for 
prevention of SSTI’s (Milstone, 2008).  
 
The Centre for Disease Control and Prevention (CDC) made 
recommendations to use hand soap containing CHX due to its residual activity 
reinforcing the effectiveness of CHX as a topical antiseptic (Boyce and Pittete, 
2002). There are many cases highlighting the superior efficacy of CHX for 
example CHX was incorporated into an alcohol hand rub and was successfully 
implemented as part of a hand hygiene programme in an Australian hospital that 
had an MRSA endemic. The study found that healthcare worker compliance to 
hand hygiene had doubled within 12 months and the number of patients with 
reported MRSA bacteraemia was reduced by 57 %. Clinical MRSA isolates had 
also dropped by 40 % hospital-wide (Johnson et al. 2005). When compared to 
povidone-iodine, CHG was shown to significantly reduce the number of vascular 
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catheter-related infections by 49 % when 4143 catheter insertions were studied 
(Chaiyakunapruk et al. 2002).  
 
More recent patient studies where CHX was successfully implemented to 
combat infections include the significant reduction of periprosthetic hip arthroplasty 
infections (Kapadia et al. 2013), and the reduction of multi-drug resistant 
microorganism infections and hospital acquired bacteraemia cases (Climo et al. 
2013). A detailed review of the scientific support for the use of CHX within the 
healthcare sector can be found in Weinstein et al. (2008). CHX has repeatedly 
been shown to significantly decrease the number of healthcare acquired infections 
across hundreds of publications that act as evidence for the necessity of CHX as 
an antiseptic in the health care sector (Milstone et al. 2008).  
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Table 1.1 A table of CHX containing topical antiseptic formulations available 
within the UK. All CHX containing topical antiseptic preparations that are currently 
available within the UK as listed within Martindale: The drug reference (Sweetman, 
2011). 
Skin disinfectant 
product 
Dosage form CHX salt and concentration 
within formulation 
Skin 
disinfection 
use 
CHX listed as a single ingredient in commercially available topical preparations in the UK 
Acriflex® Cream CHG 0.25 % (w/w) Burns and 
scalds 
Cepton® Lotion CHG 0.1 % (w/v) Acne and 
spots 
Wash CHG 1 % (w/v) Acne and 
spots 
CX powder® Powder CHX acetate 1 % (w/w) Dusting 
powder for 
general skin 
antisepsis 
Eczmol® Cream CHG 1 % w/w Eczema 
Hibiscrub® Liquid CHG 4 % (w/v) General skin 
disinfection 
Hydrex® Liquid CHG 0.5 % (w/v) General skin 
disinfection 
Savlon wound 
wash® 
Liquid spray CHG 0.45 % (w/v) Wound 
cleansing 
Spotoway® Cream CHG 1 % (w/w) Localised 
spot 
treatment 
Steripod CHG® Liquid CHG 1 % (w/v) General 
antisepsis 
CHX listed as a multiple ingredient in commercially available topical preparations in the UK 
Cathejell with 
lidocaine® 
Gel CHX HCL 0.05 % (w/w) Anaesthetic 
Chloroprep® 
 
Liquid CHG 2 % (w/v) Pre-operative 
skin 
antisepsis 
Cyteal® 
 
Liquid CHG 0.1 % (w/v) Liquid 
Dermol® Cream CHX HCL 0.1 % (w/w) Eczema 
Lotion CHX HCL 0.1 % (w/w) 
Germolene® Cream CHG 0.25 % (w/v) Haemorrhoids 
Hibi Hand Rub® Liquid CHG 2 % (w/w) General 
antisepsis 
Instillagel® Gel CHG 0.25 % (w/w) Anaesthetic 
Nystaform® Ointment CHX acetate 1 % (w/w) General 
antisepsis 
Quinoderm® Liquid CHG 0.15 % (w/v) Acne and 
spots 
Tisept® Liquid CHG 0.015 % (w/v) Wound 
cleansing 
Torbetol® 
 
Liquid CHG 0.75 % (v/v) Acne 
Savlon antiseptic® 
 
Cream CHG 0.1 % (w/w) General 
antisepsis 
Liquid CHG 0.3 % (w/v) General 
antisepsis 
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Resistance to antimicrobial compounds including preservatives and 
disinfectants is an increasing problem. Though resistance or reduced susceptibility 
to CHX is rare it is being increasingly observed for the Pseudomonas species. It 
was demonstrated that Pseudomonas stutzeri developed resistance to CHX 
acetate after repeated exposure to sub-lethal concentrations in vitro. It is thought 
that a decrease in susceptibility was due to alterations of the cell envelope 
increasing its hydrophobicity. This strain has also developed a reduced 
susceptibility to antibiotics and to other non-antibiotic compounds including 
triclosan and cetylpyridinium chloride (Tattawasart et al. 1999). Further the same 
group demonstrated that Pseudomonas aeruginosa also developed stable 
resistance to CHX acetate on repeated exposure to sub-lethal concentrations. The 
authors stated that Pseudomonas aeruginosa may develop resistance to CHX 
from ‘residual’ concentrations and that the also Gram negative, Escherichia coli, 
did not develop a reduced susceptibility (Thomas et al. 2000). 
 
Other strains that have reduced susceptibility to CHX include the oral 
pathogen Porphyromanas gingivalis that produced vesicles to bind to CHX 
reducing the bacteria’s susceptibility to CHG (Grenier et al. 2007). It should also 
be noted that contaminated CHX disinfectants have caused nosocomial infections 
due to contamination with a range of resistant opportunistic pathogens including 
Burkholderia stabalis (Heo et al. 2008), Serratia marcescens (Vigeant et al. 1998) 
and Pseudomonas cepacia (Sobel et al. 1982). The occurrence of resistance or 
lowered susceptibility of microorganisms to CHX is still very infrequent but the 
aforementioned reports do highlight the requirement of sensible disinfectant use. 
Concentrations that are significantly higher than the minimum inhibitory 
concentrations should be used and care should be taken not to leave sub-lethal 
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concentrations as a residue. To avoid contamination issues strict aseptic 
manufacturing practices, correct storage conditions and accurate dilutions with 
sterile diluent should also be followed to prevent bacterial resistance.  
 
 There is also evidence of microbial degradation of CHX. Pseudomonas 
species isolated from river bed sludge were shown to degrade CHX into a number 
of intermediates (Tanaka et al. 2005). Copious use of CHX as a disinfectant 
results in washing CHX into the waterways. It was found that the inhibitory 
concentrations for these CHX intermediates increased ten-fold for a range of 
bacteria when compared to the parent CHX. In the case of Pseudomonas 
aeruginosa and Serratia marcescens CHX had a minimum inhibitory concentration 
(MIC) of 100 µg/mL whilst the intermediates degraded by the Pseudomonas 
species had a MIC of >1000 µg/mL (Tanaka et al. 2005 and Tanaka et al. 2006). 
The products of microbial degradation of CHX were also isolated and identified 
from an ultrasonic hand washer using three dimensional HPLC (Ogase et al. 
1992). The causative and resistant strain was identified as Achromobacter 
xylosoxidans and the authors suggested the presence of CHX degrading enzymes 
degrade CHX into p-chloroaniline and p-chlorophenol. Though the studies 
mentioned provide evidence for microbial degradation of CHX there are still limited 
studies conducted in the area of investigating the microbial degradation of 
antimicrobial compounds. Further, no studies have been conducted investigating 
the effect that cutaneous enzymes have upon CHX.  
 
Investigations into the efficacy of CHX particularly using time-kill assays is a 
controversial area. Kampf has published many papers questioning the use of 
CHX. In particular, Kampf (2008) made a bold statement calling for healthcare 
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workers to remove CHX from their formulations until further efficacy data is 
available. He argues that the studies conducted in which the CDC based their 
recommendations are flawed due to a lack of validity of the results. CHX salts at 
different concentrations are known to be very difficult to neutralise (Kampf, 1998 
and Kampf, 2006) and that all the studies conducted on the efficacy of CHX did 
not validate the neutraliser step nor demonstrate the required efficacy. A 
neutraliser validation study should always be conducted first before determining 
the antimicrobial efficacy of a biocide within a particular time frame, e.g. European 
study EN1500. Such preliminary data is rarely published although it is often 
available by request from the author. Nevertheless, even if the neutraliser 
validation study was neglected, the results should not be disregarded as the 
compound still exhibits antimicrobial affects but just possibly not within the stated 
time frame of the bacteria-CHG contact time (i.e. 30 seconds for the EN 1500 
test). There are, however, an overwhelming number of studies within the literature 
supporting the clinical use of CHX. 
 
1.5.1 Contra-indications for the use of CHX.  
 
CHX is routinely used in the healthcare sector as well as in consumer 
products (e.g. mouthwash, hand sanitiser) and it appears to have a good record 
with regards to minimal adverse reactions. In rare cases, typically after parenteral 
or mucosal exposure to CHX, anaphylaxis has been observed. Krautheim et al. 
(2004) published a comprehensive review on CHX anaphylaxis that details 
26 case reports. More recently further case reports have been published (Khan et 
al. 2011, Lloyd-Lavery and Reed, 2012 and Bae et al. 2008). Life threatening and 
immediate adverse side effects are rare however there is a growing concern with 
 
25 
 
the use of CHX incorporated into medical devices such as catheters and medicinal 
products; in October 2012, the MHRA (Medicines and Healthcare products 
Regulatory Agency) released a safety alert regarding CHX incorporated products. 
All allergic reactions to CHX must now be reported to the MHRA to determine 
whether CHX should be incorporated into products that are exposed to mucosal 
membranes or parenteral routes.  
 
Minor adverse effects associated with CHX use on intact skin include 
contact dermatitis; the prevalence of contact dermatitis caused by CHX is very 
low. At St John’s Institute of Dermatology over a 19 year period there were only 
five reported cases (Goon et al. 2004). In a further study sensitization and 
dermatitis was investigated at the Turku University Hospital Dermatology 
Department, where out of 7610 patients in the study only 26 patients were found to 
sensitized to CHX (0.47 %) and CHX containing topical products were found to 
have caused contact dermatitis in 5 patients (Liippo et al. 2011). Further, 
infrequent cases of CHX causing photosensitivity have been reported (Wahlberg 
and Wennersten, 1971), as well as contact urticaria (Wong et al. 1990). 
 
CHX has a number of contra-indications; firstly it should not be used for 
antisepsis before a lumbar puncture as it can cause damage to the meninges on 
contact. It should also be avoided for use on the eyes and new tissue other than at 
very low concentrations (<0.05 %) as it has been shown to be cytotoxic (Salami et 
al. 2006). CHX must also never be used on the mucosa epithelia of the middle ear 
as it can damage the cells of the middle ear thus demonstrating ototoxicity 
(Igarashi and Oka 1988). After a number of case reports detailing the patients’ 
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allergic response to CHX digluconate that had been incorporated into an antiseptic 
urethral gel, it is now considered that CHX should not be applied to mucosal 
surfaces of the body due to the possibility of inciting anaphylaxis (Jayatthillake et 
al. 2003 and Okano et al. 1989). Irrespective of the rare anaphylaxis cases and 
infrequent dermatitis cases documented there are a significant number of products 
on the market containing CHX that have been used globally for over 2 decades; 
even CHX containing chewing gum- CHewX® is available on the Swiss market 
(Imfeld, 2006). CHX remains a low cost and effective antiseptic that is well 
tolerated by consumers and patients across the world (Weinstein et al. 2008). The 
benefits of the antibacterial compound clearly outweigh the risks. 
 
1.6 Controlled release strategies used in the drug delivery of CHX. 
 
To overcome conditions that are less than favourable for drug delivery 
researchers have turned to colloids to enhance a drug’s therapeutic affect and to 
allow targeted delivery. Most colloids can be modified for a tailored affect and 
many have enhanced properties over conventional dosage forms. 
 
To overcome the challenges in formulating CHX, such as adsorption to 
surfaces, incompatibility with anionic components and poor skin permeation, 
researchers have investigated ways to enhance the controlled and sustained 
delivery of CHX to a localized target, i.e. the skin, root canal or biofilms. 
Liposomes with encapsulated radiolabelled C14 CHX were optimised to determine 
the most effective liposomal compositions, i.e. cationic or anionic constituents 
(Jones et al. 1997). Liposomes (containing dipalmitoylphosphatidylglycerol 
(DPPG), cholesterol and stearylamine) were shown to increase the delivery of 
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CHG to the biofilms of skin-associated opportunistic pathogens (Jones et al. 
1997).  
 
CHX-containing liposomes were developed in the early 1990’s. A patent on 
liposomes containing either CHG or CHX diacetate or a naturally occurring 
surfactant was published 15 years ago. The authors cited advantages as reduced 
side effects and increase in the sustained release of CHG or CHX diacetate 
(Gonzalez et al. 1998). The same authors then incorporated CHG containing 
liposomes into skin cleansing tissues for use on the face (Gonzalez et al. 2000). 
Human albumin microspheres were also shown to provide controlled and 
sustained release of CHX dihydrochloride that exhibited enhanced efficacy against 
Gram negative and Gram positive opportunistic pathogens that cause urinary tract 
infections. The microspheres were also investigated as a biocidal catheter coating 
(Egbaria and Freidman, 1990 (a) and 1990 (b)).  
 
1.6.1 Delivery of CHX from Hydrogels.  
 
 Hydrogels are typically biodegradable, biocompatible and non-immunogenic 
three dimensional cross-linked polymer networks that swell in the presence of 
water (Bako et al. 2008). They can be designed to be pH or thermo sensitive for 
controlled drug release (Zhao et al. 2009, Gupta et al. 2002 and Xu et al. 2006). 
Their mucoadhesive and hydrophilic nature has been exploited for the controlled 
and sustained release of CHX and CHG after topical application. They are 
commonly investigated for the treatment or prevention of periodontal infection (Xia 
et al. 2010, Vitkova et al. 2011 and Vitkova et al. 2013).  
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Bako and co-workers (2008) designed nanocomposite biocompatible 
hydrogels (NCHG) for the sustained release of CHX once applied to periodontal 
infection. Nanoparticles were formed from hydroxyethyl methacrylate (HEMA) and 
polyethyleneglycol dimethylacrylate (PEGDMA) and were loaded with CHX. The 
nanoparticles were then added to a matrix to form a hydrogel through 
photopolymerization using the same monomers, and CHX was again incorporated 
within the matrix. The NCHG allowed for the sustained release of CHX (release 
over a 48 h period) when compared to the control hydrogel (24 h release period) 
and it was found that 60 % of the loaded drug was released. The swelling of the 
NCHG was observed to be much slower than the control hydrogel, though the 
NCHG had a higher water adsorbing capacity (Bako et al. 2008).  
 
Further Ma et al. (2007) developed a thermo-sensitive hydrogel (liquid at 
room temperature then rapidly gels at body temperature) for the prolonged release 
of CHG incorporated within β-cyclodextrin inclusion complex that were then added 
to a chitosan matrix containing a growth factor recombined human bone 
morphogenetic protein. The in vitro release profile for CHG was shown to be 
sustained and controlled over a 1 month period from the NCHG. The authors 
believe that the chitosan thermo-sensitive hydrogel may have vast potential for 
treatment against periodontal infections (Ma et al. 2007). One strategy to prevent 
infection has been to use thermo-sensitive hydrogels as wound dressings or to act 
as a coating for medical devices (Jones et al. 2008). NIPAA based hydrogels were 
incorporated with CHX diacetate (1 % w/w) and were shown to possess ideal 
thermo-responsive behaviour resulting in antimicrobial properties through CHX 
diacetate release. Pulsatile biocide release may aid the prevention of resistant 
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bacterial strains as it refrains from prolonged release of possible sub-lethal 
concentrations of a biocide.  
There are numerous hydrogel systems that have been developed for 
enhanced topical skin delivery of CHX however very few have been tested using 
an in vitro skin diffusion model. A thermo-sensitive vinyl-ether based hydrogel was 
designed for CHX release and a high CHX acetate loading was achieved (~36 mg 
of CHX per gram of gel). CHX acetate was released over a 27 day period in a 
concentration that was above the MIC for two microorganisms found within the 
human mouth Streptococcus mutans and Lactobacillus casei ( Kiremitçi et al. 
2007).  
 
Hydrogels containing porous (type I) collagen matrices were developed for 
the sustained release of CHG (Sulea et al. 2011). It was determined that an 
enhanced release of CHG occurred from slightly basic hydrogels when compared 
to acidic hydrogels. The CHG release was also enhanced with increasing CHG 
concentration within the porous collagen matrices within the hydrogel. Another 
example of a hydrogel designed for CHG release is the chitosan hydrogel to 
enhance the mucosal delivery of CHG (Şenel et al. 2000). Hydrogels containing 
1-2 % chitosan were prepared and characterised to determine the antifungal 
effects and release of CHG from the gels in vitro. Chitosan gels released CHG 
over a 3 h period without a lag period as did chitosan based films resulting in a 
prolonged release of CHG (Şenel et al. 2000). Reports of CHX having been 
incorporated into various hydrogel systems are within the literature however there 
does seem to be few studies using an in vitro diffusion cell model to characterise 
the release into biological membranes (i.e excised skin). It would be of interest to 
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determine the efficacy of more hydrogel systems using ex vivo skin in diffusion 
cells or in vivo studies.  
 
1.6.2 Polymeric CHX delivery systems. 
 
Polyurethane films inclusive of CHX acetate were also developed for 
controlled drug delivery (Huynh et al. 2010). The authors showed that modulation 
of CHX acetate release was possible depending on the structure of the 
polyurethane films. It was determined that CHX acetate had no interaction with the 
polyurethane as illustrated by differential scanning calorimetry (DSC) and 
attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 
and therefore sustained drug release was observed over 29 days. CHX and CHG 
were incorporated within poly(lactic-co-glycolic acid) (PLGA) microspheres for 
sustained release over a two week period. The addition of cyclodextrins reduced 
the immediate burst release of CHG and CHX resulting in controlled release of 
CHX for the prevention or treatment of periodontal disease (Yue et al. 2004). 
Sustained release of CHX has been demonstrated by incorporation in to cold 
cured polymerizing methylacrylate systems (Riggs et al. 2000). The sustained 
release of CHX digluconate was achieved from a device coated in chitosan, poly 
(lactic-co-glycolic acid) (PLGA), and polymethyl methacrylate (PMMA). By 
controlling the pore size of the PLGA and PMMA upon the device they could 
effectively control the release rate of CHX. (Lee et al. 2005a).  
 
Delivery of CHX from poly (Є-caprolactone) nanocapsules to artificially 
contaminated porcine skin achieved superior results compared to the CHX in free 
solution (Lboutounne et al. 2002). The nanocapsules encapsulating CHX 
preferentially accumulated into hair follicles, which act as bacteria reservoirs thus 
 
31 
 
ensuring targeted delivery. CHX loaded nanocapsules developed by Lboutounne 
et al. (2002) were later formulated into a hand rub (Nanochlorex®) and tested 
against the resident skin pathogen Staphylococcus epidermidis after 
contamination onto ex vivo porcine skin (Nhung et al. 2007). Sustained 
antimicrobial activity was observed for Nanochlorex® with a statistically increased 
log10 reduction of S. epidermidis. Farkas et al. (2004) utilised a vesicular 
phospholipid gel for the enhanced delivery of CHX. It was determined that 
multilamellar lipid vesicles significantly enhanced the delivery of CHG across 
dialysis membrane in a diffusion cell due to increased dispersity and fluidity.  
 
More recently preparations containing polymeric thermo-sensitive modified 
poly-N-isopropylacrylamides microspheres were investigated for the sustained 
release of CHX base at different skin temperatures (Musial et al. 2012). The 
polymeric system at skin temperature released CHX at around 60-130 minutes 
after application. At a lower temperature the CHX was released and localised 
between 80- 90 minutes.  The system is an example of controlled release however 
a long lag time may impede the delivery and localisation of CHX at the target site 
of the skin.  
 
There are many examples of colloidal CHX delivery systems and the benefits 
of such colloid systems used in topical and transdermal drug delivery include: 
 Targeting  of drugs to a localised infected area 
 Reducing drug degradation rates 
 Improving drug release profile 
 Minimising adverse effects on the skin  
(Nhung et al. 2007) 
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1.6.3 Other strategies employed for enhanced delivery of CHX. 
 
Other penetration enhancers have been used to increase the delivery of 
CHG into the upper skin strata. Eucalyptus oil was shown to enhance the 
penetration of CHG into the deeper layers of the skin (Karpanen et al. 2010). After 
CHG (2% w/v) was dosed along with 50 % (v/v) of eucalyptus oil the concentration 
of CHG within the top 100 µm of the skin after 30 minutes was 
0.398 ± 0.076 µg/mg tissue (SEM) compared to 0.077 ± 0.015 µg/mg tissue (SEM) 
when CHG was dosed alone (Karpanen et al. 2010) and (Karpanen et al. 2008). 
Further, after 2 minutes a higher concentration of CHG was observed within the 
skin after dosing CHG in a eucalyptus oil (10 % v/v) and isopropanol (70 % v/v) 
vehicle (Karpanen et al. 2010). The same authors also compared the topical 
delivery of CHG from aqueous and alcohol vehicles. It was reported that following 
a two minute exposure the concentration of CHG recovered in the top 100 µm of 
the skin was 0.023 ± 0.007 µg/mg tissue (mean ± SEM) and 0.157 ± 0.047 µg/mg 
tissue (mean ± SEM) for CHG (2 % w/v) in a 70 % (v/v) isopropanol vehicle and 
CHG (2 % w/v) in an aqueous solution (Karpanen et al. 2009). At 30 minutes there 
was no statistical difference in the concentration of CHG within the skin after 
application from an aqueous or alcoholic vehicle.  
 
1.7 Nanomaterials used for topical and transdermal drug delivery. 
 
Nanomaterials are increasingly being studied for use as topical and 
transdermal drug delivery systems for improved drug delivery kinetics (Figure 1.5). 
The nanoparticle skin delivery field is in its infancy but has the potential to yield 
fruitful drug delivery systems. Conventional passive skin penetration enhancers 
such as the chemical penetration enhancer azone and dimethylsulfoxide (DMSO) 
 
33 
 
and physical methods such as iontophoresis have not achieved commercial 
success as a result of high cost or biocompatibility problems. Nanomaterials’ 
unique physiochemical properties exerted by their large surface area are 
advantageous for use as a passive topical or transdermal drug delivery platform 
(Bouchemal et al. 2004). Their constituents, for example lipids within liposomes 
and surfactants within niosomes may penetrate the SC and act as a penetration 
enhancer after nanoparticle ruption on the SC surface (Jain, 2012). These 
constituents are known to fluidise the intercellular matrix and enhance drug 
penetration within the skin (Benson, 2005). Further, nanoparticles may act as a 
depot for sustained skin drug delivery or act as a rate limiting barrier deposited 
across the SC surface for controlled release (Jain, 2012). Previously a range of 
nanomaterials have been explored as drug delivery systems for the skin (Figure 
1.5) in an attempt to obtain controlled and targeted drug delivery for enhanced 
therapeutic efficacy.  
 
Nanoemulsions (droplet size between 20-200 nm) are increasingly utilised 
for the topical delivery of drugs due to advantages such as enhanced drug 
solubility, good thermodynamic stability and enhanced skin penetration when 
compared to conventional dosage forms (Sarker, 2005, Shakeel et al. 2007, 
Shakeel et al. 2010 and Sakeena et al. 2010). Nanoemulsions enhanced the flux 
of ketoprofen six fold compared to the control after application to mouse skin in 
vitro (Kim et al. 2008). The authors suggested the permeation enhancement was 
due to the impact of the particle’s size and a contributing factor may be due to the 
incorporation of known penetration enhancers such as oils and surfactants. 
Nanoemulsions also enhanced (between 5 and 15 fold when compared to control) 
the topical delivery of the hydrophilic compound inulin in vitro using hairy mouse 
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skin (Wu et al. 2001). The authors believe the penetration enhancement of inulin 
was due to co-transport of the drug via the follicular transport route (due to water-
in-oil nanoemulsions’ compatibility with sebum) and through surfactant-induced SC 
perturbations. A full review on nanoemulsions was compiled by Shah and co-
workers (2010).  
 
Nanocapsules are lipophilic droplets coated in a polymeric membrane to 
form a vesicular polymeric drug carrier. Nanocapsules have a number of 
advantageous properties for drug delivery; they are biocompatible and 
biodegradable, they can act as a reservoir for sustained drug delivery, the drug is 
encapsulated therefore localised tissue irritation is avoided, high drug loading 
capability and the polymer coating offers protection from drug degradation 
(Couvreur et al. 2006). Poly n-butylcyanoacrylate (PNBCA) nanocapsules with 
encapsulated indomethacin (0.5 % w/v) were applied to excised rat skin in vitro. 
After an 8 h contact time the cumulative concentration of indomethacin that had 
permeated the rat skin after application encapsulated within the PNBCA 
nanocapsules was ~9 times higher than when compared to the control (Miyazaki 
et al. 2003). Further, poly(ε-caprolactone)-nanocapsules were encapsulated with 
sunscreen (Parsol MCX) and were shown to exhibit enhanced photo-protection 
when compared to a standard topical gel (Alvarez-Roman et al. 2001).  
 
 One strategy that has received a great deal of attention over the last three 
decades for enhanced skin delivery of therapeutics is vesicular systems. Vesicles 
aid the penetration of drugs into the SC but also reduce percutaneous absorption 
for enhanced skin delivery of therapeutics by acting as a reservoir within the upper 
skin strata (Lboutounne et al. 2004). Liposomes are microscopic phospholipid 
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bubbles with a lipid bilayer membrane as an outer structure (Torchilin, 2005). 
Liposomes have been utilised for the enhanced topical skin delivery of many 
therapeutic entities (Schreier and Bouwstra, 1994, Mezei and Gulasekharam, 
1980, Tabbakhian et al. 2006, El Maghraby et al. 2008). There are a number of 
proposed mechanisms of action of liposomes including: intact vesicular 
penetration within the SC, a penetration enhancing effect caused by interaction of 
the lipids within the endogenous SC lipids, the adsorption effect and preferential 
accumulation of the liposomes within the transappendageal route (Elsayed et al. 
2007).  
 
More recently, adaptations of the classical liposome have been developed 
using a range of constituent materials within the bilayer including; transfersomes 
(Maghraby et al. 2001), niosomes (Balakrishnan et al. 2009), cubosomes 
(Esposito et al. 2005) and ethosomes (Elsayed et al. 2006). All of the 
aforementioned vesicles resulted in enhanced drug deposition within the upper 
skin strata. Samad and co-workers wrote a comprehensive review on vesicular 
drug delivery for enhanced topical drug delivery (Samad et al. 2007).  
 
Solid lipid nanoparticles (SLNs) have been investigated since the early 
nineties as an alternative to polymeric drug carriers. SLNs offer the advantages of 
being biocompatible and biodegradable, a high surface area, protection of labile 
drugs and they form an occlusive film across the skin surface for enhanced drug 
deposition and skin hydration (Müller et al. 2002 and Mehnert and Mäder, 2001). 
SLNs have been used to act as a topical drug carrier for enhanced deposition 
within the upper skin strata for many compounds including vitamin A (Jenning et 
al. 2000), sunscreen-oxybenzone (Wissing and Müller, 2002) and isotretinoin (Liu 
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et al. 2007). Though SLNs are produced from physiological materials and do not 
require organic solvents, they do suffer from low drug loading and physical 
instability during storage (Mehnert and Mäder, 2001). SLNs may exist as 
alternative colloidal structures such as liposomes, micelles and nanocrystals 
(Guterres et al. 2007). This added complexity of alternative lipid structure 
formation may be a reason for SNPs not being incorporated into a single 
pharmaceutical product on the market (though they have been used in >30 
cosmetic formulations) (Pardeike et al. 2009).  
 
Polymeric nanoparticles (nanospheres, dendrimers, hydrogels etc.) have 
also been investigated for use as topical drug delivery systems through 
encapsulation, adsorption or dispersion within the polymeric chains of the 
nanoparticle (Guterres et al. 2007). Advances in polymer chemistry have allowed 
for the design of novel transdermal and topical drug delivery systems. 
Encapsulation of drugs within a polymeric nanoparticle can modify the 
physiochemical characteristics and may act as a penetration enhancer due to the 
possession of a higher thermodynamic activity when compared to the free solution 
(Naik et al. 2004). 
 
 poly-lactic-co-glycolic acid (PLGA) nanoparticles have been used as a drug 
delivery system for various hair growth treatments using excised human scalp in 
vitro (Tsjimoto et al. 2007). It was found that the encapsulated hair growth drugs 
within the PLGA nanoparticles had an enhanced deposition (2-2.5 fold 
enhancement) within hair follicle when compared to the control. PLGA 
nanoparticles encapsulating drugs have been utilised to enhance the penetration 
of a range of therapeutics within the SC and markedly within the follicular route 
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(Haddadi et al. 2008, Naik et al. 2004 and De Jalón et al. 2001). Further, various 
other block co-polymers have been utilised to encapsulate drugs for skin delivery 
(Rastogi et al. 2009 and Choi et al. 2012).  
 
Polymeric drug delivery systems designed for skin delivery may take many 
different forms. Conventional transdermal patches are typically based on a 
polymeric matrix with the active drug dispersed or dissolved within the matrix 
(Jones, 2004). The ratio and type of polymers used can be manipulated to control 
the partitioning and diffusion of the compound from the patch into and across the 
SC (Arora et al. 2002). Therapeutic polymers are also incorporated to act as an 
anti-nucleant for the prevention of crystallisation of the drug when formulated into 
a super-saturated topical formulation (Pellet et al. 1994 and Raghavan et al. 
2000). Though on a micro-scale, it is worth mentioning the recent development of 
polymeric microneedles that have been utilised for physical skin delivery to 
circumvent the SC (Park et al. 2005, Lee et al. 2012, and Lee et al. 2008). 
Polymeric microneedles have the advantage of being biodegradable, 
biocompatible and cheaper to manufacture than their silicon counterparts (Van der 
Maaden et al. 2012). A comprehensive state of the art review was recently 
published on polymeric microneedles (Ochoa et al. 2012). 
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Figure 1.5 Schematic of commonly used nano-particulate topical and 
transdermal drug delivery systems. 
 
1.8 Introduction to PAMAM dendrimers; the chosen novel strategy for 
enhanced topical drug delivery. 
 
The novel strategy employed to enhance the deposition of a topical 
antiseptic are a type of dendrimer called polyamidoamine (PAMAM) dendrimer 
Figure 1.6). Though PAMAM dendrimers were first synthesised in the mid-eighties 
it was only recently that PAMAM dendrimers were investigated as a novel dendritic 
penetration enhancer used to improve drug delivery kinetics (See section 3.1 for 
detailed discussion). PAMAM dendrimers are highly branched polymeric 
molecules that are composed of multiple branched monomers that derive from a 
central core. A dendrimer can be thought of as three sections: a focal core, 
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internal branches of repeating units and peripheral functional groups. The number 
of branch points emanating from the core defines the generation of the 
dendrimers, e.g. G1, G2, G3, etc. (Lee et al. 2005b) as observed in Figure 1.7.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Chemical structure of a generation 3 polyamidoamine (PAMAM) 
dendrimer. An ethylenediamine core with repeating monomers of 
ethylenediamine and methyl acrylate, terminating in amine groups. 
 
The physicochemical properties of PAMAM dendrimers that make them unique are 
listed below:- 
 Uniform molecular weight with a narrow molecular weight distribution – i.e. 
they are monodispersed. 
 They have predictable three-dimensional architecture. 
 The diameter and generation number increases systematically. 
 The step-by-step controlled synthesis allows for site selective 
functionalities. 
 In high generation dendrimers (> G4) isolated interior pockets allow the 
dendrimers to host small guest molecules. 
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 The solubility of dendrimers can be controlled by the peripheral functional 
groups, e.g. by adding hydrophilic functional groups the water solubility can 
be increased. 
(Jang et al. 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Generation 2, 4 and 6 PAMAM dendrimers observed as molecular 
dynamic simulations (Adapted from Maiti et al. 2004). 
 
 PAMAM dendrimers have been utilised within this investigation and they 
are the most studied dendrimer within the literature. A search for the term ‘PAMAM 
dendrimer’ on ScienceDirect retrieved 2,616 publications (March 2013). PAMAM 
dendrimers can be commercially purchased from Dendritech in the US as they are 
now manufactured on a kilogram scale. PAMAM dendrimers can also be 
synthesised within the laboratory using a divergent method developed by Donald 
Tomalia that was published in 1985 (Tomalia et al. 1985).The divergent method for 
PAMAM dendrimer synthesis (aka Starburst® dendrimers) was first developed by 
D. Tomalia in 1978 in the Dow chemical laboratories. It is a synthetic pathway of 
iterative alkylation and amidation reactions; each resulting in one new generation 
Generation 2 Generation 4 Generation 6 
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as illustrated in Figure 1.8. PAMAM dendrimers contain an initiator core that is 
typically a molecule of ammonia or ethylenediamine.  
 
The PAMAM dendrimers used within this project have ethylenediamine 
(1,2-diaminoethane) as a core/monomer and methyl acrylate as a monomer. The 
first reaction for PAMAM dendrimer synthesis is a Michael addition between the 
primary amine groups of the ethylenediamine and the methyl acrylate which 
results in a half generation carboxyl group terminated PAMAM dendrimer. 
Amidation of a half generation carboxyl terminated PAMAM dendrimer with excess 
ethylenediamine results in an amine terminated full generation PAMAM dendrimer 
(Figure 1.8). These two reactions are then repeated to form half and full 
generation PAMAM dendrimers up to generation 12, under optimal synthetic 
conditions (Tomalia et al. 1993).  
 
 
Figure 1.8. Schematic of the synthetic steps for the divergent approach in 
synthesising PAMAM dendrimers. An iterative reaction of alkylation and 
amidation forms a full generation amine terminated PAMAM dendrimer. Schematic 
taken from Fréchet and Tomalia (2001).  
 
0 
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The physiochemical characteristics of PAMAM dendrimers can be found in 
Table 1.2. The number of surface groups, in this case primary amine groups, 
doubles and the molecular weight increases exponentially with each iterative step 
of alkylation and amidation and thus an increase in the generation (Lothian-
Tomalia et al. 1997). The PAMAM dendrimers used within this thesis are 
generations 2-5 with diameters ranging from 2.6-5.7 nm. The most commonly 
used PAMAM dendrimer within this thesis is generation 3 that is 3.6 nm in 
diameter (Table 1.2). For scale this is approximately equivalent to the diameter of 
insulin and around half the diameter of a lipid bilayer (Esfand and Tomalia, 2001). 
 
Table 1.2. Theoretical physiochemical characteristics of PAMAM dendrimers 
from generation 0-10. Table taken from Fréchet and Tomalia, 2001. 
 
 
The in vitro toxicity of PAMAM dendrimers has been investigated in a 
number of studies and the cytotoxicity appears to be dependent on the 
concentration and generation (molecular weight and number of surface groups) of 
the PAMAM dendrimer (Mukherjee and Byrne, 2012). It has been established that 
cationic dendrimers are more toxic than their anionic counterparts (Jevprasephant 
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et al. 2003 and Duncan and Izzo, 2005). There is however a discrepancy between 
the reported toxic concentrations of PAMAM dendrimers. Full generation cationic 
PAMAM dendrimers above generation 1 were shown to be haemolytic at a 
concentration of 1 mg/mL by Malik and co-workers (2000). Also the cytotoxicity 
was measured as the IC50 concentration (mg/mL) after a 72 h MTT ((3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay using  B16F10 cells 
(mouse melanoma cells). The IC50 concentration for G1, G2, G3 and G4-PAMAM-
NH2 was calculated as >2, >2, 0.05 and 0.05 mg/mL respectively. The lower 
generation PAMAM dendrimers did not incite cytotoxicity up to a concentration of 2 
mg/mL and this was also observed for the half generation carboxyl terminated 
PAMAM dendrimers (Malik et al. 2000). A more recent in vitro study on rat red 
blood cell lysis using G4-PAMAM-NH2 dendrimer showed no effects of haemolysis 
up to a concentration of 10 µM L-1 over 24 h (Labieniec et al. 2008).  When the 
toxicity of PAMAM dendrimers was investigated using a lactate dehydrogenase 
assay on caco-2 cell (human intestinal adenocarcinoma) monolayers G2-PAMAM-
NH2 and G3-PAMAM-NH2 dendrimers exhibited toxicity at a concentration of >10 
and >0.1 mM respectively (Elsayed et al. 2002). 
 
 More recently, G4, G5 and G6-PAMAM-NH2 dendrimers were tested for 
induction of cytotoxic responses as a product of the formation of reactive oxygen 
species (ROS) after endocytosis (Mukherjee and Byrne, 2012). It was found that 
these higher generation PAMAM dendrimers incited toxicity at a concentration of 
1 mM due to the formation of ROS resulting in mitochondrial membrane disruption 
(Mukherjee and Byrne, 2012). Calabretta et al. (2007) found no cytotoxicity for G5-
PAMAM-NH2 up to a concentration of 1 µg/mL against human corneal epithelial 
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cells (though below this concentration they exhibit antimicrobial properties against 
P. aeruginosa) though at the highest tested concentration 10 µg/mL 25 % of 
HCECs survived that was comparable to the positive control benzalkonium 
chloride.  
 
Few studies have been conducted in vivo on PAMAM dendrimer toxicology, 
though when PAMAM dendrimers up to Generation 5 (G7-PAMAM-NH2 dendrimer 
potentially induced problems as 1 in 5 mice died in that treatment group) were 
injected into mice at a dose of 10 mg/kg-1 they appeared to be non-toxic (Bos and 
Heegaard, 2004, Roberts et al. 1996 and Bourne et al. 2000). Chauhan et al. 
(2010) and colleagues found G4-PAMAM-NH2 and G4-PAMAM-OH dendrimers to 
be non-toxic in general after an in vivo study in mice at a low, medium and high 
dosages. It was found that at the high concentration treatment group of 
G4-PAMAM-NH2 dendrimer some toxicity was observed (i.e. declined glucose 
levels) though this was seen to recover after a 15 day recovery time.  A full review 
on the toxicity of dendrimers was recently compiled by Jain and co-workers (Jain 
et al. 2010).  
 
With regards to the PAMAM dendrimer toxicity after application to the skin 
surface, it is expected to be low as the PAMAM dendrimers’ penetration across or 
within the skin is low (for a detailed discussion on the potential for PAMAM 
dendrimers to penetrate the skin, see section 4.1) (Sun et al. 2012). As outlined in 
Sections 1.1 and 1.2 the SC is a formidable barrier composed of anucleate 
corneocytes and a dense intercellular lipid network that prevents the ingress of 
large and highly charged macromolecules such as PAMAM dendrimers. Bos and 
Meinardi (2001) stated that for significant transdermal drug delivery a permeating 
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compound must be below 500 Da in order to traverse the SC; a G3-PAMAM-NH2 
dendrimer is ~6,909 Da.  The toxicity of PAMAM dendrimers in vivo has not been 
realised and it should also be considered that if a commercially available and 
widely accepted ethanolic hand gel (60-80 % ethanol v/v) was applied to a cell 
line, low cell viability would be the result and toxicity inferred.  
 
Due to their unique physiochemical characteristics dendrimers have been 
investigated for use in a wide range of biomedical applications. These include the 
use as an improved magnetic resonance imaging (MRI) contrast agent through 
covalent conjugation to, for example Gd(III)-diethylenetriamine (GD(III)-DTPA) or 
GD(III)-tetracarboxymethyl-1,4,7,10-tetraazacyclododecane (GD(III)-DOTA) 
(Venditto et al. 2005) and (Wiener et al. 2005). After conjugation of an MRI 
contrast agent to a PAMAM dendrimer it was reported to result in increased blood 
circulation times that allows for an extended imaging time frame. Another 
advantage of the PAMAM conjugated MRI contrast agent was greater contrast and 
enhanced images as PAMAM dendrimers possess high relaxivities (Wiener et al. 
1996). PAMAM dendrimers have also found use as effective DNA transfecting 
agents through electrostatic complexation of the primary amine groups on the 
dendrimer surface and the negatively charged phosphate groups of the nucleic 
acids (Bielinska et al. 1999 and Eichman et al. 2000). PAMAM dendrimers have 
been used frequently as drug delivery agents and less commonly as biocides. A 
detailed discussion on dendrimer-biocides can be found within the introduction in 
Chapter 2. Further, the efficacy and suitability of PAMAM dendrimers as a topical 
drug delivery system has been discussed in further detail within the introduction to 
Chapter 3. 
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1.8.1 Aims and objectives of the study. 
 
The prevalence of healthcare-acquired infections, in particular, multi-drug 
resistant strains has given rise to considerable concern and the issue is 
persistently highlighted by the media. There is a clear need for innovation in 
infection control to enhance and increase the current armoury of anti-infective 
agents (Davies, 2013). The aim of this project is to develop a novel topical 
antimicrobial formulation that utilises dendritic architectures as a platform to 
enhance the permeation of anti-infective agents into the skin. PAMAM dendrimers 
have previously been shown to be antimicrobial (Calabretta et al. 2007 and Wang 
et al. 2010) however their antimicrobial efficacy against opportunistic skin 
pathogens and their mechanism of action have yet to be fully elucidated.  
 
An objective of this study is to comprehensively assess their antimicrobial 
efficacy and mechanism of action as it would be of great advantage for a topical 
drug delivery platform to also possess antimicrobial properties against skin 
pathogens. Central to the formulation is the PAMAM dendrimer and this thesis will 
examine as to whether a PAMAM dendrimer skin pre-treatment and co-treatment 
increases the distribution and localisation of the model drug, CHX within the upper 
skin strata. Further, PAMAM dendrimers’ interactions with CHG and the skin will 
also be investigated in an attempt to elucidate any enhancement effects. 
 
The topical deposition of the CHG will be chemically mapped using a novel 
time-of-flight secondary ion mass spectrometry (ToF-SIMS) method. To improve 
the bioavailability of topically-applied formulations, the permeation pathway and 
distribution of a drug and its excipients throughout the skin strata must be 
understood. The method will reveal localisation of CHG to specific histological skin 
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compartments and to visualise any permeation enhancement effects elicited by 
the application of PAMAM dendrimers.  
 
The final objective of this thesis is to develop a stable formulation that 
contains a clinically relevant concentration of CHG and a dendritic permeation 
enhancer. The formulation will be assessed to ensure increased antimicrobial 
efficacy against skin pathogens and to determine whether addition of the PAMAM 
dendrimer enhances the deposition of CHG within the upper skin strata.  
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2.0 A comprehensive study into the antimicrobial 
efficacy and mechanism of action of PAMAM 
dendrimers against opportunistic pathogens. 
 
2.1 Introduction 
  
2.1.1 Advantages of antimicrobial dendrimers 
An increasing number of bacteria are evolving into antibiotic-resistant strains 
that are threatening our ability to treat infectious diseases within a primary, secondary 
and community care setting (Rice, 2009). This growing trend of resistance has 
depleted the armoury of available effective antibiotics. This is compounded by the fact 
that the development of novel antibiotics offers the second lowest return on 
investments (Walsh, 2000). The World Health Organisation (WHO) has declared 
antibiotic resistance one of the three greatest threats to human health (WHO, 2001). 
In March 2013, the chief medical officer (CMO) for England released a second 
volume of her annual report into the state of public health in England, in which she 
focused specifically on the burden of infections and antimicrobial resistance (Davies, 
2013(a)). The CMO stated the burden of infectious diseases was estimated to cost 
approximately £30 billion each year to the economy (Davies, 2012 (a)). In 2011, 
infectious diseases had accounted for 7 % of all deaths and accounted for 8 % of all 
hospital bed use in England (Davies, 2013 (b)).The same report showed that 
Escherichia coli accounted for around 36 % of all bloodstream infections (bacteraemia) 
and there was increasing emergence of multi-drug resistant strains. In cases of patient 
mortality, multi-drug resistant E. coli accounted for 30 % whereas susceptible E. coli 
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strains accounted for 15 % (Davies, 2013 (b)). Further, the report stated that many of 
the infections arise from the patient’s own microbial flora with the most prominent 
pathogen being Staphylococcus aureus. S. aureus typically resides within the anterior 
nares and perineum (Davis et al. 2004) and those patients colonised on admission are 
at a greater risk of developing surgical site incision infections. It has also been shown 
to spread epidemically between patients and can be transferred from staff to patients 
(von Eiff et al.,2001). 
The CMO calls for prevention strategies to stop colonisation from developing 
into infection and one of the recommendations from the report emphasises the need 
for further preventative strategies and that action is required at a national and local 
level to combat antibiotic resistance (Davies, 2013 (b)). With increasing resistance and 
little to combat complex infections, the availability of modern medical advancements 
such as major surgery, dialysis, organ transplantation and chemotherapy are in 
jeopardy (Cars et al. 2008). 
To prevent a return to the pre-antibiotic era, design and delivery of antimicrobial 
drugs with improved efficacy and avoidance of drug resistance are of paramount 
importance. Innovative strategies as well as more efficient use of current antimicrobial 
compounds are mandatory. Efforts in synthetic chemistry have focussed on identifying 
orally bioavailable small-drug molecules utilising high throughput screening methods 
(McCarthy, 2005). This effort has not yet translated into the availability of novel 
antibiotics in the clinic. Biological targets, such as bacterial cell membranes, consist of 
macromolecules that rely on polyvalent interactions in their binding (Mammen et al. 
1998). Most biological targets are of a nano-scale (1-100 nm) therefore polyvalent 
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macromolecules of a nano-size may have increased biological efficacy when 
compared to small-molecule drugs due to a match in scale and multivalent binding 
(McCarthy, 2005). Nanoparticles offer unique advantages in antimicrobial therapy such 
as a reduction in acute toxicity and avoidance of resistance via alternate mechanisms 
of action (Weir et al. 2008). Nanoparticles (silver) within a 1-10 nm size range (G3-
PAMAM-NH2 having a diameter of 3.6 nm) were shown to have a greater direct 
interaction with bacteria, suggesting a size dependency (Morones et al.2005). 
Polyamidoamine (PAMAM) dendrimers have become the most widely investigated 
dendrimers for a range of biomedical applications (Svenson, 2009, Esfand and 
Tomalia, 2001 and Sajja et al. 2009).  
Due to the highly branched and globular nature of dendrimers, they possess 
unique properties enabling them to act as a multivalent biocide or a nano-platform for 
antimicrobial drug delivery (Meyers et al.,2008). The uniform branching of dendrimers 
provides a large surface area to volume ratio enabling high reactivity with micro-
organisms in vivo (Zhang et al.,2010). The highly localized and dense functional 
groups on the dendrimer’s surface can be tailored for antimicrobial efficacy or for the 
conjugation of targeting ligands to a variety of micro-organisms’ receptors (Tomalia et 
al.,1990 and Gillies and Fréchet, 2005). 
The strategies discussed in this chapter include the use of dendrimers as 
delivery platforms for conventional antibacterial drugs, (Cheng et al. 2007(a) and 
Kumar et al. 2006), competitive binding to bacteria and toxins to inhibit bacterial 
adhesion (Joosten et al. 2004) and biocidal dendrimers without complexation or 
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conjugation to conventional biocides (Wang et al. 2010, Calabretta et al. 2007 and 
Lopez et al. 2009). 
2.1.2 Glycodendrimers 
 
Glycodendrimers have been studied as to whether they prevent host-pathogen 
adhesion and thus toxin transport into the host cell. Glycodendrimers typically have 
saccharide residues on the surface though some may contain a sugar unit as a focal 
core with emanating carbohydrate branches (Cloninger, 2002). The multivalent nature 
of glycodendrimers has been exploited to improve their antimicrobial activity as the 
bacteria and their toxins can preferentially bind to the sugar group pendants on the 
surface of the glycodendrimer as opposed to the host cell in vitro (Mintzer et al. 2011).  
Polypropylene imine (PPI) and PAMAM dendrimers have been modified by the 
covalent conjugation of oligosaccharides (phenylisothiocyanate derivatised (PITC) 
galb1-3galNAcb1-4[sialic acida2-3]-galb1-4glc residues) to the amine focal core. 
These were then shown in vitro to inhibit the binding of the heat labile enterotoxin of E. 
coli  and require ~ 1000-fold lower concentration than that of the free oligosaccharide 
to achieve the same binding efficacy (Thompson and Schengrund, 1997). The same 
group also demonstrated that a PPI based glycodendrimer could beused to inhibit the 
binding of both cholera toxins and heat labile enterotoxins to a murine fibroblast cell 
line (Thompson and Schengrund, 1998).  Since then, PPI and PAMAM dendrimers 
have been modified with various oligosaccharides to inhibit the binding of a range of 
pathogenic organisms or toxins (Joosten et al. 2004, Salminen et al. 2007 and Woller 
et al.  2003). 
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2.1.3Dendrimers as biocides andantimicrobial carriers 
 
Dendrimers are emerging as novel topical antimicrobial macromolecules 
(Svenson and Tomalia, 2005). PAMAM dendrimers contain hydrophobic interior voids 
in which small non-polar drug molecules maybe encapsulated (Cheng et al. 2007(b)). 
PAMAM dendrimers also have a high density of surface functionalities allowing for the 
conjugation or complexation of antimicrobial agents (Patri et al. 2002). The use of 
dendrimers as antimicrobial drug delivery platforms offers a number of advantages 
over conventional antimicrobial drugs including increased bioavailability, decreased 
adverse side effects and increased deposition of the drug at target sites (Gardiner et 
al. 2008). Due to the hydrophilic exterior, PAMAM dendrimers can increase the 
solubility of hydrophobic drugs and this increase in solubility was shown to result in an 
enhanced antimicrobial effect in vitro when compared to the drug in free solution (Ma 
et al. 2007and Winnicka et al. 2011).  
Silver ions have antimicrobial properties and is commonly utilised in the topical 
treatment of infected wounds. Silver ion complexes of PAMAM dendrimers and silver-
PAMAM composites were shown to be effective antimicrobial compounds against, S. 
aureus, E. coli and Pseudomonas aeruginosa in vitro as shown by Balogh et al. 
(2001). Using a disc diffusion assay, they demonstrated that both compounds 
displayed antimicrobial activity that was either comparable to, or enhanced, when 
compared to standard silver nitrate solutions. 
The aqueous solubility of sulfamethoxazole (SMZ), an antimicrobial 
sulfonamide, was increased, in vitro, when PAMAM dendrimers were used as a carrier 
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system. An enhancement in antimicrobial activity was observed against E. coli. with a 
four or eight-fold increase in the anti-bacterial activity of SMZ in a dendrimer solution 
compared to pure SMZ dissolved in dimethylsulfoxide (DMSO) or a 0.01M NaOH 
solution (Ma et al. 2007). 
PAMAM dendrimers have been used to increase the aqueous solubility of both 
nadifloxacin and prulifloxacin however the increased solubility only resulted in an 
increase in the antimicrobial efficacy of prulifloxacin, as shown by Cheng et al. 
(2007a). The authors proposed the enhanced antibacterial efficacy of pruifloxacin was 
due to the PAMAM dendrimer’s disruption of the bacterial cell membrane allowing the 
quinolone entry to the bacterial cytoplasm and as a result causing damage to 
DNA.PAMAM dendrimers have also been investigated to determine whether they 
increased solubility of the antimicrobial compound, triclosan. PAMAM dendrimer 
generation 3 (PAMAM G-3) and phenylalanine conjugated PAMAM G-3 dendrimer 
both failed to enhance the solubility of the antimicrobial compound (Gardiner et al. 
2008). These studies suggest that PAMAM dendrimers may increase the solubility of 
antimicrobial drugs but that this does not directly translate into an increased efficacy in 
the case of nadifloxacin. In the case of triclosan the PAMAM dendrimer did not 
enhance the solubility therefore this effect may be dependent on the physiochemical 
interactions. 
One strategy for producing dendrimer biocides is to synthesise them with 
antimicrobial monomers or tailor the dendrimer to terminate in antimicrobial surface 
groups.A single antimicrobial dendrimer offers the benefits of desirable cost of 
manufacture and an acceptable toxicity and biocompatibility profile (McCarthy et al. 
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2005). A PPI dendrimer was functionalized with dimethyl dodecyl ammonium groups 
for potent antimicrobial properties(Chen et al. 1999). The quaternary ammonium 
functionalised dendrimer exhibited an EC50 of 12 µg/mL against E. coli, whilst its small 
molecule counterpart displayed a MIC50 of 2000 µg/mL. The quaternary ammonium 
functionalised dendrimer was also found to display antimicrobial activity against 
S. aureus at 1 µg/mL for inhibition and 10 µg/mL for bactericidal effect. 
Chen et al.(2000) used bioluminescence studies to determine the structure-
activity effects of the functionalised dendrimers and they discovered that the 
generation number (G) affected the antimicrobial activity, in the decreasing potency of 
G5 > G4 > G1 > G2 > G3. The increased potency of the higher generations was 
attributed to the dense surface functionalisation with quaternary amines, but there was 
a concurrent decrease in permeability into the bacterial cell probably owing to the 
molecular weight and diameter of the dendrimers. G5 was found to achieve the 
highest antimicrobial effect, with 64 quaternary amines at its surface and with a 
molecular weight of 27578 Da. G1 was the third most potent, possessing only 4 
surface quaternary amines and having a molecular weight of 1593 Da. This suggests 
that the number of surface groups and molecular weight influences the biocidal activity 
of dendrimers. When the antimicrobial activity was compared to that of a 
hyperbranched linear polymer with the same number of functionalities, the dendrimer 
exhibited a higher antimicrobial activity (Chen et al. 2000).Yang and Lopina (2003) 
designed the PAMAM to be an antimicrobial agent itself rather than a carrier. The 
group covalently conjugated penicillin V to G-2.5- and G-3-PEG-PAMAM dendrimers 
via amide and ester linkages. The results of the study showed that the ester-linked 
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conjugates had antimicrobial activity against S. aureus but no synergistic or enhanced 
antimicrobial effect was observed when compared to non-conjugated penicillin V 
(Yang and Lopina, 2003). 
2.1.4 Antimicrobial properties of native PAMAM dendrimers 
PAMAM dendrimers are the most studied class of dendrimers, being the first 
dendrimer structures to be synthesized (Tomalia et al. 1985). Despite extensive study 
in biomedical applications such as drug delivery and imaging, PAMAM dendrimers’ 
antimicrobial effects without conjugation or complexation to a conventional 
antimicrobial compound have only recently been discovered. Calabretta and 
co-workers were the first to publish a study on unmodified PAMAM dendrimers’ 
antimicrobial properties against ocular pathogens and the authors found that the 
amine terminated G-5 PAMAM dendrimer was extremely toxic to P.aeruginosa with 
anEC50 of 1.5 ± 0.1 µg/mL and less so for S. aureus, 20.8 ± 3.4 µg/mL. It was 
demonstrated that a partial coating of the amine groups with 
poly(ethyleneglycol)(PEG) reduced the toxicity of the G5-PAMAM against human 
corneal epithelial cells whilst retaining high toxicity against P. aeruginosa with a MIC50 
of 0.9 ± 0.1 µg/mL. PEGylation of the G-5 PAMAM resulted in a further decrease in 
efficacy against the Gram positive S. aureus (Calabretta et al. 2007). 
The same group also published further data comparing the antimicrobial 
properties of G-3 PAMAM-NH2 and G-5 PAMAM-NH2 and reported that even though 
G-5 PAMAM-NH2 has a greater localization of amines at its surface compared to G-3 
PAMAM, the potency was not increased. A microdilution broth assay measuring the 
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absorbance to calculate the MIC50 of G-3 PAMAM and G-5 PAMAM against S. aureus 
was found to be 12.5 µg/mL for both generations. The equipotent result is surprising 
as G-5 PAMAM has 96 more amine groups at its surface, theoretically.  Again the 
authors found that PEGylation of G-3 PAMAM decreased the potency against the 
Gram negative P. aeruginosa and more markedly against Gram positive S. aureus. 
This is likely due to the PEG chains shielding the protons of the amines therefore 
reducing the cationic charge and thus limiting the antimicrobial effect (Lopez et al. 
2009).  
An in vitro and in vivo investigation of PAMAM dendrimers was conducted by 
Wang and co-workers (Wang et al. 2010). G-4 PAMAM-OH, G-4 PAMAM-NH2, and G-
3.5 PAMAM-COOH were challenged against E. coli to determine the MIC50 using the 
method outlined in Lopez et al. (2009). It was found that the in vitro MIC50for G-4 
PAMAM-OH, G-4 PAMAM-NH2, and G-3.5 PAMAM-COOH was 5.4 mg/mL, 22.0 
mg/mL and 3.8 µg/mL, respectively. The study investigated the effect of the PAMAM 
dendrimers on the morphology of E. coli and the effects on the cell membrane 
including the inner and outer membrane using scanning electron microscopy (SEM). 
Whilst the preparation process for SEM may induce artifacts, the PAMAM treated 
bacteria were compared to untreated bacteria that had undergone the same 
preparative process. It was shown that G-4 PAMAM-NH2 and G-3.5 PAMAM-COOH 
caused inner and outer membrane damage leading to lysis of the E. coli, whilst G-4 
PAMAM-OH caused permeabilisation of the inner and outer membrane. Further, the in 
vivo study showed that when G-4 PAMAM-OH was applied to the cervix of a guinea 
pig, the intra-amniotic infection caused by contamination with E. coli was inhibited. The 
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amniotic fluid collected from different gestational sacs of infected guinea pigs post G-4 
PAMAM-OH treatment failed to culture E. coli due to the antimicrobial effects of the 
PAMAM in vivo (Wang et al. 2010). It has been postulated that PAMAM dendrimers 
may act like antimicrobial peptides (AMPs) in that they disrupt the cell membranes 
leading to cell lysis (Calabretta et al. 2007). The reduced activity against Gram positive 
bacteria may be due to the different membrane composition as Gram positive bacteria 
have a thick peptidoglycan cell wall and no outer-membrane compared to Gram 
negative bacteria that have a phospholipid bilayer outer membrane. The studies 
conducted within this chapter also confirm this hypothesis.  
Whilst there have been many studies investigating dendrimers as carriers of 
antimicrobial compounds or covalently conjugated antibiotics to a dendrimer, there are 
comparatively few studies that have investigated the antimicrobial effects and the 
mechanism of action of unmodified PAMAM dendrimers. The aforementioned studies 
(Wang et al. 2010, Calabretta et al. 2007, and Lopez et al. 2009), mainly focused on 
Gram negative bacteria and all selected to test only one or two PAMAM generations. 
The studies have also used different methods for determining the IC50 and none have 
used the antimicrobial susceptibility standard method or media. By utilising a 
standardised method such as the clinical and laboratory standards institute (CLSI) 
M162standard (Rennie, 2001),comparisons can be made between inter and intra 
laboratory experiments when calculating antimicrobial susceptibilities. For example, 
media deficient in magnesium or calcium cations may result in a much lower IC50 that 
is an underestimate of the bacteria count as bacteria require divalent cations for 
membrane stabilization (Reller et al. 1974 and Zimelis and Jackson, 1973). There is a 
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knowledge gap with regards to the antimicrobial efficacy and mode of action of a range 
of PAMAM generations. To determine whether the antimicrobial efficacy is indeed 
generation and thus size and charge related, a comprehensive study is required. 
There have also been limited studies into challenging the PAMAM dendrimers against 
Gram positive bacteria such as S. aureus and Staphylococcus epidermidis which are 
known skin pathogens.  
2.1.5 Aims and objectives 
The aim was to fully investigate a range of PAMAM dendrimer generations 
including amine and carboxyl terminated dendrimers against Gram positive and Gram 
negative skin pathogens. The study was designed to illustrate any differences in 
antimicrobial potency for different generations and thus differences in molecular 
weights and surface charges. The investigation into the PAMAM dendrimers’ 
antimicrobial properties were achieved by using an adapted microdilution broth test 
with a viable count assay modified from Calabretta et al. (2007). Morphological 
changes to the cell membrane and cell wall due to the PAMAM dendrimers’ interaction 
was observed using SEM. A cell membrane integrity study was conducted for a range 
of skin pathogens. An inner membrane permeabilisation study was also employed to 
determine generation and concentration effects on the PAMAM dendrimers’ 
membrane disruption potential. By characterising the dendrimers’ affect against skin 
pathogens it is hoped that ultimately they can be formulated into a topical antimicrobial 
drug delivery system. 
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2.2 Materials and methods 
2.2.1 Microdilution broth with viable count assay to determine inhibitory 
concentration (IC50) 
Bacterial culture grade petri dishes, universals and pipette tips were all 
purchased from Startstedt (Leicester, UK). Bacterial growth medium, Mueller-Hinton 
agar (MHA) and Mueller-Hinton broth (MHB) were obtained from Oxoid (Basingstoke, 
UK). The bacterial media MHA/MHB is a standardised growth media used for 
antimicrobial susceptibility testing. The cation content (Mg2+ and Ca2+) was adjusted in 
line with recommendations from the CLSI (Rennie, 2001). All salts used in diluents or 
media were reagent grade and purchased from Fisher Scientific (Loughborough, UK).  
 S. aureus (ATCC 11832) and E. coli (ATCC 8277) were plated out on 
respective cation adjusted MHA using a streak plate method to ensure growth of single 
colonies. The inoculated MHA plates were inverted and incubated at 37°C ± 1°C for 
18-24 hours in aerobic conditions. After incubation, 3-4 single colonies were swabbed 
with a sterile loop and used to inoculate 10 ml of cation adjusted MHB which was then 
incubated at 37°C ± 1°C for 18 hours. The dense overnight inoculum was then diluted 
to an absorbance of 0.140 using a UV-Vis spectrophotometer (Hitachi, U1-900, 
Berkshire, UK) to achieve an inoculum density of ~107 cells/mL. The bacterial cell 
density at an optical density of 0.140 was confirmed by diluting the bacteria and 
counting the cells using a haemocytometer. The inoculum was then further diluted in 
cation adjusted MHB to achieve a test inoculum of 1x105 cells/mL.  
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 PAMAM dendrimers of various generations (G2-G5) purchased from 
Sigma Aldrich (Dorset, UK) in varying concentrations in methanol were prepared at 
concentrations ranging from 1-500 µg/mL in ultrapure sterile water. After dilution of the 
stock in ultrapure sterile water the methanol content of the highest concentration of 
PAMAM tested was 0.125 % (v/v).  To ensure the low concentrations of methanol 
present did not inhibit the bacteria a range of methanol concentrations higher than 
those used within this assay was analysed for antimicrobial effect (data not shown). 
The results showed that a concentration of up to 30 % methanol (v/v) in sterile 
ultrapure water did not inhibit bacteria. Each PAMAM dendrimer concentration was 
tested in triplicate and 50 µl of each solution was plated onto a sterile 96-well plate. 
50 µl of the test bacteria inoculum was added to each well excluding 3 wells with 
cation adjusted MHB and sterile water only as a sterility control. The inoculum and 
PAMAM test solution of each well were then agitated 5 times with a pipette to mix 
thoroughly. A growth control was tested in parallel without the addition of PAMAM 
dendrimer and a positive control was included of gentamicin at 1 mg/mL. The 96-well 
plate was then incubated at 37°C ± 1°C for 2 hours and shaken at 200 rpm.  
 After a 2 hour incubation period, each well (excluding sterility control) was 
serially diluted 1:10 in cation adjusted MHB to achieve a range of dilutions down to 
1:100,000. Each well was further agitated using a sterile pipette tip and 50 µL of each 
dilution was plated onto a petri dish using the pour plate method with the addition of 25 
mL of molten cation adjusted MHA at ~45°C. The plates were then inverted and 
incubated for 18-24 h at 37°C ± 1°C in aerobic conditions. Post incubation, bacterial 
colonies on each plate were manually counted using a click counter. The dilutions 
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where 30-300 colony forming units (CFUs) had grown for each growth control or 
PAMAM test concentration were selected. Each test concentration was tested in 
triplicate and the inhibition percentage was calculated using Equation 2.1. The data 
was then plotted as a graph of log (inhibitor) versus normalized response to determine 
the IC50 (Equation 2.2) using GraphPad Prism
® version 5 (San Diego, USA). 
 
                              
             
                    
       
Equation 2.1 Inhibition percentage calculation 
 
  
   
                              
 
Equation 2.2 Calculation of IC50concentration 
 The log (dose) response curve follows a sigmoidal curve and the data was 
normalized to the growth control as 100 %. The normalized model forces the curve 
from 0 % to 100 %. This is ideal for the calculation of the IC50 i.e. the concentration at 
50 % growth inhibition. This model also does not assume a standard hill slope of 1.0 
but fits the hill slope from the data therefore it is a variable slope model that is ideal 
when there are many data points. The broth microdilution assays to calculate the IC50 
concentrations were ran as n=9 therefore this model was ideal. 
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2.2.2 Membrane integrity study 
S. aureus (ATCC 11832),S. epidermidis (ATCC 12228) E. coli (ATCC 8277) 
were plated out on tryptone soya agar (TSA) plates using a streak plate method to 
ensure growth of single colonies. The inoculated TSA plates were inverted and 
incubated at 37°C ± 1°C for 18-24 hours in aerobic conditions. After the incubation 
period 2-3 single colonies were removed using a sterile loop and used to inoculate 
tryptone soya broth (TSB). The inoculated TSB was then incubated for 18 h at 37°C 
± 1°C. Post incubation period the inoculated TSB was then centrifuged at 1000 x g for 
10 mins to harvest the bacterial cells. The pellet was resuspended in1x phosphate-
buffered saline (PBS) (pH 7.4). This was centrifuged (as above) and the supernatant 
discarded. The pellet was washed and resuspended in PBS and the absorbance was 
adjusted to 0.7 at 420 nm to dilute the cells to a final test suspension. A 3 mL aliquot of 
the final bacterial inoculum was added to a 3mL aliquot of the PAMAM dendrimer 
solution at a concentration of 10 x the calculated IC50 for each respective PAMAM 
dendrimer generation. The IC50 for PAMAM G=3 was calculated as 15.25µg/mL and 
this concentration was used to determine whether the PAMAM dendrimer could incite 
membrane damage. 
At different time points (20, 40, 60, and 120 min) a 1.5 mL aliquot of the sample 
was removed and immediately syringe filtered using a 0.22 µm syringe filter (Millipore 
MCE sterile 33 mm filter, Watford, UK). Filtration removed the bacteria leaving a 
particulate free supernatant to be analysed for the release of materials absorbing at 
260 nm that was assessed with a UV spectrometer (Hitachi, U1-900, Berkshire, UK). 
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The absorbance at 260 nm was plotted against each time point using GraphPad 
Prism® version 5 (San Diego, USA). 
2.2.3 Inner membrane permeabilisation assay 
Inner membrane permeabilisation was determined by the release of 
cytoplasmic β-galactosidase from E. coli into the culture medium. E. coli was cultured, 
harvested, and washed (as outlined previously) but re-suspended in 0.5 % NaCl as 
opposed to PBS (pH 7.4). E. coli was re-suspended at an absorbance of 0.6 at 420 nm 
and 100 µl of the test inoculum was transferred into each well of a 96-well plate. To 
each well 100 µl of PAMAM dendrimer (generation 2, 3, 3.5, 4 and 5 at concentrations 
of 0.1, 1, 5, 10, 25 and 50 µg/mL were added. Also 10 µl of a 30 mM ortho-nitrophenyl-
β-galactoside (ONPG) (Sigma - Dorset, UK) solution was added to each well. A blank 
of E. coli with ONPG without PAMAM dendrimer was used as a negative control and a 
vehicle control was also run in parallel.  
The production of O-nitrophenol was measured every 2 minutes for 12 minutes 
by monitoring the absorbance at 420 nm in a microplate reader (Biotek, Northstar, 
Bedfordshire, UK). The optimal time points and duration were determined by a 
preliminary assay. The study was repeated 3 times independently and the mean result 
including standard deviation of absorbance at 420nm was plotted against the different 
time points using GraphPad Prism® version 5 (San Diego, USA). Figure 2.1 illustrates 
the hydrolysis of ONPG by β-galactosidase found within the E. coli cytoplasm to form 
ortho-nitrophenol once the inner membrane has been permeabilised. 
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Figure 2.1. A reaction schematic showing the formation of O- nitrophenol. The 
scheme illustrates the hydrolysis of O-nitrophenyl-β-galactoside by cytoplasmic β-
galactosidase into O- nitrophenol.  The activity of β-galactosidase can be monitored by 
measuring the presence of the yellow compound O- nitrophenol at 420 nm using a 
spectrophotometer. 
 
2.2.4 Scanning electron microscopy  
            S. aureus (ATCC 11832) and E. coli (ATCC8277) were cultured, harvested and 
washed (as outlined above). The inoculum however was not resuspended at a lower 
density, instead an overnight culture of ~108 cells/mL was used for the study to ensure 
that bacterial cells were at a high enough density after the washes involved in electron 
microscopy preparation methods. A 200 µl aliquot of a range of concentrations of 
dendrimer from 1-200 µg/mL for G2, G3 and G4-PAMAM-NH2 and 0.0025-12.5 µg/mL 
for G5-PAMAM-NH2were constituted. For G3.5-PAMAM-COOH dendrimer the 
concentration range of solutions made were between 1-250 µg/mL. The PAMAM 
dendrimer solutions (200 µl) were added to 200 µl of the bacterial inoculum and 
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incubated at 37°C ± 1°C for 2 hours and shaken at 200 rpm. After the incubation 
period the bacteria were centrifuged at 10,000 x g for 10 mins, resuspended in PBS 
(pH 7.4), centrifuged as above and the supernatant discarded. This was repeated 3 
times to wash the harvested bacteria. The bacteria were then fixed in 2.5 % 
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4 containing 2mM CaCl2) for 2 
hours on a low speed rotator.  
            Fixative was washed from the bacteria (as described above) in sodium 
cacodylate buffer (pH 7.4 containing 2mM CaCl2) 3 times. A 100 µl aliquot of each 
fixed sample was added to a poly-L-lysine coated cover slip. Various substrates were 
tested including scanning electron microscopy filters (Millipore, Watford, UK) and 
pelleted bacteria in sterile 1.5 mL tubes, but it was found that poly-L-lysine cover slips 
retained the bacteria most effectively. The bacteria on the poly-L-lysine coated cover 
slips were then post-fixed in a solution of 1 % osmium tetroxide in sodium cacodylate 
buffer. After a 1 hour contact time the osmium tetroxide was removed by washing the 
cover slips in sodium cacodylate buffer (pH 7.4 containing 2 mM CaCl2). The cover 
slips were then submerged in 70 % ethanol and dehydrated at 4ºC for 6 days. 
             The samples were then further dehydrated for ten minutes each in 80 %, 90 % 
and 100 % ethanol. To remove the solvent from the samples they were critical-point 
dried to replace the 100 % ethanol with liquid CO2 under pressure. This was repeated 
3 times to ensure all of the ethanol had been displaced from the samples. The liquid 
CO2 was subsequently removed by increasing the temperature to 40ºC and the 
pressure until the CO2 vaporised. Samples were securedto a scanning electron 
microscope (SEM) stub mount using double-sided carbon tape. Samples were 
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carefully pressed down on to the stub to ensure efficient conductivity. Each sample 
was sputtered with gold to ensure an even coating and the samples were then placed 
in the high resolution (1.5 nm) field emission SEM (Hitachi, S4500).  
2.2.5 Statistical analysis of results 
All results within this section are reported as the mean ± SEM (standard error of 
the mean). All inner membrane permeabilisation data passed the D’Agostino and 
Pearson normality test (α = 0.05) using GraphPad Prism® version 5 (San Diego, 
USA).The data obtained within the inner membrane permeabilisation assay was 
analysed using a nested mixed model analysis in SPSS® version 19 IBM 
corp®(Armonk, NY). The fixed effects were Time within concentration within dendrimer, 
dendrimer and then concentration within dendrimer. Firstly the analysis was applied to 
the four different generations of PAMAM dendrimer to establish any significant 
differences between the inner membrane permeabilisation of E. coli between the four 
tested PAMAM dendrimer generations. Then a least significant difference (LSD) 
posttest was utilised to establish pairwise comparisons between the PAMAM 
dendrimer generations. The output of the nested mixed model analysis also included 
the mean absorbance for each concentration across all time points and the 
corresponding 95 % confidence intervals. For the data displayed in Figure 2.8 a single 
final time point of 60 minutes was chosen therefore a two-way ANOVA with a 
Benferroni posttest was used to compare the two variables of dendrimer generation 
and dendrimer concentration at that specific time point. 
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2.3 Results 
2.3.1 Microdilution broth with viable count assay to determine the inhibitory 
concentration (IC50). 
The antimicrobial activity of PAMAM dendrimers was evaluated against 
S. aureus and E. coli. The inhibitory effect of PAMAM dendrimers was determined by 
calculating the IC50 against Gram positive and Gram negative bacteria (Table 2.1). All 
of the PAMAM-NH2 dendrimers tested inhibited both strains of bacteria at low 
concentrations (<27 μg/mL). Figure 2.2illustrates the percentage inhibition of S. aureus 
against 4 generations of PAMAM-NH2 dendrimers at various dendrimer 
concentrations. The inhibition curves illustrated in Figure 2.2 were used to calculate 
the IC50 values (Figure 2.3). The IC50 values and physicochemical characteristics of 
PAMAM dendrimers that may be related to their antimicrobial activity are shown in 
Table 2.1. In order to inhibit 50 % of the S. aureus,G2-PAMAM-NH2 dendrimer 
required >9 times the concentration that was required for G5-PAMAM-NH2. With 
increasing PAMAM generation the concentration required to inhibit 50 % of S. aureus 
decreases dramatically (Figure 2.2 and Table 2.1). For the lowest concentrations of 
G2-PAMAM-NH2 and G5-PAMAM-NH2 tested, bacterial growth as opposed to 
inhibition was observed when compared to the untreated growth control.  
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Table 2.1: Calculated IC50 (μg/mL) with 95 % confidence intervals against 
S. aureus and E. coli including physicochemical characteristics of PAMAM 
dendrimer that determines their antimicrobial ability.  
 
Bacteria 
PAMAM 
generation  
Molecular weight 
Da 
No. of amine surface 
groups 
IC50 (95 % CI) 
µg/mL  
S. 
aureus 
G2-PAMAM-NH2  3,256 16 
26.77 (22.58- 
31.75) 
G3-PAMAM-NH2  6,909 32 9.374 (7.88- 11.15) 
G4-PAMAM-NH2  14,215 64 
5.962 (5.375- 
6.614) 
G5-PAMAM-NH2  28,826 128 
2.881 (2.473- 
3.355) 
G3.5-PAMAM-
COOH 12,927   64 > 250  
 
E. coli 
 
 
        
G3-PAMAM-NH2  6,909 32 4.931 (4.28- 5.679) 
G3.5-PAMAM-
COOH 12,927   64 >1000 
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Figure 2.2 Inhibition of S. aureus against decreasing concentrations of PAMAM 
dendrimer (μg/mL).(a) Corresponds to G2-PAMAM-NH2 (b) G3-PAMAM-NH2 (c) 
G4-PAMAM-NH2 and (d) G5-PAMAM-NH2. Results shown are the mean ± SEM (n=9). 
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Figure 2.3 shows the IC50 (μg/mL) against S. aureus plotted against the number 
of surface amine groups on the corresponding PAMAM-NH2 dendrimer. The IC50 
(μg/mL) against S. aureus decreased with increasing numbers of surface amine 
groups on the PAMAM dendrimer. An inhibition curve was added to the graph showing 
an R2 value of 0.9747. This trend related to the exponential increase in molecular 
weight and the number of amine surface groups with increasing PAMAM generation.  
 
 
 
 
 
 
 
 
Figure 2.3.Graph illustrating the calculated IC50 (µg/mL) concentrations.IC50 
(µg/mL)with error bars representing 95% confidence intervals against S. aureus 
plotted against the theoretical number of surface amine groups corresponding to 
G2-PAMAM-NH2, G3-PAMAM-NH2, G4-PAMAM-NH2 and G5-PAMAM-NH2 
dendrimers.  
 
The inhibitory concentrations for G3-PAMAM-NH2 against E. coli were also 
determined (Table 1 and Figure 2.4). The IC50 required to inhibit 50 % of the S. aureus 
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was ~2 fold higher than the concentration required to inhibit 50 % of the E. coli. The 
G3-PAMAM-NH2 antimicrobial activity suggests that it is much more effective against 
Gram negative bacteria than Gram positive bacteria in agreement with a previous 
paper (Calabretta et al. 2007).  
The antimicrobial activity of G3.5-PAMAM-COOH was also determined for each 
bacteria, up to a concentration of 1000 μg/mL Figure 5 (a-b). When challenged with 
S. aureus the carboxyl-terminated dendrimer inhibited the bacteria but the IC50 could 
not be calculated. The inhibition varied from 10 % up to 40 % depending on the 
G3.5-PAMAM-COOH concentration; the results produced were highly variable. The 
results indicate that, to achieve an IC50 against S. aureus the concentration of 
G3.5-PAMAM-COOH would have to be in excess of 250 μg/mL. Figure 5 (b) shows 
the inhibition curve of G3.5-PAMAM-COOH challenged against E. coli.   
At all concentrations tested the treated bacteria demonstrated growth as 
opposed to inhibition when compared to the untreated control. It is for this reason that 
the IC50 for G3.5-PAMAM-COOH challenged against E. coli could not be calculated as 
it exceeds the highest concentration tested,1mg/mL. 
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Figure 2.4.Inhibition of E. coli challenged against decreasing concentrations of 
G3-PAMAM-NH2 dendrimer (μg/mL). Results shown are the mean ± SEM (n=9). 
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Figure 2.5.Inhibition of G3.5-PAMAM-COOH dendrimer (μg/mL) against S. aureus 
and E. coli.(a) S. aureus against decreasing concentrations of G3.5-PAMAM-COOH 
dendrimer (μg/mL). Results shown are the mean ± SEM (n=9) as a consequence of 
three independent experiments. (b) E. coli challenged against decreasing 
concentrations of G3.5-PAMAM-COOH dendrimer (μg/mL). Results shown are the 
mean ± SEM (n=3). 
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2.3.2 Membrane integrity study 
The release of intracellular nuclear material was measured for two 
Gram-positive staphylococcal species including the resident skin microbe, 
S. epidermidis and the Gram negative gut microbe, E. coli after being challenged with 
5 times the calculated IC50 of G3-PAMAM-NH2 dendrimer.  For all three bacterial 
strains, the absorbance at 260 nm increased with time with a plateau at 80 minutes for 
S. aureus (Figure 2.6 (a)) and 100 minutes for both S. epidermidis (Figure 2.6 (b)) and 
E. coli (Figure 2.6 (c)) respectively. The absorbance increase for S. aureus showed a 
sigmoidal relationship when plotted against time whereas with the absorbance for 
S. epidermidis increased monotonically up to a plateau at 100 minutes. E. coli showed 
a dramatic increase in absorbance over the first 60 minutes, a slight decrease in 
absorbance at 80 minutes but increased to the highest absorbance reading taken 
across all stains tested at 100 minutes.  
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Figure 2.6.Graphs illustrating the release of nuclear material from S.aureus, 
S. epidermidis and E. Coli. (a) Absorbance at 260 nm plotted against time for 
S. aureus challenged against G=3 x 5 IC50. (b) Absorbance at 260 nm plotted against 
time for S. epidermidis challenged against G=3 x 5 IC50. (c) Absorbance at 260 nm 
plotted against time for E. coli challenged against G=3 x 5 IC50. All results are 
displayed as (n=3) mean ± standard deviation. Negative control was the absorbance at 
260 nm for the untreated bacteria group. 
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2.3.3 Inner membrane permeabilisation assay 
 
The inner membrane integrity of E. coli was determined chromogenically. E. coli 
contains the enzyme β-galactosidase within the cytoplasm of the cell; if the integrity of 
the inner membrane is compromised the β-galactosidase would be released from the 
cytoplasm into the culture medium where it would hydrolyse the substrate 
β-galactosidase (ONPG) into O- nitrophenol (Figure 2.1). The E. coli was added to 
wells containing the chromogenic substrate ONPG and various concentrations of 
PAMAM dendrimer. The production of O- nitrophenol was determined by measuring 
the change in absorbance at 420 nm over time (Je and Kim, 2006). Due to the 
possibility of substrate depletion, the measurements were taken within the first 12 
minutes of PAMAM-bacteria contact (Silvestro et al. 2000). It was found that the 
absorbance reached a plateau at around 20 minutes (data not shown).  
A mixed model analysis of the data presented in Figure 2.7 illustrated a 
significant difference in the inner membrane of permeabilisation of E. coli overall 
between all four PAMAM-NH2dendrimers tested (F=79.8 (3, 1708) p<0.001). The 
mean absorbance at 420 nm for G2-PAMAM-NH2, G3-PAMAM-NH2, G4-PAMAM-NH2, 
and G5-PAMAM-NH2 was 0.222 (95 % CI: 0.221-0.224) 0.228 (95 % CI: 0.227-0.230), 
0.228 (95 % CI: 0.226-0.229) and 0.214 (95 % CI: 0.213-0.216) respectively. An ad 
hoc LSD test (pairwise comparisons of absorbance) revealed that there was a 
significant difference in absorbance and thus inner membrane permeability between all 
PAMAM dendrimers tested (df 1708, p<0.001) with the exception of G3-PAMAM-NH2 
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when compared to G4-PAMAM-NH2 in which no statistical significance was observed 
between the two.  
For G2-PAMAM-NH2 both concentration and time had an effect of the 
absorbance at 420 nm and thus the inner membrane permeability of E. coli. Time had 
a significant effect on the absorbance at 420 nm for all concentrations (df 427, for 
1 µg/mL p<0.05 for concentrations 5-50 µg/mL p<0.001) with the exception of the 
vehicle control containing no PAMAM dendrimer and the lowest concentration tested, 
0.1 µg/mL. A pairwise comparison of the absorbance for each concentration of 
G2-PAMAM-NH2 dendrimer found that all concentrations were statistically different 
form the vehicle control (df 427, p<0.001) with the exception of 1 µg/mL. Further, all 
concentrations were different from each other (df 427, p<0.001). Interestingly, 
0.1 µg/mL was significantly different from vehicle control but 1 µg/mL was not. This 
was because the mean absorbance of the vehicle control was 0.174 (95 % 
CI: 0.170-0.178) however the mean absorbance for 0.1 µg/mL G3-PAMAM-NH2 
dendrimer was much lower at 0.165 (95 % CI: 0.161-0.169). This trend of the vehicle 
control having a higher absorbance than 0.1 µg/mL of PAMAM dendrimer was 
observed across all generations tested. 
For G3-PAMAM-NH2 dendrimer again time and concentration had a significant 
effect on the absorbance at 420 nm. Time had a significant effect on the absorbance 
at all concentrations (df 427, p<0.05 for a concentration of 1 µg/mL and p<0.001for 
concentrations 5-50 µg/mL) with the exception of the vehicle control and again the 
lowest concentration of the G3-PAMAM-NH2 dendrimer tested- 0.1 µg/mL. All 
G3-PAMAM-NH2 concentrations were statistically different from one another and the 
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vehicle control (df 427, p<0.001) with the only exception being again, 1 µg/mL when 
compared to the vehicle control. For G4-PAMAM-NH2 dendrimer, time had a significant 
effect (df 427, p<0.001) on concentrations 5-50 µg/mL only and not at the lower 
concentrations or the vehicle control. When comparing the concentration effects for 
G4-PAMAM-NH2 dendrimer on the absorbance, all concentrations were significantly 
different from one another (df 427, p<0.001) with the exception of the vehicle control, 
0.1 and 1 µg/mL when compared to each other. For the G5-PAMAM-NH2 dendrimer 
time had a significant effect on the absorbance at all concentrations (df 427, p<0.05 for 
1 µg/mL and p<0.001 for 5-50 µg/mL) with the exception of the vehicle control and the 
lowest concentration of 0.1 µg/mL.  
After comparing the absorbance of all concentrations against each other and 
the vehicle control there was a definite concentration dependency on the inner 
membrane permeabilisation (df 427, p<0.05 when the vehicle control was compared to 
1 µg/mL and p<0.001 for all other concentrations). The only exception was when the 
absorbance for the concentrations 0.1 and 1.0 µg/mL of G5-PAMAM-NH2 dendrimer 
was compared where no statistical difference was observed.  
The inner membrane permeabilisation and thus production ofO-nitrophenol, 
increased with increasing concentrations of the PAMAM dendrimer and with time 
(Figure 2.7). For all four PAMAM-NH2 dendrimer generations tested, a concentration 
as low as 5 μg/mL exhibited permeabilisation of the inner membrane at 12 minutes 
(Figure 2.7). The production of O-nitrophenol was significantly different (p<0.001) 
across the four PAMAM generations tested. The highest concentration tested 
(50 μg/mL) demonstrated the highest increase in absorbance therefore inducing the 
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highest degree of inner membrane permeabilisation. The exception to this was the 
G5-PAMAM-NH2 dendrimer. At a particular time point of 4-10 minutes, 25 μg/mL 
solution of G5-PAMAM-NH2 dendrimer showed a higher absorbance at 420 nm and 
thus O- nitrophenol production than at a 50 μg/mL concentration. G5-PAMAM-NH2 
dendrimer also demonstrated a longer lag period for absorbance increase at 420 nm. 
The trend observed, with respect to decreasing absorbance (based on the 
mean across all time points for a specific concentration) was G2>G3>G5>G4 for 
PAMAM concentrations of 5 μg/mL. At a higher dendrimer concentration of 50 μg/mL 
the absorbance measurement trend in decreasing order was G3>G4>G2>G5. A 
measurement was taken at 60 minutes to determine a final measurement 
ofO-nitrophenol production (Figure 2.8).A two-way ANOVA with a Bonferroni post-test 
was used to investigate the relationship between dendrimer generation and 
concentration in O-nitrophenol production at a 60 minute time point. There was a 
significant difference between the absorbance at 60 minutes for each dendrimer 
generation tested (F=460.8, df 4,p<0.001) and also between the different 
concentrations tested (F=1133, df 5,p<0.001). A Bonferroni posttest compared the 
different PAMAM dendrimer generations at different concentrations. It was established 
that even after 60 minutes there was no change in absorbance was observed for 
concentrations below 5 μg/mL (p>0.05). There was significant difference in 
absorbance when comparing all concentrations of each PAMAM generation to the 
vehicle control (p<0.001) with the exception of 0.1 and 1 μg/mL of PAMAM dendrimer. 
When the different PAMAM dendrimer generations were compared at various 
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concentrations there was no observed difference between generation 3 and 
generation 5 dendrimer at all concentrations.  
 A generation effect was also confirmed when comparing the absorbance at 
420 nm of various PAMAM dendrimer generations over 12 minutes (Figure 2.9). At a 
dendrimer concentration of 10 μg/mL, the absorbance increase is very similar across 
all generations tested with the exception of G5-PAMAM-NH2 showing a lag phase over 
the first 8 minutes of the assay (Figure 2.9 (a)). At the higher concentration of 
50 µg/mL (Figure 2.9 (b)) the absorbance reading was spread and the lag time of 
G5-PAMAM-NH2 was more pronounced.  
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Figure 2.7.Graphs illustrating the relationship between concentration, time and 
dendrimer generation on the inner membrane permeabilisation of E. coli. 
Absorbance at 420 nm plotted against time in minutes for a range of dendrimer 
concentrations (0.1- 50 μg/mL). (a) corresponds to G2-PAMAM-NH2 treated E. coli, (b) 
G3-PAMAM-NH2 treated E. coli, (c) G4-PAMAM-NH2 treated E. coli and (d) 
G5-PAMAM-NH2 treated E. coli. Vehicle control is displayed as the untreated control 
group. All results shown represent the mean ± SEM (n=9) as a result of 3 independent 
experiments.   
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Figure 2.8. Graph illustrating the inner membrane permeabilisation of E. coli at 
60 minutes for a range of dendrimer concentrations.Absorbance at 420 nm plotted 
against a range of dendrimer concentrations (0.1- 50 μg/mL) at 60 minutes. G2 
corresponds to G2-PAMAM-NH2 treated E. coli, G3 G3-PAMAM-NH2 treated E. coli, 
G4-PAMAM-NH2 treated E. coli and (c) G5-PAMAM-NH2 treated E. coli. VC 
corresponds to the vehicle control and is displayed as the untreated bacteria group 
control. All results shown represent the mean ± SEM (n=3). 
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Figure 2.9.Graphs illustrating the effect of dendrimer generation and time at 
specific concentrations on the inner membrane permeabilisation of E. coli. 
Absorbance at 420 nm plotted against time in minutes, (a) corresponds to each 
PAMAM generation at a concentration of 10 μg/mL challenged against E. coli, and (b) 
PAMAM generations at a concentration of 50 μg/mL challenged against E. coli. VC 
corresponds to the vehicle control and was displayed as the untreated bacteria group 
control. All results shown represent the mean ± SEM (n=9) as 3 independent 
experiments were conducted. 
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2.3.4 Scanning electron microscopy 
       The SEM images (Figure 2.10) highlight the membrane effects of PAMAM 
dendrimers particularly with regards to the cocci-shaped S. aureus. Figure 2.10 (a-b) 
shows that there was cytoplasmic debris around the untreated control however this 
may have been a result of the SEM preparation process. When compared to the 
G3-PAMAM-NH2 at a concentration of 5 times theIC50 (µg/mL) varying degrees of 
membrane damage was observed from minor blebbing through to total destruction of 
the cell membrane (Figure 2.10 (c-d)). This was also found to be the case with 
G2-PAMAM-NH2 (Figure 2.10 (e-f)) and G5-PAMAM-NH2 (Figure 2.10 (g-h)). The SEM 
images demonstrate the ability for G2-PAMAM-NH2 and G5-PAMAM-NH2 to cause 
severe bacterial cell membrane damage including blebbing of cytoplasmic contents 
from damaged cell membrane and complete cell lysis. Sheets of bacterial cell wall and 
cytoplasmic content debris can be observed in the PAMAM treated bacteria images 
(Figure 2.10 (a-h)). For G3.5-PAMAM-COOH at a concentration of 1 mg/mL (Figure 
2.10(i-j)) there is no difference in bacterial cell morphology or changes to the integrity 
of the bacterial cell membrane when compared to the untreated S. aureus group. The 
damage to the S. aureus cell membrane and thus leakage of cytoplasmic contents 
observed in the collected SEM images further supports the results determined in the 
membrane integrity study see Section 2.3.2. 
       SEM images were also collected for the Gram negative, bacillus-shaped E. coli 
bacteria. Figure 2.11 (a-b) shows the intact PAMAM untreated group micrographs. 
Figure 2.11 (c-d) illustrates the G3-PAMAM-NH2 treated group. Damage to the 
bacterial wall and cell membranes can be observed due to leakage and blebbing and 
85 
 
leakage of the cytoplasmic contents from the cell. The PAMAM dendrimer typically 
targeted the polar regions of the E. coli rods; this effect can also be observed 
elsewhere (Wang et al. 2010). Again, no changes in cell morphology were observed 
for the G3.5-PAMAM-COOH at a concentration of 1 mg/mL. The damage caused by 
the G3-PAMAM-NH2 dendrimer to the E. coli is consistent with the results of the 
membrane integrity study in Sections 2.3.2 and the inner membrane permeabilisation 
results in 2.2.3. 
 
 
 
 
 
 
 
 
 
 
Figure 2.10.Scanning electron micrographs of S. aureus challenged with PAMAM 
dendrimer. (a) Represents untreated S. aureus at a magnification of x25k, scale bar 
represents 1.2 μm. (b) illustrates untreated S. aureus at a magnification of x30k, scale bar 
represents 1 μm. (c) S. aureus treated with G3-PAMAM-NH2 at a concentration of 5x 
calculated IC50 from section 2.3.1. magnification x30k and scale bar represents 1 μm. (d) 
S. aureus treated with G3-PAMAM-NH2 at a concentration of 5x calculated IC50 from 
section 2.3.1. magnification x30k and scale bar represents 1 μm.  
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Figure 2.10. Cont. (e) S. aureus treated with G2-PAMAM-NH2 at a concentration of 
250 μg/mL, magnification x25k and scale bar represents 1.2 μm. (f) S.aureus treated 
with G2-PAMAM-NH2 at a concentration of 250 μg/mL, magnification x 40 k and scale 
bar represents 750 nm. (g) S. aureus treated with G5-PAMAM-NH2 at a concentration 
of 250 μg/mL, magnification x10k and scale bar represents 3 μm. (h) S. aureus treated 
with G5-PAMAM-NH2 at a concentration of 250 μg/mL, magnification x20k and scale 
bar represents 1.5μm. (i) S. aureus treated with G3.5-PAMAM-COOH at a 
concentration of 1000 μg/mL, magnification x25k and scale bar represents 1.2μm. (j) 
S. aureus treated with G3.5-PAMAM-COOH at a concentration of 1000 μg/mL, 
magnification x30k and scale bar represents 1 μm. 
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Figure 2.11.Scanning electron micrographs of E. coli challenged with PAMAM 
dendrimer.(a) E. coli untreated magnification x10 k scale bar scale bar represents 
3 μm. (b)  E. coli untreated magnification x40 k scale bar scale bar represents 750 nm. 
(c) E. coli treated G3-PAMAM-NH2 at a concentration of 5x calculated IC50 as 
determined in Section 2.3.1, magnification x15 k and scale bar represents 2 μm. (d) 
E. coli treated G3-PAMAM-NH2 at a concentration of 5x calculated IC50 as determined 
in Section 2.3.1, magnification x 50 k and scale bar represents 1 μm. (e) E. coli treated 
with 1000 μg/mL of G3.5-PAMAM-COOH magnification x15 k scale bar 2 μm. (f) E. 
coli treated with 1000 μg/mL of G3.5-PAMAM-COOH magnification x30 k scale bar 1. 
μm. 
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2.4 Discussion 
Although PAMAM dendrimers are biocidal there have been very few PAMAM 
dendrimers that have been tested for antimicrobial activity hence the rationale for this 
study. In order to develop more efficacious antimicrobial dendrimers it is of paramount 
importance to determine the antimicrobial properties of a range of PAMAM dendrimers 
including lower and higher generations and amine and carboxyl terminated groups. A 
modified broth microdilution assay with a viable count was used to determine the 
surviving bacterial numbers (Calabretta et al. 2007) after exposure to a range of 
generations of PAMAM-NH2 and PAMAM-COOH. A modification to the growth media 
was made to incorporate CLSI standardized growth media and a viable count assay 
was performed for an accurate measurement of surviving bacterial numbers (Rennie, 
2001).  
Typically the number of surviving bacteria is measured by reading the 
absorbance of each well (Zgoda and Porter, 2001), however the optical density 
depends on the shape, strain and growth stage of the bacteria; it also takes into 
account live and recently dead bacteria (Koch, 1994). After testing both methods it 
was decided that a viable count, though laborious, was much more accurate. It was 
found that after mixing the PAMAM dendrimer into the bacterial suspension a pellet 
formed on the bottom of each test well and therefore an accurate optical density 
measurement could not be taken. 
 Two skin pathogens, S. aureus and E. coli were tested against various 
concentrations of PAMAM dendrimers. S. aureus and particularly its meticillin-resistant 
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counterpart, is a well recognised nosocomial pathogen that causes skin and soft-tissue 
infections notably within immuno-compromised patients (Frazee et al. 2005, Leyden et 
al. 2006 and Miller et al. 2007). The skin pathogen S. aureus is known to release a 
number of pathogenic toxins including exfoliative toxin A that is the causative agent of 
bullous impetigo and scalded skin syndrome (Amagai et al. 2000). E. coli is a 
Gram-negative gut pathogen that can also be considered as a transient skin pathogen. 
The microorganism was utilised as it has been shown to be transmitted from skin to 
surfaces and vice versa resulting in the transmission of infections to 
immune-compromised patients (Fryklundet al. 1995).  
The calculated IC50values are shown in Table 2.1 along with the generation, 
molecular weight and number of theoretical amine surface groups. A clear, generation-
dependent trend was observed when the IC50 of each PAMAM generation were plotted 
against their respective theoretical number of surface amine groups. The term 
‘theoretical’ is used as the PAMAM dendrimers were used as purchased and 
occasionally structural defects can occur within the PAMAM dendrimer due to the 
incompletion of the Michaél reaction in the divergent synthesis process (Liuand 
Fréchet, 1999). Despite the possibility of structural defects, PAMAM dendrimers are 
widely accepted as being uniform, monodispersed polymers and have been 
characterized by a range of techniques including AFM (Li et al. 2000), MALDI-ToF 
mass spectrometry (Peterson et al. 2003) and zone capillary electrophoresis (Peterson 
et al. 2001).   
There was an inverse correlation between the IC50 concentration and PAMAM 
dendrimer generation (as shown in Figure 2.3). G2-PAMAM-NH2 that terminates in 
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18 amine groups required a ~10x higher concentration than G5-PAMAM-NH2 with 
128 surface amine groups to inhibit 50 % of the bacteria. It was found that by 
increasing the number of amine groups on the dendrimer surface the concentration 
required to inhibit 50 % of the bacteria dramatically decreased. Enhanced 
destabilization of bacterial membranes has been observed by increasing the number 
of amino groups on a polycation (Katsu et al. 2002).  
This, generation-dependent, trend observed was contrary to the findings 
elsewhere in Lopez et al. 2009. The authors determined the minimum inhibitory 
concentration (MIC) using a broth microdilution assay and after re-suspension of the 
formed pellet in each well the optical density was used to determine the surviving 
bacterial numbers. They found that the MIC for G3-PAMAM-NH2 and G5-PAMAM-NH2 
against S. aureus was identical at 12.5 μg/mL. A distinction in MIC value for two 
different PAMAM generations against P.aeruginosa as G3-PAMAM-NH2 and 
G5-PAMAM-NH2 exhibited a MIC of 6.3 μg/mL and 12.5 μg/mL respectively. The 
authors suggest the difference is due to the G3-PAMAM-NH2 dendrimer’s ability to 
penetrate the cell more easily due to a lower molecular weight compared to 
G5-PAMAM-NH2. One would assume that if the molecular weight was preventing the 
penetration of the PAMAM dendrimer into the cell membrane of E. coli the same affect 
would be observed for the penetration into the cell membrane of S. aureus. The MIC 
values determined do not correlate to the calculated IC50 values determined in section 
2.3.1 as MIC represents the lowest inhibitory concentration as exhibited by a sharp 
decrease in absorbance whilst IC50 determines the concentration required to kill 50 % 
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of the bacteria. The two different mechanisms of defining the antimicrobial effect of 
PAMAM dendrimers have shown opposing trends.  
Another trend apparent from the results is that PAMAM dendrimers are more 
effective against Gram-negative bacteria such as E. coli as shown in Table 2.1 Section 
2.3.1. This has been noted elsewhere asG4-PAMAM-NH2 exhibited a higher biocidal 
affect against P. aeruginosa than against the Gram-positive S. aureus (Calabretta et 
al. 2007). E. coli is Gram-negative and has a very different cell wall structure and 
composition compared to Gram-positive S. aureus. The main barrier to the ingress of 
biocides is the outer membrane which for E. coli is exterior to a thin peptidoglycan 
layer and the outer cell membrane. The outer membrane consists of 
lipopolysaccharide (LPS), phospholipids and proteins (Nikaido, 1996). LPS carries a 
high anionic charge at physiological pH due to the ionisable phosphoryl and carboxyl 
groups (Beveridge, 1999). The polycationic nature of PAMAM dendrimers would 
ensure high reactivity and affinity for the outer membrane due to strong electrostatic 
forces. The high degree of interaction and disruption of the lipid bilayer of the outer 
membrane with the polycationic PAMAM dendrimer is one possible explanation for the 
enhanced antimicrobial efficacy observed for Gram negative bacteria in Section 2.3.1 
and for G5-PAMAM-NH2tested against P. aeruginosa in Calabretta et al. (2007).  
Previously PAMAM dendrimers have been shown to form nano-holes within the 
lipid bilayer causing membrane permeabilisation and leakage of cytoplasmic contents 
however the effect was transient and the membrane integrity returned on removal of 
the G5-PAMAM-NH2 dendrimer (Hong et al.  2004 and Hong et al. 2006). Further other 
polycationic compounds such as chitosan have been shown to disrupt and 
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permeabilise the outer membrane resulting in loss of barrier function (Helander et al. 
2001). 
Gram positive bacteria such as S. aureus do not have a protective outer 
membrane but rather a dense cross-linked peptidoglycan layer with threads of anionic 
teichoic acids consisting of repeating units of glycerol phosphate, glucosyl phosphate 
and ribitol phosphate (Silhavy et al. 2010). The peptidoglycan layer is a dense mesh 
network that is around 30 nm in thickness (Shockman and Barren, 1983). It regulates 
the ingress of nutrients, controls stabilizing cations and offers protection from 
antibiotics whilst maintaining osmotic pressure (Campbell et al. 2012).The sheer 
thickness and density of the polyanionic mesh would offer the microorganism a degree 
of protection from the penetration of PAMAM dendrimers. Though teichoic acids carry 
a lesser anionic charge than LPS (Beveridge, 1999) they still confer a continuum 
anionic charge across the bacterial cell wall resulting in an electrostatic attraction 
between the Gram positive bacteria and the polycationic PAMAM dendrimers. The 
difference in antimicrobial efficacy observed for Gram positive and Gram negative 
bacteria is explained by their distinctive cell wall compositions.  
Surprisingly, at the lower concentrations tested for G2-PAMAM-NH2 and 
G5-PAMAM-NH2 PAMAM dendrimers, the number of bacteria was higher than in the 
growth control. This could be due to the polycationic PAMAM dendrimer displacing the 
membrane stabilizing cations (Ca2+ and Mg2+) and replacing them ensuring 
stabilization of the cell membrane(Chen and Cooper, 2002). This 
replacement-stabilization effect has been observed for ethylenediamine and other 
polycations (Katsu et al. 2002). This is interesting as ethylenediamine is a key 
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component of PAMAM dendrimers and is even the compound at the focal core. For 
G3.5-PAMAM-COOH the IC50 values for each microorganism are of a higher 
concentration than those tested in section 2.3.1. The carboxyl terminated dendrimer 
did inhibit S. aureus at most concentrations but the dendrimer did not inhibit 50 % of 
the bacteria, even at a concentration of 250 μg/mL therefore it is likely that a much 
higher concentration is required (Figure 2.5). Against E. coli the carboxyl terminated 
dendrimer surprisingly enhanced the growth of bacteria when compared to the growth 
control. This may be due to the growth control being inhibited by some means during 
the experiment; further replicates would have to be conducted to confirm the observed 
effect.  Wang et al. (2010) tested G3.5-PAMAM-COOH’santimicrobial affect against 
E. coli and found that very high concentrations of 6.25-100 mg/mL were required to 
inhibit E. coli.  
It is imperative to establish the mechanism of action of novel antimicrobial 
compounds in order to fully exploit biocides, discover new bacterial targets, and 
develop innovative biocidal strategies and to give an insight into possible mechanisms 
of resistance. As the IC50 values calculated in Section 2.3.1 illustrate differing efficacies 
for various PAMAM generations against Gram positive and Gram negative bacteria, it 
was thought likely that the target for antimicrobial action is the cell membrane. The 
cytoplasmic membrane is the target for most polycationic biocides resulting in 
destabilization, leakage of cytoplasmic contents and precipitation of cytoplasm (Ikeda 
et al. 1986, Ioannou et al. 2007 and Liu et al. 2004). Moreover, cytoplasmic membrane 
disruption has been observed for quaternary ammonium functionalized poly(propylene 
imine) dendrimers against both Gram positive and Gram negative bacteria (Chen and 
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Cooper, 2002). With regards to establishing interactions with the cytoplasmic 
membrane, it appears that only G4-PAMAM-NH2 has been analysed against one strain 
of bacteria, E. coli (Wang et al. 2010).  
To assess as to whether PAMAM dendrimers impair the integrity of the 
cytoplasmic contents of Gram positive and Gram negative bacteria, the leakage of 
intracellular components was monitored over time. At bacteriostatic concentrations, 
destabilization of the cytoplasmic membrane causes the loss of small ions such as 
potassium and phosphate, and this affect is reversible. At bactericidal concentrations 
leakage of DNA, RNA and other cytoplasmic contents over time occurs resulting in 
either inhibition or cell death (Chen and cooper, 2002 and Joswick et al. 1971). The 
cytoplasmic material that is released into the supernatant over time absorbs at 260 nm 
and can therefore be measured to determine the membrane integrity. The results 
indicate that G3-PAMAM-NH2 causes intracellular components to leak from S. aureus, 
S. epidermidis and E. coli within a very short time frame of 20 minutes. The integrity of 
the cytoplasmic membrane for all three bacterial strains is diminished with an increase 
in 260 nm absorbing material detected within the first 80 minutes of the assay. At 80 
minutes for the Staphylococci species and 100 minutes for the E. coli a plateau was 
reached. This is indicative that precipitation and coagulation of nucleotides with the 
high concentration of PAMAM dendrimer had occurred that has been observed with 
other cations (Hugo and Longworth, 1964). 
A differing profile of 260 nm absorbing material release was observed for each 
bacterial strain. S. aureus and S. epidermidis resulted in an immediate release of 
cytoplasmic material up to 80 minutes where a plateau was reached. For E. coli there 
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was a rapid release of cytoplasmic material up to 40 minutes and then a gradual 
release from 40-120 minutes. This trend is analogous to the intracellular contents 
release profile observed when S. aureus and E.coli was challenged with the 
polycation, chitosan acetate (Liu et al. 2004). E. coli resulted in the highest recorded 
absorbance that is in line with the increased antimicrobial efficacy of the 
G3-PAMAM-NH2 against E. coli determined in Section 2.3.1. The differing release 
profiles for Gram negative and Gram positive bacteria is due to the dissimilarity in the 
cell wall structure and composition that the biocide must first penetrate before access 
to the cytoplasmic membrane. These distinctions have been outlined in Section 2.3.1. 
The results of the membrane integrity test suggest that the biocidal activity of 
PAMAM dendrimers occurs over a very short time period of 80 minutes. The 
intracellular release profiles are indicative of an antimicrobial compound that targets 
bacterial cell membrane and its function, resulting in bacterial growth inhibition and cell 
death (Wang et al. 2010). Further analysis into the PAMAM dendrimer’s interactions 
with the bacterial membrane were studied (see Section 2.3.3 and 2.3.4). 
The permeabilisation of the inner membrane of E. coli was investigated by 
introducing a range of PAMAM dendrimer generations with a series of increasing 
concentrations. The inner membrane consists of a complex proteome within a lipid 
bilayer is formed principally from phosphatidyl ethanolamine, phosphatidyl glycerol and 
to a lesser extent cardiolipin. The latter of the two membrane lipids carries an anionic 
charge (Dowhan, 1997). The results in section 2.3.3 indicate that the polycation 
PAMAM dendrimers have a strong affinity for the anionic inner membrane of E. coli. 
The absorbance at 420 nm, corresponding to ο-nitrophenol, rapidly increased within 
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30 seconds for concentrations >10 μg/mL for G2- PAMAM-NH2, G3- PAMAM-NH2 and 
G4- PAMAM-NH2. A lag time of 2 minutes was observed for G5- PAMAM-NH2 due to 
the slower diffusion of the high molecular weight PAMAM dendrimer. PAMAM 
dendrimers permeabilise and impair the inner membrane rapidly in a concentration 
dependent manner. A concentration as low as 5 μg/mL of all PAMAM dendrimers 
tested resulted in the production of  O-nitrophenol and thus caused inner membrane 
permeabilisation.  
It was found that there was also a generation-dependent effect of the inner 
membrane permeabilisation. Within the first 12 minutes the G3-PAMAM-NH2 and 
G4-PAMAM-NH2 resulted in the highest absorbance at 420 nm. This is likely due to a 
compromise between the number of surface amine groups and the molecular weight 
for diffusion through the outer membrane to reach the inner membrane. At 60 minutes 
however the absorbance at 420 nm for G3-PAMAM-NH2 and G5-PAMAM-NH2 was 
comparable after the lag time that G5-PAMAM-NH2incurred due to its relative size and 
molecular weight. Furthermore, at a low concentration of 5 μg/mL of PAMAM 
dendrimer it was G2-PAMAM-NH2 that displayed the highest absorbance after 
60 minutes. The lower molecular weight PAMAM dendrimer incited the highest degree 
of inner membrane permeabilisation at the lower end of the concentration series 
tested. This may be an indication that PAMAM dendrimers aggregate at higher 
concentrations and for this reason diffusion throughout cell membrane and surface 
area are reduced. These novel results signify that there is an important time, 
concentration and generation dependent effect on the inner membrane 
permeabilisation of E. coli. Wang et al. reported a lag time of 20 minutes for the 
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release of O-nitrophenol when G4-PAMAM-NH2 was tested at a single concentration. 
This result seems anomalous when they reported leakage of intracellular components 
within 20 minutes at the same PAMAM concentration (Wang et al. 2010). One would 
expect that the integrity of the inner membrane must first be impaired before the 
leakage of cytoplasmic contents can occur.  
In order for the PAMAM dendrimer to contact the inner membrane the 
dendrimer must have first destabilized and traversed the outer membrane of E. coli. A 
number of cationic compounds have been reported to enhance the permeability of the 
outer membrane (Piers et al. 1994, Minnock et al. 2000, Domadia et al. 2010 and 
Katsu et al. 2002. The outer membrane is stabilized by Ca2+ and Mg2+ that have strong 
electrostatic binding affinities towards the anionic LPS. If polycations such as PAMAM 
dendrimers disturb or replace the stabilizing divalent cations, the integrity of the 
non-fluid continuum of LPS will be impaired and thus more permeable to biocides 
(Vaara, 1992 and Katsu et al. 1984). It has been observed that polycations with more 
than 4 amino groups were very affective at removing Ca2+ but to cause further 
membrane disruption bulky hydrophobic moieties were required (Katsu et al. 2002 
and, Yasuda et al. 2004). PAMAM dendrimers have been shown to exhibit chelating 
behavior of metal ions in aqueous solutions due to their high density of nitrogen 
ligands along with amine terminal groups (Diallo et al. 2005 and Diallo et al. 2004). For 
PAMAM dendrimers to perturb the inner membrane of E. coli, shown in Section 2.2.3, 
the dendrimer must have first chelated, replaced and disturbed the stabilizing cations 
resulting in a disrupted and permeable outer membrane (Chen and Cooper, 2002 and 
Wang et al. 2010). 
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SEM is a method that has been used for decades to visualise the external 
features of bacteria shown in 3D form (Khalab et al. 2008). As such, electron 
microscopy has been used to study the structural and morphological changes induced 
by a range of antimicrobial agents including chlorhexidine (Tattawasart et al. 2000 and 
Khunkitti et al. 1998), silver nanoparticles (Kim et al. 2011) and tea tree oil (Carson et 
al. 2002). Cell wall damage caused by PAMAM dendrimers was visualised using SEM, 
supporting the membrane integrity and permeabilisation studies reported within 
previous sections of this chapter. With regards to the effects visualised, the untreated 
S. aureus illustrated blebbing of cytoplasmic material on the cell surface that had been 
extruded from damaged cell membrane. Leaked cytoplasmic material, severe 
membrane damage and even separation of the cell membrane from the cell was also 
exhibited due to the irreversible damage caused by the different generations of 
PAMAM dendrimers (Figure. 2.10). Unfortunately, there was also leaked cytoplasmic 
content clustered around the bacterial cells observed in the untreated S. aureus which 
is an artefact due to the SEM preparation procedure. It has been noted that 
morphological changes are likely to occur due to repeated centrifugation during the 
washing procedure (Kai et al. 1999). Though, the severity of membrane damage 
observed for treated S. aureus was not observed in the untreated control group. This 
degree and type of membrane damage has been observed in scanning electron 
micrographs of S. aureus challenged with cationic lens biocides, polyquaternium-1 and 
myristamidopropyl dimethylamine (Codling et al. 2005). Further, comparable 
cytoplasmic membrane damage was observed for S. aureus when challenged with the 
essential oil isolated from O. Vulgare (De Souza et al. 2010). 
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Marked release of cytoplasmic contents was also observed for E. coli due to 
membrane damage inflicted by the G3-PAMAM-NH2 dendrimer (Figure. 2.11). Similar 
extracellular membrane blebbing was observed on E. coli when the bacteria were 
challenged with tea tree oil (Gustafson et al. 1998) and silver nanoparticles (Kai et al. 
1999). Within the literature there was one instance where G4-PAMAM-NH2 was 
challenged against E. coli and analysed by SEM after an eight hour contact time 
(Wang et al. 2010). The authors observed a range of detrimental morphological effects 
including ruptured cell walls, eroded cell membrane and shrinkage of bacterial cells 
(Wang et al. 2010). An incubation time of two hours was utilised in Section 2.3.4 
therefore a lower extent of morphological damage was observed.  
The membrane damage depicted in the scanning electron micrographs is 
consistent with the membrane integrity study that monitored the release of cytoplasmic 
material from the cell membrane (Section 2.3.2). Leakage of cytoplasmic contents that 
absorbs at 260 nm is a result of irreversible cell membrane damage that leads to cell 
death. Intracellular ion homeostasis is integral to all living cells as they are required for 
turgor pressure control, many metabolic processes and the divalent cations, Ca2+ and 
Mg2+  are of paramount importance for maintaining cell wall stabilisation (Shabala et al. 
2001 and De Souza et al. 2010). As membrane damage is observed in the scanning 
electron micrographs, disruption of the stabilizing cations must have occurred. This 
destabilisation affect was also observed in the membrane permeabilisation assay 
(section 2.3.3). For both E. coli and S. aureus G3.5-PAMAM-COOH did not induce any 
morphological damage at a concentration of 1 mg/mL. It has been proposed that 
carboxyl terminated PAMAM dendrimers are antimicrobial, however only at very high 
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concentrations. The mechanism of action is conceivably due to the scavenging of the 
stabilizing divalent cations leading to permeabilisation of the cell wall. The SEM 
images provide supporting evidence that the mechanism of action of PAMAM 
dendrimers is to target and disrupt the bacterial cell membrane.  
2.5 Conclusion  
Though unmodified PAMAM dendrimers have been shown to possess 
antimicrobial properties (Calabretta et al. 2007, Lopez et al. 2009 and Wang et al. 
2010) details on the antimicrobial properties of different generations, terminal 
functionalities and mechanism of action were lacking in the literature. Trends regarding 
PAMAM dendrimers’ antimicrobial effects were based on the analysis of only two 
dendrimer generations. This gap in knowledge within the literature has been 
addressed in order to develop more efficacious dendrimer biocides or dendrimer-
based formulations. The findings of the study indicate that unmodified amine-
terminated PAMAM dendrimers exhibit high antimicrobial potency at low 
concentrations, but their potency is dependent on the generation of the PAMAM 
dendrimer. Contrary to what has been published within the literature it was found that 
the antimicrobial efficacy improved with increasing numbers of surface amines and 
molecular weight. This finding correlates well with the results observed in the inner 
membrane permeabilisation assay whereby, G5-PAMAM-NH2incited the greatest 
membrane permeabilisation effect after 60 minutes possibly due to its high molecular 
weight a lag time was observed. The findings also suggest that carboxyl terminated 
PAMAM dendrimers are required in very high concentrations (> 1 mg/mL) in order to 
observe bacterial inhibition. The study has confirmed that the antimicrobial efficacy is 
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dependent on generation, concentration and terminal functionalities. There was a 
strong correlation between membrane disruption and the determined biocidal activity, 
thus making it a key contributing mechanism of action.  
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3.0 An investigation as to whether a PAMAM 
dendrimer skin pre-treatment enhances the 
permeation and deposition of CHG within porcine 
skin. 
 
3.0 Introduction 
3.1 Use of PAMAM dendrimers in transdermal and topical drug delivery 
systems 
 
PAMAM dendrimers have previously been used as percutaneous absorption 
enhancers for a number of topically applied therapeutics. This is due to their unique 
physiochemical characteristics such as their monodispersed globular structure with 
interior voids and dense surface functionalities (Uppuluri et al. 1998). PAMAM 
dendrimers are ideal for therapeutic use due to their uniform size and structure 
allowing for pharmacological reproducibility unlike their linear polymeric counterparts.  
The interior voids within the PAMAM dendrimer may encapsulate low molecular 
weight hydrophobic drugs for drug delivery (Morgan et al. 2006, Milhem et al. 2000 
and Gupta et al. 2006). PAMAM dendrimers also have dense surface functionalities; 
G4-PAMAM-NH2 consists of 64 primary amine groups at the periphery, which can be 
utilised to electrostatically complex or to covalently conjugate a range of drugs to its 
surface (Wang et al. 2010 and Cheng et al. 2008). These physiochemical properties 
of PAMAM dendrimers allows for the protection of degradable drugs, increase the 
aqueous solubility of drugs, and can allow for modified drug release, i.e. through 
thermo or pH responsive properties (Sun et al. 2012, Zhao et al. 2011 and Criscione 
et al. 2009).  
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Dendrimers, particularly PAMAM dendrimers, have been used for the delivery 
of therapeutics across a range of biological membranes including Caco-2 cell 
monolayers (Elsayed et al. 2002), rat intestine (Wiwattanapatapee et al. 2000 and Ke 
et al. 2007), ocular drug delivery (Vandamme and Brobeck, 2005) and for the 
transfection of genetic material (Eichman et al. 2000 and Shakhabazau et al. 2010). 
 
In recent years the ability of PAMAM dendrimers to enhance the permeation 
for the topical or transdermal delivery of therapeutics has been investigated. PAMAM 
dendrimers have the ability to act as drug carriers by facilitating drug transport and 
also by means of a physical perturbation of the skin barrier to enhance transdermal 
drug delivery (Venuganti and Perumal, 2008). Chauhan et al (2003) used 
G4-PAMAM-OH and G4-PAMAM-NH2 to enhance the permeation of indomethacin 
across skin in vitro, a non-steroidal anti-inflammatory drug (NSAID) that permeates 
the skin poorly. PAMAM dendrimers form a complex with indomethacin through 
electrostatic and hydrophobic bonding. A solution of G4-PAMAM-NH2 (0.2 % w/v) 
enhanced the in vitro permeation of indomethacin by a factor of 4.5, compared to the 
drug in free solution. The dendrimers were shown to be an effective penetration 
enhancer for the transdermal delivery of indomethacin.  
 
The PAMAM dendrimer enhancement effect also translated well to in vivo 
conditions. In a carrageenan-induced rat paw oedema model, pharmacokinetic data 
highlighted a 1.6 and 1.5 fold increase for G4-PAMAM-NH2 and G4-PAMAM-OH 
formulations respectively in % inhibition of paw volume. The authors proposed a 
cyclodextrin-like mechanism for the enhanced flux of drug across the rat skin in that 
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the dendrimer acts as a drug carrier. Though the dendrimer-indomethacin complex 
has a molecular weight too high to penetrate the stratum corneum (SC), the authors 
suggest the enhancement compared to the drug in free solution is a result of the 
dendrimer facilitating drug delivery to the SC in a solubilised form increasing the drug 
partitioning into the SC. Within the study it was shown that the PAMAM dendrimer 
enhanced the bioavailability of an NSAID by increasing the solubility and by 
enhancing the flux of the drug across the skin in vitro and in vivo (Chauhan et al. 
2003).  
 
 Other non-steroidal anti-inflammatory drugs in the case of ketoprofen and 
diflusinal were also electrostatically complexed with PAMAM dendrimers to 
significantly enhance the steady-state flux of both drugs across ex vivo rat skin in a 
diffusion cell study (Chauhan et al. 2004). The solubility of both drugs was 
dramatically enhanced resulting in an increased flux across the skin when compared 
to the drugs in free solution. Again, this transdermal enhancement resulted in an 
increase in bioavailability in vivo using the acetic acid induced writhing model in mice. 
Blood-drug level studies were 2.73 times higher for ketoprofen-PAMAM complex and 
2.48 times higher for diflusinal-PAMAM complex than the respective drug in free 
solution (Chauhan et al. 2004).  
 
Wang et al. created a novel polymeric drug delivery matrix using G3-PAMAM-
NH2 dendrimers combined with polyhydroxyalkonoate (PHA). When placed in a patch 
design the model drug, tamsulosin hydrochloride, was successfully transdermally 
delivered at a rate of 24.0 µg/cm2/day whilst the matrix without the presence of 
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PAMAM dendrimer has a delivery rate of only 15.7 µg/cm2/day in an in vitro study 
using a snake skin membrane. Only the drug delivery system encompassing the 
G3-PAMAM-NH2 dendrimer within the matrix achieved above the clinical aim of 
20.0 µg/cm2/day, transdermal delivery of tamsulosin hydrochloride. The authors also 
pre-dosed the skin with a G3-PAMAM-NH2 preparation to investigate the effect of the 
dendrimer alone on the skin. It was found that the PAMAM dendrimer pre-dose 
weakly enhanced the permeation of tamsulosin hydrochloride over a 24 hour time 
frame. The same enhancement effect was not observed when the tamsulosin 
hydrochloride was added directly to the snake skin in a PAMAM dendrimer solution 
(G3-PAMAM-NH2, 7.5 mM). The authors believe that the PAMAM dendrimer’s 
interaction with the drug prevented the PAMAM dendrimer’s interaction with the SC 
and thus prevented the modulation of the skin surface (Wang et al. 2003).  
 
These studies have used rat or snake skin as the model membrane for the 
percutaneous absorption studies. Diffusion studies using ex vivo rat skin have 
repeatedly shown the membrane to be significantly more permeable to a vast range 
of drugs, particularly with regards to lipophilic drugs, when compared to human skin 
membranes (Takeuchi et al. 2011, Barber et al. 1992 and Scott et al. 1987). For this 
reason rodent models are considered a poor surrogate for human skin when 
investigating the percutaneous absorption of drugs (Catz and Friend, 1990). 
Previously shed snake skin has been shown to be unreliable and misleading for the 
investigation of penetration enhancement as the membrane has been shown to 
underestimate the enhancer’s effect when compared to human skin in vitro (Rigg and 
Barry, 1990). Further, significant variability in the permeability of the model drug 
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progesterone was observed between the dorsal and ventral sites of snake skin (Haigh 
et al. 1998). Shed snake skin though ethical is not considered an acceptable model 
for human skin. It would be of interest to study the interactions of the previously 
mentioned PAMAM dendrimer-NSAID complexes upon an accepted membrane 
model such as ex vivo human or porcine skin. Though ex vivo human skin is 
considered the gold standard, porcine skin is regarded as the closest surrogate 
membrane for human skin in in vitro percutaneous absorption studies (Dick and Scott, 
1992 and Chilcott et al. 2001). Pig flank skin has similar morphological properties and 
hair follicle density to human skin and using skin from pigs of the same age, sex, site 
of the body and gene pool ensures that the model is homogenous (Davies et al. 
2004).  
 
PAMAM dendrimers from G2.5-PAMAM-COOH up to G4-PAMAM-NH2 have 
been utilised to enhance the solubility of 8-methoxypsoralene (8-MOP) after the drug 
was encapsulated within the interior voids of the PAMAM dendrimer. The drug-
PAMAM complex formed with G3-PAMAM-NH2 delivered a higher flux of the 8-
methoxypsoralene into the skin and the receptor fluid in an in vitro model using 
commercial polyvinyldifluoride (PVDF) membrane and pig ear skin (PES) membrane 
(Borowska et al. 2010). The authors describe how the PAMAM dendrimer acts as a 
carrier to an increased localised delivery whilst reducing the diffusion across the skin 
compared to the 8-MOP in free solution. The increase in retention within the deeper 
layers of the skin would allow for enhanced therapeutic effect for diseases such as 
psoriasis and atopic eczema. 
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Venuganti and Perumal (2008), investigated PAMAM dendrimers as a 
permeation enhancer of 5-fluorouracil when dosed from a range of vehicles. The 
authors successfully increased the flux of 5-fluorouracil (5-FU) across ex vivo porcine 
skin using a Franz-type diffusion cell model. A formulation containing a saturated 
dispersion of a G4-PAMAM-NH2 – 5-FU complex resulted in a 1.77-fold and 1.38-fold 
increase in flux for isopropyl myristate (IPM) and mineral oil, respectively when 
compared 5-FU alone dispersed in IPM and mineral oil. There was no significant 
increase in flux for the co-treatment applied in PBS when compared to the 5-FU 
dosed alone in PBS. To delineate the PAMAM dendrimer’s interaction with the skin 
membrane the authors also conducted a pre-dose PAMAM treatment. A G4-PAMAM-
NH2 preparation (0.2 mL, 1 mM) was dosed onto the skin for a 2, 12 and 24 h contact 
period. Afterwards, the 5-FU was applied in an IPM formulation and a significant 
increase in flux was observed for 5-FU and was found to be proportional to the 
PAMAM dendrimer pre-treatment contact time. The pre-treatment of PAMAM 
dendrimer resulted in a higher flux than the co-treatment application (Venuganti and 
Perumal, 2008).  
 
All of the vehicles were tested with PAMAM-5-FU and compared to 5-FU in the 
same vehicle. There was a significant enhancement in drug flux across the skin with 
the addition of PAMAM compared to the 5-FU in respective free solutions (with the 
exception of PBS). The PAMAM dendrimer pre-treatment results within this study that 
show ~ a tenfold increase in the penetration of CHG suggest that the PAMAM 
dendrimer has a physical effect on modulating the skin barrier as the drug flux across 
the skin was significantly higher for the pre-dose when compared to the co-dose 
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application. The enhancement in permeation was not due to the dendrimer-drug 
interactions but due to the dendrimer-skin interactions.            
 
PAMAM dendrimers were also shown to enhance the permeation of riboflavin 
in an oil-in-water (o/w) emulsion two to three-fold across porcine ear epidermis and 
polyvinyldifluoride membrane. The authors established that the G2-PAMAM-NH2 
dendrimer was the most effective at enhancing the penetration of riboflavin. The 
penetration enhancement was shown to be generation dependent and in decreasing 
order of penetration enhancement was, G2 > G3 ≫ G2.5 > G3.5 > G4 across the 
porcine epidermis (Filipowicz and Wolowiec, 2011). The authors believe that the 
enhancement is due to the solubilisation of the poorly soluble drug and due to the 
absorption of the PAMAM dendrimer. No mechanism or evidence for PAMAM 
penetration was offered or eluded to. The assumption that PAMAM dendrimers, that 
are large macromolecules, diffused ‘faster’ within the skin compared to the low 
molecular weight riboflavin was based on the detection of a fluorophore and not the 
native dendrimer. Fluorescein isothiocyanate was detected throughout the skin strata 
however there was no evidence to suggest that the fluorophore was still attached to 
the PAMAM dendrimer. Riboflavin has a molecular mass of 376.36 Da that is 
~10 times smaller than G2-PAMAM-NH2 that has a molecular mass of 3256 Da.  
 
The passive diffusion of a compound across the SC is governed by Fick’s 
second law of diffusion that contains the diffusion coefficient of a compound (Williams 
and Barry, 2012). The diffusion coefficient is dependent on the molecular size 
therefore it is unlikely that macromolecule as large as a PAMAM dendrimer would 
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diffuse through a membrane that is approximately 2500 µm in thickness (Meyer and 
Zschemisch, 2002) within a ten hour time frame. Therefore it is likely that it is the free 
fluorophore that has readily penetrated the skin rather than the dendrimer with a 
fluorophore attached, particularly in light of the 500 Da cut off for skin penetrants (Bos 
and Meinardi, 2000).  
 
As to whether the dendrimer itself permeates the skin remains a controversial 
subject with very few investigations published in the literature. A recent study 
established that generation 4 PAMAM dendrimers with various terminal functionalities 
were limited to the superficial layers of the SC once topically applied (Venuganti et al. 
2011). The authors found that -NH2 terminated PAMAM dendrimers penetrated 
further within the SC than –COOH or -OH terminated PAMAM dendrimers. This may 
be a result of the cationic PAMAM dendrimers causing perturbation of the intercellular 
lipids through a range of mechanisms such as lipid extraction and/or fluidization 
(Barry, 2004). Neutral surface engineered dendrimers were found not to penetrate the 
SC of porcine skin (Küchler et al. 2009).  
 
The degree of SC penetration of a dendrimer is severely limited due to the 
dense surface charge, hydrophilicity and the excessive molecular weight (typically 
>5000 Da) (Chauhan et al. 2003). The bulkiness of the macromolecule would 
significantly impair the ability for a PAMAM dendrimer to diffuse through the SC. The 
routes of drug penetration across the skin were discussed in detail within the general 
introduction but it should be noted that the tortuous intercellular lipid channels are 
between 0.5-40 nm wide (Cevc and Vierl, 2010 and Van der Merwe et al. 2006). 
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PAMAM dendrimers are hydrophilic and therefore diffusion across the SC along the 
tortuous intercellular lipid pathway would be unlikely. With the possible aggregation 
and coalescence of PAMAM dendrimers it is highly unlikely without a driving force 
that PAMAM dendrimers (ranging from 1- 10 nm) would be able to passively 
penetrate the SC past the superficial layers. There is a lack of free space for the 
diffusion for large macromolecules due to the restrictive nature of the densely 
organized intercellular lipids (Sun et al. 2012).  
 
The advantage of high molecular weight, skin-surface modulating enhancers is 
that they are less likely to generate irritation or an immuno-response unlike 
conventional small molecular weight chemical enhancers that easily penetrate the 
skin and cause irritation (Aoyagi et al. 1990). The mechanistic aspect of the PAMAM 
dendrimer’s modulation of the skin surface will be discussed in the following chapter. 
 
3.1.2 Rationale for the investigation of a PAMAM dendrimer skin pre-treatment 
to enhance the topical delivery of a model antiseptic, chlorhexidine 
digluconate. 
 
The poor permeability of CHG within the skin has been discussed in detail in 
Chapter 1. Increasing the deposition and permeation of CHG within the upper skin 
(i.e. SC, viable epidermis and follicles) to increase biocide contact with the resident 
bacteria would increase the efficacy. To increase the efficacy of CHG as an 
antiseptic, a novel permeation enhancement strategy is required. PAMAM dendrimers 
have been utilised as novel polymeric drug delivery systems for a variety of drugs 
discussed in Section 3.0.1. Though PAMAM dendrimers have been shown to 
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enhance the solubility of antimicrobial compounds (Cheng et al. 2007a), until this 
study an investigation into the potential use of PAMAM dendrimers as permeation 
enhancers of a topically applied antiseptic had not been conducted. This chapter 
investigates whether there is a permeation enhancement effect after a PAMAM 
dendrimer pre-treatment for the model antiseptic, CHG.  
 
3.1.3 Aims and objectives 
 
The aim of this Chapter is to investigate as to whether a PAMAM dendrimer pre-
treatment enhances the permeation of CHG within porcine skin. 
To achieve this aim a number of objectives were necessary: 
(i) To conduct studies to determine whether a pre-treatment of 
G3-PAMAM-NH2 enhanced the percutaneous absorption of CHG within 
porcine heat-separated epidermis.  
(ii) To determine whether any enhancement effect is proportional to the 
PAMAM concentration of the pre-treatment application. 
(iii) To characterise the enhanced permeation profile after a PAMAM dendrimer 
pre-treatment within the SC by conducting a gravimetric tape strip assay on 
dermatomed porcine skin.  
 
3.2 Materials and methods 
 
All in vitro percutaneous absorption studies within this Chapter were conducted using 
the following regulatory protocols as a guide; 
(i) OECD Test Guideline 428 (2004)- Skin absorption: In vitro method. 
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(ii) OECD Guidance Document No. 28 (2004) 
The above method is accepted as a reliable standard for percutaneous absorption 
studies and permits the use of porcine skin as a surrogate for human skin. In addition 
to measuring the dermal absorption of CHG, a mass balance recovery of the drug in 
the various compartments of the skin was determined at 24h.  
 
3.2.1 Preparation of porcine ear epidermis and dermatomed porcine flank 
 
The pig ears were obtained from a local abattoir prior to any steam cleaning 
treatment. The skin was washed with distilled water and carefully shaved using 
clippers so as not to damage the tissue. The ears were secured firmly by being 
pinned down on a cork board. An incision around the outer edge of the pig ear was 
made using a scalpel and, using tweezers to pull the skin taut, the scalpel was slowly 
moved along the underside of the skin above the cartilage. The skin was slowly 
separated from the cartilage and removed.  It was then placed on foil and the 
cartilage was disposed of. The skin was then placed in a beaker of stirring water at a 
temperature of 60ºC for 60 seconds. After the 60 seconds the skin was pinned 
securely to a cork board. The epidermis was removed from the dermis by gentle 
scraping using the side of a spoon whilst keeping the skin taut with a pair of tweezers. 
The epidermis was gently separated from the dermis and rolled up as it was removed 
(Bhatti et al. 1988, Dick and Scott, 1992 and Scott and Clowes, 1992). At the end of 
the pig ear, the epidermis was lifted from the dermis noting which side is the SC and 
was floated on a tray of deep water. The epidermis was then captured on to a piece 
of foil with the SC facing upwards and with the skin stretched out and with air bubbles 
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removed. The skin was then hung to dry at room temperature and once dried, labeled 
and placed in a -20 ºC freezer until use (Davies et al. 2004). 
 
Dermatomed skin was prepared from the flank of six week old pigs obtained 
from a local abattoir prior to any steam cleaning treatment. The skin was washed with 
distilled water and secured on to a wooden block. The skin was carefully shaved 
using clippers and care was taken to not damage the tissue. The subcutaneous fat 
was carefully removed using a scalpel and then the skin was dermatomed to a 
thickness of 400 µm with an electric dermatome. It was then wrapped in aluminum foil 
and frozen at -20°C until required. 
 
Heat-separated porcine ear epidermis has been shown to be an excellent 
surrogate for human epidermis for skin permeation studies as it has similar 
morphological and permeability characteristics that are closer to that of a human 
compared to a rodent model (Benech-Kieffer et al. 2000 and Schmook et al. 2001). 
For studies using a tape stripping method to determine the drug permeation profile 
within the different histological skin compartments (SC, epidermis and dermis), 
dermatomed porcine flank has been shown to be an ideal surrogate for human skin. 
Pig flank skin has similar morphological properties and hair follicle density to human 
skin and also by using skin from pigs of the same age, sex and gene pool ensures 
that the model is homogenous and therefore suitable for dermal absorption studies 
and formulation optimisation (Davies et al. 2004). 
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3.2.2 Skin integrity check 
 
    The dermatomed or pig ear epidermis was punched out with a 3 cm diameter 
punch and placed upon a stainless steel mesh support grid within a Franz cell, with 
the SC facing upwards. The application site of the Franz cell was an area of 2.54 cm2.  
To check the integrity of the skin, 4.5 mL of physiological saline (0.9 % w/w NaCl) 
was added to the receptor chamber and 2 mL of physiological saline was added to 
the donor chamber and placed in a circulating water bath on a submersible magnetic 
stirrer at 32°C for 30 minutes. After the cells had equilibrated, the transepithelial 
electrical resistance (TEER) was measured to check the integrity of the porcine skin. 
Prior to readings being taken, the instrument was calibrated using a resistor. It has 
been established that normal porcine skin in the Franz cells used should have an 
electrical resistance reading of ≥ 3 KΩ to pass the integrity check (Davies et al. 2004). 
Any diffusion cells that did not meet the integrity threshold were not included within 
the studies. TEER was used as opposed to trans-epidermal water loss (TEWL) due to 
the method being quicker whilst still correlating well with membrane integrity. 
 
3.2.3 The effect of PAMAM dendrimer pre-treatment on the in vitro permeation 
on CHG using porcine epidermis. 
 
 The diffusion cells that had passed the integrity check were removed from the 
water bath and the skin surface was allowed to air dry for 2 h at ambient temperature. 
4.5 mL of physiological saline was added to the receptor chamber of each Franz cell. 
The Franz cells were placed in the water bath (32°C ± 1°C) on a submersible stirring 
plate for 30 minutes and allowed to equilibrate. Both a G3-PAMAM-NH2 
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(0.5 mM-10 mM) and a 2 % (w/v) solution of CHG were prepared in distilled water 
from a 20 % (w/v) solution of G3-PAMAM-NH2 and a 20 % (w/v) solution of CHG 
respectively.  Once the Franz cells had equilibrated, a 0.2 mL of G3-PAMAM-NH2 
(0.5 mM-10 mM) was applied to the skin surface for a 24 h contact time or in the case 
of the controls the vehicle was dosed without the presence of PAMAM dendrimer. 
After a 24 h time period the PAMAM dendrimer layer was removed from the skin 
surface by rinsing 2 mL aliquots of distilled water (10 mL in total) over the surface of 
the dosed skin, taking care not to damage the skin. The vehicle control was treated in 
an identical way and was also washed at 24 h. The skin surface was then blotted dry 
with adsorbent paper and dosed with an infinite dose (1 mL) of the CHG solution 
(2 % w/v). This was applied to the skin surface and left for a contact time of 24 h. At 
various time points a 500 µL aliquot of receptor fluid was removed and replaced with 
fresh physiological saline. After 24 h, excess CHG was removed from the skin surface 
of each diffusion cell by rinsing with 2 mL aliquots of distilled water (10 mL in total) 
over the surface of the dosed skin. The washings were placed in a labelled 25 mL 
volumetric and made up to volume. 
 
  The pig ear epidermis was immediately placed into HPLC mobile phase (see 
Section 3.2.5 for HPLC methodology section) for CHG extraction. The CHG from the 
donor cells was also extracted in 10 mL of HPLC mobile phase overnight. The 
following day the skin samples were agitated using a vortex mixer for 15 minutes and 
sonicated for 15 minutes. An aliquot of the sample was syringe-filtered (0.2 µm, 
15 mm diameter polypropylene filters, Fisher Scientific, Loughbrough, UK) and diluted 
appropriately. The aliquots taken over the 24 h period were also filtered but not 
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diluted to prevent dilution below the limits of quantification. The samples were placed 
in 2 mL HPLC vials with a soft septum and analysed by HPLC for the CHG content. 
Only diffusion cells that had leaked upon dosing were not incorporated within the 
results. 
 
3.2.4 Franz diffusion cell studies using porcine dermatomed skin for tape 
stripping. 
 
The Franz cells were dosed as above in section 3.2.3 but the dermatomed skin 
was also tape stripped at the end of the experiment. Gravimetric analysis of SC 
content on the tape strips was conducted for each tape strip. Each tape strip was pre-
cut and allowed to sit at room temperature for 2 h to allow volatile adhesive 
components to evaporate from the tape strip (Lademann et al. 2009). This is due to 
the volatile components skewing the gravimetric analysis of the tape strips. The 
weight of each tape strip was measured to 4 decimal places on a balance (Precisa, 
262 SMA-FR, Milton Keynes, UK) before and after the tape strip was taken. A thin 
plastic mask was placed around the dosed area (2.54 cm2) so that only SC material 
that was treated would be removed on to the tape strip. Between each tape strip the 
mask was cleansed in water and ethanol as to not contaminate the skin layers below. 
Once 21 tape strips were taken they were pooled together; tape strips 1-3 were 
analysed separately, tape strips 4-6, 7-10, 11-16 and strips 17-21 were pooled 
together and CHG was extracted in 10 mL of HPLC mobile phase. The tape stripped 
skin and donor chambers were also extracted in 10 mL of HPLC mobile phase. The 
samples were left overnight and the following morning the time point aliquots were 
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syringe filtered and transferred into 2 mL HPLC vials (Trebilcock et al. 1994). The 
skin, washings, donor chamber and tape strip samples were first vortex mixed for 
15 minutes and sonicated for 15 minutes before being syringe filtered, diluted if 
appropriate and placed into 2 mL HPLC vials. The samples were analysed by HPLC 
for the detection of CHG. 
Equation 3.1 was used to normalise the concentration of drug on the tape strip to the 
amount of SC material removed was taken from Reddy et al. (2002). 
 
Cn=mn ρsc/msc,n 
 
Equation 3.1 used to normalise the concentration of drug on each tape strip to 
the amount of SC on the corresponding tape. Cn is the concentration of the drug of 
the nth tape strip accounting for the mass of SC material (deduced gravimetrically), 
mn is the mass of drug in the nth tape strip, ρsc is the density of the SC assumed to be 
1 g/cm3 (Pirot et al. 1997) and msc,n is the mass of SC on the tape strip determined 
gravimetrically. 
 
3.2.5 HPLC method and validation for the detection of CHG 
 
HPLC analysis of the samples was conducted on a Shimadzu UCFC modula 
system with an SPD M20 diode array detector using an isocratic mobile phase 
consisting of a methanol: water mixture (75:25) with 0.005 M sodium 
octane-1-sulphonate and 0.1 % (v/v) triethylamine. The pH was adjusted with glacial 
acetic acid to pH 4. The flow rate was 1.5 mL per minute on a MetLab ODS-H reverse 
phase column (150 × 4.6 mm, 5µm) that was set for 40ºC. Mobile phase was used as 
the solvent for all CHG extractions and this method was adapted from (Karpanen et 
al. 2008). The HPLC method was validated on the Shimadzu system. The limit of 
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detection (LOD) was calculated to be 0.050 µg/mL and the limit of quantification 
(LOQ) was calculated as 0.167 µg/mL. The relative standard deviation (RSD) % was 
calculated for 6 repeats of the 10 µg/mL standard and was found to be 0.40 %. For 
the skin assays conducted in this chapter the RSD % for each standard was <5 % 
and the R2 value was 0.9999. 
 
3.2.6 Statistical data analysis 
 
 All data is presented as the mean ± SEM unless otherwise stated and were 
analysed using GraphPad Prism® version 5 (San Diego, USA). Prior to statistical 
analysis all data were placed in to a histogram to check for normality. To compare the 
mean total concentration of CHG detected within the porcine epidermis after various 
skin pre-treatments (various PAMAM dendrimer concentrations and phys. saline), a 
Kruskal Wallis ANOVA test (data was non-parametric) was conducted with p<0.05 
representing significance (Section 3.3.0, Figure 3.2). A Kruskal Wallis ANOVA with a 
Dunn’s post test to compare treatment groups was also performed to determine if 
there was a different in total CHG concentration within the receptor fluid at 24 h for 
the different skin pre-treatment groups (Section 3.3.0, Figure 3.3). In Section 3.3.1 A 
Kruskal Wallis ANOVA was utilised to determine whether there was a significant 
difference between the total CHG concentration extracted from the tape strips after 
various skin pre-treatments with p<0.05 signifying statistical significance (Figure 
3.7a). In Figure 3.7b a Kruskal Wallis test with a Dunn’s post test was employed to 
determine whether there was a significant difference in CHG concentration within the 
epidermis and dermis after various skin pre-treatments.  
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3.3 Results 
3.3.0 In vitro Franz diffusion cell study investigating the effect of a PAMAM 
dendrimer pre-treatment on the permeation on CHG using porcine epidermis. 
 
CHG is known to adsorb on to a variety of surfaces including glass, cotton 
wool and skin (Denton, 1991). In vitro Franz diffusion cell studies are often used to 
provide mass balance data to determine the % recovery of a drug from the various 
diffusion cell compartments. With the knowledge that CHG adsorbs strongly on to a 
range of materials, a 100 µL aliquot of three different concentrations of CHG was 
spiked onto the compartments of a Franz cell (Table 3.1). The % of recovered CHG 
from each Franz cell compartment was very similar across the three concentrations 
tested. The average coefficient of variance for each Franz cell compartment (n=3) for 
the three CHG concentrations was 2.41 % suggesting that the adsorption of CHG 
onto the surfaces is not concentration dependent but more likely surface area 
dependent. The lowest % recovery was exhibited after spiking (a dose area of 
2.54 cm2) porcine epidermis in which across the three CHG concentrations (1, 5 and 
10 % w/v) was 84.78 ± 1.336, thus resulting in around a 15 % loss of CHG. Typically, 
6.3 % of the total amount of CHG dosed on to a strip of adhesive tape (20 mm in 
length) was not recovered. The percentage of dosed CHG that was not recovered 
from the glass donor chamber was ~9 %. A provisional study was conducted whereby 
silanised glass (silanised within the laboratory) was used in parallel to glassware that 
had not undergone silanisation. Surprisingly, it was found that the silanisation process 
of the glass did not enhance the recovery of the dosed CHG (data not shown). A 
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published silanisation protocol was used (Seed, 2001) though it is possible that the 
chlorotrimethylsilane had not covered the whole surface area of the glassware. 
Further, a range of adhesive tapes manufactured by different companies, in addition 
to the conventional Scotch 3M tape, were investigated and a range of extraction 
processes including length of time, solvent, agitation processes and temperature 
were investigated (data not shown). The optimal extraction process that was 
determined is outlined in section 3.2.3 and was found to be extraction in mobile phase 
for 24 h at room temperature followed by 15 minutes of high speed vortex mixing and 
15 minutes of sonication.  
Table 3.1 Percentage recovery of three concentrations of aqueous 
chlorhexidine digluconate after 100 µl was spiked on to each compartment of a 
Franz cell.  
CHG concentration 
  % Recovered of dose spiked onto Franz cell 
compartments after 24 h 
Epidermis Adhesive tape strip Donor chamber 
1 % (w/v) CHG 
dosed 
88 94 93 
84 92 91 
86 94 91 
Mean ± SEM 86.00 ± 1.16 93.33 ± 0.67 91.67 ± 0.67 
5 % (w/v) CHG 
dosed 
88 91 91 
82 94 88 
81 91 93 
Mean ± SEM 83.67 ± 2.19 92 ± 1.00 90.67 ± 1.45 
10 % (w/v) CHG 
dosed 
84 92 88 
86 97 94 
84 94 91 
Mean ± SEM 84.67 ± 0.67 94.33 ± 1.45 91.00 ±1.73 
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The in vitro dermal delivery and absorption of CHG applied after a range of 
G3-PAMAM-NH2 skin pre-treatments can be found within this section. The data within 
this section presents the distribution of CHG extracted from the diffusion cell 
compartments (including the epidermis) and also the rate of the absorption within the 
skin over 24 h. The data is illustrated as the concentration (µg/cm2) but also as the 
percentage of applied dose for ease of interpretation. Table 3.2 shows the absorption 
and distribution of CHG within the Franz cell system after a skin pre-treatment of 
physiological saline (0.9 %) for 24 h (to act as a control for G3-PAMAM-NH2 
dendrimer pre-treated skin). It was found that a mean concentration (815.13 ± 154.94 
µg/cm2) of CHG applied to the skin was extracted from the glass donor chamber. 
Therefore, ~10 % of the dosed CHG was possibly adsorbed onto the glass of the 
donor chamber of the Franz cell. Over 50 % of the dosed CHG was removed on 
washing the skin at 24 h leaving ~13 % of the dosed CHG absorbed. A very low 
concentration of absorbed CHG was located within the receptor fluid (3.226 ± 
1.622 µg/cm2, ~0.04 % of applied dose) and a mean concentration of 1030.668 ± 
130.917 µg/cm2 that is ~13 % of the applied CHG was extracted from the porcine 
epidermis. A mean total CHG recovery of 75.299 ± 8.715 % of the applied dose was 
obtained therefore around 25 % of the dosed CHG is unaccounted for within the data 
shown. Potential explanations for the loss of CHG and comparison of the total 
recoveries compared to the spiking assay are outlined within the discussion. 
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Table 3.2. Compartmental diffusion cell data of CHG concentration for the 
control skin pre-treatment. Percutaneous absorption (mass balance) of CHG within 
porcine epidermis after a 24 h pre-treatment of physiological saline (NaCl 0.9 %).  
Mean ± SEM (n=15) is shown. 
Sample 
(n=15) 
CHG (µg/cm2) 
 
Mean             SEM 
  % of applied dose 
 
Mean            SEM 
Donor 
chamber 
 
815.13 154.94 10.35 1.97 
Skin wash 
 
4080.06 398.89 51.82 5.07 
Epidermis 
 
1030.67 130.92 13.09 1.66 
Receptor 
fluid 
 
3.23 1.62 0.041 0.02 
Total 
recovered 
 
5929.09 686.37 75.30 8.72 
 
The rate of absorption of CHG was calculated after a physiological saline pre-
treatment in substitute of G3-PAMAM-NH2 dendrimer as a control. The mean rate of 
CHG absorption was particularly slow over the 0-24h time period at 0.10 ± 
0.02 µg/cm2/h. A 12 h lag phase was observed and the mean rate of absorption from 
15-24 h was calculated to be 0.22 ± 0.10 µg/cm2/h. As observed within Table 3.2 & 
3.3, CHG applied to skin alone has a slow rate of absorption and CHG was 
demonstrated to permeate the epidermis poorly. In order to reduce the lag time and 
increase the rate of absorption a PAMAM dendrimer pre-treatment was utilised in the 
following studies within this Section.  
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Table 3.3 Rate of absorption of CHG over 24 h after a control skin pre-
treatment. Rate of absorption (µg/cm2/h) after application of CHG (2 % w/v, 1 mL, 
24 h) within porcine epidermis. 
Cell number 
(n=15) 
Absorption rate (µg/cm2/h) 
0-12 h 15-24 h 0-24 h 
113 0.00 0.00 0.00 
118 0.00 0.00 0.00 
120 0.18 0.94 0.48 
124 0.00 0.00 0.00 
117 0.00 0.45 0.22 
128 0.00 0.76 0.38 
114 0.00 0.00 0.00 
137 0.00 0.00 0.00 
144 0.00 0.00 0.00 
156 0.00 0.00 0.00 
138 0.00 0.00 0.00 
139 0.00 0.00 0.00 
136 0.06 1.13 0.37 
151 0.00 0.00 0.00 
134 0.00 0.00 0.00 
Mean 0.016 0.22 0.10 
SEM 0.013 0.10 0.05 
 
Table 3.4 exhibits the percutaneous absorption of CHG after the skin has been 
pre-treated with a 0.5 mM G3-PAMAM-NH2 solution for 24 h. As expected, around 
57 % of CHG was recovered from the skin wash after 24 h after CHG application. It 
was found that ~4 % of the total CHG applied was recovered from the glass donor 
chamber and was therefore unlikely to be available for skin absorption. The total 
percentage of applied drug that was considered to be absorbed was ~16.5 % with 
15.3 % (1202.76 ± 177.21 µg/cm2) absorbed within the porcine epidermis and 0.4 %  
(92.01 ± 34.49 µg/cm2) absorbed within the receptor fluid over a 24 h time period. 
There was a mean total CHG recovery of 77.7 % from the applied dose which is 
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considered acceptable for cold studies under OECD 428 guidelines, but does leave  
~20 % of the applied CHG dose unaccounted for within this data set.  
Table 3.4. Compartmental diffusion cell data of CHG concentration after a skin 
pre-treatment of G3-PAMAM-NH2 dendrimer (0.5 mM). Percutaneous absorption 
(mass balance) of CHG (2  % w/v, 1 mL, 24 h) within porcine epidermis after a 24 h 
skin pre-treatment of G3-PAMAM-NH2 (0.5 mM, 0.2 mL). 
Sample 
(n=19)* 
CHG (µg/cm2) 
 
Mean              SEM 
 % of applied dose 
 
Mean                SEM 
Donor 
chamber 
 
307.79 59.48 3.91 0.76 
Skin wash 
 
4515.08 301.08 57.34 3.82 
Epidermis 
 
1202.76 177.21 15.28 2.25 
Receptor 
fluid 
 
92.01 34.49 1.17 0.44 
Total 
recovered 
 
6117.64 572.26 77.69 7.27 
*Cell 140 and 150 was excluded due to skin membrane damage. No lag phase was observed in the 
CHG absorption as the barrier integrity was impaired.  
 
 
CHG was detected within the receptor fluid at various time points over a 24 h 
period after a pre-treatment of 0.5 mM G3-PAMAM-NH2 dendrimer. Table 3.5 
highlights the rate of absorption (µg/cm2/h) that was calculated from 0-9 h and 
12-24 h (absorption time intervals were determined from steady state portion of the 
mean CHG concentration absorption profile). For the majority of the Franz cells there 
was a 9 h lag time in the permeation of CHG with a mean absorption rate of 0.340 ± 
0.25 µg/cm2/h. The rate of absorption of CHG increased over the 12 to 24 h time 
period with a mean absorption rate of 1.62 ± 0.40 µg/cm2/h. The mean rate of 
absorption of CHG within the receptor fluid from 0-24 h after a 0.5 mM 
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G3-PAMAM-NH2 dendrimer treatment was calculated to be 0.89 ± 0.21 µg/cm
2/h. At 
the lowest concentration of PAMAM dendrimer pre-treatment the absorption rate over 
24 h was increased from 0.10± 0.05 µg/cm2/h without a PAMAM pre-treatment to a 
mean 0.89 ± 0.21 µg/cm2/h;an ~10 fold increase. 
Table 3.5. Rate of absorption of CHG over 24 h after a skin pre-treatment of 
G3-PAMAM-NH2 dendrimer (0.5 mM). Rate of absorption (µg/cm
2/h) after application 
of CHG (2 % w/v, 1 mL, 24 h) within porcine epidermis after a 24 h skin pre-treatment 
of G3-PAMAM-NH2 (0.5 mM, 0.2 mL). Data is displayed as the mean n=19. 
Cell number 
(n=19) 
Absorption rate (µg/cm
2
/h) 
0-9 h 12-24 h 0-24 h 
144 0.00 0.01 0.003 
150 2.74 0.71 0.96 
157 0.00 0.00 0.00 
153 0.11 6.17 3.00 
140* 7.212 2.04* -2.58* 
151 3.57 1.80 2.43 
150** 5.02 -0.92 1.53 
144 0.00 1.99 0.81 
153 0.17 1.91 0.86 
161 0.00 1.76 0.75 
151 0.03 2.24 0.10 
157 0.00 2.97 1.30 
115 0.00 0.00 0.00 
113 0.00 1.91 0.79 
125 0.08 3.78 2.15 
118 0.02 2.06 1.020 
111 0.00 0.006 0.002 
119 0.00 0.02 0.01 
137 0.00 0.17 0.07 
Mean 0.40 1.62 0.89 
SEM 0.25 0.40 0.22 
 
 
*Cell excluded from the calculation of the mean as no lag phase (i.e. very high CHG concentration 
detected at 3 h) is observed in the CHG absorption profile which is indicative of skin membrane 
damage. 
 
Table 3.6 illustrates the mean absorption and distribution of CHG within the 
Franz diffusion cell system after a 1 mM pre-treatment of G3-PAMAM-NH2 dendrimer. 
There was approximately a 2 fold increase in the concentration of CHG extracted 
from the glass donor chamber compared to the 0.5 mM G3-PAMAM-NH2 dendrimer 
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treatment after 24 h. A mean total of ~50 % of the applied CHG dose was washed 
from the skin surface at 24 h. The mean total percentage of CHG absorbed was 
~13 % (1033.55 ± 130.31 µg/cm2) of the applied dose, with 0.60 ± 0.15 % detected 
within the receptor fluid and 12.53 ± 1.50 % of the applied dose was extracted from 
the epidermis. The mean total  % of CHG recovered was ~72 %. This is comparable 
to the recovery of CHG from the PAMAM untreated control in Table 3.2.  
Table 3.6. Compartmental diffusion cell data of CHG concentration after a skin 
pre-treatment of G3-PAMAM-NH2 dendrimer (1 mM). Percutaneous absorption 
(mass balance) of CHG (2 % w/v, 1 mL, 24 h) within porcine epidermis after a 24 h 
skin pre-treatment of G3-PAMAM-NH2 (1 mM, 0.2 mL). Data is represented at the 
mean ± SEM (n=24). 
Sample 
(n=24)* 
CHG (µg/cm2) 
 
Mean            SEM 
  % of applied dose 
 
Mean              SEM 
Donor 
chamber 
 
700.35 96.38 8.89 1.22 
Skin wash 
 
3924.29 291.12 49.84 3.70 
Epidermis 
 
986.23 118.16 12.53 1.50 
Receptor 
fluid 
 
47.32 12.15 0.60 0.15 
Total 
recovered 
 
5658.19 517.81 71.86 6.58 
* Cell 149 excluded from the calculation of the mean. 
 
The CHG absorption rate after a 1 mM G3-PAMAM-NH2 dendrimer skin 
pre-treatment is presented within Table 3.7. As with the 0.5 mM dendrimer 
concentration the first 12 h rate of CHG absorption is relatively slow due to the lag 
time having a mean absorption rate of 0.17 ± 0.06 µg/cm2/h. The absorption rate 
increases over the 15-24 h time period with a mean absorption rate of 1.10 ± 0.25 
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µg/cm2/h. An overall absorption rate over the 24 h time period was calculated to be 
0.61 ± 0.14 µg/cm2/h. This absorption rate over 24 h is a similar value to the rates 
obtained for the other PAMAM concentrations tested for this time range and it is ~6.5 
times higher than the physiological saline pre-treated control skin. 
Table 3.7. Rate of absorption of CHG over 24 h after a skin pre-treatment 
of G3-PAMAM-NH2 dendrimer (1 mM). Rate of absorption (µg/cm
2/h) after 
application of CHG (2 % w/v, 1 mL, 24 h) within porcine epidermis after a 24 h skin 
pre-treatment of G3-PAMAM-NH2 (1 mM, 0.2 mL). 
Cell number 
(n=24) 
Absorption rate (µg/cm
2
/h) 
0-12 h 15-24 h 0-24 h 
157 0.00 0.18 0.07 
135 0.00 1.35 0.61 
126 0.00 4.19 1.58 
105 0.79 1.90 2.05 
107 0.17 0.14 0.21 
149* 30.48* 4.73* 15.98* 
152 0.14 2.34 0.62 
145 0.18 0.98 0.51 
141 0.10 0.99 0.50 
146 0.02 0.06 0.04 
153 0.00 0.008 0.002 
154 0.00 0.00 0.00 
153 0.034 0.89 0.35 
140 0.032 0.87 0.36 
153 0.13 2.54 1.24 
118 0.40 3.95 1.99 
129 0.96 1.004 0.81 
102 0.11 0.73 0.37 
112 0.00 0.23 0.07 
155 0.95 1.04 0.867 
151 0.00 0.03 0.009 
102 0.00 0.08 0.02 
110 0.00 1.60 1.73 
111 0.00 0.22 0.07 
Mean 0.17 1.10 0.61 
SEM 0.06 0.25 0.14 
* Cell 149 excluded from the calculation of the mean as no lag phase (i.e. very high CHG concentration 
detected at 3 h) is observed in the CHG absorption profile which is indicative of skin membrane 
damage. 
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The absorption and distribution of CHG after treatment with the highest 
concentration of PAMAM dendrimer pre-treatment (10 mM) tested is shown in Table 
3.8. As with the 1 mM G3-PAMAM-NH2 pre-treatment, a mean of 7.836 ± 1.735 % of 
the applied dose was recovered from the glass donor chamber. Expectedly, > 50 % of 
the dosed CHG was recovered within the 24 h wash (4419.766 ± 285.820 µg/cm2). 
The total percentage of CHG absorbed after a 10 mM PAMAM pre-treatment was 
~19.1  % (1504.587 ± 203.750 µg/cm2) with ~18.1  % absorbed within the epidermis 
(1421.675 ± 187.069 µg/cm2)  and ~1.1  % absorbed within the receptor fluid (82.912 
± 16.681 µg/cm2).  
Table 3.8. Compartmental diffusion cell data of CHG concentration after a skin 
pre-treatment of G3-PAMAM-NH2 dendrimer (10 mM). Percutaneous absorption 
(mass balance) of CHG within porcine epidermis after a 24 h pre-treatment of 
G3-PAMAM-NH2 (10 mM). Data is represented at the mean ± SEM (n=24). 
Sample 
(n=24)* 
CHG (µg/cm2) 
 
Mean             SEM 
  % of applied dose 
 
Mean            SEM 
Donor 
chamber 
 
617.04 136.62 7.84 1.74 
Skin wash 
 
4419.77 285.82 56.13 3.63 
Epidermis 
 
1421.68 187.07 18.06 2.38 
Receptor 
fluid 
 
82.91 16.68 1.05 0.21 
Total 
recovered 
 
6541.39 626.19 83.07 7.95 
*With one diffusion cell (99) excluded. 
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The absorption rate for CHG after a 10 mM G3-PAMAM-NH2 dendrimer skin 
pre-treatment can be observed in Table 3.9. The first 0-12 h time period had a mean 
observable absorption rate of 0.48 ± 0.14 µg/cm2/h which increased to 1.53 ± 0.32 
µg/cm2/h at a time period of 15-24 h. Over a 24 h time period the CHG absorption 
rate was calculated as 0.98 ± 0.19 µg/cm2/h. The CHG 0-24 h absorption rate for 
10 mM PAMAM dendrimer was ~10 fold higher than for physiological saline pre-
treated skin. All PAMAM dendrimer skin pre-treatments exhibited a similar 0-24 h 
CHG absorption profile with 0.5 mM, 1 mM and 10 mM exhibiting absorption rates of 
0.89 ± 0.22, 0.61 ± 0.14 and 0.91 ± 0.19 µg/cm2/h respectively. Without a PAMAM 
dendrimer pre-treatment the absorption of CHG over 24 h was only 0.10 ± 0.05 
µg/cm2/h.  
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Table 3.9 Rate of absorption of CHG over 24 h after a skin pre-treatment of 
G3-PAMAM-NH2 dendrimer (10 mM). Rate of absorption (µg/cm
2/h) after application 
of CHG (2 % w/v, 1 mL, 24 h) within porcine epidermis after a 24 h skin pre-treatment 
of G3-PAMAM-NH2 (10 mM, 0.2 mL). 
Cell number 
(n=24) 
Absorption rate (µg/cm
2
/h) 
0-12 h 15-24 h 0-24 h 
87 0.00 0.00 0.00 
109 0.00 0.00 0.00 
86 0.83 0.59 0.65 
83 0.00 0.07 0.05 
99* 14.81* 0.84* 5.41* 
72 2.64 1.55 1.79 
94 0.00 0.13 0.03 
83 0.00 0.41 0.11 
109 0.00 0.30 0.19 
86 0.00 0.77 0.24 
99 0.88 4.15 2.85 
85 1.66 0.74 1.20 
92 0.00 2.99 1.29 
93 0.83 4.71 2.95 
60 0.36 3.51 2.01 
64 0.21 1.41 0.83 
55 0.60 3.31 2.12 
91 0.00 1.98 0.69 
117 0.54 0.26 0.49 
124 0.16 0.59 0.33 
119 1.13 4.21 2.06 
111 0.73 0.71 0.96 
130 0.007 0.70 0.28 
115 0.40 1.98 1.40 
Mean 0.48 1.53 0.98 
SEM 0.14 0.32 0.19 
 
*Cell 99 excluded from the calculation of the mean as no lag phase is observed in the CHG absorption 
profile which is indicative of skin membrane damage. 
 
A graph plotting the permeation profiles of CHG within the receptor fluid over a 
24 h time period after all pre-treatment conditions is illustrated in Figure 3.1. When 
CHG was dosed after a pre-treatment of physiological saline only 3.23 ± 1.62 µg/cm2 
of CHG had permeated into the receptor fluid at 24 h and a 9 h lag time was 
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observed. The highest total concentration of CHG detected within the receptor fluid 
was observed for 0.5mM G3-PAMAM-NH2 dendrimer pre-treated skin at 24 h (92.01 ± 
34.49 µg/cm2) compared 1 mM G3-PAMAM-NH2 dendrimer pre-treated skin that 
yielded the lowest concentration of CHG permeation within the receptor fluid (47.32 ± 
12.15 µg/cm2). The concentration profile of CHG within the receptor fluid was very 
similar across all PAMAM dendrimer concentrations tested up to a time period of 9 h. 
There was a steady increase in the concentration of CHG up to 6 h where there is a 
slight plateau until 12 h. The largest concentration increase was observed from the 12 
to 24 h time period.  Figure 3.2 illustrates the concentration of CHG extracted from 
the epidermis after 24 h for all four skin pre-treatments. Though the 10 mM 
G3-PAMAM-NH2 dendrimer skin pre-treatment yielded the highest CHG deposition 
within the epidermis no significant difference was observed between the CHG 
concentrations (µg/cm2) extracted from the epidermis for the four skin pre-treatment 
groups (Kruskal Wallis ANOVA, p>0.05). 
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Figure 3.1 Mean concentration of CHG detected within the receptor fluid over a 
24 h time period after a range of skin pre-treatments. Profile of amount of CHG 
absorbed (Mean ± SEM) over a 24 h time period after application of CHG (2 % w/v, 
1 mL, 24 h) within porcine epidermis after a 24 h skin pre-treatment of Phys. saline 
(0.9 % NaCl, 0.2 mL)  represented by turquoise circles, G3-PAMAM-NH2 (10 mM, 
0.2 mL) represented by purple squares, G3-PAMAM-NH2 (1 mM, 0.2 mL) represented 
by dark blue triangles and  G3-PAMAM-NH2 (0.5 mM, 0.2 mL) is represented by light 
blue inverted triangles.  
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Concentration of CHG within the epidermis at 24 h after a range of 
skin pre-treatments. Data is represented as the mean ± SEM. CHG was dosed in 
the same volume and concentration as the PAMAM treated groups after a 24 h pre-
treatment of phys. saline. No statistical significance was observed between groups or 
treated and untreated (p>0.05).  
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The total concentration of CHG (mean ± SEM) detected within the receptor fluid at 
24 h for a range of PAMAM dendrimer pre-treatments is displayed in graphical form in 
Figure 3.3. The data was plotted as a histogram which revealed that the data was not 
normally distributed. A Kruskal Wallis ANOVA with a Dunn’s post test confirmed that 
for all three concentrations of G3-PAMAM-NH2 dendrimer skin pre-treatment tested, 
the total concentrations of CHG absorbed within the receptor fluids at 24 h were 
statistically different (p< 0.0001) from the physiological saline pre-treated skin. No 
significant difference in the absorption of CHG at 24 h was observed between the 
different PAMAM dendrimer concentrations tested (p>0.05) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Concentration of CHG absorbed within the receptor fluid at 24 h after 
various skin pre-treatments. Illustration of the (mean ± SEM) concentration of CHG 
permeated into the receptor fluid at 24 h (µg/cm2) against the PAMAM dendrimer pre-
treatment post application of a 2 % CHG (w/v) solution. PAMAM dendrimer pre-
treated skin was significantly different from the phys. saline pre-treated skin 
(p<0.0001).   
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After application of a PAMAM dendrimer solution to the skin it was noted that a 
thin film formed once the vehicle had evaporated. The PAMAM dendrimer film was 
tacky, transparent and viscous. Figure 3.4 illustrates the difference in appearance of 
the skin surface of a vehicle control compared to that of PAMAM dendrimer dosed 
skin. The PAMAM dendrimer film was found to be water soluble and was removed 
from the skin surface by agitating water across the skin surface. Due to the 
hygroscopic nature of PAMAM dendrimers it was not possible to determine the 
transepidermal water loss (TEWL) of the layer to determine whether it could be 
considered ‘breathable’ i.e. allows for TEWL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Photograph of the skin surface comparing the control to skin dosed 
with PAMAM dendrimer. Franz cells with the donor chamber removed to reveal the 
epidermis. The Franz cell on the left was dosed with a vehicle control (H2O:MeOH)  
and the Franz cell on the right was dosed with a G3-PAMAM-NH2 dendrimer solution 
(10 mM, 0.2 mL). A dendrimer film across the skin surface is clearly visible on the 
right-hand-side. 
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3.3.1 Franz diffusion cell studies using tape stripping to profile CHG within 
porcine dermatomed skin 
 
The percutaneous absorption studies using porcine epidermis were used as a 
screening approach to determine whether a PAMAM dendrimer pre-treatment would 
enhance the permeation of chlorhexidine into the skin and which concentration would 
be most effective. The concentration chosen to be taken forward to tape stripping 
studies was the mid-range 1 mM solution of G3-PAMAM-NH2 dendrimer. The tape 
stripping method is the gold standard in determining the distribution of a compound 
within the SC (OECD, 2004). To fully remove the SC, 21 tape strips were removed 
from each dosed Franz cell (Trebilcock et al. 1994) but were weighed before and after 
so that gravimetric analysis could be used to determine the amount of SC removed 
on each tape strip. The difference in weight of each tape strip was calculated to 
determine the mass of SC material on each tape strip which was then plotted against 
the tape strip number. A number of observations during this procedure are worthy of 
note. At around tape strip 6 the skin became very moist therefore interstitial fluid was 
being removed as well as SC on the tape strips and recorded within the mass data. 
The moisture attributed to interstitial fluid also caused the epidermis to tear during the 
tape stripping process, typically after the template had been placed over the dose 
area and pressure applied to the tape strip. It is for this reason why 21 tape strips 
were not obtained from the skin in every case. 
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Figure 3.5 illustrates the mean cumulative amount of SC material plotted 
against the tape strip number. The skin that was dosed with a physiological saline 
pre-treatment then dosed with CHG (2 % w/v) had a mean cumulative amount of SC 
material of 12.24 ± 2.62 mg at tape strip 20. This was comparable to the dendrimer 
solution vehicle control (H2O: MeOH) that had a cumulative total amount of 14.08 ± 
3.27 mg at tape strip 19. The highest mass of SC material removed was after the skin 
was pre-treated with the PAMAM dendrimer and a mean cumulative mass of 23.64 ± 
8.11 mg was removed at tape strip 15. Also, it was noted that fewer tape strips were 
taken from the PAMAM dendrimer pre-treated skin as the skin was prone to tear 
during the procedure.   
 
Figure 3.5. Graph illustrating the cumulative mass of SC material on individual 
tape strips for various skin pre-treatments. Cumulative mass of SC material (mg) 
plotted against tape strip number. Light blue circles represents dermatomed (400 µm) 
porcine skin dosed for 24 h with CHG (2  % w/v), green squares corresponds to skin 
pre-treated with a 1 mM solution of G3-PAMAM-NH2 dendrimer for 24 h before dosing 
with CHG (2  % w/v for 24 h). Dark blue triangles corresponds to the vehicle control 
(H2O:MeOH). The data points are presented as mean ± SEM (CHG n=21, PAMAM 
n= 13 and vehicle control n=3). 
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Figure 3.6. (a) illustrates the mean concentration of CHG extracted from the 
corresponding tape strips resulting in a profile of the CHG distribution. The superficial 
layers of the SC considered to be removed by tape strips 1-3 exhibited the highest 
concentration of CHG after a PAMAM dendrimer pre-treatment. The first tape strip 
(that is considered as having adsorbed CHG rather than having absorbed it) exhibited  
an average CHG concentration of 4012.91 ± 919.34 µg/mL, 2339.76 ± 1131.10 µg/mL 
and 1635.24 ± 296.84 (mean ±  SEM) for PAMAM pretreated, vehicle control and 
physiological saline pretreated respectively. The higher the tape strip number (and 
thus the deeper within the SC) the lower the concentration of CHG was detected 
across all treatment groups. For example, for tape strips 7-10 the mean concentration 
of CHG extracted from the tape strips was 179.18 ± 63.06 µg/mL, 132.02 ± 
6.35 µg/mL and 99.87 ± 23.29 µg/mL for PAMAM dendrimer pretreated, vehicle 
control and physiological saline pretreated skin respectively. That is approximately a 
20 fold decrease in CHG concentration when compared to tape strip 1, but would still 
be considered a high biocidal concentration of CHG. As with tape strip 1 the PAMAM 
dendrimer pretreated skin demonstrated the highest concentration of CHG for tape 
strips 7-10, however a high variability was observed between each Franz cell. With 
each successive tape strip removed from the skin (after ~tape strip 6) the moisture 
content increased resulting in tearing of the epidermis. After the epidermis has torn 
the remaining skin is removed from the Franz cell and the CHG is extracted from the 
skin and the last tape strip which tore the epidermis is included with the skin 
compartment. Comparisons between the CHG concentrations at the higher tape strip 
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numbers were not feasible due to the low sample number of the higher tape strips 
due to tearing of the epidermis. 
 
Figure 3.6 (b) illustrates the concentration of CHG calculated per mg of SC 
material removed on the corresponding tape strip(s). The calculation used to account 
for the weight of SC material can be found in section 3.2.4, Equation 3.1. If the 
gravimetric analysis is taken into account a different CHG distribution profile is 
observed within the SC (Figure 3.6 (b)). The profile appears rather irregular which 
may be due to the issue of the moisture that was observed on tapes strips 6 and 
upwards.  
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Figure 3.6. Concentration profile of CHG detected on each tape strips. (a) 
Concentration of CHG (µg/mg) extracted from tapes into a fixed volume of solvent. 
Extraction occurred after stripping 400 µm dermatomed skin after a pre-treatment for 
24 h with a 1 mM PAMAM solution of G3-PAMAM-NH2 dendrimer, vehicle control and 
Phys. saline. (b) Concentration of CHG per mg of SC material weighed gravimetrically 
(µg/mg) after stripping 400 µm dermatomed skin after a pre-treatment for 24 h with a 
1 mM PAMAM solution of G3-PAMAM-NH2 dendrimer, vehicle control and Phys. 
saline Data is represented at the mean ± SEM (CHG n=21, PAMAM n= 13 and 
vehicle control n=3). 
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Table 3.10 illustrates the mean absorption and distribution of CHG within the 
Franz cell system after a pre-treatment of physiological saline (0.9 % NaCl, 0.2 mL). 
After the excess unabsorbed CHG was removed within the wash, in this case a mean 
of 56.09 ± 6.56 % of applied dose (4416.09 ± 516.50 µg/cm2), the skin surface was 
allowed to dry at ambient temperature. The skin was then tape stripped up to 21 
times to remove the SC and assuming that the tape strips have removed the SC the 
mean percentage of applied dose of CHG distributed throughout the SC was found to 
be 16.49 ± 3.29 % (1298.03 ± 259.40 µg/cm2). The mean percentage of applied dose 
considered to be absorbed at 24 h including tapes strips (SC), the remaining 
epidermis/dermis and the concentration detected within the receptor fluid was 
calculated to be 6.39 ± 1.18 % (503.10 ± 92.87 µg/cm2). Again ~5.5 % of the dosed 
CHG was extracted from the glass donor chamber which is comparable to the CHG 
adsorbed on to the donor chambers across the studies mentioned previously within 
this section. A total recovery of ~85 % was achieved which is considered a good 
recovery when using non radio-labeled drugs. This is a CHG recovery increase 
of~10 % when compared to the epidermis study. This is due to an increased recovery 
of CHG from the skin due to extraction of CHG using tape strips from the SC. 
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Table 3.10. Compartmental diffusion cell data (including tape strips) of CHG 
concentration for the control skin pre-treatment. Percutaneous absorption (mass 
balance) of CHG (2 % w/v, 1 mL, 24 h) within porcine dermatomed skin (400 µm 
thick) after a 24 h skin pre-treatment of phys. saline (0.9 % NaCl, 0.2 mL). Data is 
represented at the mean ± SEM (n=21). 
Sample 
(n=21) 
CHG (µg/cm
2
) 
  
Mean              SEM 
  % of applied dose 
  
Mean                SEM 
Donor 
chamber 
  
434.41 85.97 5.52 1.09 
Skin wash 
  
4416.09 516.50 56.08 6.56 
Tape strips 
  
1298.03 259.40 16.48 3.29 
Epidermis/ 
dermis 
  
503.10 92.85 6.39 1.18 
Receptor fluid 
  
0.02 0.02 0.0002 0.0002 
Total 
recovered 
  
6651.65 954.74 84.47 12.13 
 
The percutaneous absorption and distribution of CHG within the Franz 
diffusion cell after a pre-treatment for 24 h of the vehicle solution without PAMAM 
dendrimer can be observed in Table 3.11. The concentration of CHG extracted from 
the glass donor chamber is again typical of the previous studies and of the recovery 
when the donor chamber was spiked. Also typical is the mean 48.41 ± 2.59 % 
recovery of CHG within the skin wash at 24 h. The mean percentage of applied dose 
recovered from the tape strips which are assumed to have removed the SC was 
18.83 ± 6.87 % (1483.08 ± 540.78 µg/cm2). The mean percentage of applied dose of 
CHG recovered from the tape strips (SC), epidermis/dermis, and receptor fluid for the 
vehicle control was 27.95 ± 8.98 % (2200.4 ± 707.49 µg/cm2). This is a higher value 
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than the physiological saline control but still within the error range therefore the 
increase in absorbed CHG after being dosed with the vehicle solution is not 
significant (p>0.05).  
 
Table 3.11. Compartmental diffusion cell data (including tape strips) of CHG 
concentration after a vehicle control skin pre-treatment. Percutaneous absorption 
(mass balance) of CHG (2 % w/v, 1 mL, 24 h) within porcine dermatomed skin 
(400 µm thick)  after a 24 h skin pre-treatment of the vehicle solution without PAMAM 
dendrimer (H2O: MeOH, 82.5:17.5). Data is represented at the mean ± SEM (n=4). 
Sample 
(n=4) 
CHG (µg/cm2) 
 
Mean             SEM 
  % of applied dose 
 
Mean            SEM 
Donor chamber 
 
495.60 166.61 6.29 2.12 
Skin wash 
 
3812.01 204.40 48.41 2.59 
Tape strips 
 
1483.08 540.78 18.84 6.87 
Epidermis/dermis 
 
716.70 166.35 9.10 2.11 
Receptor fluid 
 
0.67 0.35 0.009 0.005 
Total recovered 
 
6508.07 1078.50 82.65 13.70 
 
Table 3.12 presents the percutaneous absorption and distribution data 
corresponding to the Franz cells dosed with a 1 mM G3-PAMAM-NH2 dendrimer 
solution pre-treatment before dosing with CHG (2 % w/v). There was an increase in 
the percentage of applied dose of CHG extracted from the tape strips and thus SC 
when compared to the physiological saline and the vehicle control. The mean 
percentage of applied dose recovered from the tape strips and thus the SC was 
25.95 ± 5.35 % (2043.10 ± 421.68 µg/cm2). This is the highest concentration of CHG 
recovered from the SC within the dermatomed study. The mean concentration of 
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CHG absorbed within the SC (tape strips), remaining epidermis/dermis and CHG 
recovered from receptor fluid was 39.64 ± 7.25 % (3121.53 ± 570.88 µg/cm2). A mean 
recovery of ~85 % of the total CHG applied to the skin was recovered.  
 
Table 3.12 Compartmental diffusion cell data (including tape strips) of CHG 
concentration after a G3-PAMAM-NH2 dendrimer (1 mM) skin pre-treatment. 
Percutaneous absorption (mass balance) of CHG (2 % w/v, 1 mL, 24 h) within porcine 
dermatomed skin (400 µm thick) after a 24 h skin pre-treatment of G3-PAMAM-NH2 
dendrimer (1 mM, 0.2 mL). Data is represented at the mean ± SEM (n=18). 
Sample 
(n=18) 
CHG (µg/cm2) 
 
Mean            SEM 
  % of applied dose 
 
Mean              SEM 
Donor chamber 
 
460.31 86.63 5.85 1.10 
Skin wash 
 
3142.01 401.61 39.90 5.10 
Tape strips 
 
2043.10 421.68 25.95 5.36 
Epidermis/dermis 
 
1077.50 148.99 13.68 1.89 
Receptor fluid 
 
0.94 0.21 0.012 0.002 
Total recovered 
 
6723.85 1059.11 85.39 13.45 
 
When the skin was pre-treated with a 1 mM solution of G3-PAMAM-NH2 a 
higher concentration of CHG was extracted from the total number of tape strips that is 
assumed to represent the SC. A mean concentration of 2043.10 ± 421.61 µg/cm2 of 
CHG was extracted from the tapes after a PAMAM dendrimer pre-treatment, 1483.08 
± 540.78 µg/cm2 after a vehicle solution pre-treatment and 1298.03 ± 259.40 µg/cm2 
was the mean CHG total extracted from all tape strips for physiological saline skin 
pre-treatment (Figure 3.7 (a)). The PAMAM dendrimer pre-treatment yielded the 
highest concentration of CHG from the total number of tape strips corresponding to 
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the SC compared to the treatment groups without the presence of the PAMAM 
dendrimer. This enhancement effect is not statistically significant due to the high 
inherent variability observed within this study.  
 
  Figure 3.7 (b) shows the mean concentration of CHG within the rest of the 
epidermis and dermis after the tape stripping procedure. The CHG concentration 
within the epidermis and dermis illustrates the same trend as Figure 3.7 (a) with 
regards to the CHG concentration within the SC. After a PAMAM dendrimer 
pre-treatment the concentration of CHG within the skin was statistically higher than 
that of the skin that had been pre-treated with physiological saline. No statistical 
difference was observed between the vehicle control and the negative physiological 
saline control (p>0.05). 
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Figure 3.7 CHG concentrations extracted from tape strips and the remaining skin after various skin pre-
treatments. (a) Graph plotting the mean total CHG extracted from the tape strips (µg/cm2) for each of the dermatomed 
skin (400 µm thick) pre-dose treatments. (b) Graph illustrating the mean total concentration (µg/cm2) of CHG extracted 
from the remaining epidermis and dermis after the SC had been removed by tape stripping. A non parametric Kruskal-
Wallis test was conducted with a Dunn’s post-test. The median for all 3 groups differed significantly (p<0.05) and the 
Dunn’s multiple comparison post-test highlighted a statistically significant difference between the G3-PAMAM-NH2 skin 
pre-treatment with a phys. saline skin pre-treatment (p<0.05). Data represented as mean ± SEM. 
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3.4 Discussion 
 
The penetration enhancement effect of the PAMAM dendrimer was not 
concentration-dependent. The data displayed within this chapter exhibited similar 
activity over the concentration range of 1-10 mM of G3-PAMAM-NH2 dendrimer used 
within the studies (Figure 3.3 showed no significant different between the PAMAM 
dendrimer concentrations in penetration enhancement p>0.05). It was shown that a 
PAMAM dendrimer pre-treatment (0.5 and10 mM) resulted in significant (~30 fold) 
increase (p<0.0001) in the concentration of CHG within the receptor fluid at 24 h 
(Figure 3.3). For a 1 mM G3-PAMAM-NH2 dendrimer skin pre-treatment ~16 fold 
increase in CHG within the receptor fluid was observed though a high variability for 
the study was observed also. This is likely due to inherent donor-donor skin variability 
as 5 skin donors were utilised for the epidermis studies. Further, after a PAMAM 
dendrimer pre-treatment the rate of CHG absorption over 24 h increased by 
~6.5-10 fold. Increasing the concentration of the PAMAM dendrimer did not 
proportionally increase the skin permeation of CHG. This effect was also reported for 
the hydrophilic drug 5-fluorouracil after a G4-PAMAM-NH2 skin pre-treatment 
(Venuganti and Perumal, 2009). This may be due to aggregation of the PAMAM 
dendrimers at high concentrations (Klajnert and Epand, 2005). 
 
It has been reported that a PAMAM dendrimer skin pre-treatment (24 h, 
unoccluded) enhanced the permeation of the hydrophobic NSAID, tamsulosin 
hydrochloride. A 7.5 mM solution of G3-PAMAM-NH2 in a chloroform vehicle resulted 
in ~4 fold increase in the amount of Tamsulosin permeated across a snake skin 
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membrane when compared to the control (Wang et al. 2003). Further; a 1 mM 
solution of G4-PAMAM-NH2  enhanced the permeation of the anti-cancer drug, 
5-fluorouracil, into the skin with an increase in the permeability coefficient of the 
hydrophilic drug by 4-fold in a mineral oil vehicle, 2.5 fold in isopropyl myristate 
vehicle but decreased by half in phosphate buffered saline (Venuganti and Perumal, 
2008). The permeability coefficient of the 5-fluorouracil increased after a PAMAM 
dendrimer pre-treatment but only from a lipophilic vehicle. Within the study outlined in 
Section 3.3.0 it was demonstrated that a PAMAM dendrimer pre-treatment (1-10 mM) 
enhanced the permeation of CHG, a hydrophilic antiseptic, across porcine epidermis 
from a hydrophilic vehicle. A comparison between the different species’ membrane 
models used and their suitability for permeation are discussed in further detail in 
chapters 4 and 6. Previously, PAMAM dendrimers had only been shown to enhance 
the topical or transdermal delivery of hydrophobic drugs or hydrophilic drugs within a 
hydrophobic vehicle. Further, this is the first study to investigate PAMAM dendrimers 
as a topical penetration enhancer of an antiseptic to increase the exposure between 
the biocide and resident bacteria.  
 
A PAMAM dendrimer pre-treatment reduced the lag time required for CHG to 
permeate the skin. Within the first 6 h it was the 10 mM PAMAM dendrimer solution 
pre-treatment that exhibited the highest CHG absorption. At 9-24 h it was 0.5 mM 
PAMAM dendrimer closely followed by 10 mM PAMAM dendrimer skin pre-treatment 
concentrations that resulted in the highest absorbance of CHG within the receptor 
fluid (Figure 3.1). This is also reflected in the calculated absorption rates of CHG 
dosed alone in aqueous solution in which the rate over 15-24 h time period is 
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considerably higher than for the 0-12 h absorption rate. The lag time for CHG 
permeation for the vehicle control was 12 h therefore the PAMAM dendrimer 
significantly reduced the lag time and would therefore have a much quicker antisepsis 
action. An efficacious antiseptic has been described by the Food and Drug 
Administration (FDA) for healthcare antiseptic drug products as- 
“a fast-acting [rapidly kills microorganisms], broad spectrum [kills a wide variety of 
microorganism species], persistent [suppresses regrowth of remaining microorganisms], 
antiseptic containing preparation that significantly reduces the number of microorganisms on 
intact skin” (Federal Register, 1994 and Art, 2005).  
  
Chlorhexidine digluconate possesses these attributes but has been shown to 
permeate the skin very slowly with a 12 h lag time therefore by decreasing the lag 
time with a PAMAM dendrimer pre-treatment the antisepsis of the deeper skin layers 
would occur within a shorter time frame. This capability therefore fulfills the first 
requirement of the FDA monograph more effectively and would result in an increased 
efficacy. The pre-treatment of PAMAM dendrimer on porcine epidermis surprisingly 
did not enhance the deposition of CHG significantly within the dermatological layer. 
Figure 3.2 illustrates that a 10 mM PAMAM dendrimer skin pre-treatment did increase 
the concentration of CHG within the epidermis but it was not statistically significant 
when compared to the vehicle control. It appears that the PAMAM dendrimer skin 
pre-treatment significantly enhanced the concentration of CHG across the skin  
 
It was observed throughout the experiments that once the vehicle had 
evaporated (ca. 3-6 h) a viscous and adhesive layer of G3-PAMAM-NH2 dendrimer 
was deposited across the skin surface (Figure 3.4). This is due to the highly 
hygroscopic nature of PAMAM dendrimers (Uppuluri et al. 1998) that extract water 
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from the surrounding environment to exist in a gel-like state. A dense PAMAM 
dendrimer layer distributed across the skin surface may reduce the TEWL from the 
skin causing skin hydration thus acting as a possible mechanism of enhancement for 
the skin permeation of CHG.  
 
Occlusion of the skin leading to increased hydration has been a known 
mechanism of skin penetration for many years (Wester and Maibach, 1995 and 
Roberts and Walker, 1993). The water content of the SC is typically 15-20 % dry 
weight of tissue but can increase up to 400 % of the dry weight of tissue under 
occlusion and increased humidity (Williams and Barry, 2012). Occlusion has been 
utilised as a permeation enhancer for a range of therapeutics and biomolecules 
including fluorescein isothiocyanate conjugated bovine serum albumin (Tan et al. 
2009) and C14 acetylsalicylic acid (Fritsch et al. 1963). The mechanism that results in 
the penetration enhancement of hydrated skin is not yet fully understood as no 
evidence of swelling within the lipids has been found but pools of water altering the 
micro-structure have been observed within the intercellular lipids using freeze fracture 
electron microscopy (Van Hal et al. 1996). On hydration of the skin, corneocytes 
within the centre of the SC become highly swollen increasing the cell volume 
(Bouwstra et al. 2003). Hydrating the skin for permeation enhancement of a wide 
range of therapeutics has been used for many years with regards to ointments and 
occlusion, but it does not enhance the skin permeation of all compounds (Bucks and 
Maibach, 1999). Further mechanisms of penetration enhancement by PAMAM 
dendrimers are explored in the following chapter. 
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A tape stripping assay on porcine dermatomed skin established an increase in 
the deposition of CHG within the SC (tape strips) and the remaining epidermis and 
dermis. Gravimetric analysis was used to quantify the amount of SC material 
removed with each tape strip. A template was used when tape stripping in order to 
remove only SC material from the 2.54 cm2 dosed region. During the experiment it 
was observed that at tape strip 6 and upwards a considerable portion of the weight 
was moisture; possibly interstitial fluid from the viable epidermis or remaining receptor 
fluid from underneath the skin. It has been shown that the SC hydration increases 
from the outer SC towards the inner stratum granulosum interface (Bommannan et al. 
1990) however it is unlikely that this would account for the degree of moisture 
observed upon the later sequential tape strips. The cumulative amount of SC material 
was calculated for the PAMAM dendrimer treated skin (G3-PAMAM-NH2, 1 mM), 
vehicle control and for skin pre-dosed with physiological saline. The cumulative 
weight of each tape strip for the vehicle control and the physiological saline pre-
treated skin were very similar with overlapping error bars (Figure 5). A considerable 
increase in the cumulative weight of SC material removed with each tape strip was 
observed after a PAMAM dendrimer skin pre-treatment. Also the number of tape 
strips that were removed before the epidermis was torn decreased after application of 
PAMAM dendrimer. This suggests that the PAMAM dendrimer caused a physical 
effect upon the skin which resulted in the increased removal of SC material.  
 
There are a number of reasons why the amount of SC material removed on a 
single tape strip can vary. Inherent experimental conditions such as anatomical site, 
age (Myer et al. 2006 and Lademann et al. 2009) and season of the skin donors were 
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accounted for as the skin was collected and prepared in parallel. Other extrinsic 
variables include the amount of pressure applied to remove each tape strip, duration 
of pressure applied and speed of tape strip removal (Löffler et al. 2004). These 
variables were reduced as all the tape stripping was conducted by the author using 
the same adhesive tape throughout and the same thumb to apply pressure to the skin 
for an equal time period of 5 seconds. The increase in SC material removed from 
each sequential tape strip for the PAMAM dendrimer pre-treatment is likely due to the 
PAMAM dendrimer itself as the applied formulation can have a marked effect on the 
tape stripping procedure (Schwarb et al. 1999 and Weighmann et al. 1999). PAMAM 
dendrimers have been shown to interact with skin lipids (Venuganti et al. 2009) and 
within chapter 4 G3-PAMAM-NH2 was shown to cause peak shifts of the amide I and 
II bands indicating alteration of the protein-lipid organisation within the SC. This 
physical effect upon the skin caused by the PAMAM dendrimer could explain the 
increased mass of SC material observed upon each sequential tape strip.  
 
Figure 3.6 (a) reports the concentration of CHG as a function of the tape strip 
number. The concentration of CHG within the first 3 tape strips was highest in the 
order of PAMAM dendrimer > vehicle control > physiological saline pre-treated skin. 
The CHG concentration was slightly higher for the vehicle control for tape strips 4-6 
but for tape strips 7-10 the PAMAM dendrimer pre-treated skin revealed a higher 
concentration of CHG. The amount of SC material removed with increasing tape strip 
number decreases as observed in Figure 3.5. Figure 3.6 (b) illustrates the same data 
but normalises (Equation 3.1) the drug concentration to the weight of the SC 
removed. The resulting permeation profile is irregular in nature which is likely due to 
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the inclusion of moisture within the gravimetric analysis, skewing the profile plot of 
CHG within the SC. It is for this reason that further analysis such as calculation of 
drug concentration as a function of SC depth was not pursued.  
 
The results of the tape strip study (Tables 3.10-12) show that after a 1 mM 
PAMAM dendrimer skin  pre-treatment a higher concentration of CHG was extracted 
from the tape strips (SC) and from the remaining epidermis and dermis (2043.095 ± 
421.683 µg/cm2 and 1077.502 ± 148.991 µg/cm2 respectively). The CHG 
concentration in decreasing order was PAMAM dendrimer > vehicle control > 
physiological saline pre-treated skin for both tape strips (and thus SC) and for the 
remaining epidermis and dermis (Figure 3.7). There was a statistically significant 
increase in CHG concentration (p<0.05) within the epidermis and dermis when the 
PAMAM pre-treated skin was compared to the physiological saline pre-treated skin. 
The results indicate that the PAMAM dendrimer pre-treatment increases the 
deposition of CHG within not only the superficial layers of the SC but also the 
epidermis and dermis. The aim of this study was to increase the penetration and 
retention of CHG within the skin and this has been demonstrated within the epidermis 
and dermatomed percutaneous absorption studies within this section. An increase in 
the deposition of CHG within the skin may improve antisepsis efficacy by increasing 
the exposure of opportunistic pathogens to CHG (Karpanen et al. 2010).  
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3.5 Conclusion 
 
The aim of this chapter was to determine whether a PAMAM dendrimer skin 
pre-treatment would enhance the permeation and distribution of CHG within the 
layers of porcine skin. This study was conducted to confirm that the PAMAM 
dendrimer without the presence of CHG does have a physical interaction with the skin 
resulting in a penetration enhancement effect. As PAMAM dendrimer pre-treatment 
studies were conducted any dendrimer-CHG interactions resulting in an increased 
permeation are shown not to be the only contributing factor to the increased skin 
delivery of CHG observed.  PAMAM dendrimers have previously been utilised as a 
novel dendritic penetration enhancer of the hydrophilic compound 5-fluorouracil 
(Venuganti and Perumal, 2008). There was a gap in the literature regarding their 
application to other hydrophilic compounds such as CHG and their mechanism of 
action. This chapter has established for the first time that a G3-PAMAM-NH2 
dendrimer pre-treatment does indeed enhance the permeation of CHG through 
porcine epidermis and also increases the concentration of CHG localized within the 
upper skin strata.  
 
This Chapter in its entirety illustrates how PAMAM dendrimers enhance the 
distribution of CHG within the skin thus increasing the interaction of the conventional 
biocide with opportunistic skin pathogens. This enhanced antisepsis could potentially 
have significant benefits to the health care sector by means of reducing the 
occurrence of nosocomial infectious diseases.   
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4.0. Elucidation of the interaction between PAMAM 
dendrimers and porcine skin. 
4.0 Introduction 
4.0.1 Interaction between PAMAM dendrimers and the skin 
 
The exact mechanism of enhanced topical and transdermal drug delivery is 
still unknown but is suggested to be in varying degrees the following; a) action as 
a drug release modifier thus increasing drug dissolution, b) preferential 
accumulation within the appendages of the skin and c) impairing the barrier 
function of the SC (Chapter 3 and Sun et al. 2012). PAMAM dendrimers have 
been suggested as a drug release modifier that has a cyclodextrin like mechanism 
in that they act as a carrier system for indomethacin (log P 4.3) (Wang et al. 2003). 
As with PAMAM dendrimers, lipophilic drugs form an electrostatic or hydrophobic 
complex with cyclodextrins that then increases the solubility of a drug within an 
aqueous vehicle. This then results in an increase in the concentration of drug that 
partition into the SC (Legendre et al. 1995). The drug that is encapsulated within 
or complexed to nanoparticles such as PAMAM dendrimers and cyclodextrins are 
in a solubilized form but are only poorly soluble within the aqueous vehicle. This 
forms a high thermodynamic driving force once the nanoparticle has carried the 
drug to the SC surface; on release the lipophilic drug partitions into the lipophilic 
SC as opposed to dissolving within the aqueous vehicle.  
 
The carrier mechanism for facilitating drug delivery to the SC would account 
for the enhanced permeation of lipophilic drugs within the skin but not for 
hydrophilic drugs therefore there must be other mechanisms at work. Another 
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example of this possible mechanism was given by Küchler et al. (2009) where it 
was demonstrated that PAMAM dendrimers did not penetrate the SC but did 
enhance the topical delivery of the lipophilic nile red (log P 3.8) by 8 fold within the 
SC and 13 fold within the viable epidermis (Küchler et al. 2009).  
 
A vehicle-dependent mechanism was proposed by Venuganti and 
co-workers, who used potent vehicles such as IPM and mineral oil in conjunction 
with lower generation PAMAM dendrimers to enhance the permeation of a 
hydrophilic drug (Venuganti et al. 2008). Using potent solvents that impair the 
barrier nature of the SC via fluidisation or extraction of skin components may aid 
the ingress of lower generation PAMAM dendrimers within the SC. The synergism 
between potent solvent and the dendrimers resulted in an increase in the 
partitioning of the hydrophilic 5-Fluorouracil (log P -0.89) within the SC. The same 
group demonstrated that the surface groups of the PAMAM dendrimer affected the 
permeability coefficient of the 5-Fluorouracil in decreasing order of 
G4-PAMAM-NH2 > G4-PAMAM-OH > G4-PAMAM-OH. They also revealed that 
the enhancement in the drug permeability coefficient was inversely proportional to 
the molecular weight of the PAMAM dendrimer. Further, structure-activity 
relationship studies showed that increasing the concentration of the PAMAM 
dendrimer did not proportionally increase the skin permeation of the 5-Fluorouracil 
(Venuganti et al. 2009). This was also observed in Chapter Three, in that 
increasing the concentration of G3-PAMAM-NH2 within the pre-treatment and co-
treatment does not result in a proportional increase in the permeation of CHG.  
 
Cationic dendrimers have been shown to have a physical effect on the skin, 
decreasing the barriers resistance. Cationic PAMAM dendrimers are protonated at 
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the pH of the skin surface which has a pH of 5 (Liu et al. 2009).  It was previously 
demonstrated using differential scanning calorimetry (DSC) and Raman 
spectroscopy that the charged G4-PAMAM-NH2 dendrimers interact with the 
hydrophilic head groups of phospholipids and can incorporate themselves within 
the lipid bilayers, altering its structure and fluidity (Gardikis et al. 2006). This 
interaction of cationic dendrimers with the hydrophilic and anionic components of 
membranes can result in an increase in permeability (Hong et al. 2004 and Hong 
et al. 2006). Shcharbin et al. (2006) also noted that PAMAM dendrimers can cause 
alteration in the lipid architecture; the importance of the intercellular lipid 
organisation as a property of the skin’s barrier was discussed in detail within the 
general introduction. Cationic dendrimers were shown to interact with the 
hydrophilic head groups of ceramides and fatty acids resulting in an increase in 
the trans-epidermal water loss (TEWL) as a result of barrier disruption (Venuganti 
et al. 2009). In mind of the PAMAM dendrimer skin pre-treatment as well as 
physical perturbation of the skin components it should also be noted that the 
cationic PAMAM dendrimers retained within the superficial layers of the SC may 
alter the ionic charge and possibly hydrophobicity of the SC. The cationic PAMAM 
dendrimers may act as a depot within the superficial layers of the SC for the 
enhanced partitioning of hydrophilic or charged drugs within the SC. 
 
Nanoparticles have been reported to preferentially accumulate within the 
hair follicles of the skin. It was shown that due to the follicular penetration of 
polystyrene nanoparticles, the topical delivery of nile red was enhanced when 
compared to the dye in free solution (Alvarez-Roman et al. 2004(a) and Alvarez-
Roman et al. 2004(b). PAMAM dendrimers labeled with a fluorescein 
isothiocyanate fluorophore were found to preferentially accumulate within follicles 
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found within the porcine skin. The follicular route may therefore heavily contribute 
to the enhanced skin permeation of a drug complexed or encapsulated within a 
nanoparticle including PAMAM dendrimers. It is possible that the cationic PAMAM 
dendrimer acts as a depot within the follicles and aids penetration of large polar 
molecules that would typically find it difficult to penetrate the intact SC. 
 
Other mechanisms that may contribute to the penetration enhancement 
effect include the extraction of skin components. Cyclodextrins have been shown 
to remove SC lipids and proteins that would decrease the barrier nature of the skin 
(Bentley et al. 1997). This mechanism of skin barrier impairment has not yet been 
investigated for PAMAM dendrimers and will therefore be covered within this 
Chapter. Hydration caused by the occlusion of the SC surface by viscous PAMAM 
dendrimers and an increase in wettability and reduction of surface tension due to 
the presence of PAMAM dendrimers should also be considered as a possible 
contributing penetration enhancing effect.  
 
4.0.2 Rationale for the investigation of a PAMAM dendrimer skin pre-
treatment interaction with the skin. 
 
In the previous Chapter it was ascertained that PAMAM dendrimers act as 
a penetration enhancer for CHG after a pre-treatment on the skin. This chapter 
aims to assess the interactions that occur between the PAMAM dendrimer and the 
skin using a range of techniques. It may be possible to design optimized PAMAM 
dendrimers and formulations for topical or transdermal delivery of therapeutics 
once the mechanism of penetration enhancement has been elucidated. This 
chapter addresses whether a cationic PAMAM dendrimer skin treatment impairs 
the SC barrier nature by increasing TEWL and decreasing the TEER. Further,  a 
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number of novel strategies employed within this chapter include optical coherence 
tomography (OCT) that is a non-destructive and non-invasive imaging system 
capable of revealing structural changes within optical cross-sections of opaque 
tissue with a thickness of up to 2 mm. This chapter undertakes an OCT 
investigation in order to delineate the mechanisms of the interactions of PAMAM 
dendrimers with the porcine skin surface. 
 
A biochemical test for the determination of protein concentration was 
conducted to determine whether PAMAM dendrimers extract skin components to 
reduce the resistance for enhanced drug delivery. Moreover, the concentration of 
cholesterol extracted from the SC by PAMAM dendrimers was determined through 
solvent extraction and HPLC methods. To investigate the direct interactions 
between the PAMAM dendrimer and the components of the SC, it is necessary to 
first isolate the SC using proteolytic enzymes (Haigh and Smith, 1994). This then 
allowed for the elucidation of the interactions between the dendrimer and SC using 
attenuated total reflectance Fourier transform infra-red spectroscopy (ATR-FTIR).  
 
4.0.3 Aims and objectives 
 
The aim of this Chapter is to explore the skin modulation effects, i.e. 
possible barrier alterations, after application of PAMAM dendrimer to porcine skin 
that may aid the penetration of drugs within the skin. 
 
To delineate the interactions between PAMAM dendrimer and porcine skin a 
number of objectives to be addressed: 
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(i) A skin barrier integrity study before and after a PAMAM application 
utilising both TEER and TEWL.  
(ii) Non-invasive visualisation of the PAMAM dendrimer on the skin surface 
by optical coherence tomography (OCT). 
(iii) Classical histological analysis of cryo-sectioned dermatomed skin 
sections after PAMAM dendrimer treatment. 
(iv)  Attenuated total reflectance Fourier transform infrared spectroscopy 
(ATR-FTIR) analysis of the PAMAM-skin interactions 
(v) To determine whether PAMAM dendrimers extract skin components, i.e. 
cholesterol and skin lipids.  
 
4.1 Materials and methods 
 
4.1.0 Measurement of Transepidermal Water Loss (TEWL) and 
Transepithelial Resistance (TEER) after a PAMAM dendrimer treatment 
 
The barrier integrity was measured after dosing porcine skin with PAMAM 
dendrimer for a 24 h contact time. The Franz cells were set-up as outlined in 
Sections 3.1.1 and 3.1.2. The treated Franz cells were dosed with 
G3-PAMAM-NH2 (10 mM) and the controls were dosed with the vehicle control 
(water:methanol, 35:65) and sodium dodecyl sulphate (SDS) (5 % w/v, 0.2 mL) as 
a positive control and were left for a 24 h contact time. After which, the 
G3 PAMAM-NH2  was removed by rinsing with 2 mL aliquots of distilled water 
(10 mL in total) over the surface of the dosed skin. When measuring the TEWL, 
the Franz cells were left to dry at ambient temperature until the skin surface was 
dry, typically around 3 h. The Franz cells were then placed in a humidity chamber 
(Stuart Scientific incubator SI60, Bibby Scientific, Stone) where the relative 
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humidity (RH%) was controlled between 40-45% measured using a precision 
hygrometer (Diplex, Meinheim, Germany) and at skin temperature of 32ºC 
(Chilcott et al. 2002). The RH% was controlled by placing a 50 mL beaker of a 
saturated solution of K2CO3 in distilled water within the humidity chamber (O’Brien, 
1947). The Franz cells were left to equilibriate within the humidity chamber for a 
minimum of 3 hours before the TEWL measurements were taken. TEWL was 
measured on an Evaporimeter EP2 (Servo-med, Varburg, Sweden) within an 
environmental chamber maintained at 32ºC and 40-45 % RH as the holding 
humidity chamber. The sensor was placed over the skin so that it gently contacted 
the skin surface for 45 seconds and then for a final 15 seconds an average TEWL 
in g/m2/h was recorded with the standard deviation.  
 
To measure the TEER after the G3-PAMAM-NH2 dose preparation had 
been washed from the skin surface, 2 mL of physiological saline (0.9 % w/v) was 
added to the donor compartment and the electrical resistance across the porcine 
skin was measured as previously outlined in Section 3.2.1.  
 
4.1.1 Optical Coherence Tomography (OCT) analysis of the skin surface after 
dosing with PAMAM dendrimers 
 
The diffusion cells that had passed the integrity check were removed from 
the water bath and the skin surface was allowed to air dry for 2 h at ambient 
temperature. 4.5 mL of physiological saline was added to the receptor chamber of 
each Franz cell. The Franz cells were placed in the water bath (32°C ± 1°C) on a 
submersible stirring plate for 30 minutes and allowed to equilibrate. Two 
generations of PAMAM dendrimers, G3-PAMAM-NH2 and G3.5-PAMAM-COOH 
161 
 
(Sigma Aldrich, UK) in two concentrations, 5 mM and 10 mM, were applied in this 
study. The vehicle solutions, the mixture of water and methanol in the ratio of 
65:35 for G3-PAMAM-NH2, and 82.5:17.5 for G3.5-PAMAM-COOH have been 
used as the control. 0.2 ml solution was placed on to the skin surface and 
incubated for a given contact time before taking OCT images. Anhydrous glycerol 
was applied to the skin surface as a positive control (0.2 mL). To determine 
whether the PAMAM dendrimer reaction with the skin is reversible, the applied 
PAMAM dendrimer layer was removed from the skin surface by rinsing 2 mL 
aliquots of distilled water (10 mL in total) across the skin surface. Care was taken 
not to impair the barrier of the skin. The skin surface was then blotted dry with 
adsorbent paper. 
 
To visualise the interaction of PAMAM dendrimers with the skin surface, a 
custom built polarization sensitive OCT was used. A laboratory built bench-top 
optic fibre-based time-domain polarization sensitive-OCT (PS-OCT) system was 
used in this study which employed a 1300 nm superluminescence diode with a 
bandwidth of 52 nm. The beam from the diode is sent through a polarizer, a 
polarizer modulator and then split 50/50 by a 2x2 all-fibre beam splitter into a 
sample and reference arm. After recombination, the polarized light is sent through 
a polarization beam splitter. The interference fringes are detected with two 
balanced detectors, for horizontal and vertical polarization. The system has an 
axial resolution of 14 μm in free space and a penetration depth up to 2 mm. The 
PS-OCT images were scanned at 100 Hz.(Bagnaninchi et al. 2007).  
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4.1.2 Histological analysis of PAMAM dendrimer dosed porcine skin 
 
Haematoxylin and eosin are classical stains which have been used to 
visualise morphological features of a vast range of biological tissue and cells. 
Haematoxylin is used to stain the nuclei of cells dark blue whilst the counter-stain, 
eosin stains the cytoplasm pink offering a great contrast. This staining technique 
was used to visualise any morphological changes apparent within the SC after 
dosing with G3-PAMAM-NH2 dendrimer for 24 h. G3-PAMAM-NH2 (10 mM, 
0.2 mL), vehicle control (water:methanol, 65:35) and a SDS (5 % w/v, 0.2 mL) 
positive control were dosed on to dermatomed skin mounted on Franz cells as 
outlined in Section 3.2.3. The samples were cryo-sectioned as opposed to tape 
stripped. The flank of the porcine skin was removed using a scalpel, leaving only 
the dosed skin area. The samples were snap frozen in liquid nitrogen and then 
embedded in optimal cutting temperature embedding material. They were placed 
in the cryostat chamber set to a temperature of -28ºC before being sectioned in to 
8 µm thick sections using a Leica CM1850 cryostat. Occasionally cryospray 
(Cellpath, UK) was used to reduce the temperature of the anti-roll plate to prevent 
the porcine skin slices from curling. The skin sections were then captured onto 
poly-L-lysine covered microscope slides and rested in a trough of 3 % glacial 
acetic acid in methanol (v/v) to fix the samples to the slide. 
 
 The skin sections were placed in a tray of haematoxylin and were left for 
60 s. To remove excess haematoxylin, the samples were placed under a gentle 
flow of warm tap water to act as a weak alkali to oxidise the hematoxylin to form 
an insoluble blue aluminium haematin complex that stains the nuclei of the cells 
dark blue (Cooksey, 2010). The sections were then differentiated in a 0.3 % 
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HCL/ethanol solution until the background tissue that was unstained appeared 
colourless. The sections were then rinsed under tap water and placed in an eosin 
solution made up in water. To remove excess eosin the samples were rinsed in 
50 % ethanol (v/v). The sections were tapped dry and dehydrated in a series of 
ethanol solutions. The sections were placed in a 50 %, 70 %, 80 % and 100 % 
series of ethanol/ water solutions for 3 minutes at each ethanol concentration. The 
sections were cleared using histoclear to improve the contrast of the staining and 
mounted using dibutyl phthalate in xylene (DPX) mountant (Khitam, 2011). The 
skin sections were visualized on a Nikon Eclipse E200 microscope and the images 
were captured on a Nikon DS-Fi 1 with a Nikon digital sight at various 
magnifications (x10-x40). 
 
4.1.3 Isolation of porcine SC 
 
The porcine SC was isolated by floating porcine epidermis prepared as 
outlined in Section 3.2.1 onto a trypsin solution (0.01 % w/v made up in PBS). The 
samples were then placed in a shaking incubator (150 RPM) at 37ºC for 6 h. The 
digested epidermis was carefully washed from the SC with distilled water and the 
SC was floated on distilled water and captured on aluminium foil. The SC was 
gently refloated until the membrane was stretched out without any air bubbles on 
to the foil. The SC was then washed with ice cold acetone for 10 s and placed in a 
dessicator over zeolite for 72 h. This method was adapted from Yamane et al.  
1995.  
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4.1.4 ATR-FTIR analysis of the interaction between PAMAM dendrimer and 
porcine SC 
 
To determine whether there are any conformational changes through direct 
interactions between PAMAM dendrimers and isolated SC, ATR-FTIR spectra 
were obtained and analysed for differences in PAMAM treated and untreated 
samples. SC was isolated as previously outlined in section 4.1.3. After the drying 
process a hole punch was used to punch out 5 mm disks of SC and the foil 
backing was removed. Each sample was incubated at 32ºC in 200 µL of 10 and 
5 mM solutions of G3-PAMAM-NH2, a 5 mM G3.5-PAMAM-COOH, respective  
vehicle controls (water:methanol), and a PBS negative control. After a 24 h contact 
time the SC was removed from the solutions and blotted dry on filter paper. Each 
sample was placed on the diamond of the ATR attachment (GladiATR, Pike 
Technologies, Wisconsin, USA) on a Thermo Scientific Nicolet iS10 (Hemel 
Hempstead, UK). 32 scans were taken with an 8 cm-1 resolution. The spectra were 
analysed using OMNIC software suite (Thermo Scientific, Hemel Hempstead, UK). 
 
4.1.5 Determination of skin cholesterol extraction by PAMAM dendrimers 
 
PAMAM dendrimers were incubated on the skin surface of porcine 
dermatomed skin (400 µm thick) to determine whether skin cholesterol or skin 
lipids were extracted during a 24 h time frame. Franz cells were set-up as outlined 
in Sections 3.2.1-3.2.3 and 200 µL of a positive control (cholesterol: methanol, 
3:2), a vehicle control (water:methanol, 65:35) and a 10 mM solution of 
G3-PAMAM-NH2 dendrimer were applied to the skin. The Franz cells were kept 
under occluded conditions with Vaseline rubbed around the top of the donor 
chambers so that the taut parafilm was secure as to not leave gaps for the dosed 
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vehicle to evaporate. After a 24 h contact time at 32ºC ± 1ºC, 4 mL of physiological 
saline (0.9 % w/v) was added to each of the donor chambers in 2 mL aliquots and 
agitated over the skin surface with a Pasteur pipette. The 4 mL of physiological 
saline was added to a vial that contained 4 mL of diethyl ether. The vials were 
vortex mixed to agitate the solvent extraction and were left for a 4 h period. After 
this, the 4 mL aqueous phase was decanted into a labeled vial and placed into the 
fridge (4ºC ± 1ºC) until required.  
 
The diethyl ether phase was centrifuged at 5000 RPM for 5 minutes and the 
supernatant was decanted into a solvent cleansed vial. This was then blown down 
under a stream of nitrogen until the ether had evaporated and reconstituted in 
1 mL of isopropanol. The samples were then transferred into a clean and labeled 
2 mL HPLC vial for HPLC analysis. This method was modified from an outlined 
method found in Legendre et al. 1995. The HPLC method used to determine total 
cholesterol content was an isocratic acetonitrile: isopropanol 50:50 mobile phase 
at a flow rate 1 mL per min, the column oven temperature was set to 25°C 
(Duncan et al. 1979). The injection volume was 50 µL and detector channel 
wavelength used was set to 200 nm.  
 
A cholesterol standard (Sigma Aldrich, Loughborough, UK) was used as 
purchased and a series of standard solutions made up in isopropanol ranging from 
1-100 µg/mL were used to validate the method on the Shimadzu HPLC described 
previously in Section 3.2.5. The results of the validation assay can be found in 
appendix 2. The standards were found to be linear over the concentration range 
chosen (1-100 µg/mL) as shown by an R2 value of 0.9992 and were also found to 
be reproducible with an RSD% of 1.15% for 6 replicate injections of the cholesterol 
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standard 25 µg/mL. The limit of quantification was calculated to be 1.186 µg/mL 
using Equation 4.1 and the limit of detection was calculated to be 0.356 µg/mL 
using Equation 4.2 (n=6). 
          
  
 
  
 
Equation 4.1 Calculation of the limit of quantification. SD corresponds to the 
standard deviation and m corresponds to the gradient of the slope. 
 
         
  
 
  
Equation 4.2 Calculation of the limit of detection. SD corresponds to the 
standard deviation and m corresponds to the gradient of the slope. 
 
4.1.6 Determination of skin protein extraction by PAMAM dendrimers 
 
The aqueous phases of the solvent extractions from section 4.19 were used 
to determine the concentration of soluble proteins extracted from the skin by 
PAMAM dendrimers. All chemicals used within the protein quantification assay 
were used as purchased from Sigma Aldrich (Dorset, UK). A micro Lowry assay 
with Peterson’s modification was used; the Lowry solution contains sodium 
dodecylsulphate (SDS) which enables solubilisation of lipo-proteins (Lowry et al. 
1951). Peterson’s modification was used to overcome interference from other 
biomolecules such as amino acids, EDTA, sucrose by precipitating the protein in 
deoxycholate (DOC) and trichloroacetic acid (TCA) (Peterson, 1977). The protein 
quantification occured as a result of two chemical reactions; (i) biuret reaction, in 
which alkaline cupric tartrate reagent forms complexes with the peptide bonds of 
the protein and (ii) reduction of the Folin and Ciocalteu’s phenol reagent which 
generates a deep purple colour. This colour change was monitored by measuring 
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the absorbance at a wavelength of 700 nm. Firstly, 1 mL protein standard (bovine 
serum albumin) solutions were prepared in distilled water at a protein 
concentration range of 50-400 µg/mL. 1 mL of each of the aqueous phase 
dendrimer-skin extraction samples was transferred into a 2 mL snap cap tube. 
Also, a blank of 1 mL of distilled water was also placed in a labeled 2 mL snap cap 
tube. To the standards, blank and samples, 0.1 mL of a 0.15% DOC solution (w/v 
aqueous solution) was added. The 2 mL snap cap tubes were then vortex mixed 
and left to stand for 10 minutes. After a 10 minute contact time, 0.1 mL of a 72 % 
(w/v) solution of TCA was added to each 2 mL snap cap tube and then each 
sample was again vortex mixed and left for 10 minutes. After the protein had 
precipitated the supernatant was decanted and removed.  
 
The protein pellets were dissolved in 1 mL of Lowry reagent (5 % w/v 
aqueous solution) and were then transferred into a test tube. 1 mL of distilled 
water was used to wash the 2 mL snap cap tube and transferred into the 
respective test tube.  The samples were left to stand for 20 minutes to allow the 
protein to dissolve. Then, 0.5 mL of Folin and Ciocalteu’s phenol reagent were 
rapidly mixed into each test tube and the purple colouration was allowed to 
develop for 30 minutes. Immediately after a 30 minute time point, 1 mL of the 
standards, blank and samples were transferred to a quartz cuvette and the 
absorbance at a wavelength of 700 nm was recorded. The BSA protein standards 
were used to construct a calibration curve used to calculate the protein 
quantification of the unknown dendrimer-skin extraction solutions. The R2 value of 
the calibration curve was 0.9900. 
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4.1.7 Statistical data analysis 
 All data is presented as the mean ± SEM unless otherwise stated and were 
analysed using GraphPad Prism® version 5 (San Diego, USA). Prior to statistical 
analysis all data were placed in to a histogram to check for normality. To 
determine whether the difference in TEER was significant, when comparing the 
PAMAM dendrimer treated skin with the vehicle control treated skin, a Mann 
Whitney test was conducted as the data was not normally distributed. The same 
statistical analysis was also applied to determine if there was a significant 
difference in TEWL comparing the PAMAM dendrimer treated skin with the vehicle 
control treated skin (see section 4.2.0). In section 4.2.6 a Kruskal Wallis test was 
conducted to determine whether a peak shift after application of 10 mM and 5 mM 
G3-PAMAM-NH2 dendrimer to isolated SC is significantly different from the vehicle 
control dosed SC (Figure 4.15). Further in section 4.2.6 a Mann Whitney test was 
applied to the data in Figure 4.19. This was to determine whether the shift in peak 
corresponding to the CH3 asymmetric stretch was significantly different between 
the G3.5-PAMAM-COOH dendrimer treated SC and the vehicle control treated SC 
(p<0.05). 
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4.2 Results section 
 
4.2.0 Measurement of Transepidermal Water Loss (TEWL) and 
Transepithelial Resistance (TEER) after application and removal of G3-
PAMAM-NH2 dendrimer. 
 
The previous chapter showed that by pre-treating the skin with a PAMAM 
dendrimer application, a significant increase in the CHG concentration can be 
achieved within the skin. This section was conducted to establish a mechanism of 
enhancement. TEWL and TEER are commonly used methods to determine any 
changes to the integrity of the skin barrier. Both methods were utilised to illustrate 
the change in TEWL or TEER after a 24 h contact time with the highest PAMAM 
dendrimer solution tested (G3-PAMAM-NH2, 10 mM). Figure 4.1 shows the 
change in TEWL and TEER that occurred after dosing the skin with a 
G3-PAMAM-NH2 solution (10 mM, 0.2 mL) for 24 h and the vehicle solution (water: 
methanol, 65:35, 0.2 mL) after a 24 h contact time. The mean change in TEER 
when comparing pre-dose integrity to post dose integrity was 2.55 ± 0.53 kΩ for 
G3-PAMAM-NH2 dendrimer (10 mM, 0.2 mL) compared to 2.45 ± 0.47 kΩ for the 
vehicle control treated skin (mean ± SEM, n=18 ). A Mann Whitney test (U=162.0, 
n=18, p>0.05 two-tailed) showed that there was no significant difference in TEER 
(non-parametric data) between the PAMAM treated skin (median-2.23 kΩ) and the 
vehicle control treated skin (2.04 kΩ). The mean change in TEWL when comparing 
pre-dose integrity to post dose integrity was 2.76 ± 1.47 g/m2h for 
G3-PAMAM-NH2 (10 mM, 0.2 mL) compared to 3.08 ± 1.31 g/m
2h for the vehicle 
control treated skin (mean ± SEM, n=18). A Mann Whitney test (U=129.0, n=18, 
p>0.05, two-tailed) showed that there was no significant difference in TEWL (non-
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parametric data) between the PAMAM treated skin (median-2.25 g/m2h) and the 
vehicle control treated skin (median- 3.73 g/m2h). 
  
The highest change in TEER and TEWL in the PAMAM dendrimer 
treatment group corresponds to the same skin donor. A 5% SDS (w/v) solution 
was also applied to Franz cells (n=3) as a positive control to indicate severe 
damage to the skins barrier integrity. The positive control yielded a decrease in 
TEER of 5.34 ± 0.82 kΩ and an increase in TEWL of 48.74 ± 4.32 g/m2h that 
indicates the surfactant had caused an extensive reduction in skin barrier integrity 
as anticipated.  
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Figure 4.1. Measurement of the barrier integrity of the skin before and after dosing with PAMAM dendrimer (a) Difference in 
TEER before and after dosing with G3-PAMAM-NH2 dendrimer (10 mM, 0.2 mL) for 24 h (mean – 2.55 ± 0.53 kΩ) and the 
difference in TEER before and after dosing the skin with a vehicle control solution (2.45 ± 0.47 kΩ mean ± SEM). (b) corresponds 
to the difference in TEWL before and after dosing with PAMAM dendrimer (10 mM, 0.2 mL) for 24 h (2.76 ± 1.46 g/m2h) and the 
difference in TEWL before and after dosing the skin with a vehicle control solution (water: methanol, 65:35) for 24 h (3.08 ± 1.31 
g/m2h) (n=18 ± SEM)
a b 
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4.2.1 Optical Coherence Tomography (OCT) to delineate the interactions of 
PAMAM dendrimers with the porcine skin surface.  
 
4.2.1.0 The effect of amine functionality of the PAMAM dendrimer on the 
porcine skin surface  
 
The OCT images shown in Figure 4.2 illustrate non-invasive imaging of 
porcine dermatomed skin (400 µm in thickness). The plane of polarized light forms 
a hyper-reflective entrance signal on the skin surface where the polarized light 
reflects off the keratin of the corneocytes. In Figure 4.2 the untreated sample 
shows this hyper-reflective band on the skin surface and also a reflective band on 
the bottom of the dermatomed skin corresponding to the stainless steel support 
grid of the Franz cell. The skin had been dosed with a 10 mM solution of 
G3-PAMAM-NH2 (0.2 mL) and a 5 mM G3-PAMAM-NH2 (0.2 mL) shown in Figure 
4.2 (a) and (b) respectively. After 30 minutes the constant entrance signal 
observed in the untreated skin surface had sporadically disappeared. The 
distribution of the entrance signal across the skin surface had significantly altered 
as a consequence of a change in the refractive index (RI) due to the presence of 
the PAMAM dendrimer. After a 20 hour contact time the water/methanol vehicle 
had evaporated leaving a viscous G3-PAMAM-NH2 film. The distribution of the 
entrance signal was sporadic as opposed to the constant entrance signal 
observed for the untreated control image. Figure 4.2 (a) & (b) demonstrates the 
skin surface at different time points and up to 6 h appears to be increasingly 
undulated with a disrupted and dense entrance signal. Though, at 20 hours the 
entrance signal disruption seems to recover. The distribution of the entrance signal 
was altered at all PAMAM concentrations tested. 
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Figure 4.2 OCT images of porcine skin dosed with various concentrations of 
G3-PAMAM-NH2 dendrimer taken at various time points. (a) OCT images of 
G3-PAMAM-NH2 (0.2 mL, 10 mM) dosed porcine dermatomed skin (400 µm) 
imaged at different time points. A typical example illustrated is Franz cell sample 
127 which is representative of the replicate samples (n=3) (b) OCT images of G3-
PAMAM-NH2 (0.2 mL, 5 mM) dosed porcine dermatomed skin (400 µm) imaged at 
different time points. A typical example illustrated is Franz cell sample 153 which is 
representative of the replicate samples (n=3) 
  
 
Entrance signal 
Support grid 
Skin 
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The skin dosed with a water:methanol vehicle that was equivalent to the 
prepared PAMAM dendrimer solution did not alter the entrance signal on the skin 
surface in comparison to untreated skin specimens. The intensity and distribution 
of the entrance signal of the vehicle control treated skin samples typically 
remained constant as shown in Figure 4.3, particularly at a 2 hour time period as 
at this point the water:methanol vehicle had evaporated. This was due to the skin 
samples being mounted on Franz cells that were incubated at a skin temperature 
of 32ºC ± 1ºC between the imaging times. At the 6 hour and 20 hour time points 
the ‘white layer’ of the entrance signal resembled that of the pre-dose image. 
 
 
Figure 4.3. OCT images of porcine skin dosed with the vehicle control taken 
at various time points. Vehicle control (water: methanol, 65:35) dosed porcine 
dermatomed skin (400 µm) imaged at a range of time points. A typical example 
illustrated is Franz cell sample 150 which is representative of the replicate 
samples (n=3).  
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4.2.1.1 The effect of carboxyl functionality of the PAMAM dendrimer on the 
porcine skin surface 
 
Half generation 3.5 PAMAM dendrimers (G3.5-PAMAM-COOH) terminate 
in carboxyl groups. G3.5-PAMAM-COOH dendrimers were also dosed on to the 
skin to observe any changes after the alteration of the surface groups on the 
optical characteristics of the skin. Figure 4.4 demonstrates the OCT images taken 
after dosing the skin with 5 mM G3.5-PAMAM-COOH dendrimer at various time 
points. The distribution of the entrance signal was disrupted after 30 minutes but 
not to the extent that was observed for the amine terminated PAMAM dendrimers. 
The entrance signal was very sporadic in distribution at 5.5 h after dosing with 
G3.5-PAMAM-COOH. Figure 4.4 (b) illustrates the skin dosed with the vehicle 
control and the hyper-reflective signal can be observed intact and remained the 
same as the pre-dose sample.  
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Figure 4.4 OCT images of porcine skin dosed with the G3.5-PAMAM-COOH 
dendrimer and corresponding vehicle control taken at various time points. 
(a) OCT of G3.5-PAMAM-COOH (0.2 mL, 5 mM) dosed porcine dermatomed skin 
(400 µm) imaged at different time points. A typical example illustrated is Franz cell 
sample 156 which is representative of the replicate samples (n=3). Figure 4.4 (b) 
OCT images of the vehicle control (water: methanol, 82.5:17.5) dosed porcine 
dermatomed skin (400 µm) imaged at a range of time points. A typical example 
illustrated is Franz cell sample 152 which is representative of sample replicates 
(n=3).  
 
4.2.1.2 The effect of the known tissue clearing agent glycerol on the porcine 
skin surface  
 
Glycerol was dosed on to the porcine skin surface using the same 
experimental parameters as for the PAMAM dendrimer treatment and the skin was 
imaged using the OCT at a range of different time points. Figure 4.5 illustrates the 
OCT skin images after application of glycerol at various time points. The entrance 
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signal disappeared from the skin surface after application of glycerol. The 
alteration of the OCT image is clearly observed in the comparison of the untreated 
skin with the skin treated with glycerol for a 15 minute contact time in Figure 4.6.  
 
Figure 4.5 OCT images of porcine skin dosed with glycerol at various time 
points. Anhydrous glycerol (0.2 mL) dosed porcine dermatomed skin (400 µm) 
imaged at three time points. A typical example illustrated is Franz cell sample 112 
which is representative of the replicate samples (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. In situ OCT images of porcine skin dosed with glycerol. OCT 
images that correspond to (a) porcine dermatomed skin (400 µm) dosed with 
0.2 mL of anhydrous glycerol and (b) image taken in situ after 15 minutes 
illustrating the ‘clearing’ of the tissue.  
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4.2.2 The transient nature of the PAMAM dendrimer’s effect on the skin  
 
To determine whether the optical changes that occur due to the interaction 
of the PAMAM dendrimer with the skin are reversible, the skin was imaged using 
the OCT on removal of the PAMAM dendrimer layer. Figure 4.7a displays OCT 
images of untreated skin, skin dosed with 10 mM G3-PAMAM-NH2 in situ for 1 h 
and the skin post wash after the PAMAM application. The re-appearance of the 
hyper-reflective entrance signal after removal of the PAMAM dendrimer is clearly 
visible. The OCT image returns to a state that was observed before treatment. 
Figure 4.7b illustrates OCT images taken post removal of the G3-PAMAM-NH2 
PAMAM dendrimer layer with increasing incubation time. Again, the hyper-
reflective entrance signal returns to resemble that of the pre-dose image.  
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Figure 4.7a OCT images showing porcine skin before, during and after 
application of G3-PAMAM-NH2 dendrimer. Images displaying porcine 
dermatomed skin prior to G3-PAMAM-NH2 treatment, after dosing with 
G3-PAMAM-NH2 (10 mM, 0.2 mL) for a ten minute contact time (PAMAM in situ) 
and after removal of G3-PAMAM-NH2 layer with a 10 mL wash (2 mL aliquots 
agitated over skin surface) of ultrapure water (n=2). N.B the recovery of the 
hyper-reflective entrance signal post PAMAM removal. 
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Figure 4.7b OCT images showing porcine skin after removal of applied G3-
PAMAM-NH2 dendrimer. Images displaying porcine dermatomed skin prior to G3-
PAMAM-NH2 treatment, after dosing with G3-PAMAM-NH2 (10 mM, 0.2 mL) for a 
range of time points after removal of G3-PAMAM-NH2 layer with a 10 mL wash 
(2 mL aliquots agitated over skin surface) of ultrapure water (n=2). N.B the 
recovery of the hyper-reflective entrance signal post PAMAM removal. 
 
The reduction in the pixel grey value (pixel intensity) was used to 
investigate the optical changes to the skin caused by the application of the 
PAMAM dendrimer solution. A Yellow line was placed at the same representative 
co-ordinates (x=158, y=0) on both images and each had the contrast enhanced to 
an equal degree of 0.4 % saturation of pixels. A grey value plot profile was 
conducted along the yellow line to determine and changes to the intensity of the 
skin tissue. The entrance signal can be observed where the light propagates the 
skin at a depth of around 0.16 mm on the plots of Figure 4.8. This signal 
decreases on dosing the skin with 0.2 mL of a 10 mM solution of G3-PAMAM-NH2 
which is consistent across the whole PAMAM dosed data set. Figure 4.9 
represents a plot of the pixel grey value at the depth of where the hyper-reflective 
entrance signal is observed. It was found that there was a reduction in the pixel 
grey value and profile after dosing the skin with PAMAM dendrimer when 
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compared to the pre-dose skin pixel grey values at the same depth. A grey scale 
line plot could be a valuable method to semi-quantify the optical changes that 
occur after application of a novel penetration enhancer such as PAMAM 
dendrimers or a drug.  
 
Figure 4.8. OCT image analysis of porcine dermatomed skin prior and post 
G3-PAMAM-NH2 treatment. (a) Corresponds to untreated porcine skin (b) after 
dosing with G3-PAMAM-NH2 (10 mM, 0.2 mL) for a contact time of 15 minutes. 
Image (c) corresponds to (a) and image (d) corresponds to image (b) with the 
contrast enhanced to an equal degree of 0.4% saturation of pixels (e) is a gray 
scale line plot of the untreated skin and (f) corresponds to a gray scale line plot of 
the G3-PAMAM-NH2 dosed skin. The yellow line was placed at co-ordinates x=158 
and y=0 that was the location used to take a gray scale line plot on both (c) and 
(d).  
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Figure 4.9. Graph showing pixel gray value against depth illustrating a 
change in the gray values after application of G3-PAMAM-NH2 dendrimer 
(10 mM, 0.2 mL) compared to skin before treatment.  
 
4.2.3 Histological analysis of PAMAM dendrimer dosed porcine skin 
 
The haematoxylin and eosin stained the anucleate corneocytes of the SC 
pink in contrast to the dark blue nuclei found within the viable epidermis and the 
dermis. The micrographs of the stained skin sections illustrate slight morphological 
differences in the structure of the SC.  In Figure 4.10 (a-b) that was dosed with the 
vehicle control, the SC appears intact. This is not observed for the G3-PAMAM-
NH2 dendrimer dosed skin (Figure 4.10 (c-d)) where the SC appears thin and 
dense compared to that of the vehicle control. The SC of the PAMAM dendrimer 
dosed skin sections again appears dissimilar to the surfactant damaged SC 
(Figure 4.10 (e-f)). As expected the positive damage control in Figure 4.10 (e-f) 
illustrates severe structural damage to the SC that would result in a significantly 
impaired barrier. The SDS application had caused the layers of the SC to detach 
from the viable epidermis (Figure 4.10 (f)).  
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Figure 4.10. Haematoxylin and eosin stained porcine dermatomed skin cryo-
sections after application of PAMAM dendrimer, vehicle control and an SDS 
positive control. Images of the skin cryo-sections (400 µm depth, 8 µm thickness) 
were taken at a magnification of x 40. The skin was dosed for 24 h at 32ºC with (a-
b) vehicle control (water: methanol, 65:35), (c-d) G3-PAMAM-NH2 (10 mM, 0.2 mL) 
and a positive control (e-f) SDS (5 % w/v, 0.2 mL).  
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4.2.4 Determination of total cholesterol concentration extracted by PAMAM 
dendrimer from porcine dermatomed skin. 
 
In Section 3.2.0 it was shown that there was no significant reduction to the 
barrier integrity of the skin. It was then considered that perhaps the effect of the 
PAMAM on the skin was more subtle or temporary as shown in Section 4.2.1 with 
regards to the optical changes conferred by the PAMAM dendrimer on the skin 
surface. These solutions were analysed for the presence of cholesterol (Figure 
4.11). The mean concentration of cholesterol extracted from the skin was 1.486 ± 
0.280 µg/mL (mean ± SEM, n=3) and 0.293 ± 0.142 µg/mL (mean ± SEM, n=10) 
for the positive control and the G3-PAMAM-NH2 dendrimer solution respectively. 
No cholesterol was detected within the vehicle solution. The cholesterol 
concentrations for all treatment groups however are below the calculated LOQ 
(1.186 µg/mL) therefore the results are only tentative (and as such no statistical 
analysis was applied). 
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Figure 4.11 Concentration of total cholesterol (µg/mL) extracted from the 
dermatomed porcine skin (400 µm) after a 24 h contact time under occluded 
conditions. (a) positive control- (chloroform: methanol, 3:2) which extracted an 
average concentration of 1.486 ± 0.280 µg/mL of cholesterol (n=3 mean ± SEM ) 
(b) vehicle control- (water: methanol, 65:35) from which no cholesterol was 
detected (n=3 mean ± SEM) and (c) G3-PAMAM-NH2 (10 mM, 0.2 mL) that 
extracted on average 0.293 ± 0.142 µg/mL of cholesterol (n=10 mean ± SEM). No 
cholesterol was detected for the negative control (0.2 mL distilled water, n=3). The 
concentrations of cholesterol extracted from the skin by all treatment groups are 
however below the calculated LOQ. 
 
4.2.5 Determination of skin protein concentration extracted by PAMAM 
dendrimer from porcine dermatomed skin. 
 
To establish whether a PAMAM dendrimer extracts protein from the skin 
after application of a 10 mM G3-PAMAM-NH2 solution a Lowry assay with a 
Peterson’s modification was conducted (Legendre et al. 1995). The Peterson’s 
modification is a protein precipitation step (addition of DOC and TCA) that 
removes the protein from all interfering substances such as ammonium sulphate, 
guanine, urea, sucrose, detergents and also EDTA (Ethylenediaminetetraacetic 
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acid) (Peterson, 1977). One of the monomers of the PAMAM dendrimer is 
ethylenediamine and it is likely that it would act as an interfering substance within 
the biuret reaction that forms the colouration for the protein determination. The 
assay has a working detection sensitivity range of 1-1500 µg/mL therefore the 
results are on the border of the LOD of the assay (according to the kit’s 
specification (Anon, 2012). Only a very low concentration of protein was extracted 
from the skin with regards to the positive control. The positive control was a 
solution of chloroform:methanol (3:2) which under occlusive conditions extracted a 
mean protein concentration of 0.741 µg/mL (<LOD) in one Franz cell and no 
protein was extracted within the other two Franz cells. Therefore the positive 
control failed and did not extract a detectable concentration of protein from the 
skin. The vehicle control again extracted a minute concentration of protein, 0.136 
µg/mL (<LOD) from a single cell and no protein was extracted from the other two 
Franz cells. The PAMAM dendrimer extracted a mean concentration of 1.979 ± 
0.756 µg/mL of protein from the skin which is more than 2.5 times that of the 
positive control (Figure 4.12). The protein concentration extracted by the PAMAM 
dendrimer solution was however only 0.979 µg/mL over the LOD therefore again 
the results displayed in Figure 4.12 should be considered tentative.  
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Figure 4.12. Concentration of protein (µg/mL) extracted from the 
dermatomed porcine skin (400 µm) after a 24 h contact time under occluded 
conditions. (a) positive control- (chloroform:methanol, 3:2) which extracted an 
average concentration of 0.741 ± 0.741 µg/mL of protein (n=3 ± SEM) (b) vehicle 
control- (water: methanol, 65:35) that extracted 0.1358 ± 0.1358 µg/mL (n=3 ± 
SEM) and (c) G3-PAMAM-NH2 (10 mM, 0.2 mL) that extracted 1.979 ± 0.756 
µg/mL (n=9 ± SEM). No protein was detected for the negative control (0.2 mL 
distilled water, n=3). N.B LOD for the assay is 1 µg/mL.  
 
4.2.6 ATR-FTIR analysis of the interaction between PAMAM dendrimers and 
porcine SC 
 
Figure 4.13 exhibits the stacked spectra of the PAMAM in aqueous solution, 
the isolated SC alone and dosed with the vehicle control and the PAMAM 
dendrimer solution. General peak changes to the spectra can be observed but 
also the similarities between the aqueous PAMAM dendrimer spectrum and the 
untreated isolated SC spectrum. The overall spectra have been utilised to focus on 
specific peak shifts that are explained further in the Chapter. The peak 
assignments for the PAMAM dendrimer spectrum (Figure 4.13 (a)) are 3250 & 
3050 cm-1 corresponding to –NH-, 1450 cm-1 corresponding to –CH2- and 1650 & 
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1550 cm-1 corresponding to the –HN-CO-. It was found that the –C(O)NH- peak of 
the G3-PAMAM-NH2 PAMAM dendrimer overlaps with the amide I peak of the SC. 
 
 
 
Figure 4.13 ATR-FTIR spectra of isolated native SC and isolated SC dosed 
with PAMAM dendrimer and the corresponding vehicle control. (a) 
Corresponds to an aqueous solution of G3-PAMAM-NH2 dendrimer (10 mM, 
0.2 mL)  (b) SC dosed with the vehicle control (water: methanol, 65:35, 0.2 mL), (c) 
untreated SC and (d) SC dosed with 10 mM G3-PAMAM-NH2.  
2 
Figure 4.14 represents three replicate spectra corresponding to 
G3-PAMAM-NH2 dendrimer dosed SC and the red spectrum which corresponds to 
the vehicle control. The spectra highlight a shift in amide I graph and amide II 
which is possibly due to changes in the β-sheet (~1629 cm-1) structure of keratin 
(Lin et al. 1996). There are no observable changes in the scissoring mode at 1454 
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cm-1 suggesting no alterations in the lateral chain packing. There is a peak shift in 
the CH2 wagging mode with the PAMAM dendrimer dosed SC. The peak is at 
1150 cm-1 but the vehicle control peak shifts to 1175 cm-1. A peak at 1410 cm-
1equates to CH2 bending present in the vehicle control SC (red) but not in the SC 
that was dosed with PAMAM dendrimer.  
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Figure 4.14. ATR-FTIR spectra of isolated SC dosed with 10 mM G3-PAMAM-NH2 dendrimer overlaid with the vehicle 
control spectrum. Overlaid spectra of G3-PAMAM-NH2 dendrimer dosed SC replicates (purple, pink and green). The red spectrum 
corresponds to the vehicle control (water:methanol, 65:35). Differences in wavenumber or peak shape between PAMAM dendrimer 
treated and the vehicle control treated SC are marked on the spectra.
VC-red 
VC-red 
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The wavenumber of the amide bond corresponding to the protein within the 
SC was plotted against each treatment group to determine whether there was a 
significant peak shift. Figure 4.15 demonstrates the shift in wavenumber from the 
vehicle control for 5 mM and 10 mM G3-PAMAM-NH2 dendrimer treated SC. A 
5 mM PAMAM dendrimer solution resulted in a shift of the amide band for two (out 
of four replicates) of the SC samples as high variability within the 5 mM replicates 
was observed. This may possibly be due to the 5 mM concentration being on the 
cusp of the concentration that induces a shift in the amide I band. The SC was 
isolated from a range of pig donors therefore possible donor or regional variations 
in the SC may account for the split in amide I band shift observed for the 5 mM 
PAMAM dendrimer concentration. Differences in the contact between the SC and 
the diamond or possibly due to differences between the wavenumber or depths of 
penetration (Grdadolnik, 2002) may account for variability observed between the 
replicate samples. There was no statistically significant difference between the 
peak shifts for 10 mM and 5 mM PAMAM dendrimer treated SC and the vehicle 
control treated SC (Kruskal Wallis ANOVA, p>0.05). 
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Figure 4.15 Graph illustrating the peak shift of the amide I band for 10 mM 
and 5 mM G3-PAMAM-NH2 dendrimer treated SC and for the vehicle control 
treated SC. The data is presented as the mean ± SEM (n=4), a Kruskal Wallis 
ANOVA found no statistical significance (p>0.05). 
 
The amine II band also saw a shift in wavenumber after treatment with a 
10 mM G3-PAMAM-NH2 dendrimer solution when compared to that of the vehicle 
solution treated (Figure 4.16). No shift in peak was observed for the 5 mM 
G3-PAMAM-NH2 dendrimer solution. The amide II band is due to the N-H bending 
vibration of the protein within the SC and C-N stretching vibration. This may be 
evidence of a change in conformation.  
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Figure 4.16. Graph illustrating the peak shift of the amide II band for 10 mM 
G3-PAMAM-NH2 dendrimer treated SC and for the vehicle control treated SC. 
(n=4)  
 
Carboxyl terminated PAMAM dendrimers (G3.5-PAMAM-COOH) were 
dosed onto SC and analysed by ATR-FTIR also. Figure 4.17 illustrates the 
differences to the peak shape and frequency shifts that correspond to the 
G3.5-PAMAM-COOH dendrimer dosed SC. There is a peak shift of the CH2 
scissoring peak at 1410 cm-1 where it alters when the SC was dosed with the 
carboxyl terminated PAMAM dendrimer. A magnification of the peak shift at 
2979 cm-1 illustrating G3.5-PAMAM-COOH dendrimer (5 mM, 0.2 mL) compared 
to the vehicle control (Figure 4.18). 
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Figure 4.17 ATR-FTIR spectra corresponding to G3.5-PAMAM-COOH (5 mM solution) and corresponding vehicle control 
applied to the SC. The PAMAM treated spectra is displayed as pink, purple and green and a spectrum corresponding to the 
vehicle control solution is red. The changes in peak shape and frequency are marked on the spectra. 
VC-red VC-red 
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Figure 4.18. Magnification of ATR-FTIR spectra demonstrating peak shift 
after application of G3.5-PAMAM-COOH dendrimer to isolated SC compared 
to vehicle controlled dosed SC. G3.5-PAMAM-COOH dendrimer (5 mM, 0.2 mL) 
dosed SC corresponds to the pink, purple and green spectra and a spectrum 
corresponding to the vehicle control solution dosed SC is displayed in red. 
 
The wavenumber of the CH3 asymmetric stretch was plotted against the SC 
treatment. Figure 4.19 demonstrates the shift in frequency of the CH3 asymmetric 
stretch for the vehicle control treated SC compared to the G-3.5-PAMAM-COOH 
dendrimer treated SC though this was not significantly different (Mann Whitney 
test p>0.05).  
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Figure 4.19 Graph illustrating the peak position of C-H stretch at 2981 cm-1 
after application of G3.5-PAMAM-COOH dendrimer to SC compared to the 
vehicle control treated SC. The data is presented as the mean ± SEM (n=3). 
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4.3 Discussion 
 
The studies within this section showed that a PAMAM dendrimer skin pre-
treatment enhanced the permeation and distribution of CHG within porcine skin. 
The mechanism of action behind the PAMAM dendrimer’s effect upon the skin is 
unknown. To determine whether PAMAM dendrimers impair the integrity of the 
barrier of the skin the TEER and TEWL was measured. The TEER was used to 
measure the electrical resistance across the skin to determine whether there was 
a significant decrease in the resistance caused by the PAMAM dendrimer’s 
application to the skin. No significant difference was observed between the TEER 
determined before application and after application of PAMAM dendrimer (Figure 
4.1 (a)). This suggests that no significant damage to the barrier nature of the skin 
was sustained due to a contact time of 24 h with the highest concentration of 
G3-PAMAM-NH2 dendrimer tested (10 mM).  
 
Further to this, TEWL was also measured which has been utilised to 
measure the damage incited by a range of skin penetration enhancers including 
micro-needles (Badran et al. 2009), ethanol/propylene glycol solutions (Levang et 
al. 1999), surfactants (Elmahjoubi, 2009) and terpenes (Gao and Singh, 1997).  
Macroscopic damage to the skin would result in a sharp increase in the TEWL 
measurements however damage to the skin’s barrier integrity on a micro scale 
may not be detected by TEWL measurements (Netzlaff et al. 2006). Figure 4.1 (b) 
illustrates the TEWL measurements recorded. It was found that the data was 
spread around the mean. G3-PAMAM-NH2 dendrimer (10 mM) treated skin had a 
mean measurement (mean ± SEM, n=18)  of 2.71 ± 1.46 g/m2h and the untreated 
skin control skin had a mean result of 3.08 ± 1.31 g/m2h. There was no statistically 
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significant difference between PAMAM treated skin and the control. There was 
greater variability found within the TEWL data when compared to the TEER data. 
The increase in variability for the TEWL measurements may be due to the 
increase in variables such as temperature, humidity or due to interference from 
residual (not removed after wash procedure) hygroscopic PAMAM dendrimer 
bound to the superficial layers of the SC. 
 
The results within this section from both TEER and TEWL studies are in 
very good agreement in that the PAMAM dendrimer pre-treatment does not incite 
significant macroscopic skin barrier impairment, however to the contrary Venuganti 
and Perumal (2008 and 2009) reported a significant increase in TEWL and a 
decrease in TEER. The authors reported a 40 % reduction in skin resistance after 
application of cationic and neutral PAMAM dendrimers and a significant increase 
in TEWL measurements (ratio mean ± SEM) of 2.9 ± 0.7 for G4-PAMAM-NH2 
10 mM when normalized to pre-dendrimer value). However it is worth noting that 
the study had a very low sample number of n=3 and the temperature of the 
laboratory fluctuated by 6°C during the measurements. An increase of 7- 8°C in 
temperature doubles the rate of TEWL in normal skin (Grice et al. 1971) and 
TEER measurements are also significantly affected by changes in temperature 
(Blume et al. 2010). A 40 % decrease in electrical resistance across the skin is a 
substantial decrease in the barrier nature of the skin and was only observed in this 
study for the SDS 5 % (w/v) positive control. 
 
For the positive SDS control, visually it was apparent that the surfactant had 
extensively damaged and permeabilised the skin lipids and protein. This was not 
observed for the PAMAM dendrimer pre-treated skin which appeared intact 
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therefore a 40 % reduction in electrical resistance appears to be a very high value. 
The authors do not mention whether the PAMAM dendrimer is still present on the 
skin surface during the TEWL and TEER measurement or as to whether it has 
been removed. As PAMAM dendrimers are strongly cationic and extremely 
hygroscopic, measurement of the skins barrier integrity using TEER and TEWL in 
the presence of the PAMAM dendrimer may give inaccurate results. This may 
account for the opposing findings between the two studies.  
 
The OCT images throughout this Chapter consistently demonstrate that the 
PAMAM dendrimers have caused an interaction with the skin resulting in the 
alteration of the hyper-reflective entrance signal on the skin surface. Two 
hypotheses may explain the mechanism behind this. Firstly, it could be due to a 
refractive index (RI) match (or close approximation the RI) that reduces the 
random back scattering of light from the skin surface (Vargas et al. 1999). When 
focusing a plane of light on to the skin surface to record the images, photons travel 
within different media; from air across an interface into skin tissue which contains 
interstitial fluid and a range of proteins and lipids. These skin components possess 
significantly different refractive indices for example hydrated collagen found within 
the dermis has an RI of around 1.43 (Wang et al. 1996). The major contributor to 
the random scattering of photons is due to the filamentous keratin found within the 
corneocytes of the epidermis and it has an RI of approximately 1.62 (Xu et al. 
2003). Air has a RI of 1.000, and skin has an approximate average RI of 1.440 
(Tearney et al. 1995), hence the strong reflective entrance signal at the skin-air 
interface. PAMAM dendrimers (G3-PAMAM-NH2) have a RI of 1.367 at 20ºC 
(compounds specification, Sigma-Aldrich). One possibility is that the PAMAM 
dendrimer reduces the back-scattering of light and thus the mismatching of the RI 
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at the air-skin interface. This would result in a significant reduction to the hyper-
reflective entrance signal at the skin-air interface that has been observed 
throughout the OCT studies.  After application of the vehicle control to the skin, 
there was no change in the hyper-reflective entrance signal.  The vehicle control 
was a water/methanol solution that has a RI of around 1.328 (Phillips, 2013). This 
indicates that it is the PAMAM dendrimer that is influencing the optical changes 
observed at the skin-air interface.  
 
The second mechanism proposed by the author is that the changes occur 
due to the hydration effect that the PAMAM dendrimers exert upon the skin. The 
G3-PAMAM-NH2 dendrimer, could hydrate the skin for prolonged periods of time 
because PAMAM dendrimers are very hygroscopic (Uppuluri et al. 1998) and are 
known to adsorb moisture from the atmosphere (Topp et al. 1999). PAMAM 
dendrimers may absorb water from the atmosphere and make it freely available at 
the SC surface. Occlusion is another possible mechanism of skin hydration as a 
result of the viscous PAMAM dendrimer layer distributed across the skin surface. 
Either one or both of these hydration mechanisms would result in an increase in 
SC hydration. Typically SC hydration results in an increase in the topical or 
transdermal penetration of both hydrophilic and lipophilic drugs (Williams and 
Barry, 2012). Previously, aqueous colloidal layers including films and hydrogels 
have been utilised to enhance the topical delivery of drugs (Das et al. 2006 and 
Luo et al. 2000). There is the possibility that the PAMAM dendrimer adsorbs 
moisture from the SC. This would reduce the size of the corneocytes and result in 
a lower permeation of topically applied drugs in particular hydrophilic drugs (Barry, 
1987). This mechanism is unlikely however as the PAMAM dendrimers have 
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enhanced the deposition and penetration of CHG within the skin as discussed in 
chapter three and five.  
 
After a 20 hour contact time of PAMAM dendrimer dosed on to the skin 
surface the water/methanol vehicle had evaporated leaving a viscous 
G3-PAMAM-NH2 dendrimer layer. The strong reflective entrance signal was 
sporadic in appearance at the air-skin interface. The sporadic disruption of the 
entrance signal caused by the PAMAM dendrimer may be a result of preferential 
accumulation of the PAMAM dendrimer within the skin furrows and undulations. 
After application to the skin, polymeric nanoparticles were reported to be localised 
within the furrows and pores of the skin with preferential accumulation detected 
within the hair follicles (Alvarez-Román et al 2004a). Accumulation of amine 
terminated PAMAM dendrimers within hair follicles was also shown using confocal 
microscopy (Venuganti et al. 2011). The sporadic alteration to the optical 
characteristics of the SC may be due to an uneven distribution of the dendrimers 
across the skin surface. Another possible explanation for the intermittent entrance 
signal is that PAMAM dendrimers self-aggregate when applied to the skin. 
PAMAM dendrimer aggregation was observed using DSC when applied to model 
membrane lipids (Klajnert and Epand, 2005).  
 
The immediate surface reflection reduction effect has been observed 
elsewhere for topically applied ointments and glycerol (Welzel, 2001). These 
hyper-osmotic compounds such as paraffin oil, glycerol and petroleum have been 
shown to be tissue clearing agents (Welzel et al. 2004). A clearing agent is a 
compound that matches the refractive index of the tissue. Glycerol has an RI of 
1.48 (Diaspro et al. 2002) and the refractive index of the skin was calculated to be 
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approximately 1.44 (Tearney, 1995). The clearing agent enhances the delineation 
of the epidermis and the dermis and allows for a more detailed image of skin 
appendages to be collected. It also allows for a deeper depth profile to be obtained 
due to the reduction of random scattering. A white, hyper-reflective entrance signal 
was not observed in the OCT images when dosed with glycerol with the exception 
of the pre-dosed images. At the 90 minute contact time the underlying viable 
epidermis becomes clearer and the structures of the skin become more 
pronounced. This is due to the anhydrous glycerol matching the refractive index of 
the viable epidermis, allowing enhanced visualisation of the skin. This effect of 
reducing the random scattering has been noted elsewhere for glycerol and occurs 
shortly after skin application (Vargas et al. 1999).  
 
Azone, a known chemical skin-penetration enhancer, has also been shown 
to act as a skin-clearing agent and reduces the back scattering of light within skin 
tissue (Xu and Zhu, 2007). The PAMAM dendrimers may also partially act as a 
clearing agent as the PAMAM dendrimer has a similar RI to that of glycerol and 
the skin. After application of a PAMAM dendrimer solution to the skin surface, it 
was apparent that the underlying morphology or microstructures of the epidermis 
and dermis did not become clearer or more defined. This is expected as the 
PAMAM dendrimers are large macromolecules (>2500 Da) and are not expected 
to traverse the SC due to their high molecular weight and strong ionic charge. 
PAMAM dendrimers have been shown to act as a penetration enhancer (chapter 
three, Venuganti and Perumal, 2008, Chauhan et al. 2003 and Wang et al. 2003) 
as has glycerol (Bettinger, 1998) for a range of topically applied drugs. The 
PAMAM dendrimers’ (Topp et al. 1999) and glycerol’s (Hara and Verkman, 2003) 
hygroscopic nature may result in skin tissue hydration. It has been noted that 
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hydration of skin tissue can reduce the refractive index (Knuttel and Boehlau-
Godau, 2000 and Sand et al. 2006). This study has also demonstrated a further 
commonality between glycerol and PAMAM dendrimers in their ability to reduce 
the light attenuation of the SC after topical application (Welzel, 2001).  
 
The optical effect that the PAMAM dendrimer exerts upon the skin surface 
appears to be temporary in nature and this is an important characteristic in a 
topical penetration enhancer (Idson, 1971). After rinsing off the applied PAMAM 
dendrimer, the strong reflective entrance signal on the interface of the skin re-
appeared on OCT images. A PAMAM dendrimer is a large macromolecule with 
limited permeation capacity and is confined to the superficial layers of the SC. This 
allows for a transient and reversible effect as shown throughout the OCT images. 
This section provides further evidence that dendrimers are of benefit in the dermal 
delivery of topical pharmaceuticals. 
 
Light microscopy after haematoxylin and eosin (H&E) staining revealed no 
major morphological changes to the SC (Figure 4.10). The only difference visible 
between the vehicle control and the PAMAM dendrimer dosed skin was that the 
SC appeared to be more compact. After PAMAM dendrimer application the SC 
appears compact and dense which has been observed in clinical trials after 
microdermabrasion (Shim et al. 2001) and after tretinoin treatment (Ellis et al. 
1990). These studies however, were conducted in vivo over many weeks and 
therefore the compaction is due to metabolic activity. As the dermatomed porcine 
skin is ex vivo and is not metabolically active the compaction is due to an extrinsic 
physical affect. That could be an artifact of the cryo-sectioning process though 
cryo-sectioning compared to other sectioning techniques has been shown to result 
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in minimal tissue compression in the z axis (Gardella et al. 2003). Another 
possibility is that the dense, aqueous and cationic PAMAM dendrimer layer causes 
compaction of the SC and thus reduction of the path-length for the permeation of 
CHG. This hypothesis would support the percutaneous absorption data in which 
PAMAM dendrimers were shown to enhance the localization of CHG throughout 
the dermatological layers of the skin. Further studies would be required to confirm 
this hypothesis. After application of a 5 % SDS solution (w/w) the damage to the 
SC was significant with disruption and severe disintegration to the SC layers. This 
degree of alteration to the SC barrier was not observed after application of the 
PAMAM dendrimer solution. 
 
The barrier integrity, OCT and histology studies suggested that the PAMAM 
dendrimer’s effect on the skin was not on a macro scale. Cyclodextrins are large 
macromolecules that demonstrated to have a permeation enhancement effect 
upon the skin. It has been reported that cyclodextrins can extract skin components 
which may be a contributing mechanism of action to their drug penetration 
enhancement effect (Legendre et al. 1995). Whilst the PAMAM dendrimer solution 
did extract cholesterol (over 24 h) from the skin (0.293 ± 0.142 µg/mL), the positive 
control extracted more than five times the concentration of cholesterol. The vehicle 
control did not extract any detectable levels of cholesterol; this was expected as 
lipid loss from the skin does not occur due to water: methanol solutions (Abrams et 
al. 1993). Under all test concentrations only very low concentrations of cholesterol 
below the calculated LOQ were detected; particularly when compared to the 
cyclodextrin 2-hydroxypropyl β-cyclodextrin that extracted a concentration of 
7 µg/cm2 of cholesterol from rat skin (Legendre et al. 1995). The total cholesterol 
content of the SC is 38.8 % (w/w) (Walters and Roberts, 2005) therefore a minimal 
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concentration of cholesterol was extracted by the PAMAM dendrimer. Cholesterol 
extraction due to the PAMAM dendrimer may be an almost insignificant 
contributing factor to their drug penetration enhancement effect upon the skin. As 
the positive control failed to extract a concentration of cholesterol above the LOQ, 
extraction over a larger skin area (this study used 2.54 cm2 skin area) should be 
examined in future work. Other possibilities include increasing the sensitivity of the 
detection system or replacing the positive control with a more effective cholesterol 
extractor. 
 
To further investigate the skin’s modification as a result of contact with 
PAMAM dendrimers a Lowry protein assay with a Peterson’s modification was 
used to detect and quantify extracted protein from the skin. The concentrations 
detected were again very low, the positive control yielded a protein concentration 
below the LOD of the assay (1 µg/mL) of 0.741 µg/mL in only one Franz cell (n=3). 
One would expect a higher concentration of protein extraction from the skin after a 
24 h contact time with chloroform:methanol solution. The PAMAM dendrimer 
solution yielded a concentration of protein >2.5 times that of the positive control. 
The low concentrations of protein extracted are at the LOD which for bovine serum 
albumin was calculated to be 3 µg/mL (Sözgen et al. 2006). This assay is however 
sensitive to different protein compositions therefore diverse proteins result in 
different absorbance values (Winters and Minchin, 2005). The results suggest that 
the PAMAM dendrimer solution may extract a higher concentration of protein from 
the skin than the positive control but as the results are at the LOD further studies 
would have to be conducted for confirmation. Again the positive control failed to 
yield a concentration of protein above the LOD and the PAMAM dendrimer 
extracted protein only marginally over the LOD. For future assays a larger surface 
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area of skin should be utilised for the extraction procedure to ensure any protein 
extracted is above the LOD.  
 
ATR-FTIR was utilised in an attempt to elucidate the interactions between 
the amine and carboxyl terminated PAMAM dendrimers and isolated SC. The 
ATR-FTIR spectra did show some evidence of interaction between the PAMAM 
dendrimer and the isolated SC. The amide I band arises from the C=O stretching 
vibration and the amide II band arises from the C-N stretching and the N-H 
bending (Shakeel et al. 2008). These correlate to the proteins of the SC. Shifts in 
the amide bands are related to changes in the hydrogen bonding of the proteins to 
the heads of the ceramides. It is this hydrogen bonding that affords support to the 
bilayers of the intercellular lipids and thus plays an integral part of the skin’s barrier 
properties (Panchagnula et al. 2005 and Moore et al. 2001). The polycationic 
PAMAM dendrimers may have disrupted the network through competitive 
hydrogen bonding with the amide head groups of the ceramides causing a shift in 
the amide I and amide II bands. Terpenes which are also penetration enhancers 
are thought to disrupt the hydrogen bonding due to competitive bonding between 
the terpene and ceramide which results in lower activation energy required for 
diffusing drug molecules (Jain et al. 2008). This mechanism may explain the 
increase in permeation of CHG within the skin after a G3-PAMAM-NH2 dendrimer 
pre-treatment.  
 
Further, a peak shift was observed in the conformation sensitive CH2 
wagging and scissoring modes after G3-PAMAM-NH2 dendrimer treatment. CH2 
wagging modes are very sensitive to alterations in the chain and packing order of 
lipids (Mendelsohn et al. 2000). This suggests that the G3-PAMAM-NH2 dendrimer 
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alters the packing and organisation of the intercellular lipids. Perturbation of the 
skin lipids would result in an impaired SC and would thus result in an enhanced 
topical drug delivery as observed for CHG within Chapter 3. A different change in 
spectra was observed when the isolated SC was incubated with 
G3.5-PAMAM-COOH dendrimer. For the amide I band it appears that there is a 
shoulder peak resulting from the overlap of the amide I band with the -OH- peak 
resulting from water within the sample. There was a change in the wavenumber of 
the CH2 scissoring peak which corresponds to conformation changes to the 
densely packed lipids (Bouwstra et al. 2003). 
 
There was no difference in the wavenumber of the symmetric and 
asymmetric methylene stretching modes at around 2850 and 2920 cm-1 for G3-
PAMAM-NH2 (when compared to the vehicle control) but a peak shift did occur 
after application of G3.5-PAMAM-COOH (Figure 4.18) (Moore and Rerek, 2000). 
There were frequency shifts when the native SC was compared to the G3-
PAMAM-NH2 vehicle control so that it is the water:methanol solution that disorders 
the fatty acid and ceramide chains and not the cationic G3-PAMAM-NH2 
dendrimer in this case. Figures 4.18 and 4.19 do however show that the carboxyl 
terminated PAMAM dendrimer causes a shift in wavenumber (when compared to 
the vehicle control) corresponding to disorder of the fatty acid and ceramide chains 
(though this was not shown to be significant). 
 
The ATR-FTIR spectra confirms that both amine and carboxyl terminated 
PAMAM dendrimers exhibit a disordering effect of the intercellular lipid packing 
and the hydrogen bonding of the SC proteins to the ceramide head groups. This 
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perturbation of the SC barrier may explain the enhanced drug deposition observed 
in Chapter 3.  
 
4.4 Conclusion  
 
This Chapter addresses a number of gaps in the literature about the 
mechanism of action of PAMAM dendrimers and their properties as penetration 
enhancers. In the present work there was no observed PAMAM dendrimer 
induced damage to the skin on a macro scale as illustrated by barrier integrity 
studies including TEER, TEWL and histological analysis of haematoxylin and 
eosin stained cryo-sectioned skin. It was determined that PAMAM dendrimers 
extract negligible concentrations of cholesterol and protein from the skin. Though 
the results obtained were below the LOQ extraction of skin components by the 
dendrimer should not yet be ruled out may still be a minor contributing cause of 
enhanced topical drug delivery. Disruption of the packing and organisation of the 
SC lipids, hydrogen bonding between SC proteins and ceramide head groups was 
made evident by the collected ATR-FTIR spectra. Further, the OCT images 
suggest that the PAMAM dendrimers accumulate within the follicles and 
undulations of the skin. The OCT images also allude to a transient PAMAM 
dendrimer affect as the alterations to the optical characteristics of the SC 
recovered after the PAMAM dendrimer was washed from the SC surface.  This 
Chapter has illustrated that it is likely there are a range of contributing factors that 
allow for PAMAM dendrimers to act as topical and transdermal penetration 
enhancers. This new information may aid the optimisation and design of future 
dendritic architectures as a platform for efficacious topical and transdermal drug 
delivery.   
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5.0 The use of time-of-flight secondary ion mass 
spectrometry to map the distribution of CHG within 
tissue. 
 
5.0 Introduction  
 
5.0.1 Techniques available for imaging drug-skin deposition 
 
In order to develop more efficacious strategies towards effective topical 
antisepsis it is imperative to first understand the localization and distribution of the 
antimicrobial compound throughout the skin strata, following its application to the 
skin, in order to determine whether the compound reaches the microbial reservoir. 
This also stands for all topically applied compounds including antiperspirants, 
antifungals, cosmetics that are applied to the skin intentionally, in addition to 
pesticides and industrial chemicals that may come in contact with the skin during 
normal use. Mapping the location of a compound in situ within a biological tissue as 
complex as the skin, may also aid in elucidating the permeation pathway and 
mechanism of action. Conventional diffusion studies, such as those conducted using 
Franz-type skin diffusion cells, combined with tape stripping can yield informative 
dermatopharmacokinetic data (N’Dri-Stempfer et al. 2009 and Alberti et al. 2001) for 
topically applied drugs.  
 
The existing gold standard is a tape stripping technique that was described in 
Chapter 3. Whilst it is a widely accepted method for investigating the 
dermatopharmacokinetics of topically applied drugs and chemicals where the method 
has been validated in human volunteer studies (Trebilcock et al, 1994) there are 
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some methodological flaws leaving scope to develop alternative novel methods. 
There is great inter-laboratory variability with regards to tape stripping methods and 
the methods are also laborious and time-consuming (Marttin et al. 1996). There are 
also difficulties in standardizing the tape stripping to determine the amount of a 
compound in different layers of the epidermis due to the removal of varying amounts 
of the stratum corneum (SC) (Van der Molan et al. 1997, Lademann et al. 2009 and 
Dreher, 2007). Whilst there have been advances in quantifying SC material on each 
tape strip, in a purely comparative sense, some tape stripping approaches are still 
laborious and time consuming. Gravimetric analysis (Higo et al. 1993) and others 
require destructive techniques, for example: a modified protein Lowry assay (Dreher 
et al. 2005). Other protein quantification techniques require further analytical 
equipment such as a microscope (Lindemann et al. 2003), spectroscopic equipment 
(Weighmann et al. 2003) and an infra-red densitometer (Voegeli et al. 2007 and Hahn 
et al. 2010). The ToF-SIMS technique is rapid in comparison and as well as detecting 
the drug or biomolecules of interest, it also has means of only including SC material in 
the analysis. 
 
Imaging techniques that have been applied to mapping percutaneous 
absorption include Confocal Laser Scanning Microscopy (CLSM) (Alvarez-Roman et 
al. 2004), Infra Red (IR) imaging (Mendelsohn et al. 2006), Confocal Raman 
Microscopy (Zhang et al. 2007), Stimulated Raman Scattering Microscopy (Saar et al. 
2011) and Matrix-Assisted Laser Desorption/Ionisation - Time of Flight mass 
spectrometry (MALDI-ToF) analysis. Confocal studies have the advantage of being 
able to capture 3D optical images of the skin but the information obtained is based 
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upon a fluorophore, that may limit the application of the technique, particularly as 
species often require fluorescent “tagging”. This restricts the number of compounds 
that can be analyzed by confocal microscopy; fluorescently tagging a compound may 
yield localization information within tissue that does not necessarily reflect that of the 
native compound. IR and Raman microscopes have an achievable spatial resolution 
(pixel size) of around 4-10 µm (Kazarian and Chan, 2013) and ~1 µm (Krafft et al. 
2009), respectively. 
 
 Recently with the advent of stimulated Raman scattering microscopy, low 
sensitivity and interference signals from the coherent non-resident background have 
been overcome, therefore it now offers label-free, non-invasive and real-time skin 
imaging (Freudiger et al. 2008). Stimulated Raman scattering microscopy is a 
relatively new and non-destructive skin-imaging technique that has been used to 
image skin drug delivery of retinoic acid, the distribution of DMSO (Freudiger et al. 
2008) and the chemical distribution of ibuprofen and ketoprofen throughout 
mammalian skin (Saar et al. 2011). Raman spectroscopy techniques offer the 
advantages of being a non-invasive, 3D high resolution imaging technique 
(Lademann et al. 2012). Mass spectral imaging techniques offer unparalleled 
sensitivity. MALDI-ToF has been employed successfully to characterize the 
deposition of pharmaceutical compounds within skin but again lacks the desired 
spatial resolution (each pixel corresponds to 0.2 mm × 0.2 mm) (Bunch et al. 2004). 
Within the Bunch et al. paper the mass spectrum obtained had to be overlaid onto a 
haematoxylin and eosin stained skin Section, which may be considered somewhat 
subjective. Whilst there is advanced MALDI software available to superimpose MALDI 
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spectra over an optical image, it is not possible to distinguish morphological features 
only the tissue outline (Walch et al. 2008). Therefore typically the tissue Section 
would have to be histologically stained to correlate the tissue with the MALDI IMS 
spectra (Chaurand et al. 2006).  There are nevertheless advancements being made 
and commercially available imaging MALDI instruments that have achieved a 20 µm 
spatial resolution when analyzing biological samples (Lagarrigue et al. 2011). 
 
5.0.2 Time-of-flight Secondary Ion Mass Spectrometry 
 
Time-of-Flight Secondary Ion Mass Spectrometry (ToF-SIMS) is a highly 
sensitive surface analytical technique that characterises the surface chemistry of a 
sample accompanied by the spatial distribution. It was initially predominantly used for 
the analysis of inorganic samples such as semiconductors (Zanderigo et al.  2000 
and Douglas and Chen, 1998), polymers (Wien, 1997, Briggs, 1998) and Urquhart et 
al. 2008) and solid state therapeutics (Prestidge et al. 2010). With the advent of liquid 
metal cluster ion sources such as Bin 
+ and polyatomic cluster ion sources such as 
C60
+ and Ar superclusters it became possible for improved data analysis of higher 
mass biomolecules. This advancement meant that more efficient primary ions could 
be produced resulting in an increased yield of secondary ions and thus an increase in 
sensitivity when analysing large biomolecules. The incorporation of a flood gun 
ensuring charge neutralisation allowed for the analysis of organic material. The use of 
a cryostage enabled hydrated biological tissue to be kept frozen at a temperature 
< 70°C whilst under ultra high vacuum to maintain the morphology of the tissue 
Sections.  
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ToF-SIMS analysis involves rastering a pulsed primary ion beam onto the 
sample surface that is supported by a cryostage in vacuo (Figure 5.1). This 
bombardment of ions results in a collision cascade on the sample surface (~1 - 2 nm 
of the outermost surface) resulting in the liberation of secondary ions (Figure 5.2). 
These secondary ions are made up of monatomic and polyatomic particles, whole 
molecules and fragment ions, some of which will carry a positive or negative charge 
and many will remain neutral (Barnes et al. 2011). They occur due to a range of 
processes including fragmentation, gaining of protons, loss of protons or less 
frequently due to molecular re-arrangement. The charge of the ion is dependent on 
the species’ ionisation efficiencies (Grams, 2007).  The liberated secondary ions of 
the same polarity and thus kinetic energy are then accelerated into the drift field of the 
time-of-flight analyzer (Schueler, 1992). The secondary ions are separated according 
to their mass-to-charge ratio, which is dependent on the time taken for the ion to 
reach the detector. With the sputtering of charged species from the sample surface 
an electron flood gun is used to then neutralise the sample (Barnes et al. 2011).  
 
A significant benefit of utilising a ToF-analyser is that it can simultaneously 
detect all secondary ions of the same polarity resulting in each pixel of the spatial 
map representing a full mass spectrum (Belazi, 2009). As a result, ToF-SIMS has the 
ability to characterise the spatial distribution of a compound within the surface of 
complex tissue; this can yield information on the distribution of the drug within the 
tissue and may allow elucidation of the mechanism of action (Benninghoven, 1994). 
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Figure 5.1 Schematic of the analysis of a skin cryo-Section by ToF-SIMS. 
Primary ions from a Bi3
+ are rastered onto the frozen skin Section surface and after a 
collision cascade, secondary ions are emitted. Those of the selected polarity are 
accelerated by an electric field into the flight path of a time-of-flight mass 
spectrometer in which the ion’s mass to charge ratio is determined. The detector 
receives chemical and spatial information therefore a chemical distribution image can 
be retrospectively built. 
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Figure 5.2. Schematic of the SIMS process taken from: 
http://www.phi.com/surface-analysis-techniques/tof-sims.html [Accessed on 
11/3/13]. 
 
5.0.3 Characteristics of ToF-SIMS  
 
The advantages of ToF-SIMS include high mass resolution (>7,000), a wide 
mass range, from the detection of elements up to the detection of macromolecules, 
excellent spatial resolution (in the burst alignment mode) and an ability to 
simultaneously detect fragment ions over a wide mass range that can be analysed 
retrospectively (Chabala et al. 1995). These capabilities are unsurpassed by 
spectroscopy techniques or other imaging mass spectral methods such as MALDI-
ToF. Chemical images of selected secondary ions can be retrospectively 
reconstructed for the analysed areas or a selected region of interest (Figure 5.1). 
Each pixel within the chemical image corresponds to a full mass spectrum, yielding 
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substantial chemical and spatial information for each sample. The ability to analyse 
the data retrospectively reduces the number of samples that would need to be tested, 
particularly in light of new information. For example, if the ToF-SIMS analysis reveals 
that a drug has a particular affinity for a specific biomolecule, previously obtained data 
can be re-analysed incorporating that biomolecule. This capability would be ideal in 
drug development and toxicology. Furthermore, as the ToF analyser detects all 
secondary ions liberated of the same polarity, the technique has the potential for 
analysing the localisation of not only the active therapeutic but also many other 
components of a complex dose formulation. This has the potential for analysis of 
excipients in parallel, e.g. in topical preparations the preservatives that may act as a 
skin irritant, or visualisation of the distribution of silicones across the skin surface.  
 
ToF-SIMS chemical distribution maps not only highlight the localization of an 
exogenous compound within the tissue but can also profile the organic components of 
the different histological compartments of the tissue sample, allowing the depth of 
permeability to be estimated. The localization of the therapeutic agent within a 
particular tissue layer or the binding to a particular biomolecule may elucidate a 
drug’s permeation or any drug depot effects (Andanson et al. 2009 and Teichman et 
al. 2005). This effect has been observed within this Chapter where CHG was shown 
to be highly associated with the SC in both cryo-Sections of skin tissue and on tape 
strips. Another benefit of the technique is that it is not dependent on the penetration of 
a reagent or probe reactivity and is not adversely affected by background staining 
(Malmberg et al. 2011). ToF-SIMS is the analysis of native molecules such as 
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un-labelled exogenous chemicals or endogenous biomolecules within un-fixed 
organic tissue.  
 
The limitations of ToF-SIMS include its inherent inability for quantification due 
to matrix effects (Benninghoven, 1994). The yield of secondary ions is dependent on 
the ionization energies of the various species analysed, i.e. the secondary ion yield 
for a particular species is dependent on the strength of the bonding to the matrix 
(Piantadosi and Smart, 2002).  If the matrix is kept consistent then the secondary ion 
yield should be proportional from sample to sample over a specific area for 
comparison. When analysing samples as complex as biological tissue, only semi-
quantitative analysis is possible due to these matrix effects. ToF-SIMS is an analytical 
technique and as such the system may incur instrumental drift (Thompson, 1991). 
One limitation to the analysis of biological material is that ultra-high vacuum 
conditions must be maintained throughout the analysis. To maintain morphology 
cryo-preparation such as those techniques used in electron microscopy must be 
utilised. Confirmation of the tissue structure integrity and cell morphology is however 
possible by using conventional histological analysis after ToF-SIMS analysis (as 
conducted within this Chapter). 
 
Though ToF-SIMS analysis of biological samples is in its infancy, a broad 
range of biologics have been analysed to date including; mouse adrenal gland cortex 
(Malmberg et al.  2011), xenopus leavis oocytes (Fletcher et al. 2007), He La cells 
(cervical cancer cell line) (Fletcher et al. 2008) and Sections of rat brain (Benabdellah 
et al. 2010 and Nygren et al. 2005). Previous studies have been limited regarding 
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ToF-SIMS and skin tissue analysis. Previous studies included the analysis of the 
incorporation of pseudo-ceramides into the SC delivered from a cosmetic formulation 
(Okamoto, et al. 2006) and (Tanji et al. 2008). These studies used high resolution 
chemical images of the skin surface to which the pseudo-ceramides had been applied 
in order to demonstrate that synthetic pseudo-ceramides can effectively partition into 
the SC. The analysis of the cosmetic formulation treated skin samples resulted in two 
unique ion peaks that were unique to the pseudo-ceramides and were not present in 
untreated samples. The unique fragment ions giving rise to the two additional ion 
peaks were clearly attributed to the pseudo-ceramides as the peaks were not present 
in the analysis of native ceramides. The difference in mass spectra between the 
native and pseudo-ceramide was exploited by the authors to investigate the 
incorporation of pseudo-ceramides within the SC. This study showed that ToF-SIMS 
can provide valuable information regarding the distribution of cosmetic components 
within the skin.  
 
The application of ToF-SIMS to biomedical and biophysical applications has 
been shown previously. For example, photo-ageing effects on skin, before and after 
UV irradiation, were determined and changes in the ToF-SIMS chemical images of 
key skin components such as collagen and lipid molecules within a cross Section of 
human skin were reported (Lee et al. 2008). A ToF-SIMS study into the analysis of 
human skin lipids has previously been conducted, where the authors characterised 
the chemical distribution profile of skin lipids and vitamin E within normal human skin 
(Belazi et al 2009). Despite these studies having produced novel and biomedically 
relevant chemical distribution data for human skin, no subsequent follow up ToF-
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SIMS studies have since been published. This Chapter outlines the use of analyzing 
the localization of a common topically applied antiseptic and investigates a novel 
permeation enhancer. There is great scope to further develop the ToF-SIMS method 
from both an efficacy and toxicology point of view with wide ranging biomedical 
applications discussed further in the Chapter.  
 
Whilst CHG has been used extensively in topical antimicrobial formulations, it 
has been shown in Franz cell diffusion studies to permeate into and across the skin 
poorly (Lafforgue et al. 1997) and (Karpanen et al. 2008), leaving potential pathogens 
viable within the deeper layers of the skin. To develop novel and efficacious 
antisepsis strategies it is imperative to first understand the drugs deposition on the 
skin surface and within the epidermis as little is understood about its distribution post 
topical application. There is increasing interest in the development of suitable 
protocols and applications for imaging techniques that do not require radiolabelling or 
laborious sample preparation. ToF-SIMS has the potential to determine the 
distribution of CHG and other topically applied antimicrobials to fully elucidate a 
biocide’s permeation pathway. At the time of writing there are no published studies 
investigating the application of ToF-SIMS to skin permeation and distribution of 
therapeutic agents. Thus, this is the first time ToF-SIMS has been utilised to visualize 
the distribution of a topical antiseptic applied to the skin. 
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 5.0.4 Aims and objectives 
 
The primary aim of this study was to use ToF-SIMS to map the distribution and 
localization of a clinically relevant, topical dose of chlorhexidine digluconate (2 % w/v) 
once applied to dermatomed porcine skin. In order to validate the results and ensure 
no artifacts due to the cryo-preparation are involved, a tape stripping study was 
undertaken in parallel with using cryo-Sectioned skin. These tape strips were also 
analysed by ToF-SIMS to determine the potential application of combining 
conventional tape stripping skin studies with a novel ToF-SIMS detection system.  
 
The aims of this Chapter are as follows- 
 
(i) To develop a simple and rapid method for dosing ex vivo porcine skin for 
ToF-SIMS analysis. 
(ii) To determine whether CHG can be distinguished from endogenous skin 
components and whether unique fragment ions for the drug can be 
detected. 
(iii) To use the developed novel method to map the distribution and permeation 
of CHG once topically applied to ex vivo porcine skin. Further, to establish 
whether it is possible to make semi-quantitative measurements of CHG 
ingress into the skin. 
(iv) To combine the novel ToF-SIMS method with the widely accepted tape 
strip method to determine whether a permeation profile could be created 
from the ToF-SIMS analysis of individual tape strips. This may also be 
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developed further to allow for the measurement of ingress of exogenous 
chemicals within the skin. 
 
PAMAM dendrimers were shown to enhance the permeation of chlorhexidine in 
Chapter 3. An additional aim of this Chapter was to visualize the permeation 
enhancement effect of a PAMAM dendrimer pre-dose on the model antiseptic, 
CHG. The ToF-SIMS method developed in this Chapter may be applied in the 
analysis of the efficacy and localization of permeation enhancers.  
 
5.1.0 Materials and Methodology 
 
5.1.1 Materials  
 
Chlorhexidine digluconate (CHG) 20 % (w/v) and NaCl for physiological saline 
(0.9 % w/w) were purchased from Sigma Aldrich, UK. Tape stripping was performed 
using Scotch tape, 3M, UK. Analytical grade methanol, chloroform and hexane were 
obtained from Fisher, UK and were used to solvent-clean glass cover-slips prior to 
sample mounting. De-gassed ultra pure water was used for the preparation of 
receptor fluid and for skin surface washings. Skin integrity was measured using 
Trans-Epithelial Electrical Resistance (TEER) LCR Databridge, Tansley, UK. Skin 
Sectioning was conducted using a cryostat (Leica, CM1850). The temperature of the 
cryostat chamber was found to be optimal for cryo-Sectioning skin Sections at -28°C. 
Samples were embedded within OCT embedding material, supplied by Fisher 
scientific, UK. OCT is an inert mounting medium containing 10.24 % (w/w) polyvinyl 
alcohol 4.26 % (w/w) polyethylene glycol 85.5 % (w/w) non-reactive ingredients. As 
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the OCT embedding material is frozen on contact with the skin sample at -28°C there 
should be minimal interaction between the mounting agent and tissue and is widely 
considered inert.  
  
5.1.2 Skin preparation 
 
  Skin was prepared from the flank of six week old pigs obtained from a local 
abattoir prior to any steam cleaning treatment. The skin was washed with distilled 
water and carefully shaved using clippers so as to not damage the integrity of the 
tissue. The subcutaneous fat was carefully removed using a scalpel and then the skin 
was dermatomed to a thickness of 400 µm with an electric dermatome. It was then 
wrapped in aluminum foil and frozen at -20°C until required. The dermatomed skin 
was then punched out with a 3 cm diameter punch and placed upon a stainless steel 
mesh support grid within a Franz cell, with the SC facing upwards. To check the 
integrity of the skin, 4.5 mL of physiological saline was added to the receptor chamber 
and 2 mL of physiological saline was added to the donor chamber and placed in a 
circulating water bath on a submersible magnetic stirrer at 32°C for 30 minutes. After 
the cells had equilibrated, the TEER was measured to check the integrity of the 
porcine skin. Prior to readings being taken, the instrument was calibrated using a 
resistor. It has been established that healthy and intact porcine skin in Franz-type 
cells used should have an electrical resistance reading of ≥ 3 KΩ to pass the integrity 
check (Davies et al. 2004). 
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5.1.3 Diffusion (Franz-type) cell study 
 
 The diffusion cells that had passed the integrity check were removed and the 
skin was allowed to air dry for 2 h at ambient temperature. 4.5 mL of physiological 
saline was added to the receptor chamber of each Franz cell. The Franz cells were 
placed in the water bath (32°C) on a submersible stirring plate for 30 minutes and 
allowed to equilibrate. A 2 % (w/v) solution of CHG and a 10 mM solution of 
G3-PAMAM-NH2 were prepared in distilled water from a 20 % (w/v) solution of CHG 
and a 20 % (w/v) solution of G3-PAMAM-NH2 stock.  Once the Franz-type cells had 
equilibrated, the G3-PAMAM-NH2 (0.2 mL, 10 mM) was dosed for a 24 h contact 
period. After 24 h the G3-PAMAM-NH2 was washed from the skin surface of each 
diffusion cell by rinsing with 2 mL aliquots of distilled water (10 mL in total) over the 
surface of the dosed skin. Once the skin surface was dry (left at ambient temperature 
to dry for 2-3 h) an infinite dose (1 mL) of the CHG solution was applied to the skin 
surface and left for a contact time of 24 h. Excess CHG was removed from the skin 
surface of each diffusion cell by rinsing with 2 mL aliquots of distilled water (10 mL in 
total) over the surface of the dosed skin, taking care not to damage the skin. The skin 
was then allowed to air dry at ambient temperature, after which the Franz-type cells 
were dismantled and the skin destined for the cryo-Section experiment was snap 
frozen in liquid nitrogen. Skin samples intended for the tape stripping study were 
stripped immediately after as described in Section 3.2.4 and as outlined elsewhere 
(Trebilcock et al. 1994) and (OECD, 2004). Samples were then transported to the 
cryostat and the ToF-SIMS instrument on dry ice. 
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5.1.4 Sample preparation for ToF-SIMS analysis 
  
The frozen skin samples were mounted on a cryostat using Optimal Cutting 
Temperature (OCT) embedding material. Vertical cross Sections of skin of an 8 µm 
thickness were cut and placed on to a clean glass cover-slip (1 cm × 1 cm). The cover 
slips were first rinsed in ultra-pure water followed by methanol, chloroform and lastly 
hexane before the skin sample was loaded. For the tape strip experiment, 21 tape 
strips were taken to remove the SC. The strips were then freeze-dried and placed on 
a solvent-cleaned microscope slide ready for analysis. 
 
5.1.5 ToF-SIMS analysis 
 
Full credit for the ToF-SIMS analysis must go to Dr David Scurr at the 
Laboratory of Biophysics and Surface Analysis at the School of Pharmacy, University 
of Nottingham. ToF-SIMS was performed on a ToF-SIMS IV instrument (IONTOF, 
GmbH, Münster, Germany) using a Bi3
+ cluster primary ion source and a single-stage 
reflectron analyzer. ToF-SIMS data was analysed using SufaceLab 6 software. The 
cover-slip containing the samples was mounted onto a cryo-stage with a cold-finger 
mechanism and frozen to -80°C using a liquid nitrogen cooling system. The mounted 
skin samples were then exposed to an ultra high vacuum. A primary ion energy of 
25 kV along with a pulsed target current of approximately 1 pA and post-acceleration 
energy of 10 kV were employed throughout the analysis (Mains et al. 2011). The 
primary ion dose density was maintained at less than 1 × 1012 ions per cm2 
throughout to ensure static conditions. Spectra were acquired in both the positive and 
negative modes at a resolution of 256 × 256 pixels by scanning a primary beam over 
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the sample area. Charge compensation of the sample was performed by irradiating 
the sample with a pulsed beam of electrons using an electron flood gun. Samples 
were analysed using both bunched and burst alignment modes thereby providing both 
high mass and spatial resolution data, respectively. A reference sample of OCT was 
analysed whereby a small amount of the OCT embedding material was applied to a 
solvent cleaned cover slip.  
 
Data processing was performed using SurfaceLab 6, IONTOF (Münster, 
Germany) for both spectroscopy and image analysis. Although data was collected in 
both positive and negative polarity, only the negative ion data will be presented as the 
positive ion data, though supportive, is much less informative. A scheme of the 
sample preparation and analysis can be observed in Figure 5.1. 
 
5.1.6 Statistical analysis of data 
 
All data shown within this Chapter are displayed as the mean ± SEM/ SD (as 
stated) followed by the sample number. To determine whether there was statistical 
significance between the data presented in Figure 5.18 (the measured CHG ingress 
(µm) within the skin, with and without a PAMAM dendrimer pre-treatment) a two way 
T test was conducted after confirming the data was normally distributed in a 
histogram using the software GraphPad Prism® version 5 (San Diego, USA). 
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5.2.0 Results 
5.2.1 Method Development  
5.2.1.1 Identification and analysis of fragment ions characteristic of 
chlorhexidine digluconate (CHG). 
 
To discover fragment ions that are unique or characteristic of CHG, 
dermatomed porcine skin (400 μm in thickness) was dosed with a 2 % solution of 
CHG (w/v) overnight and unabsorbed CHG was washed from the skin surface. Once 
analysed in the negative polarity an overview spectra corresponding to treated and 
untreated skin was obtained (Figures 5.3 and 5.4). The overview spectra with an 
equivalent scale were used to indicate characteristic ion peaks in the CHG treated 
spectra that were more intense or were not present in the untreated spectra. The 
peak corresponding to chlorine was highly prominent in the CHG treated skin 
compared to the untreated skin. A peak at 151 atomic mass units (amu) was 
documented within the overview spectrum (Figure 5.3 (a)) and was calculated to be 
C7H4N2Cl
- (m/z = 151). The structure of this fragment ion was determined (Figure 5.3 
(b)) and it corresponded to a fragment of one of the aromatic branches of 
chlorhexidine. This peak is not present for the untreated skin as observed in the 
spectrum magnification (Figure 5.3 (c)). Survey spectra illustrating the ion peaks of a 
higher mass (160-550 amu) contained the molecular ion ([M-H]-) for chlorhexidine 
(Figure 5.4 (a)). At 505 amu a peak corresponding to the [M-H]- can be observed for 
CHG treated skin but no ion peaks are observed for the untreated skin at this mass 
(Figure 5.4 (b-c)). These characteristic element and fragment ions have been used as 
a marker for CHG within this study. 
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Figure 5.3 (a) Identification of characteristic CHG markers. ToF-SIMS overview spectrum detected in the 
negative polarity of un-dosed porcine skin and skin dosed with a 2 % CHG (w/v) solution after a 24h contact 
time and wash. CHG markers, chlorine and C7H4N2Cl
- 
fragment ion can be observed. 
 
Figure 5.3 (b) Structure of fragment ion 
unique to CHG identified from negative 
polarity overview spectra of CHG treated 
porcine skin. 
 
Figure 5.3 (c) Magnification of CHG unique 
fragment ion within ToF-SIMS overview spectrum 
for un-dosed porcine skin and skin dosed with a 
2 % CHG (w/v) solution after a 24 h contact time 
and wash. 
Untreated skin 
CHG treated 
skin 
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Figure 5.4 (a) Identification of the molecular ion for CHG. ToF-SIMS overview spectrum detected 
in the negative polarity of un-dosed porcine skin and skin dosed with a 2 % CHG (w/v) solution after a 
24h contact time and wash. CHG markers, chlorine and C7H4N2Cl
- 
fragment ion can be observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass (u)
200 250 300 350 400 450 500
-2
x10
0.5
1.0
1.5
2.0
2.5
-2
x10
0.5
1.0
1.5
2.0
2.5
S
c
a
le
d
 I
n
te
n
s
it
y
Untreated skin 
CHG treated 
skin 
[M-H]
- 
Mass (u)
501 502 503 504 505 506 507 508 509
-5
x10
1.0
2.0
3.0
4.0
5.0
-5
x10
1.0
2.0
3.0
4.0
5.0
S
c
a
le
d
 I
n
te
n
s
it
y
NHNH
N
-
NH
NHNH
NH
NH
NHNH
Cl Cl
Molecular ion assigned 
CHG treated 
skin 
Untreated skin 
[M-H]
- 
Figure 5.4 (b) Molecular ion of 
chlorhexidine [M-H]
- 
identified within the 
overview spectra of the porcine skin dosed 
with a 2 % CHG (w/v) solution. 
 
Figure 5.4 (c) Magnification of 
chlorhexidine [M-H]
- 
 within the ToF-SIMS 
overview spectrum for un-dosed porcine 
skin and skin dosed with a 2 % CHG (w/v) 
solution after a 24h contact time and wash. 
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 To visualise the chosen markers from Figures 5.3 and 5.4, the chemical 
distribution map of the selected markers were obtained from the surface of 2 % CHG 
(w/v) dosed porcine skin. The justification for the use of porcine skin as a surrogate 
for human skin was discussed previously in Chapter 3. It was observed that though 
the ion intensity of chlorine was higher for the CHG treated skin it was still readily 
observed on the surface of the untreated skin (Figure 5.5). The two markers, 
C7H4N2Cl
- (m/z = 151) and the [M-H]- C22N10H30Cl2 (m/z = 505) were visualized clearly 
and were found to be distributed evenly across the skin surface. At the lower left hand 
corner of the chemical distribution maps there is a shadow, even in the total ion 
intensity chemical distribution maps. This is likely due to the uneven topography of 
the skin surface and therefore may be out of the range of the pulsing primary ion 
beam.  
 
 The difference in mass resolution for the two operating modes is evident using 
the 37Cl- ion when shown in Figure 5.6. A compromise between high spatial resolution 
and high mass resolution must be made by either analyzing the sample in the burst 
alignment mode (high spatial resolution, low mass resolution) or the bunched mode 
(high mass resolution, low spatial resolution). The ions indicative of the drug should 
therefore be selected in the bunched mode to achieve the highest mass resolution for 
fragment ion identification and assignment. All CHG markers were chosen from 
spectra that were operated in the bunched mode. 
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Figure. 5.5 ToF-SIMS images of various secondary ions chosen as markers for CHG. ToF-SIMS images of Cl-, 
C7H4N2Cl
- and [M-H]- of the negative control and 2 % CHG (w/v) dosed porcine dermatomed skin (400 µm thick). Data 
taken from skin surface after washing negative control and dosed skin surface with 10 mL of ultrapure water. Scale bar 
equates to 20 µm, TC represents the total ion count for the specific ion of interest. 
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Figure 5.6. Mass spectra illustrating the difference in mass resolution between 
the two ToF-SIMS operating modes. ToF-SIMS spectra of 37Cl- present in cryo-
Sections (8 µm thick) of untreated control dermatomed porcine skin (400 µm) and 
skin dosed with 2 % CHG (w/v). The spectra were obtained in negative polarity using 
burst alignment and bunched mode to demonstrate the difference in observed mass 
resolution. The bunched mode can resolve 37Cl- and C3H
- ion peaks unlike the burst 
alignment mode. 
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 To observe differences in the spatial resolution of the two operating modes, a 
proof of concept study was conducted on a CHG-treated skin cryo-Section.  It was 
found that the integrity of the skin tissue was impaired due to the cryo-preparation 
process and the SC had folded on to the dermis (Figure 5.7). In the bunched mode 
the chemical distribution maps illustrate a high ion intensity for all CHG markers. The 
high molecular weight [M-H]- ion also exhibited a strong ion intensity within the 
displaced SC layer. Though the ion intensities of the CHG markers are prevalent, the 
spatial resolution in the bunched mode is clearly lacking. The spatial resolution 
achieved in the burst alignment mode is excellent as the morphology of the differing 
histological skin layers can be observed (Figure 5.7). The high spatial resolution is 
particularly distinguishable when compared to images obtained in the bunched mode 
(Figure 5.7). The ion intensities of the CHG markers in the burst alignment mode are 
not as high. The lack of mass resolution is exhibited by the difficulty in visualisation of 
the [M-H]-  ion in the burst alignment mode. 
 
 The chemical distribution images show that the skin Section was not intact. 
Haematoxylin and eosin was used to stain the skin cryo-Section and a light 
microscope with an attached camera was used to image the cryo-Sectioned skin. 
Figure 5.8 illustrates the folding of the SC on to the dermis which is due to the 
preparation process. This displacement of the SC was clearly identifiable in the 
chemical distribution maps (Figure 5.7) and the haematoxylin and eosin staining was 
found to be an easy technique to confirm the skin integrity.  
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Figure 5.7. Imaging of selected CHG marker ions within the skin. Various CHG ion marker chemical images of 2 % 
CHG (w/v) dosed porcine dermatomed skin (400 µm thick) vertically cryo-Sectioned into 8 µm thick Sections. Curling of 
the sample occurred when adsorbing the Section onto solvent cleaned coverslip (10 mm x 10 mm). Scale bar equates to 
100 µm, TC is the total ion count for the specific ions of interest.
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Figure 5.8. Histological analysis of skin sample after ToF-SIMS analysis. Haematoxylin and eosin stained cryo-
Section of dermatomed porcine skin (400 µm) post dosing with 2 % CHG, illustrating the folding of the SC and viable 
epidermis onto the dermis. (a) ×10 magnification (b) ×40 magnification. 
SC 
(a) (b) 
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5.2.2. ToF-SIMS analysis of chlorhexidine digluconate treated porcine skin 
cryo-Sections. 
 
After identification and assignment of secondary ions indicative of CHG, cryo-
Sections of CHG treated skin and untreated skin were analysed by ToF-SIMS. 
Figure 5.9 shows an example of the magnified mass spectra for the selected CHG 
markers within dermatomed porcine skin. OCT that was used as an embedding 
material for the cryo-Sectioning was also analysed in parallel as a reference material 
to determine any peak overlap. Baseline noise can be observed for the OCT and the 
untreated skin, however unsaturated ion peaks exhibiting high signal to noise 
intensities for 37Cl-, C7H4N2Cl
- (m/z = 151) and C22H30N10Cl2
- (m/z = 505) were 
detected for the CHG treated skin. 
 
The chemical distribution images of three replicates and the untreated skin 
cryo-Sections are shown in Figure 5.10. The two drug ion markers for CHG, 37Cl- and 
C7H4N2Cl
- (m/z = 151), can be observed within the SC. The highest ion intensity for 
the drug markers was found to be in the superficial layers of the skin and the SC. No 
significant signal intensity was detected for the drug markers within the lower 
epidermis or the dermis. No ion intensity for either of the drug markers were observed 
for the untreated skin Section. Figure 5.10 also illustrates the PO2
- (m/z = 61) 
distribution images that were utilised as a marker for the viable epidermis. The ion 
PO2
- (m/z = 61) was typically found distributed throughout the upper viable epidermis 
and the ion intensity for the CHG markers were localised within the SC layers above 
the ion intensity corresponding to the PO2
- (m/z = 61) and thus the viable epidermis.  
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Figure 5.9 Magnified mass spectra of CHG marker ions within skin tissue. ToF-
SIMS mass spectra of various fragment ions (37Cl-, C7H4N2Cl
- and [M-H]- -
C22N10H30Cl2
-) present in OCT embedding material, untreated control skin and skin 
dosed with 2 % CHG (w/v). The spectra were obtained in the negative ion mode. 
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Figure 5.10. ToF-SIMS images of various CHG marker ions distributed within the skin. ToF-SIMS images of various 
CHG markers of the negative control and 2 % CHG (w/v) dosed porcine dermatomed skin (400 µm thick), where the scale 
bar represents 100 µm, MC = maximum ion count per pixel and TC = total ion count for the specific ion of interest.
238 
 
The ToF-SIMS instrument is also capable of selecting a region of interest 
(ROI) by changing the area that is rastered and also the pixel density can be altered 
thereby changing the resolution of the resulting image. An area of SC was selected 
as an ROI to clearly identify the distribution of CHG within the skin (Figure 5.11). The 
ion CNO- (m/z = 41) is indicative of biological tissue and was used to determine the 
tissue-glass interface of the magnified skin cryo-Section.  
 
Chlorine was used as a CHG marker that is characteristic of CHG and was 
found to be distributed within the outer layers of the SC. Again, the ion PO2
- 
(m/z = 61) was found to be distributed throughout the viable epidermis. In order to 
achieve a high enough spatial resolution for the magnification the analysis must be 
operated in the burst alignment mode. In this mode, longer timed pulses of primary 
ions are focussed on to the skin sample surface. This allows for a higher spatial 
resolution as observed in Figure 5.11. Due to a compromise in the mass resolution 
the ion intensity for the more discriminatory CHG markers were too low to observe. It 
was established that burst alignment and bunched mode are highly complementary 
for the analysis of exogenous and endogenous compounds within the skin. For a 
complete ToF-SIMS chemical analysis of skin tissue it is necessary to analyse the 
samples in both modes (Figures 5.10 and 5.11). 
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Figure. 5.11 ToF-SIMS images of CHG markers within the skin taken in the burst alignment operating mode. ToF-
SIMS images taken in burst alignment of various CHG markers liberated from the skin sample of 2 % CHG (w/v) dosed 
porcine dermatomed skin (400 µm thick). The SC was magnified to enhance the visualisation of the ion distribution. MC = 
maximum ion count per pixel and TC = total ion count for the specific ion of interest. 
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5.2.3 ToF-SIMS analysis of chlorhexidine digluconate treated porcine skin tape 
strips. 
 
To characterise the ingress of CHG into the skin, a tape-stripping study was 
conducted in parallel to the cryo-Section study. Once the unabsorbed CHG (2 % w/v) 
was washed from the skin surface after a 24 h contact time, 21 tape strips were 
removed from the skin. Each tape strip was analysed in series in the bunched mode 
after being freeze dried to remove water from the SC material. To determine as to 
whether there are any overlap ion peaks with regards to the tape strip adhesive and 
the CHG ion markers an untreated control was analysed in parallel. Figure 5.12 
illustrates the ion distribution maps for tape strips 1 to 21.    
 
The control tapes at the top of the table show no intensity for the chosen CHG 
ion markers with the exception of natural noise for 37Cl-. The intensity for the ion PO2
- 
is more marked for the control tape strips 1 and 2 than for the treated tape strips 1 
and 2. All 21 tapes strips from the CHG treated skin sample show high ion intensity 
for 37Cl- even at tape strip 21. The distribution of the ion intensity of C7H4N2Cl
- (m/z = 
151) is evenly distributed up to tapes strip 11 -14 where the distribution becomes 
uneven but a higher signal intensity is observed. This sporadic but intense distribution 
of C7H4N2Cl
- (m/z = 151) on the tape strips then continues until the final tape strip. 
Interestingly, from tape strip 14 and onwards the PO2
- ion intensity signal increases as 
the viable epidermis is approached (Figure 5.12). It can also be observed that there is 
a general decrease of SC coverage on the tape strips with increasing tape strip 
number. 
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 Figure 5.13 exhibits the magnified mass spectra of the CHG ion markers for 
the untreated tape strip, tape strip 2 and tape strip 20. Only baseline noise was 
observed in the mass spectra for the untreated sample therefore no difficulties with 
interfering ion peaks were encountered. Tape strip 2 showed the most intense peak 
for the CHG ion markers- 37Cl-, C7H4N2Cl
- (m/z = 151) and C22H30N10Cl2
- (m/z = 505). 
For tape strip 20 a reduction in peak intensity and broadening of peak shape was 
observed. The peak for [M-H]- (C22H30N10Cl2
-) (m/z = 505) cannot be distinguished 
from the noise of the baseline. A decreasing ion intensity signal was observed from 
tape strip 1 to tape strip 21 for all CHG markers.  
 
The chemical distribution images corresponding to the mass spectra discussed 
above can be found in Figure 5.14. Great coverage of SC material on the adhesive 
tape was observed for the untreated sample in the total ion distribution image (Figure 
5.14). There was low level distribution of  37Cl- across the SC material on the tape 
strip for the untreated sample and low level baseline noise for C7H4N2Cl
- (m/z = 151)  
and the [M-H]- (m/z = 505). For tape strip 2, full coverage of SC material was 
observed in the total ion distribution image and the ion intensity for both 37Cl- and 
C7H4N2Cl
- (m/z = 151) was found to be high and localised to the SC material. For the 
[M-H]-  (m/z = 505) the intensity was low but evenly distributed across the SC material 
for tape strip 2. For tape strip 20, only moderate SC coverage was observed and 
therefore the intensity of the CHG markers was dramatically decreased. Though the 
distribution of the ion intensity for 37Cl-, C7H4N2Cl
- (m/z = 151) and to a certain extent 
[M-H]-  (m/z = 505) can still be clearly observed on tape strip 20 that was found to be 
localised to the SC coverage.  
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As the SC coverage decreases and becomes sporadic in distribution the signal 
intensity for CHG markers also significantly decreases. To obtain an accurate 
distribution profile within the skin it was necessary to determine whether the CHG 
markers’ ion intensity was decreasing due to a reduction of SC material being 
recovered or whether it is a correct CHG distribution profile within the skin.  
Using the SurfaceLab 6 software mass spectra and ion images can be acquired for 
selected ROIs. This application was applied to the selection of SC material (ROI) and 
to discount the tape strip background. The ROI selection was accomplished by 
thresholding the very different chemical compositions of biological tissue contrasting 
to the tape adhesive. Once an ROI had been selected the mass spectra and 
distribution images were rebuilt for the total ion and CHG markers. The ion intensity of 
the highly discriminatory CHG marker, C7H4N2Cl
- was normalised to the total ion 
within the ROI to obtain a representative ion intensity. This allowed for the 
determination of an accurate permeation profile as the decrease of SC removal with 
increasing tape strip number was accounted for.  
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Figure 5.12 ToF-SIMS images of CHG marker ions and biomolecules for 21 
consecutive tape strips. ToF-SIMS images of various CHG specific ions and PO2
- of 
the negative control and tape strips 1-21 taken from 2 % CHG (w/v) dosed porcine 
dermatomed skin (400 µm thick), MC = maximum ion count per pixel and TC = total 
ion count for the specific ion of interest. 
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Figure 5.13. ToF-SIMS mass spectra of various CHG ion markers distributed 
across the surface of various tape strips.  37Cl-, C7H4N2Cl
- and CHG molecular ion- 
present on the surface of control tape, tape strip 2 and tape strip 20 from skin dosed 
with 2 % CHG (w/v). The spectra were obtained in the negative ion mode. 
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Figure. 5.14 ToF-SIMS images showing the distribution of CHG marker ions 
across various tape strips. ToF-SIMS images of various CHG specific ions of the 
negative control and representative tape strips 2 and 20 taken from 2 % CHG (w/v) 
dosed porcine dermatomed skin (400 µm thick), MC = maximum ion count per pixel 
and TC = total ion count for the specific ion of interest. 
 
The permeation profile obtained from the ROI on the tape strip was plotted on 
a graph of C7H4N2Cl
- (m/z = 151) ion intensity against the tape strip number. The 
C7H4N2Cl
- (m/z = 151) ion intensity decreased dramatically for the first 3 tape strips 
but then from tape strip 4 to 11 a steady and slight fluctuation in the CHG marker 
intensity was observed before a gradual ion intensity decrease from tape strip 16 to 
21 (Figure 5.15 (b)). This trend was observed for all four samples analysed. This 
profile was compared to the profile obtained from solvent extraction/ HPLC analysis 
conducted in Chapter 3 (Figure 5.15 (a)). To ensure the concentration of CHG was 
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above the LOD of the HPLC, tape strips are typically pooled together. Though the 
ToF-SIMS analysis is semi-quantitative only, a great deal of complementary data can 
be obtained as highlighted in Figure 5.15. The ion intensity for each tape strip can be 
analysed elucidating subtle trends in the permeation profile that can not be achieved 
by conventional tape strip analysis (Figure 5.15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 Graphs showing the distribution of CHG throughout the SC using 
two complementary techniques; HPLC and ToF-SIMS. (a) Concentration of CHG 
extracted from tape strips and analysed by HPLC see Section 3.3.1 (n=14 ± SEM).(b) 
Fragment ion (C7H4N2Cl
-) assigned to CHG intensity for 21 consecutive tape strips 
taken from CHG dosed (2 % w/v) porcine skin (n=4 ± SD). Ion intensity normalised 
against total ion content of SC material on the tape strip giving a semi-quantitative 
permeation profile. 
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Chapter 3 illustrated the use of PAMAM dendrimers as a novel permeation 
enhancer for CHG. The novel ToF-SIMS method developed as outlined within this 
Chapter was tested to determine whether it could be applied to observing the 
permeation enhancement affect of chemical permeation enhancers. The chemical 
distribution images were used to visualise the enhanced distribution and permeation 
of CHG after a G3-PAMAM-NH2 pre-dose treatment (Figure 5.16). For the PAMAM 
pre-treated skin a more intense distribution of all CHG markers was observed across 
the upper skin strata. A very intense distribution of CHG markers 37Cl- and C7H4N2Cl
- 
was observed throughout the SC. When CHG was dosed without a G3-PAMAM-NH2 
pre-treatment the ion intensity for the [M-H]- was lacking, however after a 
G3-PAMAM-NH2 pre-treatment [M-H]
- can be observed throughout the SC with good 
contrast (Figure 5.16). All three replicates of G3-PAMAM-NH2 pre-treated skin dosed 
with CHG (2 % w/v) support the results obtained in Chapter 3 in that PAMAM 
dendrimers act as a permeation enhancer.  
  
Comparison of the distribution images of the G3-PAMAM-NH2 pre-treated 
compared to the CHG alone, clearly illustrates a much deeper permeation and 
ingress of CHG into the upper skin strata. Figure 4.17 shows three replicates of the 
C7H4N2Cl
- distribution for G3-PAMAM-NH2 and non G3-PAMAM-NH2 treated side-by-
side, unmistakably the ion intensity is markedly increased for all three G3-PAMAM-
NH2 pre-treated skin Sections. The chemical distribution images have confirmed that 
PAMAM dendrimers act as a permeation enhancer by visualising an enhanced topical 
delivery of CHG (Figures 5.16 and 5.17).
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Figure 5.16. ToF-SIMS images showing the distribution of CHG ion markers throughout the upper skin strata after a PAMAM dendrimer skin pre-
treatment. ToF-SIMS images of various CHG markers distributed within skin after a 24 h pre-treatment with G3-PAMAM-NH2 (10 mM, 0.2 mL dose) 
followed by an application of 2% CHG (w/v) onto porcine dermatomed skin (400 µm thick). MC = maximum ion count per pixel and TC = total ion count for 
the specific ion of interest. 
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Figure 5.17. A comparison of ToF-SIMS images of various CHG markers distributed within skin with and without a 
24 h pre-treatment with PAMAM dendrimer.  A pre-treatment of G3-PAMAM-NH2 (10 mM, 0.2 mL dose) followed by an 
application of 2 % CHG (w/v) onto porcine dermatomed skin (400 µm thick) was compared to porcine skin dosed only with 
2 % CHG (w/v). Scale bar represents 100 µm, MC = maximum ion count per pixel and TC = total ion count for the specific 
ion of interest. 
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Another interesting feature of the ToF-SIMS is that is can also act as a 
scanning electron microscope (SEM). The distance in which the CHG had permeated 
was measured from the chemical distribution images using the SurfaceLab 6 
software. The unique C7H4N2Cl
- fragment ion was used as a marker for CHG ingress 
for the G3-PAMAM-NH2 pre-treated skin samples and 
37Cl- was used as a marker for 
the CHG alone treated skin samples. This is due to the increase in intensity for the 
CHG markers when pre-treated with G3-PAMAM-NH2, the 
37Cl- signal was too intense 
to accurately measure the permeation of the ingress and likewise for the samples 
where CHG was dosed alone the intensity of  C7H4N2Cl
- was too low. The average 
distance the CHG had permeated into the skin was found to be 32.22 μm ± 1.412 and 
47.56 μm ± 3.980 for PAMAM untreated and PAMAM pre-treated skin. The results 
are reported as the mean ± SEM and are an average of n=9. The average distance 
the CHG had permeated after a G3-PAMAM-NH2 pre-treatment was found to be 
statistically different from the skin samples where CHG was dosed alone (T test, 
t=4.07, p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
252 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18. A graph showing the depth permeated by CHG (2 % w/v) with and 
without a G3-PAMAM-NH2 (10 mM, 0.2 mL) pre-treatment as measured using 
SufaceLab 6 software. The Average measurement of ingress for PAMAM untreated 
and PAMAM treated samples were 32.22 μm ± 1.41 and 47.46 μm ± 3.91, 
respectively. Data is presented as the mean ± SEM (n=10). The permeation distance 
of CHG within the PAMAM pre-treated skin is statistically different from the PAMAM 
untreated skin as shown by a two tailed T test t=4.07, p<0.001. 
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5.3.0 Discussion 
 
The ToF-SIMS technique provides a highly detailed mass spectral map of the 
biological sample being analyzed (Wu et al. 2007). Biological material can yield 
hundreds of secondary ions (Figure 5.2) making the interpretation difficult. This 
intricacy occurs as a result of fragmentation of larger secondary ions liberated from 
the complex biological sample surface. These complex spectra hold the detailed 
chemical information about the composition, distribution and surface order of the 
sample (Graham et al. 2006). In order to identify and assign secondary ion peaks, it is 
imperative to run reference samples e.g. drug sample, embedding and substrate 
materials, in order to understand characteristic spectral differences. Control biological 
tissue should also be analysed in parallel (Piwowar et al. 2011). This enables for 
accurate peak assignments of exogenous and endogenous molecules. 
 
To study the deposition of CHG within the skin it was important to first 
elucidate characteristic fragment ions unique and indicative to the presence of CHG. 
The overview of the negative polarity spectra obtained (Figure 5.3(a)) illustrates the 
secondary ion peaks detected having a mass range 1-160 (amu) from the surface of 
dosed (2 % (w/v) solution of CHG) and un-dosed porcine skin. Chlorhexidine (Figure 
5.4(b)) consists of two chlorinated aromatics; therefore chlorine might be an 
anticipated ideal marker of the drug within the tissue. This was found not to be the 
case and chlorine was only used as supplementary supporting data as the element is 
abundant within tissue and is not unique to the presence of chlorhexidine. Chlorine is 
observed in the un-dosed control skin surface as highlighted in the survey spectra 
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(Figure 5.4(a)) and associated chemical images (Figure 5.6).  A fragment ion thought 
to be characteristic of chlorhexidine was observed at 151 amu, with the proposed 
secondary ion assignment C7H4N2Cl
- (m/z = 151) (Figure 5.3). The magnification of 
the overview spectra for this fragment ion (Figure 5.3(c)) highlights a potential issue 
of analyzing biological tissue in that a low intensity endogenous peak is detected 
within the skin tissue itself at 150.8 amu. Great care must be taken integrating the 
151- C7H4N2Cl
- (m/z = 151) fragment ion to prevent overlap, resulting in noise within 
the spectral image (Figures 5.3 and 5.5). However, due to the high mass resolution, 
peak identification and assignment is typically straightforward. 
 
The overview spectrum (Figure 5.4(a)) highlights the C22N10H30Cl2
- [M-H]- ion 
peak for chlorhexidine (m/z = 505). This molecular ion peak is clear evidence for the 
identification and localization of chlorhexidine; however, due to the high molecular 
weight the intensity is relatively low. The low ion intensity amongst the noise and 
interference of complex biological substrates results in low chemical contrast and thus 
impedes the ability to obtain detailed chemical images. Spectral images (Figure 5.5) 
were generated after the secondary ion peaks were identified and assigned as CHG 
markers. The spectral images visualize the distribution of chlorhexidine upon the 
surface of dosed and un-dosed skin. The skin was analysed post-wash therefore the 
presence of such intense ion intensity for CHG-assigned fragment ions and molecular 
ions as observed in Figure 5.5 suggests that the cationic CHG strongly binds to the 
superficial layers of the skin. The strong binding affinity of CHG to the skin protein has 
been described elsewhere (Lim and Kam, 2008). It is clear in Figure 5.5 that Cl- is not 
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a strong candidate as a characteristic CHG marker due to its abundance upon the 
skin surface, in contrast to the other selected markers, C7H4N2Cl
- and [M-H] – . 
 
 ToF-SIMS analysis can be undertaken in two modes (the bunched mode, with 
high mass resolution and low spatial resolution, or the burst alignment mode, with 
high spatial resolution and low mass resolution). The differences in mass and spatial 
resolution achievable in the two different operational modes are illustrated in Figures 
5.6 and 5.7, respectively. The decrease in mass resolution associated with burst 
alignment mode can result in the inability to discriminate one peak from another, as 
exemplified in Figure 5.6 where the 37Cl- and C3H
- ion peaks can not be resolved in 
the burst alignment spectrum. Figure 5.6 illustrates the mass spectra obtained in both 
operating modes for chlorine on the surface of the skin. The data obtained in the two 
operating modes is highly complementary and together offer high mass resolution 
and high spatial resolution. Sodhi, 2004 discussed the principles behind both 
operating modes at great length (Sodhi, 2004). 
 
Cryo-Sections of skin were investigated to determine the penetration depth 
and the distribution of chlorhexidine within the skin. During the method development 
process it became apparent that the sample preparation stage would be of 
importance to the integrity and quality of the ToF-SIMS data achieved. Figure 5.7 
demonstrates an artefact identified from the cryo-Sectioning process where the SC 
had ‘curled’. When the skin is not effectively adsorbed onto the cover slip occasionally 
the SC and upper viable epidermis fold over onto the dermis. The occurrence of this 
issue is easily identifiable using the ToF-SIMS technique as the change in topography 
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is readily observable. The ToF-SIMS system can also act as a SEM that can be 
utilised to check the tissue integrity. Further, complementary histology such as 
haematoxylin and eosin staining can be performed following ToF-SIMS analysis 
(Figure 5.8) to confirm tissue integrity or skin structures of interest. Although the 
Sectioning of the skin sample in Figure 5.6 was found to be sub-standard due to 
tissue curling, the drug markers assigned from the mass spectra analysed in the 
bunched mode on the skin surface were found to be of high enough intensity to image 
the deposition and distribution of CHX within the skin.  
 
Once the sample preparation was optimised, to further validate the results, 
reference materials of OCT embedding material and a standard solution of CHG were 
analysed using ToF-SIMS in bunched mode (high mass resolution) revealing 
characteristic fragment ions. The following mass peaks were assigned as 
characteristic negative fragment ions within the skin corresponding to chlorhexidine 
digluconate: chlorine (m/z = 35 and 37), C7H4N2Cl
- (m/z = 151) and the [M-H]- ion 
(m/z = 505). No secondary ion peaks corresponding to the OCT embedding material 
overlapped with the secondary ions characteristic of the CHG. Figure 5.9 shows a 
comparison of spectra demonstrating a range of secondary ions that illustrate that the 
ion peaks are characteristic only of the CHG and are not inherent within the porcine 
tissue Sections. The OCT embedding material and undosed control skin both show a 
low intensity secondary ion peak for chlorine as it is abundant within the natural tissue 
and environment. For this reason it would not act as a discriminatory peak for the 
compound of interest. The higher molecular weight fragment ion, C7H4N2Cl
- (m/z = 
151) and the chlorhexidine molecular ion (m/z = 505) are very distinctive and unique 
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respectively to CHG and this specificity is confirmed by their absence in the controls 
as shown in Figure 5.9. The selected CHG markers are in abundance within the 
dosed tissue where a clear intensity peak is demonstrated in the mass spectrum of 
Figure 5.9 (c).  
 
It is possible to use the specific fragment ions to map the permeation of 
chlorhexidine into dosed porcine tissue. Figure 5.10 shows the distribution and 
localization of the CHG markers in dosed porcine skin and are absent within the 
untreated skin. The chlorine (m/z = 37) ion intensity for the 2 % CHG (w/v) treated 
skin sample is much higher and localized to the skin surface in contrast to the 
untreated sample. The chlorhexidine-treated sample has a higher ion intensity within 
the upper strata of the skin and there is a clear trend that with each skin sample 
illustrated the chlorine and the C7H4N2Cl
- ion (m/z = 151) are strongly associated with 
the layers of the SC. The CHG characteristic ions are absent at a significant intensity 
within the deeper skin strata. The explicit localization trend of the ions characteristic 
of the CHG was observed repeatedly with the CHG 2 % (w/v) dosed porcine skin 
samples (Figure 5.10, (b-d)). The three replicate samples dosed with CHG (Figure 
5.10, (b-d)) illustrate a very similar distribution trend of CHG that implies 
reproducibility of the method and a consistent distribution of CHG once topically 
applied.  
 
The chemical images obtained demonstrate the strong affinity that 
chlorhexidine has for the skin as it binds to the SC (Aki and Kawasaki, 2004). The 
lack of CHG associated ions within the deeper skin strata illustrates the need for a 
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permeation enhancement strategy in order to effectively neutralize bacteria found 
below the superficial layers of the SC. 
 
ToF-SIMS has the capability to simultaneously image molecular ions 
associated with the applied compound and native fragment ions occurring within the 
tissue. A phosphate ion intensity signal was also detected and imaged within the 
viable epidermis that was utilised to compartmentalize the tissue Section into 
histological components; in this case, to identify the distinction between the viable 
epidermis and the SC. Phospholipids are not present in the SC due to the 
cornification process as free esterified sterols accumulate instead (Elias et al. 2005, 
Lampe et al. 1983 and Reinertson, and Wheatson 1959). This interesting feature may 
aid the understanding of a dosed compound’s localization within a complex tissue or 
highlight the presence of co-localization with native tissue molecules i.e. co-
localisation of penetrants within the SC, other dermatological layers or features of the 
skin such as sebaceous glands.  
 
To further investigate the localization of CHG within the skin, the samples were 
analyzed using the burst alignment mode (high spatial resolution). Although the 
overall mass resolution of the burst alignment mode spectra is reduced, each of the 
characteristic ions for CHG can still be resolved. High resolution chemical images of 
tissue samples were obtained and are shown in Figure 5.11. Once the ions of interest 
are assigned in the high mass resolution spectra, the burst alignment mode can offer 
a wealth of spatial information. For example, Figure 5.11 clearly shows the 37Cl- (m/z = 
37) attributed CHG is strongly associated with the SC and the chlorine is clearly 
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observed at a relatively high intensity within the SC layers on the magnified burst-
alignment image (Figure 5.11). Again, only very low ion intensity for CHG markers 
was observed within the deeper skin strata.  
 
To confirm the ingress of the CHG into the upper skin strata as opposed to 
being adsorbed to superficial outer layers, a conventional tape-stripping experiment 
was conducted in parallel to the cryo-Sectioning experiments. To remove the SC, 21 
tape strips were taken from the dosed and washed skin samples. They were then 
freeze-dried and analysed using the method previously described (Section 5.5), to 
visualize the distribution of the characteristic CHG ions across the surface of the tape 
(Figure 5.12). An overview of the ion intensities for CHG markers 37Cl- and C7H4N2Cl
- 
(m/z = 151) can be observed on all tapes even on tape strip 21 (Figure 5.12). This 
confirms what was observed within the skin cryo-Sections in that CHG is distributed 
throughout the SC layer. Interestingly, from tape strips 9-13 there is an observed 
increase in the signal intensity of the CHG ion marker C7H4N2Cl
- (m/z = 151). The 
applied compound CHG is hydrophilic in nature and this trend of CHG intensity that 
increases at around tape strip 9 coincides with the SC water gradient. The SC water 
content is typically around 15-30 % but dramatically increases to 70 % at a depth of 
around 10-15 µm at the boundary layer of the SC-viable epidermis (Capsers et al. 
2001). Speculatively, this may be the reason for the residual effect CHG pertains 
once applied to the skin. It is possible that the SC acts as a depot or reservoir 
particularly close to the SC-viable epidermis boundary layer where a higher water 
content is observed. Moisture, however, does impede the tape stripping process as 
the adhesive fails to adhere to the SC material in the presence of water.  
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As the tape stripping progresses deeper into the SC a decreasing mass of 
material was removed from the sample with each tape strip removed, as observed in 
Figures 5.12 and 5.14. A feature of the ToF-SIMS software is that a region of interest 
(ROI) can be selected i.e. only the SC material. Once an ROI has been selected the 
mass spectra can be re-analysed thus removing the background tape that contributes 
to the overall image and mass spectrum. The intensity of the compound fragment ion 
of interest within the selected ROI (SC material only) is normalized against the total 
ion intensity count for the selected ROI. The ability to analyse only the SC material 
can give a more accurate analysis of the drug deposition and absorption throughout 
the layers of the SC and can thus confirm the substantivity of a compound within the 
superficial layers of the skin. 
 
There was a decreasing trend observed for the CHG content for the ROI on 
tape strips 1 to 21.  The C7H4N2Cl
- (m/z = 151) fragment ion generally decreases with 
the number of tape strips taken, with a small increase in ion intensity from tape strip 9 
to 13. Tape strips 1 and 2 show a high concentration of C7H4N2Cl
- (m/z = 151) that 
may correspond to adsorbed chlorhexidine that was not completely washed from the 
superficial layers of the SC due to strong adsorption with skin proteins. It is clear from 
the tape strip experiment (Figures 5.12 and 5.14) that CHG is localized to the upper 
layers of the SC that is consistent with the results obtained for the cryo-Sectioned 
tissue (Figures 5.9 and 5.10). The strong binding within the upper skin strata and poor 
permeation has also been observed elsewhere (Lafforgue et al. 1997) and (Karpanen 
et al. 2008). 
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Typically, beyond tape strip 5, it would be normal to pool the tape strips 
together (Trebilcock et al. 1994) in order to achieve a concentration higher than the 
limit of detection (LOD) when using analytical instrumentation such as a high 
performance liquid chromatography (HPLC). The LOD for CHG extracted form skin 
Section samples using conventional HPLC assays were 0.016 µg/mL (Reinertson et 
al. 1959) and 0.050 µg/mL (Carret et al. 1997). The ppm sensitivity of ToF-SIMS 
(Chabala et al. 1995) circumvents this issue, where significant ion intensity can still be 
observed at tape strip 20 (Figures 5.12 and 5.14). A semi-quantitative depth profile 
was obtained from the ToF-SIMS analysis and compared to the depth profile obtained 
from extracting the CHG and analysing the samples by HPLC (Figure 5.15).  The 
permeation profile obtained from analysing the tape strips by ToF-SIMS offers a 
highly detailed profile as it is not limited by a high LOD due to the ppm sensitivity. 
Subtle trends and fluctuations can be observed in the permeation profiles within the 
SC that are not present when the tape strips are analysed by HPLC (Figure 5.15). 
The enhanced detail achieved from ToF-SIMS analysis could help to establish the 
dermatopharmacokinetics of a drug and would be an extremely powerful and 
complementary technique when combined with quantitative HPLC tape strip studies.  
 
The ToF-SIMS data has shown that CHG applied to the skin surface as a 2 % 
w/w solution binds to the upper layers of the SC and demonstrates poor permeation 
into the deeper tissues of the skin over the duration of the diffusion experiment. This 
lack of permeation may lead to an inefficient reduction in the microbial flora of the 
deeper skin strata as described in Section 1.4 (Brown et al. 1989), and also within the 
skin appendages where propionibacteria and staphylococcal bacteria are found 
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(Touitou et al. 1998). This may suggest that the incorporation of a permeation 
enhancer within a formulation may be required in order to provide a more 
comprehensive reduction in the skin’s microflora, particularly below the SC. This is 
particularly important for when the skin barrier is impaired such as prior to a surgical 
site incision or in cases of skin conditions such as eczema or psoriasis. 
 
In Chapter 3 it was shown that a G3-PAMAM-NH2 skin pre-treatment enhanced 
the permeation of topically applied CHG. ToF-SIMS data was used to visualise the 
permeation enhancement of CHG due to the pre-treatment with PAMAM dendrimer to 
support the findings of the conventional Franz cell studies in Section 3.3.0 (Figures 
5.16-18). G3-PAMAM-NH2 was also analysed by ToF-SIMS as a reference material. 
The fragment ions detected that correspond to the dendrimer were not sufficiently 
unique to be distinguished from the endogenous skin components. This is due to 
PAMAM dendrimers being constituted of polymeric branches of amides and carboxyl 
groups.  As such no evidence of PAMAM permeation was detected.  A clear intensity 
increase of the CHG markers within the upper skin strata was observed (Figure 5.16). 
This was attributed to the penetration enhancement effect of the PAMAM dendrimer. 
When the PAMAM dendrimer-treated skin is compared to the skin treated with CHG 
alone, the considerable penetration and deposition enhancement is clearly evident 
(Figure 5.17). It is also possible to measure the permeation depth of a topically 
applied compound using the SurfaceLab 6 software (Figure 5.18). A semi-quantitative 
permeation depth was obtained from the chemical distribution images of the skin 
Sections. A statistically significant (t=4.07, p<0.001) penetration depth increase was 
observed after the skin was pre-treated with PAMAM dendrimer (Figure 5.18). After a 
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PAMAM dendrimer pre-treatment on average the CHG had permeated ~15 μm 
further into the skin than without a PAMAM dendrimer pre-treatment. 
 
The ToF-SIMS method developed and outlined within this Chapter has 
successfully been applied to visualise the distribution and penetration of the 
conventional topically applied antiseptic, CHG, and has established the effectiveness 
of a novel dendrimer permeation enhancer. A higher concentration of CHG within 
deeper layers of the upper skin strata may result in an increased reduction of 
opportunistic pathogens within the skin. The ToF-SIMS method has wide ranging 
potential applications including the ability to investigate the diffusivity of a drug within 
the skin and the dermatopharmacokinetics of a topically applied drug. Other potential 
biomedical applications include establishing biochemical differences between healthy 
and diseased skin and the technique could also be applied to establish whether toxic 
compounds such as pesticides are systemically absorbed after treatment to the skin 
surface. 
 
5.4.0 Conclusion 
 
This study has demonstrated that ToF-SIMS is capable of providing rapid, 
spatially-relevant data for a topically applied compound once dosed on to the skin. 
Currently, the method is only semi-quantitative, and that is no different to a range of 
other established skin visualization techniques, including classical histology and 
spectroscopic methods. ToF-SIMS is a highly sensitive and powerful imaging 
technique that in this study has shown itself to be highly complementary to 
conventional Franz-type diffusion cell studies that measure skin penetration. In 
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addition, the ToF-SIMS approach has provided a detailed qualitative profile of CHG’s 
permeation into the skin, particularly its penetration into the stratum corneum. This 
investigation has also demonstrated that the ToF-SIMS technique can be applied to 
observe the effects of a novel dendritic permeation enhancer (G3-PAMAM-NH2) of 
CHG. This visualisation technique therefore shows great promise for the 
characterisation of a compound’s skin permeation profile. This may in turn allow for 
the development of more effective topical or transdermal formulations of 
pharmaceutical compounds.  
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6.0 An investigation into the co-formulation of a 
PAMAM dendrimer-CHG skin treatment and the 
development and optimisation of a suitable topical 
formulation that will ultimately deliver an increased 
concentration of CHG within the skin. 
 
6.0 Introduction 
6.0.1 PAMAM dendrimers’ interactions with small drug molecules 
 
Chapter 3 focused on a PAMAM dendrimer pre-treatment to investigate the 
physical interactions between the dendrimer and the skin. This Chapter focuses of 
a co-treatment of PAMAM dendrimer applied in a vehicle with CHG. A one step 
application would be more convenient, cost-effective and enhance patient 
compliance and adherence to treatment (Jorge et al. 2011).  
 
Numerous research groups have investigated PAMAM dendrimers as a 
topical or transdermal drug delivery system. The effects of PAMAM dendrimer skin 
pre-treatment has been discussed in Section 3.1, this chapter will discuss the 
co-application of PAMAM dendrimers with a range of small molecule drugs. 
Co-application of ketoprofen and clonidine with G3-PAMAM-NH2 dendrimer 
(0.373 µmol solution) within a transdermal patch did not result in an enhanced 
transdermal drug delivery across an in vitro snake skin model (Wang et al. 2003a). 
The same group also investigated the transdermal delivery of tamsulosin 
complexed to G3-PAMAM-NH2 dendrimer however the co-application of the 
PAMAM dendrimer with the drug did not enhance the permeation of the NSAID 
across snake skin while the PAMAM dendrimer skin pre-treatment did. The 
authors believe this is due to the interaction of the PAMAM dendrimer with the 
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drug as opposed to the enhancement effect caused by the PAMAM dendrimer’s 
interaction with the skin (Wang et al. 2003b).  
 
Conversely, the flux of indomethacin complexed with G4-PAMAM-NH2 
dendrimer (0.2 % w/v) increased by an enhancement factor of 4.5 when compared 
to that of the free drug across rat skin in an in vitro model. This flux increase was 
also observed in vivo in a Wistar rat model with the dendrimer-drug complex 
resulting in a [AUC]0-24h 2.27 times higher for G4-PAMAM-NH2 when compared to 
the free drug (Chauhan et al. 2003). An enhanced accumulative concentration was 
observed for G5-PAMAM-NH2 dendrimer complexed with both ketoprofen and 
diflunisal in vitro from an aqueous rat model and in an in vivo rat model the 
ketoprofen-PAMAM had a 2.73 time higher bioavailability and the diflusinal-
PAMAM had a 2.48 time higher bioavailability (Cheng et al. 2007). It is interesting 
to note that in contrast to the Cheng et al. 2007 paper no enhancement was 
observed for ketoprofen complexed to G3-PAMAM-NH2 across snake skin in a 
chloroform/methanol vehicle (Wang et al. 2003a).  The variation in results for the 
PAMAM dendrimer-ketoprofen complex is likely due to the different model skin 
membranes used. Pig and rat skin is acknowledged as a surrogate for human skin 
by the OECD unlike snake skin which is used in the studies above (OECD, 2008). 
Cnubben et al. have shown that rat skin is more permeable than human skin and 
transdermal absorption in vivo in rats is 1.5-2.5 times higher than for human skin. 
The same authors show that perfused pig ear epidermis is a good surrogate model 
for human skin (Cnubben et al. 2002). Also, the studies utilise different PAMAM 
dendrimer generations and concentrations throughout the studies.  
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PAMAM dendrimers co-applied with hydrophilic drugs have also resulted in 
an enhancement in percutaneous absorption. Co-application of PAMAM 
dendrimers with 5-Fluorouracil resulted in an increased flux of drug across the 
porcine skin from a mineral oil and isopropyl myristate vehicle but not from PBS 
(Venuganti and Perumal, 2008). Again it was found that a PAMAM dendrimer pre-
dose was more effective than simultaneous application of the PAMAM-drug.  
Another hydrophilic drug simultaneously applied with PAMAM dendrimer was 
riboflavin. A co-treatment of G2-PAMAM-NH2 and riboflavin in an oil in water 
emulsion resulted in an increased permeation of riboflavin within porcine ear skin 
(Filipowicz and Wolowiec, 2011). 
 
PAMAM dendrimers have been formulated into a variety of drug delivery 
systems. For example PAMAM dendrimers have been incorporated into a 
polyhydroxyalkanoate matrix into a transdermal drug delivery patch that delivered 
a clinical concentration of tamsulosin across the skin (Wang et al. 2003). Further, 
Devarakonda et al. (2004) characterised hydrogels containing nifedipine, 
G3-PAMAM-NH2/ G5-PAMAM-NH2 with hydroxyl propyl methyl cellulose (HMPC) 
as a gelling agent. The authors discovered that the amount of nifedipine released 
from the gels increased with increasing PAMAM dendrimer concentration. A 
generation dependent effect was also observed with G5-PAMAM-NH2 resulting in 
a higher flux of drug release when compared to G3-PAMAM-NH2. The dendrimer 
also prevented recrystallization of the drug therefore inferring stability on the 
formulation. The authors did not test the dendrimer containing hydrogels on an in 
vitro skin model. A detailed review on dendrimers and their effects on the 
pharmacodynamics and pharmacokinetics once complexed to drugs were 
compiled by Cheng and Xu (2008).  
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More recent topical formulations including PAMAM dendrimers include a 
hydrogel incorporating the antifungal, ketoconazole, and G2 and G3 PAMAM-NH2 
and PAMAM-OH (Winnicka et al. 2012). The authors found that the PAMAM 
dendrimers increased the solubility of ketoconazole and the PAMAM-NH2 
dendrimers resulted in up to a 16 fold enhancement in antifungal properties. The 
PAMAM-NH2 dendrimer incorporated hydrogel was found to out-perform the 
commercially available ketoconazole formulations. Recently, PAMAM dendrimers 
were also incorporated into a topical crème formulation with silver sulfadiazine and 
silver nanoparticles for a novel topical treatment for burn-wound infections 
(Strydom et al. 2012). The incorporation of PAMAM dendrimers exerted stability 
within the formulation and also resulted in an enhanced antimicrobial efficacy. 
 
Dendrimers have found a role in cosmetics and personal care topical 
formulations. Unlike linear polymers, dendrimers are unique in that the intrinsic 
viscosity increases with increasing molecular weight to a maximum after which the 
viscosity decreases with molecular weight in a bell shaped curve (Tolia and Choi, 
2008). This is an interesting characteristic that allows for high molecular weight 
dendrimers to be easily formulated without issues with viscosity. There are a vast 
number of patents which include amine terminated dendrimers due to their unique 
characteristics. For example, Revlon filed a patent on amine terminated 
dendrimers complexed with anti-acne molecules to treat acne vulgaris within a 
cosmetically acceptable formulation (Wolf and Snyder, 1995). Starpharma have 
also filed for a patent using amine terminated PAMAM dendrimers in deodorant 
formulations as the water soluble active odour-reducing agent. This is because 
some basic compounds have the ability to reduce body odour. PAMAM 
dendrimers were shown to limit body odour for up to 20 hours (Forestier and 
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Rollat-Corval, 1999). PAMAM dendrimers are also covered in a patent filed by 
L’Oreal which outlines a self-tanning formulation, which, combined with the active 
dihydroxyacetone, forms a more natural looking tan (Allard and Forestier, 1998).  
PAMAM dendrimers have wide ranging potential within topical drug delivery and 
cosmetics and personal care.  
The advantages of utilising PAMAM dendrimers within a dermatological 
formulation discussed above are summarised below; 
(i) Enhances the permeation of drugs within the skin (Venuganti and 
Perumal 2008, Wang et al. 2003 and Filipowicz and Wolowiec, 2011). 
(ii) Increases drug solubility and bioavailability (Devarakonda et al. 2004, 
Milhem et al. 2000 and Yiyun et al. 2005). 
(iii) Exhibits antimicrobial properties (Observed in Chapter 2 and Calabretta 
et al. 2007 and Wang et al. 2010). 
(iv) Exhibits anti-inflammatory properties (Chauhan et al. 2009). 
(v) Has been shown to reduce irritation through binding to anionic 
surfactants (Derici et al. 2005). 
(vi) Odour absorbing properties (Forestier and Rollat-Corval, 1998). 
(vii) Ideal intrinsic viscosity properties (Tolia and Choi, 2008). 
(viii) Water soluble and compatible with organic solvents (Liu and Fréchet, 
1999).  
(ix) Good bioadhesion (Vandamme and Brobeck, 2005). 
6.02 Rationale for the investigation of a topical preparation using a CHG-
PAMAM complex.  
 
    In Chapter 2, it was shown that a PAMAM dendrimer skin pre-treatment 
enhanced the permeation of CHG within the upper skin strata. A PAMAM 
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dendrimer skin pre-treatment enhances the penetration of therapeutics across 
the skin (Chapter 2, Wang et al. 2003, and Venuganti and Perumal, 2009) 
though co-application of a drug with the dendrimer enhancer would be more 
convenient in a one-step application. Various PAMAM dendrimer-drug 
complexes are discussed in section 6.01 however no in vitro skin absorption or 
drug-dendrimer interaction studies have been conducted on the co-application 
of an antimicrobial compound-PAMAM dendrimer complex formulation. 
Moreover, there are limited studies available within the literature where 
PAMAM dendrimers have been formulated into a cosmetically acceptable 
topical formulation (Winnicka et al. 2012 and Strydom et al. 2012).  
 
6.03 Aims and objectives 
 
The aim of this chapter is 2 fold; to firstly investigate whether a PAMAM 
dendrimer-CHG co-application enhances the permeation of CHG within porcine 
skin and secondly to develop a cosmetically acceptable formulation for the co-
application. 
To achieve these aims a number of objectives were necessary; 
(i) To investigate the interactions between G3-PAMAM-NH2 dendrimer and 
CHG. 
 
(ii) To conduct studies into determining whether a co-application of 
G3-PAMAM-NH2 –CHG enhanced the percutaneous absorption of CHG 
within porcine heat separated epidermis. To also determine whether any 
enhancement effect is proportional to the PAMAM concentration within 
the co-dose application. 
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(iii) To develop a formulation for the co-application of PAMAM dendrimer-
CHG that out performs formulations already available in terms of 
antimicrobial efficacy but is still cosmetically acceptable. The properties 
of the formulations will be characterised and then an optimal formulation 
will be tested in an in vitro porcine percutaneous absorption model.  
 
6.1 Materials and methods 
 
6.1.0 Investigation into the interactions between chlorhexidine digluconate 
and PAMAM dendrimers 
6.1.1 Imaging and measurement of crystal formation 
 
Within 12 h of contact G3-PAMAM-NH2 and CHG formed a precipitate in an 
aqueous solution forming crystals. These crystals were then magnified and 
imaged on a Leica light microscope (model- MZ8, Milton Keynes, UK) and the 
crystals were illuminated using a cold light source (Schott light, KL1500, 
Massachusetts, US). The images were captured on an attached Infinity X camera 
(Lumenera, Ottawa, Canada). The length of crystals formed was measured using 
a calibrated graticule on the microscope.  
 
6.1.2 Matrix assisted laser desorption ionization Time of Flight (MALDI-ToF) 
mass spectrometry 
 
A 10 mg sample of vacuum dried (24 h on a high vacuum line) precipitate 
was sent to the EPSRC National Mass Spectrometry Service Centre at Swansea 
University. The sample was analysed on a Voyager De-STR (Applied biosystems)  
with a nitrogen laser (λ=355 nm) using a 3-indoleacrylic acid, and a 1:1 ethanol: 
acetonitrile matrix.  The spectra were collected in positive linear mode. 
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6.1.3 Single crystal x-ray diffraction 
 
A sample of the crystals in aqueous solution was sent to the UK National 
Crystallography Service, University of Southampton. The diffractometer used was 
the beamline I19 situated on an undulator insertion device with a combination of 
double crystal monochromator, vertical and horizontal focussing mirrors and a 
series of beam slits (primary white beam and either side of the focussing mirrors). 
The experimental hutch (EH1) was equipped with a Crystal Logic 4-circle kappa 
geometry goniometer with a Rigaku Saturn 724 charged coupled device (CCD) 
detector and an Oxford Cryosystems Cryostream plus cryostat (80-500 K). The 
beamline operates at 18 KeV. 
 
6.1.4 Formulation of the co-application (G3-PAMAM-NH2 dendrimer–CHG) 
formulation  
 
The G3-PAMAM-NH2 dendrimer–CHG complex was stabilised in a water: 
ethanol solution (varying in volume ratio from 10-90 % ethanol content) within 
2 mL amber glass vials. The water used in the formulation was ultrapure and the 
ethanol was HPLC grade (Fisher Scientific, Loughborough). The samples were left 
for three months at ambient temperature. The ideal organic solvent/water mixture 
was chosen based on the absence of precipitation. 
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6.1.5 Recovery of CHG after addition of PAMAM dendrimer in occluded and 
unoccluded conditions. 
 
     G3-PAMAM-NH2 was added in varying concentrations (0.2 mL of 0.5, 1 
and 10 mM) to CHG (0.2 mL, 2 % w/v) in a 50:50 ethanol:water vehicle in a 3 mL 
vial. The samples were mixed and placed in a water bath at 32°C ± 1°C (skin 
surface temperature) and were either occluded or unoccluded. The samples were 
left for 24 h after which they were syringe filtered (0.2 µm, 15 mm diameter 
polypropylene filters, Fisher Scientific, Loughbrough, UK) and diluted to an 
appropriate level.  An aliquot of each sample was removed and placed in a clean 
quartz cuvette and after running a blank the absorbance at 254 nm was measured 
on a UV-VIS Varian Cary® 50 Bio spectrometer (West Sussex, UK). The equation 
of the line after analysing a series of CHG standards to form a calibration graph 
was y=0.034x+0.321 which was linear over a concentration range of 0-100 µg/mL 
(R2 = 0.9998).  
 
6.1.6 Microdilution broth with viable count assay to determine inhibitory 
concentration (IC50) 
 
To determine whether the addition of the PAMAM dendrimer would result in 
synergistic or antagonistic antimicrobial effects, a microdilution broth assay with a 
viable count was conducted. The method is outlined fully in section 2.1.1. Various 
concentrations ranging from 1-0.005 µg/mL of CHG in a 50:50 water: ethanol 
vehicle and various concentrations of G3-PAMAM-NH2 dendrimer and CHG 
(1-0.005 µg/mL) were tested against S. aureus.   
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6.1.7 Co-application of various dendrimer concentrations (G3-PAMAM-NH2) 
formulated with CHG in an ethanolic vehicle to porcine epidermis. 
 
The co-application was dosed onto porcine epidermis to determine whether 
the addition of PAMAM dendrimer increases the permeation of CHG within the 
skin. The method is outlined in full in Sections 3.2.1-3.2.3. Various concentrations 
of G3-PAMAM-NH2 were tested (0.5-10 mM, 0.2 mL) in combination with CHG 
(2 % w/v) in a 50:50 water:ethanol vehicle.  
 
6.1.8 Formulation development and characterisation 
 
A range of formulations were developed in high grade 30 mL glass 
universals and the constituents were all HPLC or reagent grade. Each formulation 
was created in triplicate. The ethanol used was HPLC grade (Fisher Scientific, 
Loughborough, UK), the hydroxyl propyl cellulose (HPC, 100,000 mw) was 
purchased from Sigma Aldrich (Dorset, UK), CHG (20 % w/v) was purchased from 
Sigma Aldrich (Dorset, UK) also as was the glycerol and the dimethicone. All 
formulations were mixed on a Retsch mm200 mixer mill (Castleford, UK) for 5 
minutes at a frequency of 30 cycle per second and then left to stir over night at 
200 RPM on a stirrer plate (Stuart, UC152, Stone, UK).  
 
6.1.8.1 Measurement of the pH of the topical gel formulations 
 
For each formulation 1 g was weighed out (Precisa, 262 SMA-FR, Milton 
Keynes, UK) in to a clean conical flask (Grade A glassware, 25 mL) and was made 
up to 10 g with ultra-pure water (SG, HYXO, Kerava, Finland). The conical flask 
was swirled until the formulation had completely dissolved. The pH was measured 
using a pH probe (HANA instruments, pH 210 microprocessor, Bedfordshire, UK) 
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that had been buffered to pH 4.1, 7.1 and 9.1 prior to use, the temperature was 
accounted for (19.8 °C) by the inclusion of the temperature probe with the pH 
probe. The pH was measured in triplicate.  
 
6.1.8.2 Measurement of the spreadability of the topical gel formulations 
 
The spreadability of the formulations was determined by weighing out 1 g of 
the topical gel formulation onto a clean glass plate (20 x 20 cm) after which a top 
plate (20 x 20 cm) was placed over the top of the bottom glass plate that had been 
standardised to a weight of 132 g. After 60 seconds the diameter of the 
formulation spread was measured in mm using a standard ruler (error ± 0.5 mm) in 
the vertical and horizontal direction. The measurements were recorded and the 
spreadability capacity was calculated using Equation 1. Again, the measurements 
were taken in triplicate (Lardy et al. 2000 and Garg et al. 2002). The spreadability 
of a commercially available alcohol hand gel ‘Safemate original’ (151 Products 
Limited, Manchester, UK) was also measured in parallel for comparative reasons. 
The ‘Safemate original’ gel contained ethyl alcohol 62 % as the active ingredient. 
 
6.1.8.3 Extraction of CHG from formulations (drug content and uniformity) 
 
To determine the concentration of CHG available within the formulation 
(Shafiullah et al. 2005), CHG was extracted from 1 g of each formulation. In 
triplicate 1 g of each formulation was weighed into a 100 mL volumetric flask 
(grade A glassware) and made up to volume with ultra-pure water. The volumetric 
flask was inverted until the formulation had dissolved. Then, 1 g of the diluted 
solution was added to a 25 mL volumetric flask and made up to volume with ultra-
pure water and inverted ten times. A 1.5 mL aliquot was removed and placed in a 
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clean quartz cuvette and after running a blank the absorbance at 254 nm was 
measured on a UV-VIS Varian Cary® 50 Bio spectrometer (West Sussex, UK). 
This was repeated for each formulation and the percentage of CHG recovered was 
calculated from a calibration curve created by measuring the absorbance of 6 
CHG standards (1-50 µg/mL). The line equation was y=0.0321x+ 0.0154 
(R2= 0.9991).  
 
6.1.8.4 Viscosity of topical gel formulations 
 
Before measurement of the rheology or viscosity of the formulations was 
undertaken all formulations were placed in a vacuum for 2 h to ensure removal of 
any trapped air bubbles. The rheology of the topical formulations (20 mL) was 
measured from 1-12 RPM and back down from 12-2 RPM on a DV-E Brookfield™ 
system with an LV spindle set (Essex, UK). The accuracy of the calibrated DV-E 
Brookfield™ system is ± 0.1 %. 
 
6.1.8.5 Antimicrobial efficacy of topical gel formulations 
 
A modified agar cup method (Orafidiya et al. 2001 and Wannachaiyasit and 
Phaechamud, 2010) was utilised to determine the antimicrobial efficacy of the 
formulations against three bacteria Staphylococcus aureus (ATCC 11832), 
Escherichia coli (ATCC 8277) and pseudomonas aeruginosa (ATCC 10848). The 
bacteria were cultured, harvested and diluted as outlined in Section 2.1.1. For 
each bacteria, an inoculum of ~105 was achieved. Cation adjusted Mueller Hinton 
agar (MHA) was poured into 90 mm petri dishes (25 mL) and allowed to cool at 
room temperature. Once the agar was set a sterile borer was used to bore 
3 x 10 mm holes within the agar of each petri dish. Each hole was labelled with the 
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formulation reference and the plate was labelled with the bacteria name. A 1 mL 
syringe was used to add 0.1 mL of the gel formulation into the hole in the agar 
taking care not to spill any formulation on the agar surface. Once each of the holes 
in the agar had been filled, 0.2 mL of the inoculum (~105) was vortex mixed with 
7 mL of molten MHA that had been cooled to 40 °C. The inoculated MHA was then 
immediately poured on top of the agar plate and thus the holes filled with the 
topical gels. Great care was taken as to not disturb the topical gels as the 
inoculated MHA was poured very slowly. Once the top MHA layer had set the petri 
dish was inverted and incubated at 37 °C for 24 h. Each formulation was made up 
in triplicate and each formulation was tested in duplicate therefore for each 
formulation (n=6) against each bacteria. After 24 h the zone of inhibition was 
measured using a standard ruler (error ± 0.5 mm) and the average and standard 
deviation as calculated.  
 
6.1.8.6 Attenuated total reflectance Fourier transform infra-red spectroscopy 
(ATR-FTIR) of topical gel formulations  
 
Each formulation and the corresponding starting materials were measured 
using the same ATR-FTIR as outlined in Section 4.1.4. After a background 
spectrum was obtained, 50 µL of the topical gel was transferred onto the diamond 
and immediately a spectrum was collected. Differences and similarities between 
the starting materials and the formulations were recorded. 
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6.1.8.7 Percutaneous absorption of chlorhexidine digluconate from selected 
formulations determined by tape stripping dermatomed porcine skin after 
24 h 
The permeation of CHG within dermatomed porcine skin was measured by 
using a tape stripping procedure as previously detailed in Sections 3.2.3-3.2.4. 
Three of the developed formulations were selected F4(a), F5 and F6 and 1 mL of 
each formulation was placed on the skin surface of each Franz cell for 24 h (n=5).  
 
6.1.9 Analysis of results 
 
 All data is presented as the mean ± SEM unless otherwise stated and were 
analysed using GraphPad Prism® version 5 (San Diego, USA). Prior to statistical 
analysis all data were placed in to a histogram to check for normality. To compare 
the percentage recovery of CHG after addition of the PAMAM dendrimer under 
occluded and uncoccluded conditions (section 6.2.6) a one way ANOVA with a 
Dunnett’s post test was conducted (n=3). The calculation of the IC50 of the co-
formulation of G3-PAMAM-NH2 –CHG (section 6.2.7) was conducted as outlined in 
section 2.2.1 (n=3). In section 6.2.8 a Kruskal-Wallis ANOVA with an ad hoc 
Dunn’s test was used to show significance between the PAMAM dendrimer-CHG 
co-treated skin compared to the CHG control (n=6)  (Figure 6.9). Also in section 
6.2.8, a one way ANOVA (normally distributed data) was conducted on the total 
concentration of CHG (µg/cm2) detected within the receptor fluid at 24 h after co-
application of G3-PAMAM-NH2-CHG as well as CHG (n=6) (Figure 6.10). No post 
test was conducted however due to p>0.05. In Section 6.2.9.2 a one way ANOVA 
was conducted to confirm any significant difference between the spreadability 
diameters as a function of altering the formulation compositions. Further, a 
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Tukey’s multiple comparison was utilised to determine specific significant 
intracomparisons (p<0.05). A one way ANOVA analysis was also used in Section 
6.2.9.3 to analyse the differences within the uniformity and concentration of CHG 
within the formulation.  
 
6.2 Results 
6.2.1 Investigation into the interactions between chlorhexidine digluconate 
and PAMAM dendrimers 
 
A 10 mM solution of G3-PAMAM-NH2 was slowly added to a solution of a 
clinically relevant concentration of CHG (2 % w/v) (Figure 6.1). Immediately on 
contact it was observed that the solution had turned cloudy and after 6 h a 
crystalline precipitation occurred. The precipitate was magnified and photographed 
and the micrograph is illustrated in Figures 6.2 and 6.3. It was discovered that 
shard crystals formed and that the crystal shape was dependent on the order of 
addition. Crystal formation occurred at 10, 1 and 0.5 mM concentration of 
G3-PAMAM-NH2. It was discovered that the crystal shape was dependent on the 
order of addition for example Figure 6.2 shows the crystal formation when the 
formulation was added in the following order: water-G3-PAMAM-NH2-CHG and 
Figure 6.3 shows the crystal structure after an addition order of 
CHG-G3-PAMAM-NH2 water.  
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Figure 6.1. Chemical structure of a PAMAM dendrimer and CHG (a) Chemical 
structure of G3-PAMAM-NH2 dendrimer linear formula: 
[NH2(CH2)2NH2]:(G=3);dendriPAMAM(NH2)32, molecular Weight: 6908.84 and 
(b) Chemical structure of chlorhexidine digluconate, molecular formula: 
C22H30Cl2N10.2(C6H12O7), molecular weight: 897.56. 
 
 
 
 
 
 
 
 
 
 
 
(b) 
(a) 
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Figure 6.2. Photograph of shard crystals formed on addition of CHG to 
PAMAM dendrimer. Crystallised precipitate after addition of water (up to 200 µL) 
followed by G3-PAMAM-NH2 followed by CHG. Images were taken 24 h after 
contact at a magnification of (a) x2, (b) x4 and (c) x11. Shards of transparent 
crystal can be observed emanating from a focal point. 
 
 
(a) 
 
(b) 
 
(c) 
 
(c) 
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Figure 6.3. Photograph of short shard crystals emanating from a focal core  
after addition of CHG to PAMAM dendrimer. Crystallised precipitate after 
addition of CHG, G3-PAMAM-NH2 and then water (up to 200 µL). Images were 
taken 24 h after contact at a magnification of (a) x2, (b) x4 and (c) x11. Small 
shards of crystal emanating from a rounded single focal core much like that of 
petals of a flower can be observed.  
 
(a) 
 
(b) 
 
(c) 
 
(c) 
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6.2.2 Measurement of the melting point 
 
 The crystalline precipitate was dried under vacuum at 50°C and the 
melting point was determined. The crystals began to melt at 109°C and had 
completely melted at 115°C; two further replicates of each crystal shape confirmed 
the melting point.  
 
6.2.3 Measurement of crystal lengths 
 
 The length of the crystals was measured on a calibrated Leica 
microscope at a 6.4 x magnification. The mean shard crystal length obtained in 
from Figure 6.2 was 0.578 ± 0.0013 mm (mean ± SD, n=5) and the mean diameter 
of the ‘flower’ shaped crystals from Figure 6.3 was 0.128 ± 0.0022 mm (mean ± 
SD, n=5). 
 
6.2.4 MALDI-ToF analysis of precipitate 
 
             The crystalline precipitate was dried under vacuum at 50°C and was 
analysed in parallel with G3-PAMAM-NH2 dendrimer reference material. The mass 
spectra for G3-PAMAM-NH2 reference material and the precipitate can be 
observed in Figures 6.4 and 6.5. The mass accuracy of this particular mass 
spectral system is +/- 2 Da. Isotopically resolved species could not be obtained in 
reflectron mode. The sample appears to be a mixture and the species are likely to 
be [PAMAM+H]+ and possibly [PAMAM+Na]+. Figure 6.4 illustrates the mass 
spectra of G3-PAMAM-NH2 reference material with the overview spectrum (a) and 
(b) magnified spectrum showing a mass of 1000-4400 (m/z) and (c) magnified 
spectrum showing 4855-7525 (m/z). Figure 6.5 shows the spectra corresponding 
to the vacuum dried precipitate after addition of CHG to G3-PAMAM-NH2 
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dendrimer; (a) is an overview spectra, (b) magnification at 1000- 2475 (m/z) and 
(c) magnification of spectrum at 5970- 7505 (m/z).  
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Figure 6.4. MALDI-ToF mass spectra of G3-PAMAM-NH2 dendrimer (a) overview spectrum  
 
 
 
 
 
 
Theoretical molecular weight- 6909 Da 
(a) 
286 
 
 Figure 6.4. MALDI-ToF mass spectra of G3-PAMAM-NH2 dendrimer (b) magnified spectrum showing a mass of 1000-4400 
(m/z) and (c) magnified spectrum showing 4855-7525 (m/z).
(b) 
(c) 
(b) 
(c) 
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Figure 6.5. MALDI-ToF mass spectra of G3-PAMAM-NH2 and CHG precipitate (a) is an overview spectrum, (b) spectrum magnification 
at 1000- 2475 (m/z) and (c) magnification of spectrum at 5970- 7505 (m/z). 
 
(b) 
(c) 
(a) 
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6.2.5 Single crystal x-Ray Diffraction (XRD) on precipitate 
 
The XRD results of the crystalline precipitate analysis are illustrated below 
in Table 6.1. The crystal system was found to be a monoclinic system that is a 
rectangular prism with a parallelogram at its base. The crystal was a colourless 
platelet and was found to have a molecular weight of 639.55 Da. The two nitrogen 
atoms closest to the 4-chlorophenyl group are protonated. CHX (base), four water 
molecules and an oxocarbon anion were detected within the crystal. For full details 
on the XRD data please refer to Appendix 3 A structure built from the XRD data is 
displayed in Figure 6.6 as a ball and stick structure. 
 
Table 6.1 Crystal data obtained from XRD analysis. 
Crystal data 
Empirical formula C23H40Cl2N10O7 
Formula weight 639.55 
Crystal system Monoclinic 
Crystal Platelet; Colourless 
Crystal size 0.10  0.04  0.01 mm3 
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 Figure 6.6 Chemical structure obtained from XRD analysis of a single crystal of the precipitate.  
 
Red-oxygen 
Blue-nitrogen 
Green-chlorine 
Grey-Carbon 
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6.2.6 Formulation of CHG-PAMAM dendrimer  
  
On addition of CHG to a G3-PAMAM-NH2 dendrimer solution it was shown 
that the CHG precipitates out of solution. Once the two components were added to 
an ethanol:water solution (50:50), the co-dose formulation became stable. No 
precipitate was observed over a 3 month period under occluded conditions, stored 
away from light at ambient temperature. A lower percentage of CHG was 
recovered from the unoccluded samples with the lowest being the control 
containing only CHG and no PAMAM dendrimer (Table 6.2). Under unoccluded 
conditions the formulation containing 0.5 mM G3-PAMAM-NH2 resulted in the 
highest recovery of CHG from the formulation (59.22 ± 2.00 %) followed by 10 mM 
(51.77 ± 2.63 %) and lastly 1 mM G3-PAMAM- NH2 dendrimer (47.25 ± 5.44 %). 
This is compared to a recovery of only 34.44 ± 3.33 % for the formulation 
containing no PAMAM dendrimer and only CHG. Under occluded conditions a 
significantly higher recovery of CHG was observed for all formulations. The lowest 
recovery was observed for the 10 mM G3-PAMAM-NH2 formulation at 
79.24 ± 1.23 % but it was observed that the solution had turned white and 
pearlescent in appearance. The 0.5 and 1 mM G3-PAMAM-NH2 dendrimer 
formulations enhanced the recovery of CHG (85.94 ± 1.16 % and 92.56 ± 1.84 % 
respectively) when compared to the control formulation that contained no PAMAM 
dendrimer (84.27 ± 1.96 %). 
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Table 6.2 Percentage recovery of CHG after addition of PAMAM dendrimer 
under occluded and unoccluded conditions. Recovery of CHG from a co-
formulation of various concentrations of G3-PAMAM-NH2 that were maintained in 
occluded or unoccluded conditions at 32°C ± 1°C (skin temperature) for 24 h.  
* Formulation turned white and pearlescent. 
 
Figure 6.7 displays the CHG recovery data in which the difference between 
the occluded and unoccluded formulations is evident.  A one way ANOVA with a 
Dunnett’s post test (F=12.02, df=11, 332.8, p<0.05) showed a statistically 
significant difference between the formulation without PAMAM dendrimer and the 
1 mM G3-PAMAM-NH2. Further, statistical significance was observed between the 
control and the 0.5 mM and 1 mM G3-PAMAM-NH2 (one way ANOVA with a 
Dunnett’s post test F=7.046, df=11, 1126 and p<0.05). Interestingly under 
occluded conditions only the 1 mM G3-PAMAM-NH2 dendrimer formulation 
resulted in a significant CHG percentage recovery. Conversely under unoccluded 
conditions it was only the 1 mM G3-PAMAM-NH2 dendrimer formulation that didn’t 
result in a significant enhanced recovery of CHG. 
  
Co-
formulation 
Percentage recovery of CHG from co-formulation (%) 
Sample 
(n=3) 
Unoccluded at 32°C 
Mean               SEM 
Occludded at 32°C 
Mean              SEM 
No PAMAM 
dendrimer 
34.44 3.33 84.27 1.96 
0.5 mM + 
CHG 
59.22 2.00 85.94 1.16 
1 mM + CHG 47.25 5.44 92.56 1.84 
10 mM + CHG 51.77 2.63 79.24* 1.23 
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Figure 6.7. Bar chart of percentage recovery of CHG from a co-formulation of 
various concentrations of G3-PAMAM-NH2 and CHG. The formulations were 
maintained in occluded or unoccluded conditions at 32°C for 24 h. Data are shown 
as the mean ± SEM (n=3). Statistical significance was observed when 1 mM was 
compared to the CHG control (p<0.05) under occluded conditions and also 
significance was observed when comparing 0.5 and 10 mM PAMAM dendrimer to 
the CHG control under unoccluded conditions (p<0.05).  
 
6.2.7 The effect of PAMAM dendrimer on the efficacy of CHG 
 
It was determined that the addition of CHG to G3-PAMAM-NH2 did not alter 
the antimicrobial efficacy of CHG. The IC50 concentration was calculated to be 
0.056 µg/mL and for CHG in an ethanol:water (50:50) vehicle and 0.057 µg/mL for 
CHG-G3-PAMAM-NH2 complex in an ethanol:water (50:50) vehicle. Thus the 
calculated IC50 were within 0.001 µg/mL of each other. (Figure 6.8) 
 
C
o
n
tr
o
l
0
.5
 m
M
 
1
 m
M
1
0
 m
M
C
o
n
tr
o
l
0
.5
 m
M
1
 m
M
1
0
 m
M
0
20
40
60
80
100
%
 r
e
c
o
v
e
ry
 o
f 
C
H
G
Occluded Unoccluded 
*p<0.05 
*p<0.05 
**p<0.05 
293 
 
-2.0 -1.5 -1.0 -0.5 0.0
-100
-50
0
50
100
150
Log [concentration of CHG
 in EtOH/H2O vehicle]
In
h
ib
it
io
n
 o
f
S
ta
p
h
y
lo
c
c
u
s
 a
u
re
u
s  
(%
)
 
-2.0 -1.5 -1.0 -0.5 0.0
-50
0
50
100
150
Log [concentration
of G3-PAMAM-NH2 - CHG]
In
h
ib
it
io
n
 o
f
S
ta
p
h
y
lo
c
c
u
s
 a
u
re
u
s
 (
%
)
 
Figure 6.8. Inhibition curves used to calculate the IC50 concentrations of CHG 
alone in an ethanol:water (50:50) vehicle and for G3-PAMAM-NH2 –CHG in an 
ethanol: water (50:50)  vehicle (a) CHG in ethanol:water vehicle the IC50 was 
calculated to be 0.056 µg/mL (95 %CI: 0.02582-0.1212 µg/mL) and (b) CHG-G3-
PAMAM-NH2 formulation calculated IC50 0.057 µg/mL (95 %CI: 0.04620-0.07120 
µg/mL) Results are represented as the mean ± SEM (n=3). 
 
  
(a) 
(b) 
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6.2.8 Co-application of various dendrimer concentrations (G3-PAMAM-NH2) 
formulated with CHG in an ethanolic vehicle, applied to porcine epidermis 
 
A co-application of PAMAM dendrimer was added in combination with CHG 
(2 % w/v) at three different concentrations (0.5, 1 and 10 mM) in an ethanol:water 
solution (50:50). The data from the studies is shown in Tables 6.3, 6.4, 6.5 and 
6.6, corresponding to no PAMAM dendrimer, 0.5, 1 and 10 mM respectively. A 
much lower concentration of CHG was recovered across all skin treatment groups 
with a mean of around 57 % in the amount of CHG dosed recovered. The highest 
concentration of CHG was detected within the skin wash at 24 h, and the second 
highest was extracted from the glass donor chamber. A mean concentration of 
CHG permeated into the porcine epidermis for the formulation without the 
presence of PAMAM dendrimer was 211.370 ± 33.189 µg/cm2 compared to 
775.857 ± 283.070 µg/cm2, 384.209 ± 153.937 µg/cm2 and 621.711 ± 
98.818 µg/cm2 for 0.5, 1 and 10 mM PAMAM dendrimer co-application 
respectively (Figure 6.9). A Kruskal-Wallis ANOVA test showed that the median 
concentration of CHG within the epidermis for CHG dosed alone compared to 
10 mM G3-PAMAM-NH2 dendrimer was statistically lower. A high variability for the 
CHG concentration within the epidermis for the 1 mM G3-PAMAM-NH2-CHG 
formulation was observed after application to porcine skin. 
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Table 6.3. Percutaneous absorption (mass balance) of CHG within porcine 
epidermis after a 24 h of CHG (2 % w/v) formulation in ethanol:water (50:50). 
Data is represented as the mean ± SEM (n=6) for each diffusion cell compartment 
for both the CHG concentration (µg/cm2) and for the percentage of dosed applied. 
 
 
 
 
Table 6.4 Percutaneous absorption (mass balance) of CHG within porcine 
epidermis after a 24 h treatment with 0.5 mM-PAMAM dendrimer CHG 
formulation in ethanol:water (50:50). Data is represented as the mean ± SEM 
(n=6) for each diffusion cell compartment for both the CHG concentration (µg/cm2) 
and for the percentage of dosed applied. 
 
 
 
Compartment      
(n=6) 
CHG (µg/cm2) 
Mean             SEM 
% of applied dose 
Mean                 SEM 
Donor 
chamber 
632.610 60.470 8.010 0.810 
Skin wash 
3189.095 355.540 40.500 1.440 
Epidermis 
211.370 33.189 2.684 0.421 
Receptor 
fluid 
9.100 2.087 0.116 0.026 
Total 
recovered 
4042.175 451.286 51.310 2.679 
Compartment 
(n=6) 
CHG (µg/cm2) 
Mean                  SEM 
% of applied dose 
Mean                SEM 
Donor 
chamber 
910.700 144.835 11.623 1.815 
Skin wash 
2738.010 419.365 34.888 5.305 
Epidermis 
775.857 283.070 9.853 3.594 
Receptor 
fluid 
6.574 1.899 0.083 0.024 
Total 
recovered 
4431.141 849.169 56.447 10.738 
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Table 6.5 Percutaneous absorption (mass balance) of CHG within porcine 
epidermis after a 24 h treatment with 1 mM-PAMAM dendrimer- CHG 
formulation in ethanol:water (50:50). Data is represented as the mean ± SEM 
(n=6) for each diffusion cell compartment for both the CHG concentration (µg/cm2) 
and for the percentage of dosed applied. 
 
 
Table 6.6 Percutaneous absorption (mass balance) of CHG within porcine 
epidermis after a 24 h treatment with 10 mM-PAMAM dendrimer- CHG 
formulation in ethanol:water (50:50). Data is represented as the mean ± SEM 
(n=6) for each diffusion cell compartment for both the CHG concentration (µg/cm2) 
and for the percentage of dosed applied. 
 
Compartment 
(n=6) 
CHG (µg/cm2) 
Mean                SEM 
% of applied dose 
Mean               SEM 
Donor 
chamber 
754.335 140.909 9.695 1.805 
Skin wash 
2980.024 266.673 37.800 3.487 
Epidermis 
621.711 98.818 7.895 1.255 
Receptor 
fluid 
17.980 2.407 0.228 0.030 
Total 
recovered 
4374.050 508.807 55.618 6.577 
 
 
Compartment 
(n=6) 
CHG (µg/cm2) 
Mean                SEM 
% of applied dose 
Mean              SEM 
Donor 
chamber 
1123.050 431.425 14.333 5.505 
Skin wash 
3600.000 621.857 45.786 7.999 
Epidermis 
384.209 153.937 4.879 1.954 
Receptor 
fluid 
9.047 5.076 0.115 0.064 
Total 
recovered 
5116.306 1212.295 65.113 15.522 
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Figure 6.9. Total concentration of CHG within the epidermis (µg/cm2) at 24 h 
after application of CHG alone, 0.5 mM, 1 mM and 10 mM PAMAM dendrimer 
with CHG in an ethanol: water vehicle (50:50). Data is presented as the mean ± 
SEM (n=6). A Kruskal-Wallis test with an ad hoc Dunn’s post test (histogram 
showed the data was non-parametric) derived that the medians between CHG and 
10 mM-PAMAM-NH2 –CHG formulations were statistically different from one 
another (p<0.05).  
 
The PAMAM dendrimer-CHG co-treatment did not result in a significant 
increase in the concentration of CHG that had permeated the epidermis into the 
receptor fluid at 24 h (Figure 6.10). Without the presence of PAMAM dendrimer a 
total concentration of 9.100 ± 2.087 µg/cm2 of CHG was detected within the 
receptor fluid at 24 h compared to 6.574 ± 1.899, 9.047 ± 5.076 and 17.980 ± 
2.407 for 0.5, 1 and 10 mM of G3-PAMAM-NH2 respectively.  
 
Application of the CHG in parallel to PAMAM dendrimer did not significantly 
enhance the permeation through the epidermis into the receptor fluid but did 
significantly increase the deposition of CHG within the epidermis for the 10 mM 
G3-PAMAM-NH2-CHG co-treatment (p<0.05) (Figure 6.9). The total concentration 
of CHG increased within the receptor fluid at 24 h with increasing concentration of 
PAMAM dendrimer within the co-treatment. The total concentration of CHG within 
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the receptor fluid at 24 h for 10 mM-PAMAM-NH2 dendrimer was ~2 x higher than 
for the CHG dosed without PAMAM dendrimer (Figure 6.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10. Total concentration of CHG absorbed within the receptor fluid 
(µg/cm2) at 24 h after application of, 0.5, 1 and 10 mM PAMAM dendrimer and 
CHG alone.  The dose preparation consisted of CHG in an ethanol:water vehicle 
(50:50) with the aforementioned PAMAM dendrimer concentrations. Data is 
presented as the mean ± SEM (n=6). No significant difference (p>0.05) was 
observed using a one-way ANOVA test (normally distributed data).  
 
6.2.9 Formulation Development and characterisation 
 
After formulating an alcoholic hand gel, an ointment, a cream and a lotion it 
was decided that an alcohol hand gel would be the ideal formulation for a PAMAM 
dendrimer-CHG complex. Alcohol hand gels are antimicrobial, widely used 
clinically and the PAMAM dendrimer is likely to be more stable in an ethanolic 
solution (according to the manufacturer’s specification). A range of alcohol gels 
were formulated (20 g in total). Each formulation was formulated in triplicate see 
below (Tables 6.7-9). No PAMAM dendrimer was added to the formulations in the 
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developmental stage until the formulations were optimised due to the high cost of 
the dendrimer. 
 
Table 6.7 Weight of constituents of formulations F-F4 with alteration of the 
ethanol content of the formulation. 
 
 
 
 
 
 
 
 
 
In appearance formulation F4 turned cloudy after 12 h at room temperature. 
It was observed that at concentrations above 75 % ethanol the CHG precipitates 
out therefore an optimal concentration of 70 % ethanol was chosen (Table 6.7). 
 
Table 6.8 Weight of constituents of formulations F4(a) to F6(a) with the 
alteration of HPC content in formulation (mw of HPC was 100,000).  
 
Constituent 
Weight of constituent in formulation (F) in grams 
F 4(a) F5 F6* F7* F6a 
Ethanol 
(Absolute) 
14 14 14 14 14 
Hydroxy 
propyl 
cellulose 
(HPC) 
2 2.5 3.0 3.5 1.4 
Water 
(ultrapure) 
2 1.5 1 0.5 2.6 
Chlorhexidine 
digluconate 
2 2 2 2 2 
 
Constituent 
Weight of constituent in formulation (F) in grams 
F (60 % 
EtOH) 
F1 (65 % 
EtOH) 
F2 (70 % 
EtOH) 
F3 
(75 % 
EtOH) 
F4 
(80 % 
EtOH) 
Ethanol 
(Absolute) 
12 13 14 15 16 
Hydroxy 
propyl 
cellulose 
(HPC) 
1.6 1.6 1.6 1.6 1.6 
Water 
(ultrapure) 
4.4 3.4 2.4 1.4 0.4 
Chlorhexidine 
digluconate 
2 2 2 2 2 
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*It was observed that formulation F6 and F7 turned opaque immediately 
(and the HPC had not dissolved after 24 h of shaking and 15 minutes of vigorous 
mixing on a mixer mill) and were discarded. F6a was formulated with a lower HPC 
concentration. The formulations were shaken overnight at 250 RPM to ensure the 
HPC had dissolved. Table 6.8 shows the range of different HPC compositions 
within the formulations. 
 
Table 6.9. Weight of constituents of formulations F7 and F8 with the 
addition of glycerol 
Constituent 
Weight of constituent in formulation (F) 
in grams 
F 7 F8 
Ethanol 
(Absolute) 
14 14 
Hydroxy 
propyl 
cellulose 
1.6 1.6 
Water 
(ultrapure) 
2.2 1.8 
Chlorhexidine 
digluconate 
2 2 
Glycerol 0.2 0.6 
 
Initial observations were that the formulations appeared stable (with the 
exception of the noted formulations), were all transparent in appearance and had a 
strong alcohol odour. In my personal experience when applied to the skin the 
formulations were easy to spread across the skin surface and were fully 
evaporated within 30-60 seconds of application. A thin, flexible and transparent 
film was left on the surface of the skin which was again non-irritating and water 
soluble (White, 1994). The film was formed due to an interaction between CHG 
and the HPC in which the CHG acts as a plasticiser. The control formulation which 
did not include CHG formed no film. The film formed with formulations 7 and 8 that 
included glycerol and remained tacky for a prolonged period of time possibly due 
301 
 
to the hygroscopic nature of the glycerol (Table 6.9). The formulations that 
contained dimethicone are not included as they were disregarded due to 
effervescing on addition to the formulation. 
The formulations were characterised by the following parameters- 
 Appearance 
 Odour 
 pH (1 in 10 dilution in ultrapure water) 
 Available CHG (uniformity of CHG concentration) 
 Spreadability diameters 
 Antimicrobial affect (modified agar cup method) 
 ATR-FTIR 
 Viscosity profile 
 
6.2.9.1 pH of formulations 
 
To ensure that the formulations were compatible with the skin, the pH was 
determined for each formulation and can be found below in Table 6.10. All 
formulations were found to be within the neutral range. A general trend was 
observed where the pH decreased by 2.27 with increasing ethanol content (from 
60-80 % ethanol) with formulations F-F4.  
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Table 6.10. Measured pH for the formulations after a 1 in 10 dilution in 
ultrapure water. The results are presented as the mean ± SD (n=3). 
 
Formulation 
 
Mean pH ± SD (n=3) 
F 7.79 ± 0.02 
F1 7.72 ± 0.03 
F2 7.62 ± 0.07 
F3 6.93 ± 0.07 
F4 5.52 ± 0.14 
F5 5.67 ± 0.06 
F4(a) 7.04 ± 0.28 
F6(a) 6.96 ± 0.01 
F7 6.99± 0.07 
F8 6.91 ± 0.07 
Control no CHG (n=1) 7.04  
Control no HPC (n=1) 6.93 
 
6.2.9.2 Spreadability of formulations 
 
The spreadability of the gel formulations were determined by measuring the 
spread diameter under set conditions for each formulation (Table 6.11). The 
highest mean diameter corresponded to the formulation with the lowest HPC 
content (Formulation F6(a)). Formulation 4 and formulation 3 had the highest 
ethanol content and therefore resulted in the second and third highest mean 
spreadability diameters, respectively, after formulation 6(a) that consisted of the 
lowest HPC polymer concentration.  All formulations with Φ >70 mm are classified 
as fluid gels. Formulation 4a and formulation 5 have a mean of 70 > Φ > 55 mm 
and are therefore considered to be semi-fluid gels. This was anticipated as these 
two formulations contained the highest HPC content and was therefore more 
viscous resulting in a lower spreadability diameter. The addition of glycerol within 
formulation 7 (mean diameter of 83.17 ± 1.17 mm) and formulation 8 (mean 
diameter of 81.00 ± 2.79 mm) significantly increased the spreadability diameter 
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when compared to formulation 2 (mean diameter 76.17 ± 1.02) that had the same 
composition minus the glycerol (p<0.05). A one way ANOVA confirmed that the 
spreadability diameters were different as a function of altering the ethanol and 
HPC content as well as the inclusion of glycerol (F=72.20, d=65, 345.7 p<0.05). 
Intracomparisons were made by conducting a Tukey’s multiple comparison test. 
There was no significant difference between formulations 4(a), 6(a) and 7 when 
compared to the commercially available alcohol gel ‘Safemate original’ (p>0.05). 
Based on a subjective personal experience the ‘Safemate original’ and 
formulations with a comparable spreadability (formulations 4(a), 6(a) and 7) were 
possibly the least favourable in terms of skin application as a lack of viscosity 
resulted in the formulation running from the site of application. All of the 
formulations tested however resulted in excellent skin coverage due to an 
agreeable spreadability capacity. 
 
 
 
 
 
 
 
 
 
 
 
 
304 
 
Table 6.11. Displays the calculated spreadability diameter of the 
formulations after application of a known weight and time period. The 
spreadability diameter was calculated from a mean ± SEM (n=3). 
 
Formulation 
Diameter  
↕ (mm) 
Mean  ± SEM  
↕ (mm) 
Diameter  ↔ 
(mm) 
Mean  ± SEM ↔ 
(mm) 
Total mean  ± 
SEM (mm) 
Fa 69 
73.33 ± 2.19  
71 
72.67 ± 0.88 73.00 ± 1.53 Fb 76 74 
Fc 75 73 
F1a 76 
76.67 ± 0.67 
79 
77.67 ± 1.33 77.17 ± 1.00 F1b 78 79 
F1c 76 75 
F2a 75 
75.33 ± 0.88  
77 
77.00 ± 1.16 76.17 ± 1.02 F2b 77 79 
F2c 74 75 
F3a 84 
82.33 ± 1.20 
87 
85.00 ± 1.00 83.67 ± 1.10 F3b 80 84 
F3c 83 84 
F4a 86 
84.67 ± 0.67 
89 
86.67 ± 1.20 85.67 ± 0.94 F4b 84 86 
F4c 84 85 
F4(a)a 70 
70.00 ± 0.58  
68 
69.33 ± 0.88 69.67 ± 0.73 F4(a)b 71 71 
F4(a)c 69 69 
F5a 65 
63.33 ± 0.88 
63 
63.67 ± 1.33 63.50 ± 1.11 F5b 65 64 
F5c 61 63 
F6(a)a 90 
89.00 ± 0.58 
90 
89.67 ± 0.33 89.34 ± 0.46 F6(a)b 89 89 
F6(a)c 88 90 
F7a 83 
82.67 ± 0.88 
81 
83.67 ± 1.45 83.17 ± 1.17 F7b 81 84 
F7c 84 86 
F8a 83 
79.67 ± 2.40 
85 
82.33 ± 3.18 81.00 ± 2.79 F8b 81 86 
F8c 75 76 
control no 
CHG a 
81 
81.67 ± 0.67 
82 
82.33 ± 0.88 82.00 ± 0.78 b 83 81 
c 81 84 
‘Safemate’ a 89 
87.67 ± 0.67 
90 
90.33 ± 0.88 89.00 ± 0.77 b 87 92 
c 87 89 
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6.2.9.3 Concentration of available CHG within formulation (CHG 
concentration and uniformity). 
 
The available CHG concentration within the formulation was determined 
(Table 6.12). After extraction of CHG from 1 g of each formulation it was 
established that there was a consistent loss of ~14 % of CHG. The loss in CHG 
was not due to the interaction with HPC but perhaps due to adsorption of CHG to 
the glass of the volumetric flasks. CHG strongly binds to glass resulting in loss of 
the biocide (Denton, 1991). Future work should ideally utilise silanized glassware 
to reduce the amount of CHG adsorbed onto glass surfaces (Musial et al. 2012). 
The control formulation without addition of HPC to the formulation resulted in a 
5.52 ± 0.51 % loss of CHG.  
Table 6.12. Recovered CHG from formulations after dissolving 1 g of each 
formulation in ultra-pure water. The results are displayed as the mean CHG 
concentration extracted ± standard deviation (n=3).  
 
Formulation 
Extracted CHG from 
formulation (µg/mL) 
Percentage recovery 
(%)  
F 16847.06 ± 138.8 84.24 ± 0.69 
F1 17099.58 ± 267.1 85.49 ± 1.35 
F2 16819.11 ± 98.92 84.10 ± 0.50 
F3 17193.22 ± 496.5 85.97 ± 2.58 
F4 17665.84 ± 313.9 88.32 ± 1.57 
F5 17660.25 ± 232.6 88.30 ± 1.16 
F4(a) 17477.11 ± 67.5 87.39 ± 0.34 
F6 17067.31 ± 547.8 85.34 ± 0.43 
F7 17679.57 ± 412.2 88.39 ± 2.06 
F8 18359.52 ± 844.3 91.79 ± 4.22 
Control no CHG (n=1) 0 0 
Control no HPC  18897.87 ± 101.5 94.48 ± 0.51 
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6.2.9.4 Viscosity of formulations 
 
All formulations exhibited non Newtonian behaviour; a typical example is 
illustrated in Table 6.13 and Figure 6.11 corresponding to formulation F (a-c). 
Shear thinning was observed as the viscosity decreased with increasing RPM. 
Figure 6.11 shows a plot of the viscosity (m.Pas) against the RPM. A hysteresis 
was observed however it is not indicative of thixotropy but is due to the variability 
observed between the replicate formulations as the error bars (SEM) overlap. 
Despite measuring the viscosity under experimental conditions (temperature 19 ± 
1°C) variability was observed between replicate formulations. The rate of 
evaporation over a 10-15 minute period (an approximate time to conduct the 
viscosity analysis) was minimal (<0.1 % loss in weight of the formulation). This 
may have contributed to the variability observed however the effect would likely be 
negligible. 
Table 6.13. Measured torque for increasing and then decreasing shear rates 
for formulation F(a-c). The data is presented as the mean ± SEM (n=3). 
 
 
 
 
 
 
 
 
 
 
RPM 
Viscosity (mPas) 
Mean (n=3) 
SEM 
2 1550.000 102.632 
2.5 1510.000 104.083 
3 1466.667 96.148 
4 1373.000 120.000 
5 1378.000 76.000 
6 1366.667 73.277 
10 1344.000 68.235 
12 1312.000 63.319 
12 1313.667 61.431 
10 1318.000 61.830 
6 1348.333 70.848 
5 1362.000 77.149 
4 1427.667 98.930 
3 1513.333 97.696 
2.5 1583.333 69.841 
2 1586.667 113.186 
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Figure 6.11. RPM plotted with the viscosity (m.Pas) for formulation F 
illustrating non Newtonian behaviour. Data is represented as the mean ± SEM 
(n=3).  
 
6.2.9.5 Antimicrobial efficacy of formulations. 
 
 
It was necessary to determine whether CHG still exhibited antimicrobial 
characteristics after interaction with HPC within the formulations. A modified agar 
cup method was conducted and established that the formulations did possess 
antimicrobial properties. Figure 6.12 is a photograph taken of a typical agar plate 
after formulation F (n=3) was challenged against P. aeruginosa. A large inhibition 
zone (halo effect) can be observed whereby the CHG had diffused through the 
agar until a sub-lethal concentration was achieved. That is the point where P. 
aeruginosa persists. In parallel with the formulations ‘Safemate’ original sanitising 
gel was also tested using the same method; Safemate was the hand sanitiser 
used after an antimicrobial hand wash in the microbiology laboratory. The 
inhibitory zones were measured with a ruler (accuracy ± 0.5 mm) and recorded in 
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Table 6.14 for each formulation against three opportunistic human pathogens; S. 
aureus, E. coli and P. aeruginosa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12. Photograph of an agar plate (cationic adjusted Mueller Hinton 
agar) illustrating formulation F challenged against P. aeruginosa using a 
modified agar cup method. The diameter of the zone of inhibition was measured 
and the results of all formulations tested can be observed in Table 6.14. 
             
              Table 6.14 displays the zones of inhibition that is evidence for CHG still 
retaining antimicrobial efficacy despite the interaction of CHG with HPC to act as a 
plasticizer. All formulations exhibited antimicrobial activity against all three 
pathogens.  The control formulation that did not contain CHG did not show any 
antimicrobial activity. Further, a solution of 75 % ethanol and ‘Safemate’ that 
contains 62 % ethanol also did not result in a zone of inhibition for any of the 
bacteria tested. Formulation F2 (70 % ethanol) was the most effective 
antimicrobial formulation across all three bacteria (mean 30.3 ± 1.06 mm inhibition 
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zone across all three bacteria n=18), however there was no observable trend 
between the formulation composition and antimicrobial efficacy. 
Table 6.14. Diffusion zone of formulations challenged against the Gram 
negative E. coli and P. aeruginosa and the Gram positive S. aureus. The 
semi-quantitative results are presented as mean ± SD (n=6). 
 
 
 
Zone of inhibition mm (mean ± SD, n=6) 
Formulation 
Escherichia 
coli 
Staphylococcus 
aureus 
Pseudomonas 
aeruginosa 
F 24.50 ± 0.87 25.00 ± 0.87 23.83 ± 0.60 
F1 24.00 ± 0.87 24.17 ± 0.33 24.33 ± 1.67 
F2 28.50 ± 2.29 29.00 ± 0.16 33.33 ± 0.73 
F3 19.33 ± 3.01 26.33 ± 1.59 20.00 ± 2.29 
F4 19.00 ± 1.32 27.33 ± 0.67 20.17 ± 0.88 
F5 20.50 ± 1.80 20.67 ± 0.17 24.17 ± 0.60 
F4(a) 25.17 ± 0.76 20.50 ± 0.76 21.34 ± 0.72 
F6 31.00 ± 1.32 26.33 ± 0.44 23.50 ± 0.58 
F7 24.17 ± 0.76 26.17 ± 1.36 22.17 ± 0.17 
F8 22.50 ± 1.73 25.17 ± 0.60 23.00 ± 0.50 
Control- no CHG 0 0 0 
Control-75 % 
EtOH 
0 0 0 
Safemate 
alcohol hand gel 
0 0 0 
 
6.2.9.6 ATR-FTIR of formulations 
 
                 ATR-FTIR analysis was conducted to visualize the interactions between 
CHG and HPC within the formulations. There are differences between the free 
drug (Figure 6.13 (a)) and the formulation (F used as an example) Figure 6.13 (b). 
Peaks corresponding to the C-H and C-O stretch of ethanol can be observed on 
the spectra. Peaks corresponding to CHG shift when the CHG is formulated in 
ethanol with HPC for example the C=N stretch peak for free CHG is found at 
1633 cm-1 but in the formulation after interaction with HPC the C=N peak shifts to 
1647 cm-1 (Shafiullah, 2005). The vibrational modes of the chlorophenyl group can 
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be observed at 1492-1533 cm-1 in Figure 6.13 (a) (Suci et al. 2001) but these 
peaks change when the CHG is added within the formulation with HPC and a peak 
at 1380 cm-1 is apparent.  Figure 6.13 (b) also shows additional peaks 
corresponding to the (aliphatic) C-H stretch for HPC and ethanol at 2975 and 
2896 cm-1. Further, C-H bending due to the aromatic ring on CHG can be 
observed at 878 cm-1 within the formulation that is not present in the CHG alone 
spectrum. The minor peak shifts observed in the spectra in Figure 6.13 indicate an 
interaction between CHG and HPC in the presence of ethanol and water. The 
range of formulations were very similar when the spectra were overlaid therefore 
no differences were observed in the spectra between formulations.  
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Figure 6.13. ATR-FTIR spectra of (a) a CHG (2 % w/v) solution and (b) Formulation a. The spectra were collected as a result 
of 32 scans resulting in a resolution of 8 cm-1.  
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6.2.9.7 Percutaneous absorption of chlorhexidine digluconate from selected 
formulations determined by tape stripping dermatomed porcine skin after 
24 h 
 
           The permeation of CHG within porcine dermatomed skin was determined 
from the formulations F4, F5 and F6 (Tables 6.15, 6.16 and 6.17). Previously 
within this chapter it was observed that the CHG interacts with HPC to form a 
plasticizer that results in film formation after solvent evaporation. It was of interest 
to the project to characterise the penetration of CHG into the skin from the film 
formed across the skin surface. Across all three formulations tested, no CHG was 
detected within the 21 tape strips removed from the SC or the remaining 
epidermis/dermis. It was observed that after 6 h the solvents had evaporated 
leaving a film across the skin. At 24 h it was attempted to remove the film by 
washing the skin surface however hydration caused the film to become tacky and 
removal by water was not sufficient. The films were then carefully removed from 
the skin surface at 24 h using tweezers and the CHG was extracted from the film. 
The highest concentration of CHG was recovered from the washed films. The 
concentrations within the film were; 3110.062 ± 347.9 µg/cm2 for F4, 3561.948 ± 
278.4 µg/cm2 for F5 and 3200.972 ± 298.4 µg/cm2 for F6. These concentrations 
are equivalent to ~ 40 % of the applied CHG dose.  
 
          A high concentration of CHG was extracted from the glass donor chambers. 
The mean concentration across the three formulations was 2589.71 ± 
167.45 µg/cm2 that is equivalent to around 33 % of the applied dose of CHG. This 
can be accounted for as it was observed that on deconstruction of the Franz cell a 
proportion of the film was removed with the donor chamber. Attempts were made 
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to recover the film from the donor chamber however this was not achieved due to 
the strong adhesion of the film to the glass. In previous studies conducted in 
chapter 3 (section 3.3.0 and 3.3.1) the highest concentration of CHG was 
recovered within the 24 skin wash. With regards to this study, only low 
concentrations of CHG was recovered within the 24 h skin wash with an average 
percentage of applied dose recovered of 6.03 ± 1.63 %. The mass recovery of 
CHG was consistent with the CHG concentrations recovered from the formulations 
under occluded conditions in section 6.2.6. 
 
Table 6.15 Concentration of CHG extracted from the different compartments 
of the in vitro diffusion cell after dosing with formulation 4 for 24 h. Data is 
represented as the mean ± SEM (n=5) for each diffusion cell compartment for both 
the CHG concentration (µg/cm2) and for the percentage of dose applied. 
 
Formulation F4 
(n=5) 
CHG (µg/cm2) 
Mean               SEM 
% of applied dose 
Mean              SEM 
Donor chamber 2603.558 211.921 33.065 2.691 
Skin wash 355.3078 58.090 4.512 0.738 
Film 3110.062 347.901 39.498 4.418 
Epidermis & tape 
strips 
<LOQ* <LOQ <LOQ <LOQ 
Receptor fluid <LOQ <LOQ <LOQ <LOQ 
Total recovered 6068.928 617.912 77.075 7.847 
 
*Limit of quantification calculated from HPLC validation data found in appendix 1 
using the equation 10*(STD/slope of line). LOQ was calculated to be 0.168 µg/mL. 
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Table 6.16 Concentration of CHG extracted from the different compartments 
of the in vitro diffusion cell after dosing with formulation 5 for 24 h. Data is 
represented as the mean ± SEM (n=5) for each diffusion cell compartment for both 
the CHG concentration (µg/cm2) and for the percentage of dose applied. 
 
 
 
 
Table 6.17 Concentration of CHG extracted from the different compartments 
of the in vitro diffusion cell after dosing with formulation 6 for 24 h. Data is 
represented as the mean ± SEM (n=5) for each diffusion cell compartment for both 
the CHG concentration (µg/cm2) and for the percentage of dose applied. 
Formulation F5 
(n=5) 
CHG (µg/cm2) 
Mean           SEM 
% of applied dose 
Mean              SEM 
Donor chamber 
2560.291 101.621 32.516 1.290 
Skin wash 
714.382 473.923 9.073 6.019 
Film 
3561.948 278.400 45.237 3.536 
Epidermis & tape 
strips 
<LOQ <LOQ <LOQ <LOQ 
Receptor fluid 
<LOQ <LOQ <LOQ <LOQ 
Total recovered 
6836.621 853.944 86.826 10.845 
Formulation F6 
(n=5) 
CHG (µg/cm2) 
Mean            SEM 
% of applied dose 
Mean               SEM 
Donor chamber 
2604.653 188.801 33.079 3.790 
Skin wash 
353.456 47.823 4.489 0.607 
Film 
3200.972 298.410 40.652 2.398 
Epidermis and tape 
strips 
<LOQ <LOQ <LOQ <LOQ 
Receptor fluid 
<LOQ <LOQ <LOQ <LOQ 
Total recovered 
6159.081 535.034 78.22 6.795 
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6.3 Discussion 
 
         On addition of the PAMAM dendrimer to CHG a crystalline material formed in 
aqueous solution. Different crystalline shapes and particle sizes confer different 
physiochemical properties which can in turn effect the bioavailability of drugs 
(Khankari and Grant, 1995). Crystallisation of the drug is also important in terms of 
stability of any formulation. It is of paramount importance that the crystal structures 
are fully characterised to not only understand the interaction between CHG and 
the PAMAM dendrimer but to also understand the differences in crystal structures 
formed and any possible effects on the bioavailability of the drug. Co-crystals of 
water-drug molecules within an aqueous environment are important in determining 
the stability of such hydrate crystal systems (Han, 2006). The crystals formed in 
the hydro-methanolic solution on the addition of the CHG solution.  
 
 Two different crystal structures were observed depending on the order of 
addition of the CHG, G3-PAMAM-NH2 dendrimer (in methanol) and the water 
(Figures 6.2 and 6.3).  Previously it has been shown that the water activity (energy 
status of water within a system) is very important in the formation of such drug 
crystals in an organic solvent and water mixture. The organic solvent and the 
water mixture compositions affect the physical stability of the drug crystalline 
phases. It has been shown to affect the nature of the crystallising drug phase for 
drugs such as theophylline (Zhu et al. 1996) and ampicillin (Zhu and Grant, 1996). 
As such the composition of the organic solvent and water mixtures are likely to 
affect the crystallisation of CHG and may account for the differences observed in 
Figures 6.2 and 6.3. Longer shards of microcrystalline material formed after there 
was an initial excess of water whereas shorter shards radiating form a focal point 
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occurred as the PAMAM dendrimer was added to CHG in a reduced volume of 
water before the addition of water up to full volume.  
 
         The aqueous solubility (% w/w) of CHG is >70 % (Farkas et al. 2001). It is 
also soluble in alcohol(s), however the addition of CHG to neat alcohol(s) will 
result in precipitation (Denton, 1991). The CHG was not added to neat alcohol as 
the water was added to the dendrimer in methanol in the first instance before the 
addition of CHG. CHG is soluble in water and methanol solutions. The control co-
formulation without the addition of PAMAM dendrimer did not form a crystalline 
material. The crystal formation was therefore attributed to the addition of the G3-
PAMAM-NH2 dendrimer and crystal formation occurred at a range of dendrimer 
concentrations (0.5- 10 mM). Figures 6.2 and 6.3 are micrographs illustrating the 
differences in crystal shape and size after addition of the CHG in a differing order. 
The length of the crystals was measured and the crystals formed in Figure 6.2 
were on average 4.5 times longer than those formed in Figure 6.3. The crystals 
formed were fully characterised. The melting points were obtained from vacuum-
dried crystalline material and were both determined to be between 109-115 °C; 
CHX has a melting point between 132-136 °C (Lam et al. 1993). CHG does not 
exist as a solid but as a viscous liquid therefore the melting point data may 
suggest that the precipitate is not just a case of the CHX base having precipitated 
out of solution. 
 
           A vacuum-dried sample of the crystalline precipitate and G3-PAMAM-NH2 
dendrimer reference material was sent to the EPSRC National Mass Spectrometry 
Centre for MALDI-ToF analysis to determine the molecular weight of the samples. 
Figures 6.4 and 6.5 show the resulting spectra and it was determined that the 
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vacuum-dried sample was a mixture. It is possible that the G3-PAMAM-NH2 
dendrimer in solution was dried in vacuo conditions onto the precipitate resulting in 
a mixture of CHX and dendrimer. The theoretical molecular weight of 
G3-PAMAM-NH2 dendrimer is 6909 Da but the spectra shows that the molecular 
weight determined was 6940 Da for the reference material and 6938 Da for the 
CHG-PAMAM mixture. The mass resolution of the system was ± 2 Da which may 
account for the discrepancy between the two spectra. The observed species that 
are higher in mass than the theoretical mass may be [PAMAM+K]+ or possibly 
[PAMAM+Na]+ which are a result of ionisation of salt impurities within the sample 
or they may be a result of a minor structural defect within the dendrimer (Peterson 
et al. 2003).  
 
          The MALDI-ToF spectra indicating a mixture was sent for analysis therefore 
in order to determine the actual composition of the crystalline material it was sent 
for single crystal X-Ray diffraction analysis. The crystalline material was sent in 
aqueous solution to the EPSRC National Crystallography Centre that was in turn 
forwarded the sample to the Diamond beam line in Oxford. Table 6.1 and Figure 
6.6 exhibit the crystal data and structure respectively. The XRD data clearly shows 
the chlorhexidine structure which is associated with four water molecules and an 
oxocarbon anion with a calculated molecular weight of 639.55 Da. The molecular 
weight of the dosed CHG within the formulation was 897.8 Da, on removal of the 
oxocarbon anion and the water molecule’s molecular weight the resulting 
molecular weight is 507 Da that corresponds to the CHX base with two nitrogen 
positions protonated. The XRD data shows that the digluconic acid is missing from 
the structure and in its place are four water molecules and an oxocarbon anion. It 
is possible that the polycationic PAMAM dendrimer had scavenged the gluconic 
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acid resulting in precipitation of the CHX base due to a lack of solubility in aqueous 
solution (solubility; 0.008 % w/v in water, Farkas et al. 2001). The crystalline 
precipitate may have occurred due to the oxocarbon anion (the counter ion) 
forming a salt through an anion exchange group such as –NHR- present on the 
CHX structure (Yoshimura, 2011). Further, another reason could be that the pH 
was too high and that the counter ion-CHX base had precipitated out. The pH of 
the G3-PAMAM-NH2-CHG co-formulation was ~ pH 9 as analysed by a standard 
pH universal indicator test strip. It has previously been reported that the CHX base 
can precipitate out in high pH conditions i.e. > pH 8 (Denton, 2000).  
 
            The results within this chapter have shown that a PAMAM dendrimer-CHG 
complex does not form in aqueous solution but that the CHX loses its gluconic 
acid salt, possibly through interaction with the polycationic PAMAM dendrimer or 
possibly due to the high pH. No precipitate formed when the CHG was added to 
the PAMAM dendrimer in ethanol, methanol or isopropanol. This is interesting as 
the CHX free base is also practically insoluble in alcohols (Modak and Sampath, 
2007). This result may question the proposed idea that the PAMAM dendrimer 
scavenged the gluconic acid from the CHG as that would likely have occurred in 
an alcoholic solution also. Previously, to graft gluconic acid to a G3-PAMAM-NH2 
dendrimer a coupling agent (1-ethyl-3-(dimethylaminopropyl)carbodiimide) was 
required in conjunction with an activating agent (N-Hydroxysuccinimide). The 
coupling reaction was then left overnight in a sonicator to activate the 
condensation reaction (Tao et al. 2013). The coupling agents are required as the 
condensation reaction between a carboxylic acid such as that of gluconic acid and 
an amine group such as that on the PAMAM dendrimer surface is a very slow 
reaction. This suggests that the interaction demonstrated in Sections 6.2.1-6.2.5 is 
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likely to be an electrostatic interaction between the amine groups of the PAMAM 
dendrimer and the carboxyl group of the gluconic acid.The presence of an 
oxocarbon anion may indicate an interaction between the gluconic acid of CHG 
with the PAMAM dendrimer. The carbonate anion (CO3)
2- detected within the 
crystal structure using XRD is due to the removal of all protons from a 
corresponding acid carbonic acid (Moore and Khanna, 1991) that was possibly 
provided by the gluconic acid (Figure 6.14).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14 A possible schematic for the formation of the oxocarbon anion 
detected within the single molecule crystal using XRD analysis. 
 
 
There was an electrostatic interaction between the carbon anion and the 
protonated nitrogen next to the 4-chlorophenyl due to the electron withdrawal 
characteristic of this moiety. Four water molecules were also detected within the 
crystal that was hydrogen bonded to the electron dense 4-chlorophenyl moiety. 
The electrostatic potential of CHX can be observed in Figure 6.15. The red areas 
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correspond to the delocalised positive charge of the amine groups on the 
biguanide structure and the blue regions correspond to the electron dense 
chlorophenyl moieties (Blackburn et al. 2007). Though only one molecule of CHX 
was presented it is likely that the crystal structure is a repetitive pattern of CHX 
with carbonate anions associated with any of the red areas corresponding to the 
amines of the biguanide structure and water molecules that have hydrogen 
bonded to the blue electron dense chlorophenyl groups.  
 
Figure 6.15 Image showing the electrostatic potential plotted on an 
electrostatic density image of CHX. The structure is represented as space 
occupied by the Van Der Waals radius of the molecule. Green corresponds to 
neutral, blue corresponds to the strongest negative electrostatic potential and red 
corresponds to the strongest positive electrostatic potential. Taken from Blackburn 
et al. (2007). 
 
In an ethanol-water solution no precipitate was formed on addition of 
PAMAM dendrimer to CHG. No precipitate was formed for 3 months within a 50:50 
water: ethanol vehicle, therefore this was the chosen vehicle for the co-dose 
application. The recovery of CHG was determined for a variety of PAMAM 
dendrimer concentrations under occluded and unoccluded conditions (Table 6.2). 
At a skin surface temperature of 32°C ± 1°C under occluded conditions the 
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recovery of CHG was comparable to that of the control where PAMAM dendrimer 
was absent (~10-20 % loss of CHG). The ~15 % loss of the dosed CHG in the 
control solution without the PAMAM dendrimer (in occluded conditions) may be 
due to degradation of the compound in light at 32°C ± 1°C. It is unlikely that such a 
high loss of CHG would occur solely from adsorption on to the glass surface of the 
vial. The lowest percentage recovery of CHG was at the higher 10 mM PAMAM 
dendrimer concentration, but it was observed that the formulation had turned a 
pearlescent white colour indicating precipitation of a constituent. Perhaps the 
semi-solid formulation appeared pearlescent due to the dispersion of particles of 
the incompatible polymer (excess G3-PAMAM-NH2 dendrimer) (Lu, 1986).  
  
Under unoccluded conditions a low recovery of CHG was achieved for the 
control corresponding to 2 % CHG (w/v) in an ethanol: water (50:50) vehicle. Only 
34.44 ± 3.33 % of the dosed CHG was recovered at 24 h which was likely due to 
evaporation of the vehicle at 32°C ± 1°C resulting in precipitation of CHG. Under 
unoccluded conditions a higher concentration of CHG was recovered from the 
CHG-PAMAM dendrimer formulations than from the control without the addition of 
PAMAM dendrimer. For example, the addition of 0.5 mM PAMAM dendrimer to 
2 % CHG (w/v) significantly enhanced (p<0.05) the percentage recovery of dosed 
CHG by ~25 % (Figure 6.7). The extremely hygroscopic PAMAM dendrimer 
possibly extracted atmospheric moisture allowing a higher concentration of CHG 
to be dissolved within the hydrated PAMAM dendrimer layer rather than precipitate 
into an insoluble salt or the CHX base.  
 
           It was established that the interaction between CHG and G3-PAMAM-NH2 
dendrimer did not have synergistic nor antagonistic effects on the antimicrobial 
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efficacy of CHG. The calculated IC50 against S. aureus for the CHG-PAMAM 
dendrimer was only 0.001 µg/mL higher than for the calculated IC50 for CHG in the 
same water: ethanol (50: 50) vehicle.  Therefore the PAMAM dendrimer does not 
inhibit or enhance the antimicrobial efficacy of CHG in a co-formulation. The 
PAMAM dendrimer did not enhance the antimicrobial efficacy of CHG because the 
IC50 of CHG (0.056 µg/mL, 95 % CI: 0.02582-0.1212 µg/mL against S. aureus) is 
much lower than the IC50 of G3-PAMAM-NH2 dendrimer (9.374 µg/mL 95 % 
CI: 7.88-11.15 µg/mL against S. aureus within an ethanol:water vehicle). PAMAM 
dendrimers have been observed to enhance the antimicrobial efficacy of silver 
sulfadiazine (Strydom et al. 2012). This may be due to the biocide having a much 
higher IC50 than the PAMAM dendrimer; silver sulfadiazine was shown to have an 
IC50 of 85 µg/mL against S. aureus (Maple et al. 1992). Thus after the addition of 
the PAMAM dendrimer, that has a calculated IC50 of 9.374 µg/mL (see Section 
2.2.1), to the silver sulfadiazine it is not unexpected that the dendrimer would 
enhance the antimicrobial efficacy. 
 
           The co-formulation was applied to porcine skin to determine whether the 
PAMAM dendrimer would still act as a permeation enhancer of CHG when applied 
in a one-step application as opposed to a skin pre-treatment. Previously in Section 
6.2.6 it was shown that G3-PAMAM-NH2 enhanced the recovery of CHG under 
unoccluded conditions. This was also observed after the co-dose formulation had 
been applied to porcine skin in vitro for 24 h, though there was still a 37- 45 % loss 
of CHG across all 3 PAMAM dendrimer concentrations. Without the presence of 
PAMAM dendrimer there was ~49 % of the dosed CHG that was not recovered. 
This is very low compared to the ~75-85 % of dosed CHG recovered after a 
PAMAM dendrimer pre-treatment in sections 3.3.0 and 3.3.1 The low percentage 
323 
 
recovery of CHG may be due to a number of reasons; there is the possibility that 
an increase in the permeation of CHG occurred within the epidermis due to the 
penetration enhancement effects of the ethanolic vehicle and possibly due to the 
action of the PAMAM dendrimer. The extraction procedure may not have been 
effective in extracting CHG from the deeper layers of the porcine epidermis 
therefore resulting in a reduction of CHG recovery and an underestimate of the 
CHG concentration within the epidermis. Another possibility for the loss of CHG 
could be that once the ethanol: water vehicle had evaporated, the interaction of 
CHG with the PAMAM dendrimer in aqueous solution caused the loss of the 
digluconic acid from the CHG resulting in the insoluble crystalline precipitate of 
oxocarbon anion associated with the CHX base (Figure 4.16). This precipitate 
would therefore be syringe filtered out and discarded before HPLC analysis 
resulting in a high loss of applied CHG. This is also consistent with the recovery 
values observed in Table 6.2 where the available CHG (after addition of PAMAM 
dendrimer in unoccluded conditions) was found to approximately half the dosed 
CHG concentration. It should be noted however that ~1 % CHG solution (w/v) 
does still exhibit strong antimicrobial effects.  
 
The one-step co-application did result in an increase in the concentration of 
CHG within the skin for 0.5 and 10 mM G3-PAMAM-NH2 dendrimer (Figure 6.9). A 
10 mM PAMAM dendrimer co-treatment with CHG resulted ~3 fold increase of 
CHG within the epidermis that was statistically significant when compared to CHG 
dosed alone (p<0.05). A high variability was observed for the 0.5 and 1 mM 
PAMAM dendrimer-CHG formulations. This may be due to the inherent variability 
between the two porcine donor skins utilised within the study. Another possible 
explanation for the high variability may be due to the vehicle evaporating from the 
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skin at different rates (forming an unstable saturated solution) therefore leaving the 
CHG and PAMAM dendrimer to form an insoluble salt at different time points.  
 
Speculatively, perhaps the significant increase (p<0.05) of CHG within the 
epidermis after a 10 mM G3-PAMAM-NH2- CHG co-application was due to the 
PAMAM dendrimer acting as an anti-nucleant polymer. It is possible that the 
10 mM PAMAM dendrimer solution retarded the formation of crystal growth for 
longer as the vehicle evaporated from the skin. This would allow a prolonged time 
frame for the CHG to permeate the skin compared to CHG dosed alone from an 
ethanolic vehicle before the saturated solution becomes unstable. Perhaps the 
saturated solution (caused by evaporation or skin absorption of the ethanolic 
vehicle), which the 10 mM PAMAM dendrimer solution prolonged the stability of, 
enhanced the flux of CHG into the skin due to the formulation possessing a high 
thermodynamic activity (Kemken et al. 1992). This has been observed previously 
for piroxicam in supersaturated solutions whereby HPC prevented the formation of 
pseudopolymorphs such as the hydrate form of the drug that is less stable than 
the anhydrous form in aqueous solution. The addition of the HPC within the 
saturated solutions was shown to enhance the drug’s flux concentrations in vitro 
using excised human skin as a membrane (Pellet et al. 1997).  
 
  A concentration increase of 564.487 µg/cm2 of CHG within the skin was 
recorded for the 0.5 mM G3-PAMAM-NH2 dendrimer-CHG formulation when 
compared to the CHG dosed alone. This however was not statistically significant 
due to the high variability observed between each of the diffusion cells as 
previously mentioned. There was no significant increase in the concentration of 
CHG after a co-treatment with PAMAM dendrimer within the receptor fluid at 24 h 
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when compared to the control (Figure 6.10).  The 10 mM-PAMAM-NH2 –CHG 
formulation resulted in the highest CHG concentration within the receptor fluid at 
24 h (17.980 ± 2.407 µg/mL) that was a marginal increase compared to CHG 
dosed alone (9.100 ± 2.087 µg/mL). The concentrations of CHG detected within 
the receptor fluid would still exhibit considerable antimicrobial inhibitory effects 
(Odore et al. 2000).  
 
The aim of the PAMAM dendrimer skin treatment is to increase the CHG 
deposition within the skin to enhance the antiseptic’s efficacy. The CHG 
concentrations detected within the epidermis were much lower for the co-treatment 
than for the pre-treatment concentrations detailed in Chapter 3. For example when 
comparing the no PAMAM dendrimer controls, the physiological saline pre-treated 
skin followed by application of CHG 2 % (w/v) in aqueous solution resulted in 
1030.668 ± 130.017 µg/mL of CHG within the epidermis whereas the CHG co-
treatment control (CHG dosed in a 50:50 ethanol: water vehicle) resulted in a CHG 
concentration of 211.370 ± 33.189 µg/mL of CHG within the epidermis. The 24 h 
pre-treatment of physiological saline before the addition of the CHG may have 
contributed to the ~ 5 fold increase in CHG within the epidermis. Another possible 
explanation for the increase may be due to the difference in vehicle that the CHG 
is applied to the skin within. Karpanen et al. (2009) observed a significant 
reduction (p=0.008) in the permeation of CHG within excised human full thickness 
skin when CHG was delivered from a 70 % isopropanol vehicle when compared to 
CHG delivered from an aqueous vehicle. Though alcohols are considered a 
penetration enhancer (Benson, 2005) it appears that CHG permeates the skin in a 
higher concentration when applied in an aqueous vehicle compared to an alcohol-
aqueous vehicle.  
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           When developing a formulation inclusive of CHG it is important to first 
consider the large number of CHX incompatible materials that would typically be 
used within topical formulations. Chlorhexidine is considered to be compatible with 
cationic materials such as PAMAM dendrimers but as observed in Section 6.2.1 
compatibility is dependent on the vehicle and the nature of the second cationic 
species (Denton, 2000). CHG is inactivated in the presence of non-ionic 
surfactants and may form insoluble salts with inorganic anions including 
phosphates and chlorides, carbonates, nitrates, sulphates and dyes. It is also 
incompatible with organic anions, due to micelle formation, that includes many 
soaps, sodium carboxymethyl cellulose, tragacanth and alginates (Larson, 1988). 
Within a formulation CHG must retain its antimicrobial efficacy and not become 
neutralised by incompatible detergents or anions.  
 
            A number of formulations were developed including a cream, lotion and 
hydrogel however based on the skin feel, aesthetics, stability of CHG and 
ultimately PAMAM dendrimer within the formulation, an alcohol hand gel was 
chosen as an ideal formulation. PAMAM dendrimers are more stable long term in 
ethanol than water (according to manufacturer’s specification) and ethanol also 
has the advantage of being antimicrobial in its own right.  Alcohol gels are also 
readily accepted in the healthcare sector for use as an antiseptic (Larson et al. 
2006) and have been used to reduce HCAIs within hospital wards (MacDonald et 
al. 2004, Bischoff et al. 2000 and Girou et al. 2002). Alcohol gels are cost effective 
(Johnson et al. 2005) and low risk with regards to contamination when compared 
to other topical antiseptic strategies (Kampf et al. 2005). Alcohol gels have been 
shown to be better tolerated and have even been used to reduce dermatitis 
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caused by antiseptic soaps (Pittet et al. 2000, Jungbauer et al. 2004 and Newman 
and Seitz, 1990).  
 
            A range of alcohol gels were developed with HPC (hydroxypropyl cellulose, 
~100,000 mw) as it is a cellulose derivative that has shown to be compatible with 
CHG and is typically used in synergy within toothpastes (Lehmann, 2000). 
Hydroxyethyl cellulose (HEC) has also been shown previously using Raman 
spectroscopy to solubilise the protonated CHX (dication) that was a consequence 
of protonation caused by a second polymer, polycarbophil within an aqueous 
semi-solid formulation (Jones et al. 2000). The first variable to be optimised was 
the concentration of ethanol. Formulations with a high ethanol concentration 
possess the highest antimicrobial efficacy (i.e. 70-90 %), with the exception of 
absolute ethanol (Kramer et al. 2002). At a concentration of 80 % and 75 % 
ethanol the formulation turned cloudy on addition of HPC and CHG, even after 
stirring for 24 h at 200 RPM followed by a 15 minute period of vigorous shaking in 
a mixing mill, the CHG and HPC did not fully dissolve. Therefore the optimal 
concentration of ethanol was determined to be 70 % as the CHG and HPC had 
fully dissolved. This would be considered the lowest concentration that would be 
considered an effective against a broad spectrum of microorganisms (Reynolds et 
al. 2006). The consistency and viscosity are important parameters for a topical gel 
in terms of acceptability by consumers (whether that be patients or healthcare 
workers) and antimicrobial efficacy. It has been shown that antimicrobial activity is 
lower for alcohol gels when compared to alcohol liquids due to the lower 
concentration of ethanol within the formulation as a result of the inclusion of a 
thickener (Pietsch, 2001). A thickener system may also inhibit the release of 
alcohol in turn reducing the antimicrobial efficacy of the formulation (Maiwald, 
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2008 and Guilhermetti et al. 2010). It is for this reason that a number of 
formulations were produced with a range of HPC concentrations (Table 6.8). 
Further, to improve the perceived feeling of the formulations glycerol, a known 
humectant that hydrates the skin, was incorporated as well as dimethicone. 
Formulations including dimethicone were not used due to incompatibility as an 
unknown gas effervesced from the sample.  
 
           The appearance of all formulations was determined by visual inspection; all 
were transparent, free from particulates and fibres. All formulations had a strong 
alcohol odour. The formulations was applied to the skin and unexpectedly after 
evaporation of the solvents (ethanol: water) a transparent and flexible film formed 
across the skin surface within 30-60 seconds of application (after physically 
rubbing a thin layer of the formulation across the skin). The film formed containing 
glycerol within the formulations was tacky and not agreeable with regards to 
acceptability by a consumer. After a further patent search it was reported that HPC 
is an ideal viscosifying agent that retards the evaporation of alcohol thus 
increasing the exposure time to microorganisms. The formulations were described 
as evaporation-stabilised (White, 1994). Also reported was an antimicrobial film 
formation for the prevention of surgical site incision infections. The formulations 
incorporated CHG and ethyl cellulose which was shown to interact and form a 
plasticiser, CHG has a strong affinity for cellulose and its derivatives. The resulting 
films that had formed were antimicrobial, allowed for TEWL and were ductile, 
smooth and flexible (Khan and Hoang, 1998). An advantage of the CHG-HPC film 
is that it is easily removed from laundry and would not decolourise and stain on 
contact with sodium hydroxide which is a significant problem for the healthcare 
laundry sector. The film-forming compositions developed within this chapter were 
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found to be covered by a patent however until this chapter there have not been 
studies investigating the permeation of CHG from the films into skin. 
 
            The pH of all the formulations was determined to ensure compatibility with 
the skin. The SC is described as an ‘acid mantle’ as the pH of the skin surface is 
around 4.5-5.3 that increases with increasing depth into the SC (Fluhr and Elias, 
2002). It is important the pH of the skin is not altered as the acidic pH plays an 
integral part in the antimicrobial barrier of the skin (Schmid-Wendtner and Schmid-
Wendtner, 2007). The pH of the formulations varied from the highest being 7.787 ± 
0.02 for formulation F to 5.517 ± 0.14 the lowest pH detected that corresponds to 
formulation F4. Formulations F4 and F5 had a pH of around 5.5 which would be an 
ideal and compatible pH for a topical skin preparation.  
 
            The spreadability of a formulation is an important factor not only in terms of 
sensation upon application but also so that a user can spread an even layer 
across the skin for optimal drug delivery (Garg et al. 2002). Acceptability of a 
semisolid formulation is based upon a range of characteristics including; 
greasiness, appearance, odour, stickiness, spreadability and sensation on 
application (Barry and Grace, 1972). Efficacy and ultimately the success of a 
semisolid formulation are also based on rheological properties, spreadability and 
bioadhesion (Jones et al. 1997). Cellulose polymers such as HPC, sodium 
carboxymethyl cellulose (Na CMC) and hydroxyethyl cellulose (HEC) exhibit a 
range of excellent bioadhesive, textural and viscoelastic properties (Jones et al. 
1997). The spreadability was measured to ensure the formulation’s behaviour was 
optimised with a compromise between viscosity and thus retention upon the skin 
for drug delivery but also spreadability and the stiffness of the formulation texture. 
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Measuring spreadability of a formulation upon skin is very difficult because 
individuals apply a different pressure or motion on application however a parallel 
plate method can be used to approximate the spreadability of a semisolid 
formulation (Vennat et al. 1998 and Vennat et al. 1995). A simple study was 
conducted as described elsewhere whereby the diameter of the spread was 
measured under experimental conditions and interpreted against the following 
terms; Φ >70 mm corresponds to a fluid gel, 70 > Φ > 55 mm would be classed as 
a semi fluid gel and 55 > Φ > 47 mm a semi stiff gel (Lardy et al. 2000). All 
formulations were classified as fluid gels with the exception of F4 and F5 that are 
classified as semi-fluid gels. The gels were easy to spread across a volunteer’s 
skin (the author) and high coverage and distribution was achieved. The 
spreadability diameters were significantly different from one another depending on 
the ethanol and HPC content and the inclusion of glycerol (p<0.05).   
 
           The available concentration of CHG within the formulations (to investigate 
CHG concentration and uniformity) was determined by extracting CHG from 1 g of 
each formulation as it is known that CHG interacts with HPC to act as a plasticiser 
(Khan and Hoang, 1998). Across all formulations there was ~14 % deficit of CHG 
not recovered from the formulation though a formulation inclusive of 1.72 % CHG 
would still exhibit a strong antimicrobial effect. A percentage recovery of CHG from 
a control formulation that did not include HPC yielded a CHG recovery at 94.48 ± 
0.51 %. This suggests that the CHG-HPC interaction does not alone affect the 
extraction of CHG from the formulations but that it may be due to adsorption on to 
glass or ineffective extraction of CHG from formulation. The CHG concentration 
and uniformity of the gels were comparable across all formulations as there was 
no difference in CHG recovery as a function of formulation (p>0.05). The CHG 
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recoveries observed from the film formulations are comparable to that 
demonstrated elsewhere from carbohydrate based films where the recovery of 
CHG was between 76 – 87 % of applied dose (Shafiullah, 2005). 
 
               A formulation under an applied shear stress flow will occur at a shear 
rate that is determined by the viscosity and/or the rheology (Morrison, 2001). The 
gel formulations exhibited non Newtonian behaviour which means that there was a 
non-linear relationship between the shear stress and the shear rate (Figure 6.11). 
Table 6.13 shows the viscosity of formulation F(a) but as the formulations exhibit 
non-Newtonian behaviour, the viscosity is not an absolute constant and 
instantaneously changes depending on the shear conditions. The viscosity is not 
an absolute constant and instantaneously changes depending on the shear 
conditions. The viscosity of the formulations showed shear thinning, with viscosity 
decreasing as the shear rate was increased.  The viscosity modifier used in the 
formulation was hydroxypropyl cellulose (HPC) polymer, which been shown 
by Paradkar et al. 2009 to possess shear thinning properties.  The process of 
shear thinning was described by Osswald as a reduction of the entanglement of 
the polymer chains as the shear force aligns them, allowing them to pass over one 
another more readily and thus reducing the viscosity (Osswald, 1998). The 
rheology of the HPC-CHG semi-solid formulations could not be fully characterised 
as there was only a viscometer available for use.   
 
            The gel formulation’s antimicrobial efficacy was determined using a 
modified agar cup method against three opportunistic pathogens (Orafidiya et al. 
2001 and Wannachaiyasit and Phaechamud, 2010). The agar cup method 
determines the diffusivity of an antimicrobial component from a topical preparation 
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added to a bore within standardised MHA (Figure 6.12). A zone of microbial 
inhibition can be observed and the concentration of the antimicrobial compound 
decreases logarithmically until a point is reached where bacterial growth occurs 
(Bhende and Spangler, 2004). The zone of inhibition whereby the presence of 
CHG is high enough to prevent microbial growth was measured in triplicate for 
each formulation. All formulations were antimicrobial against the three 
opportunistic pathogens tested; S. aureus, E. coli and P. aeruginosa. The zones of 
inhibition were similar across all formulations and all bacteria were susceptible to 
the formulations. The results indicate that CHG is not inactivated within the 
formulations and still exhibits a strong inhibitory effect against Gram negative and 
Gram positive bacteria. 
 
               The modified agar cup method is not suitable for measuring the 
antimicrobial efficacy of instantaneous biocides such as alcohol solutions. As 
Table 6.14 shows for the control and commercially available alcohol gel, the 
alcohol had evaporated from the agar as opposed to diffusing through it so that it 
does not inhibit microbial growth. The agar cup method is semi quantitative as with 
the disk diffusion method as it is likely that the zone of inhibition is an 
underestimate of the inhibitory effect of CHG. This is because of the presence of 
inorganic components within the agar required by microorganisms for growth, such 
as casein that contains calcium, phosphorous (Anon, 2013) and anionic 
agaropectin chains within the agar (Samiey and Ashoori, 2012) that may be 
incompatible with CHG. Further, the agar cup assay relies on the ability of the drug 
to diffuse through the agar.  
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            The interaction between CHG and HPC within the ethanolic formulation 
was investigated using ATR-FTIR. It was observed that peaks corresponding to 
CHG, notably the region at 1492-1533 cm-1 attributed to the chlorophenyl group, 
are dramatically reduced in intensity and the peak shapes had altered on contact 
with HPC. It has been reported that CHG binds to cellulosic material (Khan and 
Hoang,. 1998) and as discussed below the interaction and affinity of CHG to the 
HPC results in no permeation of CHG into the SC (see section 6.2.9.7). The strong 
sorption of CHG to cellulose materials is because of electrostatic interactions 
between the amine groups of CHG and the carboxylic acid groups of the cellulose 
and in minor contribution, hydrogen bonding between the biguanide residues and 
the para-chlorophenyl moieties of CHG with the hydroxyl groups of the cellulose 
(Blackburn et al. 2007). The same authors also determined that at a high CHG 
concentration there is evidence of monolayer and bilayer aggregation upon 
cellulosic materials. The electrostatic and hydrogen bonding interactions between 
CHG and HPC was likely to have caused the C=N stretching peak shift. The C=N 
bonds on the biguanide moiety are protonated due to the electron withdrawing 
nature of the para-chloropheynl group and is therefore the most likely site for 
electrostatic interaction with the carboxyl groups of the cellulosic material HPC. A 
minor contribution of the interaction is between the 4-chlorophenyl group and the 
hydroxyl groups of the HPC (Yoshida forces) (Blackburn et al. 2007). The C-Cl 
stretching observed in Figure 6.13 (a) for the free CHG is masked by the dominate 
C-O stretch from the ethanol within the formulation therefore this interaction was 
not evident ATR-FTIR spectrum.  
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            After characterisation of the formulations they were then applied to porcine 
dermatomed skin and a tape stripping assay was conducted to determine the 
permeation of CHG within the skin from the films. Formulation 4(a), 5 and 6(a) 
were chosen for the studies and after application of the topical gels to the porcine 
skin it was noted that a thick film deposited across the skin surface after 
evaporation of the vehicle. At 24 h a 10 mL wash (2 mL aliquots) of ultra-pure 
water was agitated across the surface of the films in an attempt to remove any 
excess drug not absorbed within the skin. Previously, for all other skin studies the 
highest concentration of CHG was recovered from the 24 h wash (typically >50 % 
of dose applied). For formulation 4(a) and 6(a) only ~5 % of the dosed CHG was 
recovered from the 24 h wash and ~9 % of the applied CHG was detected within 
the formulation 5 wash. This suggests that the CHG-HPC film formed strongly 
retains the CHG. The highest concentration of CHG was extracted from the films 
that were previously washed then prised from the skin surface using tweezers. It 
was noted that on removal of the film superficial layers of the SC were also 
removed because they adhered to the underside of the film.  
 
                Around a third of the dosed CHG was recovered from the glass donor 
chamber. The reason for the high concentration associated with the donor 
chamber was because the film had strongly adhered to the glass. Removal of the 
film from the glass was only possible after the donor chamber was dissolved in 
HPLC mobile phase as an extraction solvent overnight. No CHG was detected on 
the tape strips removed from the SC or the remaining epidermis/dermis across all 
three formulations. Further, no CHG was detected within the receptor fluid. The 
data presented in Tables 6.15-17 indicates that the CHG is strongly associated 
with HPC within the film adhered to the superficial layers of the SC. No CHG had 
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permeated into the SC and was thus confined to the skin surface interface. The 
film forming alcohol gels did not enhance the deposition of CHG within the upper 
skin strata but would have potential benefits for surgical incision antisepsis. The 
antimicrobial film-forming formulations developed within this chapter would form a 
‘breathable’, flexible and transparent protective layer from transient 
microorganisms. The antimicrobial film could prevent skin infections by offering an 
antimicrobial barrier to the colonisation of transient pathogens.  
 
              Previously, Khan and Hoang (1998) incorporated pluronic surfactants 
within the film forming formulation (containing HEC) that aided the release of CHG. 
Non-ionic surfactants although not incompatible can reduce the antimicrobial 
efficacy of antiseptics depending on concentration and surfactant type (Denton, 
1991). The next step in this study would be to add in a CHG compatible non-ionic 
surfactant and test to determine if the surfactant added reduces the efficacy of 
CHG. Once an optimised formulation is developed and fully characterised, 
including measuring the tensile strength etc., then the PAMAM dendrimer may be 
added and experiments could then be conducted into the stability, compatibility 
and CHG release once applied to the skin in future work. Speculatively, perhaps 
the polycationic PAMAM dendrimer would interact with the HPC becoming 
immobilised within the film allowing for the skin permeation of CHG.  
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6.4 Conclusion 
 
The objective of this chapter was to characterise the interaction between 
CHG and G3-PAMAM-NH2 dendrimer. It was discovered that the choice of solvent 
was an important factor with regards to instilling stability within the co-formulation. 
The antimicrobial activity of CHG was not altered when combined with the 
G3-PAMAM-NH2 dendrimer. It was observed that the co-application of 
G3-PAMAM-NH2 dendrimer-CHG enhanced the deposition of CHG within the 
upper skin strata. This has the potential to increase the contact between the 
antiseptic and bacteria and, as such, increase the effectiveness of skin antisepsis. 
The characterisation of the drug-dendrimer interactions may help to design more 
efficient topical drug delivery platforms. A range of cosmetically acceptable 
formulations were investigated for the co-application of the antiseptic and 
dendrimer. Whilst these were not ideally suitable for the topical delivery of CHG, 
they may well have significant potential as an effective approach in the prevention 
or treatment of surgical site infections.  
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7.0 Conclusions and general discussion 
7.1 Summary of findings 
 
It has been shown within this thesis that PAMAM dendrimers are a novel 
topical drug delivery platform of the model antiseptic, chlorhexidine digluconate. 
The aims and objectives of my research have been addressed within this thesis 
and are briefly summarised below.   
 
Firstly, this investigation has established that PAMAM dendrimers are 
antimicrobial without complexation or conjugation to a conventional antimicrobial 
compound and that the mechanism of action is most likely due to bacterial 
membrane permeabilisation/disruption (Chapter 2). In addition, PAMAM 
dendrimers have been shown to enhance the permeation of CHG within porcine 
skin by either skin pre-treatment or by co-application of CHG within a hydro-
ethanolic vehicle (Chapter 3 and 6). The mechanisms of action of the dendrimer-
enhanced penetration enhancement effect have been investigated. The effect is 
likely to be multifactorial, including perturbation of intercellular lipids and hydration 
of the stratum corneum (SC) (Chapter 4). Further elucidation of the dendrimer’s 
action on the skin is required.  
 
The key findings of this thesis include the confirmation that PAMAM 
dendrimers are antimicrobial in their own right against the opportunistic skin 
pathogens Staphylococcus aureus and Escherichia coli. The dendrimer’s 
antimicrobial efficacy was shown to increase with increasing concentration and 
also increases with increasing PAMAM dendrimer generation i.e. the number of 
amine surface groups. SEM micrographs and cell membrane integrity studies 
demonstrated that the mechanism of action of PAMAM dendrimers was severe 
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membrane permeabilisation and cell membrane disruption (Chapter 2). This was 
shown to lead to leakage and precipitation of the bacterial cells’ cytoplasmic 
contents resulting in inhibition and, in bactericidal concentrations, cell death. The 
inner membrane permeabilisation assay was used to discover that the PAMAM 
dendrimers’ effect was once again not only concentration dependent but also 
generation dependent. G3-PAMAM-NH2 and G5-PAMAM-NH2 possessed a very 
similar inner membrane permeabilisation effect that is due to a compromise 
between the number of surface amine groups and molecular size and weight for 
ease of diffusion into the bacterial cells. The inner membrane permeabilisation 
assay also confirmed that PAMAM dendrimers diffuse within the bacterial cell after 
reducing the integrity of the cell membrane. 
 
This thesis has also established that a PAMAM dendrimer pre-treatment 
significantly enhanced the permeation and deposition of the antiseptic CHG within 
porcine skin compared to CHG pre-treated with physiological saline. An increase 
in the concentration and depth of permeation of CHG within the skin will increase 
the contact between the biocide and the flora within the skin layers. Disinfection of 
deeper layers of the skin strata, as opposed to just the superficial layers of the SC, 
as observed for conventional antiseptics, would reduce the microbial load of the 
skin. The strategy to reduce the bio-burden of the skin through more effective 
antisepsis may have considerable benefit to reduce the incidence of skin and soft 
tissue infections.    
 
It was observed that PAMAM dendrimers did not incite any major changes 
in the skin integrity that significantly altered the TEER or TEWL measurements 
that are indicative of significant damage to the barrier properties of the skin. The 
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ATR-FTIR analysis did however suggest that the PAMAM dendrimers may perturb 
the intercellular lipid packing and organization due to observed peak shifts. The 
suggested ultrastructural alterations such as lipid disorder within the SC barrier 
were attributed to the presence of the PAMAM dendrimers (both G3-PAMAM-NH2 
and G3.5-PAMAM-COOH) as made evident by the ATR-FTIR spectra. 
Speculatively, this mechanism may be reversible on removal of the PAMAM 
dendrimer as their size and charge retards their permeation into the skin resulting 
in a transient effect. OCT imaging revealed that PAMAM dendrimers 
(G3-PAMAM-NH2 and G3.5-PAMAM-COOH) temporarily reduced the attenuation 
of light on the skin, for example through a reduction in the back-scattering of light 
at the SC-air interface. This change in the optical characteristics at the air-skin 
interface was shown to be temporary. A transient penetration enhancement effect 
would be ideal as to not cause significant skin barrier impairment that may allow 
for the ingress of other toxic xenobiotics or micro-organisms. Further 
experimentation may determine if the temporary nature of the optical properties at 
the SC-air interface transpires as a temporary penetration enhancement effect.  
The OCT results also suggest that the PAMAM dendrimers are not evenly 
distributed across the skin surface but accumulate within furrows and pores. 
Future investigation into whether there are any changes in surface tension after 
application of CHG with the PAMAM dendrimer would aid understanding of 
deposition of the PAMAM dendrimer across the skin surface. The OCT images 
suggest that PAMAM dendrimers (nanoparticles that are 3.6 nm in diameter) may 
preferentially accumulate within the undulations of the skin. This effect after 
application of PAMAM dendrimers to the skin has been previously observed using 
confocal microscopy (Venuganti et al. 2011). The skin appendages act as a 
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bacterial reservoir (Selwyn and Elias, 1972) therefore accumulation of 
antimicrobial dendrimers (observed with Chapter 2) within these follicles, pores 
and furrows will aid skin disinfection. The PAMAM dendrimers may also be 
exploited for the delivery of other drugs to the follicles such as anti-acne drugs, 
anti-fungal drugs or hair re-growth drugs. 
 
A novel ToF-SIMS method was developed to chemically map the 
distribution and localisation of a topically applied drug within the skin. The ToF-
SIMS method was used to characterise the distribution of CHG once applied to the 
skin and also to visualise and measure the enhanced permeation of CHG following 
PAMAM/dendrimer skin pre-treatment. The ToF-SIMS images supported the 
observations in the quantitative Franz cell studies with porcine skin and the in vitro 
skin tape stripping studies. All the evidence gained within this study supports the 
hypothesis that the PAMAM dendrimer acts as a penetration enhancer for CHG.  
 
During the co-dose formulation development investigations a 
microcrystalline precipitate formed on addition of CHG to a PAMAM dendrimer 
solution. The crystals were fully characterised by MALDI-ToF and single crystal 
XRD. It was found that in aqueous solution PAMAM dendrimers scavenge the 
gluconic acid resulting in a carbon anion-CHX hydrate precipitate. It was 
discovered that PAMAM dendrimers and CHG were stable when co-applied in a 
hydro-ethanolic vehicle. The co-application of CHG and PAMAM dendrimers 
enhanced the permeation of CHG within porcine skin. The degree of permeation 
enhancement was found to be dependent on the PAMAM dendrimer’s 
concentration within the co-dose formulation (Chapter 6). The only statistically 
significant enhancement of CHG permeation within the epidermis (for the 
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co-application) was observed for the highest PAMAM dendrimer concentration 
(10 mM G3-PAMAM-NH2). A series of hydro-ethanolic gel formulations were 
developed with the ultimate aim of incorporating the co-application of CHG with 
PAMAM dendrimers after optimisation. Antimicrobial film-forming alcohol gels 
(without the presence of PAMAM dendrimers) were characterised and optimised 
that would have potential use in pre-surgical incision skin disinfection.  
 
7.2 Implications of research and future work 
 
The implications of specific findings of this project have been discussed 
within each relevant chapter. A number of the novel findings of the thesis 
potentially have broader implications for topical drug delivery and the wider 
Healthcare sector which will be discussed further. PAMAM dendrimers have been 
used previously as drug carriers for topical or transdermal drug delivery for a very 
limited range of therapeutics (Sun et al. 2012). The results presented within this 
thesis investigate their use as a novel topical delivery platform for CHG. For this 
reason, the permeation enhancement effect is seen in co-dosing but is not 
specifically dependent on the drug-dendrimer interaction as the research within 
this thesis has also shown that as a skin pre-treatment, PAMAM dendrimers 
enhanced the penetration of subsequently applied CHG within the skin. This 
illustrates a physical enhancement effect (and possibly a depot effect) due to 
modulation of the superficial layers of the SC and not as a result of drug-dendrimer 
interactions. It is therefore expected that a PAMAM dendrimer skin pre-treatment 
will enhance the permeation of a vast range of topically applied therapeutics 
including antimicrobial compounds.  
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There is also very little evidence that PAMAM dendrimers permeate the SC. 
No evidence was observed for this within this thesis and it is suspected that this 
limited permeation is due to the dense surface charge and the high molecular 
weight of the PAMAM dendrimers. This would be an ideal property for a 
penetration enhancer to possess so that irritation and toxicity problems are 
avoided. 
 
When synthesising any dendritic architecture inclusive of PAMAM 
dendrimers there is great scope to tailor and functionalise the nanoparticles for 
sustained and targeted release. For example, an anti-cancer dendritic pro-drug 
comprising of G5-PAMAM-NH2 dendrimer functionalised with fluorescein 
isothiocyanate (FITC) for fluorescent imaging, folic acid as an active targeting 
ligand and the anti-cancer drug methotrexate for therapeutic effect were previously 
designed (Gurdag et al. 2006). This pro-drug system was designed for injection 
though there is scope for the pro-drug system to be exploited for topical and 
transdermal drug delivery. For example the OCT data within this thesis showed 
that the PAMAM dendrimers may accumulate within the undulations and pores of 
the skin. This could be used as a passive targeted drug delivery mechanism to the 
hair follicles. Additionally, a fluorescent tag conjugated to the PAMAM dendrimer 
would enable visualisation of the complexed or conjugated dendrimer-drug’s 
localisation and distribution. Further, esterase enzymes are distributed throughout 
the SC and the viable epidermis (Lau et al. 2012 and Morris et al. 2009). The 
resulting hydrolysis of esterase linkages once the dendrimer pro-drug had been 
topically applied could be exploited to cleave the drug from the dendritic carrier 
after distribution within the hair follicles or across the skin surface. 
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Drug-dendrimer interactions such as those that increase the solubility of a 
drug may be responsible for an enhancing effect, as well as physical effects such 
as perturbation of the intercellular lipid packing (as observed within the ATR-FTIR 
work within this thesis). Further work would be required to fully elucidate the 
multiple factors involved with regards to the PAMAM dendrimer’s skin penetration 
enhancement effects. One approach could include investigations to delineate the 
interactions of PAMAM dendrimers with SC lipids using atomic force microscopy 
(AFM) and differential scanning calorimetry (DSC). These methods would further 
clarify the dendrimers’ interactions with SC lipids. Elucidation of the mechanism of 
action is imperative to optimise the design of synthetically tailored dendrimers 
aimed at improving topical and transdermal delivery.  
 
For a one step co-application of PAMAM dendrimers with CHG, a range of 
hydro-ethanolic gels were first developed. It was discovered that due to the 
electrostatic interactions and to a lower extent, hydrogen bonding between HPC 
and CHG, no CHG was detected within the SC. The CHG was retained within the 
films that had formed across the skin surface. Though the designed films were 
shown to be unsuitable for the topical delivery of CHG they have the potential for 
widespread application in forming an antimicrobial skin barrier prior to surgical site 
incisions. It would also be of interest to investigate whether addition of the PAMAM 
dendrimer in the film-forming formulation would react with the HPC instead of the 
CHG to allow it to permeate into the upper skin strata. Whether or not the PAMAM 
dendrimer would still act as a penetration enhancer whilst immobilised within a 
polymeric film on the skin surface would also require further experimentation. 
Once a formulation for the co-application had been determined and optimised it 
would be of interest to perform a bioequivalence test to ascertain the efficacy of 
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the formulation containing PAMAM dendrimer against a commercially available 
formulation. 
 
The ToF-SIMS method used CHG as a model drug in this instance and as 
such this method may be applied to a vast range of topically applied compounds. 
This method would have significant benefits in determining whether pesticides on 
contact with skin would permeate to the depth of the microcirculation of the viable 
epidermis. This could conclude to a high sensitivity (femtomolar detection limit) as 
to whether a pesticide would be available for systemic absorption. Further, the 
method could also be utilised to determine the distribution of other topically applied 
compounds and to reveal any co-localisation with specific biomolecules. 
Information such as affinity for particular biomolecules and distribution within the 
different histological tissue compartments can aid elucidation of mechanisms of 
action. As such, more effective formulation strategies or physiochemical 
alterations to drugs could be employed in light of such valuable chemical 
distribution information. As ToF-SIMS also detects secondary ions from 
endogenous biomolecules it would also be of interest to investigate biopsied skin 
due to a range of pathologies and compare them to that of healthy skin. Chemical 
distribution maps may aid characterisation of pathological conditions such as basal 
cell carcinoma or psoriasis that could support the investigation into treatment or 
prevention of such skin diseases.  
 
The novel findings within this thesis, notably that the PAMAM dendrimer 
acts as an effective topical biocide delivery platform and the ToF-SIMS method 
developed to image this, have the potential for widespread biomedical 
applications.  One area that is clearly important in healthcare institutions is 
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effective antisepsis to reduce the incidence of skin and soft tissue infections. More 
effective treatment regimes, including the approaches described in this thesis, 
could have a positive impact on morbidity and mortality rates due to hospital-
acquired infections.  
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Appendix 1 CHG HPLC validation 
 
Replicate calibration standards 
CHG 
conc. 
µg/mL 
1 2 3 4 
1 14439 13875 14188 13910 
5 118606 117841 118689 117685 
10 198679 198982 197655 196938 
50 783109 779946 779962 777602 
100 1666449 1667049 1673436 1675335 
500 7905666 7885445 7879440 7896623 
 
Average calibration graph 
 
 
Reproducibility check of a mid-range CHG standard 
 
 
CHG 
conc. 
µg/mL  
Peak 
area 
10 198649 
10 198756 
10 198860 
10 198679 
10 196938 
10 198982 
SD 763.9978 
Mean 198477.3 
RSD % 0.40 % 
 
y = 15739x + 31840 
R² = 0.9998 
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Appendix 2 Cholesterol HPLC validation 
Replicate calibration standards 
 
Cholesterol 
conc. 
µg/mL 
1 2 3 4 5 6 
1 11878 12242 10334 15904 15805.3 14312.3 
5 53007 51986 55511.6 54474.5 54103.9 53571.3 
10 106637 111163 107249.2 107995.9 107969.9 107880.4 
25 252090 248911 
Mis- 
sample 
249356.5 252602.1 253165 
50 502508 492690 491906.5 488131.8 493188.9 490044.4 
100 1038812 1020199 1044811 1035963 1044405 1040312 
 
Average calibration graph 
 
Reproducibility check of a mid-range CHG standard 
Chol. 
Conc. 
µg/mL 
Peak 
area 
10 106637 
10 111163 
10 107249.2 
10 107995.9 
10 107969.9 
10 107880.4 
Mean 108149.2 
SD 1568.926 
RSD % 1.450705 
 
y = 10283x - 1177.7 
R² = 0.9992 
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Appendix 3 – x Ray diffraction information 
 
 
 
 
 
 
 
 
Table 1. Crystal data and structure refinement details. 
 
 
Identification code  2012ncs0132dlsaa     
Empirical formula  C23H40Cl2N10O7 
Formula weight  639.55 
Temperature  100(2) K 
Wavelength  0.68890 Å 
Crystal system  Monoclinic 
Space group  P21/c  
Unit cell dimensions a = 17.727(13) Å  = 90° 
 b = 21.018(15) Å  = 92.296(6)° 
 c = 8.447(6) Å   = 90° 
Volume 3145(4) Å
3
 
Z 4 
Density (calculated) 1.351 Mg / m
3
 
Absorption coefficient 0.263 mm
1
 
F(000) 1352 
Crystal Platelet; Colorless 
Crystal size 0.10  0.04  0.01 mm
3
 
 range for data collection 2.92  24.21° 
Index ranges 21  h  21, 25  k  23, 10  l  9 
Reflections collected 25271 
Independent reflections 5508 [Rint = 0.1394] 
Completeness to  = 24.21° 99.5 %  
Absorption correction Semiempirical from equivalents 
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Max. and min. transmission 0.9974 and 0.9742 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 5508 / 24 / 439 
Goodness-of-fit on F
2
 1.055 
Final R indices [F
2
 > 2(F
2
)] R1 = 0.0801, wR2 = 0.1921 
R indices (all data) R1 = 0.1246, wR2 = 0.2214 
Largest diff. peak and hole 0.389 and 0.419 e Å
3 
 
 
Diffractometer: Beamline I19 situated on an undulator insertion device with a combination of double crystal monochromator, vertical and 
horizontal focussing mirrors and a series of beam slits (primary white beam and either side of the focussing mirrors).  The experimental 
hutch (EH1) is equipped with a Crystal Logic 4-circle kappa geometry goniometer with a Rigaku Saturn 724 CCD detector and an Oxford 
Cryosystems Cryostream plus cryostat (80-500K). For conventional service crystallography the beamline operates at a typical energy of 18 
keV  (Zr K absorption edge) and a Rigaku ACTOR robotic sample changing system is available. Cell determination and data collection: 
CrystalClear-SM Expert 2.0 r5 (Rigaku, 2010). Data reduction, cell refinement and absorption correction: CrystalClear-SM Expert 
2.0 r5 (Rigaku, 2010). Structure solution: SUPERFLIP (Palatinus, L. & Chapuis, G. (2007). J. Appl. Cryst. 40, 786-790).  Structure 
refinement: SHELXL97 (Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122). Graphics: OLEX2 (Dolomanov, O. V., Bourhis, L. J., 
Gildea, R. J., Howard, J. A. K. & Puschmann, H. (2009). J. Appl. Cryst. 42, 339-341). 
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